The effects of preconditioning  coronary artery disease patients with hyperbaric oxygen prior to  coronary artery bypass graft surgery & cardiopulmonary bypass by Yogaratnam, Jeysen Zivan
  
 
THE UNIVERSITY OF HULL 
 
The Effects of Preconditioning 
Coronary Artery Disease Patients With 
Hyperbaric Oxygen Prior To 
Coronary Artery Bypass Graft Surgery 
& Cardiopulmonary Bypass 
(PROPHYlACTiC) 
 
Being a thesis submitted for the degree of 
Doctor of Philosophy (PhD) 
In the 
University of Hull 
By 
Mr. Jeysen Zivan Yogaratnam 
MB.BCh, BAO, LRCP & SI 
Royal College of Surgeons in Ireland 
MRCS 
Royal College of Surgeons of Edinburgh 
& 
Royal College of Physicians & Surgeons of Glasgow 
 
June 2011 
  
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“It Always Seems Impossible 
Until It is Done” 
~Nelson Mandela 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
iii 
 
Acknowledgement 
“Behind every successful man is a loving woman and as such, 
I would like to dedicate this thesis to my loving wife Melanie, who willingly 
endured me during my endeavours to complete this PhD. She has certainly 
been the pillars to my success. I would like to thank Gerard for his constant 
support and for being one of my most trusted advisors during my pursuit of 
this PhD. I would also like to thank Mr.S.Griffin and Mr.A.Cale for their 
continued encouragement, wisdom and guidance, without which this study 
would not have been possible. I would like to thank Dr.L.Madden for all his 
laboratory expertise, assistance and teachings. I would like to thank and 
acknowledge Dr. E.Gardiner for all this statistical assistance and 
contributions in analysing the study data. I would like to thank                   
Dr. Anne-Marie Seymour and Prof.J.Greenman for their expert laboratory 
supervision and assistance in writing up this thesis. I would like to thank                      
Mr. L.Guvendik and Mr. M.Cowen for all their assistance in facilitating this 
study. I would like to thank the seven cardiothoracic anaesthetist                                                            
(Dr. S. Bennette, Dr. C. Riggs, Dr. V. Hong, Dr. S.Gower, Dr. P.Evans,      
Dr. Ananthakrishnan, Dr. R.O. Smith, Dr. A. Saleh) for standardising their  
anaesthetic practice during this study and for their assistance with the 
pulmonary artery catheters. I would like to thank the 30 intensive care 
nurses for ensuring that the haemodynamic measurements were recorded as 
accurately as possible, despite the daily challenges of their roles. I would like 
to thank the Hull & East Yorkshire NHS Trust for kindly sponsoring this 
study. I would like to thank Air Products for kindly awarding me with a 
medical research grant which enabled the funding this study. And last but 
not least, I would like to thank the 81 patients who kindly donated their time 
and consented to participate in in this study, in the hope of assisting us to 
improve clinical practice. Without them, none of this would have been 
possible.”        
Jeysen Z Yogaratnam 
  
iv 
 
Abstract 
Introduction 
 
Coronary artery bypass graft (CABG) is associated with periods 
of ischaemia and reperfusion, which may lead to myocardial dysfunction. In 
clinical studies, hyperbaric oxygen (HBO2) treatment following an acute 
myocardial infarction (AMI), has been shown to limit myocardial injury and 
improve myocardial function. The primary efficacy objective of this study was 
to determine if systemically preconditioning coronary artery disease (CAD) 
patients with HBO2, prior to first time elective on cardiopulmonary bypass 
(CPB) CABG surgery, leads to a remote preconditioning like effect that is 
capable of improving myocardial function following CABG. The main 
secondary objectives of this study were to assess the safety of HBO2 
preconditioning and, its effects on myocardial injury and post operative 
intensive care unit (ICU) length of stay. The exploratory secondary objectives 
were to assess the effects of HBO2 preconditioning on surrogate serum 
biomarkers of endothelial and neutrophilic adhesiveness and, myocardial 
biomarkers of cardioprotection.    
 
Methods 
In this single centre, randomised control study, 81 patients, who 
were having first time elective on CPB CABG surgery, were recruited. 40 were 
randomised to the Control Group and 41 to the HBO2 Group. Treatment with 
HBO2 preconditioning was completed approximately 2 hours prior to CPB and 
consisted of two 30 minute sessions of 100% oxygen at 2.4 atmospheres 
(ATA) separated 5 minutes apart. Efficacy was measured by determining peri-
operative haemodynamic measurements using a pulmonary artery (PA) 
catheter. Safety was measured by collecting peri-operative data on myocardial 
injury and adverse events (AEs) and, post operative days spent in ICU. Using 
collected peri-operative venous blood, myocardial injury was determined by 
measuring the concentration of serum Troponin-T. In these same venous blood 
samples, endothelial and neutrophilic adhesiveness was indirectly assessed by 
measuring the concentrations of sE-selectin, sP-Selectin and sICAM-1 and, 
sPSGL-1, respectively. Using intra-operative right atrial biopsies, the degree of 
cardioprotection provided by HBO2 preconditioning was determined by 
measuring the quantity of myocardial eNOS and Hsp72. Analysis of the serum 
and myocardial biomarkers were done by ELISA. 
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Results 
 
Compared to the Control Group, the HBO2 Group demonstrated 
a significant improvement in left venticular stroke work (LVSW) 24 hours post 
CPB (p=0.005). While there were no significant safety findings, there were 
fewer cardiovascular, pulmonary, renal and neurological AEs in the HBO2 
Group. This group also had a significantly shorter post operative ICU length of 
stay. 1 hour post HBO2 preconditioning, the concentration of sPSGL-1 
increased significantly in the HBO2 Group. At all time points, the peri-oprative 
concentration of sPSGL-1 was higher in the HBO2 Group but none of the 
changes were significant. The latter was also the case for the peri-operative 
concentration of sP-Selectin, apart from following the period of ischaemic and 
reperfusion, when it was lower in the HBO2 Group. Intra-operatively, the 
concentration of sE-Selectin increased significantly in the HBO2 Group and 
was higher in this group throughout the peri-operative period. During this 
intra-operative period also, the concentration of sICAM-1 was higher in the 
HBO2 Group and the increase was particularly significant following the period 
of ischaemia and reperfusion. 24 hours post CPB, the concentrations of all the 
serum soluble adhesion molecules were higher in the HBO2 Group. No 
significant differences were observed between the groups with respect to the 
concentrations of serum Troponin-T and, the quantity of myocardial eNOS and 
Hsp72. However, in the HBO2 Group, the peri-operative concentrations of 
serum Tropinin-T, eNOS and Hsp72 were lower. Furthermore, while there was 
a pre-CPB reduction of both eNOS and Hsp72, following ischaemia and 
reperfusion, the quantity of both these myocardial biomarkers were increased. 
 
Conclusion 
 
From this study, it can be concluded that HBO2 preconditioning of 
patients with CAD prior to on CPB CABG, is capable of improving 
myocardial function 24 hours post CABG. Additionally, the data suggest that 
this may also be a safe modality of treatment as it did not lead to significant 
post operative AEs, limited peri-operative myocardial injury and reduced post 
operative ICU length of stay. It also led to increased post operative 
concentrations of the measured surrogate biomarkers of endothelial and 
neutrophilic adhesiveness, with a number of significant peri-operative changes. 
Finally, while HBO2 treatment did not lead to significant changes in the 
myocardial biomarkers of cardioprotection, the quantities of these increased in 
the HBO2 Group following ischaemia and reperfusion, suggesting that it may 
be capable of inducing endogenous cardioprotection following ischaemia and 
reperfusion.  
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1. Introduction 
 
Coronary artery bypass graft (CABG) surgery has been shown 
to be a life saving procedure (Guyton, 2006) which leads to longer 
survival (Eagle et al., 2004) and better quality of life (Loponen et al., 2007) 
when compared with medical therapy or percutaneous intervention, in specific 
groups of patients suffering from coronary artery disease (CAD) (Eagle et al., 
2004). This surgical procedure, when performed during cardiopulmonary 
bypass (CPB), requires a relatively bloodless operating field without any 
myocardial contractions. This is achieved by clamping the aorta with a cross-
clamp, which induces a controlled global myocardial ischaemia due to the 
reduced coronary perfusion. As a result of this myocardial ischaemia, the heart 
becomes relatively motionless heart and this facilitates the anastamosis of the 
bypass conduit to the coronary artery (distal anastamosis). In order to protect 
the myocardium during this period of ischaemia, one of two very different 
myocardial protective strategies maybe utilised. One strategy involves the use 
of a potassium enriched solution known as St. Thomas Cardioplegia 
solution (Hearse et al., 1976) during the global ischaemic period. This 
hyperkalaemic solution causes a cardiac arrest and stand still, while at the same 
time providing the myocardium with substrates necessary to keep it 
metabolically viable (Rosenkranz, 1995). The other strategy, known as 
hypothermic (28oC-32 oC) intermittent ischaemic fibrillatory arrest (Lucas et 
al., 1980), involves the use of short, repeated intervals of controlled global 
ischaemia, by clamping the aorta, together with a controlled electrically 
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induced ventricular fibrillation. This leads to a relatively motionless heart 
while also protecting the myocardium (Abd-Elfattah et al., 1995).    
While on CPB CABG using either of these myocardial 
protective strategies has been shown to be a safe and effective means of 
providing myocardial protection (Alex et al., 2005, Alhan et al., 1996, 
Anderson et al., 1994, Liu et al., 1998, Scarci et al., 2009), the need for the 
application of an aortic cross-clamp to achieve a bloodless operating field 
without myocardial contractions, followed by its removal, also means that 
during CABG surgery, the myocardium is exposed to durations of ischaemia 
followed by durations of reperfusion. This ischaemia and reperfusion leads to 
an injury known as ischaemic reperfusion injury (IRI) (Venugopal et al., 2009) 
which can cause mortality, myocardial infarction (MI), unstable angina, 
ventricular failure, life-threatening arrhythmia, renal insufficiency and 
stroke (Alexander et al., 2005, Desai et al., 2004, Eagle et al., 2004, Edwards et 
al., 1994, Ferguson et al., 2002, Manning and Hearse, 1984). Despite efforts to 
improve the post operative outcomes, post CABG adverse events (AEs) remain 
common and add substantially to hospital costs for this procedure (Brown et 
al., 2008). It has been reported that over half of in-hospital deaths after CABG 
occur in patients with normal baseline left ventricular function and, are related 
to IRI and low cardiac output (CO) in post operative period (O'Connor et al., 
1998). Furthermore, 25% to 45% of patients dying soon after CABG have 
histological evidence of IRI at autopsy (Bulkely and Hutchins, 1977, Moore 
and Hutchins, 1981, Weman et al., 2000). 
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 1.1 Myocardial Ischaemic Reperfusion 
Injury 
The common denominator of myocardial IRI involves the acute 
interruption of coronary blood flow, due to obstruction, followed by the return 
of coronary flow when that obstruction is removed or bypassed (Piper et al., 
1998, Prasad et al., 2009). During the period of no flow, cells are metabolically 
compromised by hypoxic conditions that cause cellular dysfunction and 
eventually lead to cell death. When the coronary blood flow is restored, this 
return of myocardial perfusion, paradoxically, despite restoring the ischaemic 
myocardium with oxygen (O2) and metabolic substrates, leads to another form 
of myocardial damage termed ‘reperfusion injury’ (Ferrari et al., 1993, Prasad 
et al., 2009). This is defined as the death of myocytes, alive at the time of 
reperfusion, as a direct result of one or more events initiated by 
reperfusion (Braunwald and Kloner, 1985). One of the causes for reperfusion 
injury is a second period of decreased flow that occurs during reperfusion. This 
is known as the no-reflow phenomenon (Ito, 2006, Kloner et al., 1974, Krug et 
al., 1966). This phenomenon is associated with an increased incidence of acute 
myocardial infarction (AMI), myocardial rupture and death (Abbo et al., 
1995). The mechanism underlying this reperfusion injury is attributed to 
plugging of the vasculature with neutrophils (Engler et al., 1983) and 
platelets (Michaels et al., 2000), capillary endothelial damage and intraluminal 
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swelling (Engler et al., 1983) and, cellular oedema compressing the 
capillaries (Manciet et al., 1994).  
The cellular damage that results from myocardial ischaemia and 
reperfusion can be reversible or irreversible and is related to the duration of the 
preceding ischaemic insult (Jennings and Reimer, 1983). When myocardial 
ischaemia is limited to periods of less than 20 minutes, reperfusion leads to 
recovery following transient changes in cellular structure, function and 
metabolism. These changes manifest clinically as depressed myocardial 
contractility, which may persist for a variable period of time. This condition is 
not associated with myocardial necrosis and is termed ‘myocardial stunning’. 
This is defined as the mechanical dysfunction that persists after reperfusion of 
previously ischaemic tissue in the absence of irreversible damage including 
myocardial necrosis (Hess and Kukreja, 1995). However, when myocardial 
blood flow is restored after an ischaemic period of greater than 20 minutes, the 
myocardium sustains a reperfusion injury that results in myocardial necrosis 
and the extent is directly proportional to the duration of the ischaemic 
insult (Jennings and Reimer, 1983).  
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1.2  The Inflammatory Response of 
Ischaemic Reperfusion Injury 
 
Myocardial ischaemia elicits an acute inflammatory response 
that is greatly augmented by reperfusion (Hearse and Bolli, 1992, Steffens et 
al., 2009, Suleiman et al., 2008). In the human heart, this acute inflammatory 
response is associated with the production of reactive oxygen species (ROS) 
and lipid peroxidation products and, is accompanied by intra-coronary release 
of pro-inflammatory cytokines and vasoactive substances (Vaage and Valen, 
1993). Part of this ischaemic-reperfusion induced inflammatory damage is 
mediated by neutrophils which accumulate in myocardium under the influence 
of chemo-attractants (Entman et al., 1991, Mehta et al., 1988, Reimer et al., 
1989, Vinten-Johansen, 2004). In addition to physically plugging 
capillaries (Engler et al., 1983), neutrophils also bind to the endothelial surface 
and cause endothelial cell dysfunction and tissue destruction through a variety 
of cytotoxic mechanisms that involve ROS, cytotoxic enzymes and 
cytokines (Inauen et al., 1990).  
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1.2.1 Neutrophil & Endothelial Adhesion 
Molecules 
Neutrophil mediated endothelial injury is dependent on the 
interaction of adhesion glycoproteins [L-selectin, Sialyl Lewisx, P-selectin 
glycoprotein ligand-1 (PSGL-1), and CD11/CD18] expressed on the surface of 
circulating neutrophils, with adhesion molecules expressed on the surface of 
the endothelium [P-selectin, E-selectin, and intracellular adhesion molecule-1 
(ICAM-1)].  
1.2.1.1 The Selectin Family Of Adhesion Molecules 
The selectin family of adhesion molecules mediates the initial 
capture of neutrophils from the blood stream, before their firm adhesion and 
diapedesis at the sites of tissue injury and inflammation (Ebnet and Vestweber, 
1999). L-selectin is expressed constitutively on  neutrophils (Bevilacqua and 
Nelson, 1993) and is rapidly shed after neutrophil activation (Kishimoto et al., 
1989). P-selectin, is constitutively stored in the Weibel-Palade bodies of 
endothelial cells and in the α granules of platelets and, is rapidly mobilised to 
the cell surface in response to various inflammatory stimuli like thrombin, 
histamine, and ROS (Lorant et al., 1991, Patel et al., 1991). E-selectin 
expression is largely restricted to endothelial cells and is activated by stimuli 
such as endotoxins, the pro-inflammatory cytokine interleukin (IL)-1 and 
tumour necrosis factor (TNF) (Bevilacqua et al., 1989). Unlike P-selectin, E-
selectin expression takes 4-8 hours to occur following stimulation (Lasky, 
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1995) as E-selectin expression requires de novo messenger mRNA and protein 
synthesis. It usually returns to baseline levels 24 hours after the stimulating 
event. 
In the first 20 minutes after tissue injury, neutrophil rolling on the 
vascular endothelium is mainly mediated by P-selectin, with minimal L-
selectin contribution (Griffin et al., 1990). Subsequently, the role of P-selectin 
diminishes due to internal degradation, and L-selectin becomes the principal 
mediator of neutrophil rolling. There is little appreciable role for E-selectin in 
the early response to injury. Rather, initial interaction between the neutrophil 
and the vascular endothelium, mediated via P-and L-selectins, is later followed 
by a stronger interaction involving E-selectin and subsequently integrins, prior 
to extravasation of the neutrophil, via the blood vessel wall, into lymphoid 
tissues and to the sites of inflammation (Lasky, 1995). To date, the best 
characterised cell adhesion ligand for P- and E-selectins is PSGL-
1 (Cummings, 1999), which is found on the surface of neutrophils. It is a 
stronger ligand for P-selectin than for E-selectin (Moore et al., 1992).  
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1.2.1.2 ICAM-1  
ICAM-1, is expressed on the surface of endothelial cells, 
epithelial cells and fibroblast (Rothlein et al., 1986). Its expression is induced 
by cytokines IL-1, IL-6 and TNF-α (Frangogiannis et al., 2002, Frangogiannis 
et al., 1998). Once stimulated, its expression is significantly increased within 4 
hours of induction and cell surface levels may remain elevated for 
days (Lindsberg et al., 1996). ICAM-1 is one of the primary ligands for the 
neutrophilic adhesion molecule, CD-18 (Albelda et al., 1994).  
1.2.1.3 Ischaemic Reperfusion Injury & Adhesion 
Molecules 
 In experimental mouse models, ischaemia followed by 
brief (Palazzo et al., 1998a) and prolonged (Jones et al., 2000) periods of 
reperfusion have been shown to upregulate P-Selectin expression in the 
coronary circulation and enhance neutrophil accumulation. However, in mice 
that were made genetically deficient for P-Selectin, neutrophil accumulation 
and myocardial injury were attenuated following IRI (Jones et al., 2000, 
Palazzo et al., 1998a). Similarly, it also been demonstrated that E-Selectin was 
upregulated in the mouse myocardium following ischaemia and 
reperfusion (Jones et al., 2000), and that genetic deficiency of E-Selectin 
conferred myocardial protection by limiting myocardial infarct size owing to 
the attenuation of neutrophil accumulation (Sligh et al., 1993). It has also been 
demonstrated that mice that were made genetically deficient of ICAM-1, 
showed a significant reduction in myocardial necrosis in association with an 
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attenuation of myocardial neutrophil infiltration following both brief (Palazzo 
et al., 1998b) and extended (Jones et al., 2000) periods of reperfusion.  
Due the deleterious effects of neutrophil-endothelial 
interactions via the selectin group of adhesion molecules, many selectin 
inhibitory therapies have been developed. These therapies involve the use of 
monoclonal antibodies (Nigam and Kopecky, 2002), Sialyl Lewisx analogues, 
PSGL-1 analogues (Ley, 2003), nitric oxide (NO) enhancing agents  (Li et al., 
2009) and small-molecule selectin antagonist (Onai et al., 2003). More 
recently, there has also been evidence to suggest a role for hyperbaric oxygen 
(HBO2) in limiting neutrophil-endothelial interactions (Buras and Reenstra, 
2007). 
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1.3  Ischaemic Reperfusion Injury & 
Reactive Oxygen Species 
While the lack of oxygen during ischaemia is deleterious to 
myocardial survival, the restoration of oxygen during reperfusion of the 
previously ischaemic myocardium, paradoxically, has also been demonstrated 
to lead to a myocardial injury which is worse than the injury induced by 
ischaemia alone (Hearse et al., 1973).  It has now been established that the 
presence of oxygen during the early moments of reperfusion of the ischaemic 
myocardium leads to an oxidative stress via a burst of ROS (Kevin et al., 2003, 
Park and Lucchesi, 1999). These ROS arise from a variety of sources, such as 
the xanthine oxidase system, activated neutrophils, the electron transport chain 
of mitochondria, and the arachidonic acid pathway (Kloner et al., 1989, 
Kukreja and Hess, 1992).   
ROS have been suggested to be responsible for the post 
ischaemic myocardial dysfunction characterized by myocardial stunning and 
post ischaemic arrhythmia (Kevin et al., 2005, Kloner et al., 1989, Kukreja and 
Hess, 1992). At present, controversy exist as to as to whether ROS leads to MI 
as there have been some experimental studies which support the use of anti-
oxidant (Ambrosio et al., 1986, Chi et al., 1989, Kilgore et al., 1994, Naslund 
et al., 1986) and others (Downey et al., 1991, Nejima et al., 1989, Ooiwa et al., 
1991, Uraizee et al., 1987, Vanhaecke et al., 1991) which do not support the 
use of anti-oxidants to limit the possibility of ROS induced MI.  
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In an experimental study, it was demonstrated that when the 
myocardium was exposed to ischaemia, the generation of ROS rapidly 
increased, but this increase did not occur at the same rate during subsequent 
episodes of ischaemia and reperfusion (Das et al., 1999b). It was suggested that 
the initial ischaemia and reperfusion led to the development of an oxidative 
stress that adapted the myocardium to the subsequent oxidative stresses of 
ischaemia and reperfusion and this, resulted in the observed ROS mediated 
reduction in ischaemia-reperfusion induced injury. The myocardial protective 
abilities of the ROS adapted myocardium were completely abolished when the 
myocardium was pre-perfused with N-acetyl cysteine to scavenge ROS, 
suggesting that redox signaling may play a crucial role in generating survival 
signals during myocardial adaptation to ischaemia (Maulik et al., 1998). In 
keeping with this, ROS have been demonstrated to function as signaling 
molecules (Herrlich and Bohmer, 2000, Rosette and Karin, 1996). By initiating 
genetic expression and, the consequent synthesis of a variety of functional and 
structural proteins, ROS signaling may allow for the adaptation and survival of 
the cells (Das and Maulik, 2003, Das and Maulik, 2004) or, depending on the 
intensity and duration of the signal, activate the processes responsible for the 
cell damage or death (Buttke and Sandstrom, 1994, Das, 2001). Thus, it is 
possible that an oxidative attack may induce either a loss or a gain of a 
function or lead to a switch to a different function. 
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1.4  Ischaemic Reperfusion Injury, Nitric 
Oxide & Nitric Oxide Synthase 
The administration of NO donors prior to ischaemia have been 
demonstrated to reduce myocardial infarct size and endothelial dysfunction as 
a result of IRI (Bolli, 2001). Furthermore, pre-treatment with drugs that 
enhance NO release such as statins (Lefer et al., 1999), calcium channel 
antagonist (Asanuma et al., 2001), ACE inhibitors (Hartman et al., 1994) and 
dexamethasone (Hafezi-Moghadam et al., 2002), have also been shown to 
protect the myocardium against IRI. While these provide evidence to support 
the role for exogenous administration of NO to initiate protection against IRI, 
there is also evidence, based on models of ischaemic preconditioning (IPC), 
demonstrating a role for endogenously induced NO in mediating early (Han et 
al., 2008b) and delayed (Bolli, 2000) myocardial protection against IRI.  
1.4.1  Nitric Oxide  & Nitric Oxide Synthase 
NO, first characterized as endothelium-derived relaxation factor, 
is a ubiquitous signalling messenger molecule that is involved in 
neurotransmission, inflammatory and immune responses and, vascular 
homeostasis (Gong et al., 2004, Moncada et al., 1988). It is formed by the 
oxidation of  the guanidine moiety of L-arginine resulting in the products NO 
and L-citrulline (Schulz et al., 2004). This reaction is catalysed by nitric oxide 
synthase (NOS). Once formed, it diffuses freely and has a  half-life of only 3-5 
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seconds (Tuteja et al., 2004) before being rapidly oxidized to the stable 
inactive end products of nitrite and nitrate (NO-2  and NO-3) (Geller and Billiar, 
1998).  
At present, there are three known isoforms of NOS, neuronal 
NOS (also known as nNOS or NOS 1), inducible NOS (also known as iNOS or 
NOS 2) and endothelial NOS (also known as eNOS or NOS 3). All three 
isoforms have been shown to be present in the myocardium (Forstermann et al., 
1994, Massion et al., 2005, Xuan et al., 2000) and all have been found to play a 
role in myocardial NO production (Jugdutt, 2002).  nNOS and eNOS are 
continuously present and are thereby termed constitutive NOS (cNOS). In 
contrast, iNOS, which is not typically expressed in resting cells, must first be 
induced by a stress such as ischaemia (Bolli et al., 1997), hypoxia (Jung et al., 
2000), lipopolysaccharides (Yin et al., 2007) and cytokines (Balligand et al., 
1994). 
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1.4.2  Nitric Oxide &  Its Mechanisms for 
Myocardial Protection 
NO has a negative inotropic and chronotropic (Finkel et al., 
1992) effect on the myocardium. The capacity for NO to reduce myocardial 
contractility (Brady et al., 1993) serves to reduce oxygen consumption and 
demand. This NO function involves cyclic guanosine monophosphate (cGMP),  
a secondary messenger produced by the action of NO on soluble guanylate 
cyclase (Mittal CK, 1982). Guanylate cyclase catalyses the conversion of 
guanosine triphosphate (GTP) to cGMP. cGMP exerts it protective effects by 
reducing the influx of calcium through L-type calcium channels (Han et al., 
1996, Mery et al., 1993). This, prevents calcium overload which is one of the 
critical features of mitochondrial dysfunction during IRI (Jennings and Reimer, 
1991). 
NO has also been shown to maintain coronary vasodilatory 
tone (McGowan et al., 1994), reduce post ischaemic hyperpermeability (Kubes 
and Granger, 1992, Noel et al., 1995), decrease platelet adhesion and 
aggregation (Radomski et al., 1987), reduce neutrophil adherence, migration 
and associated injury (Conger and Weil, 1995, Jordan et al., 1999, Ronson et 
al., 1999) and, impair mast cell activation (Johnson et al., 1990). It also inhibits 
neutrophilic generation of the ROS superoxide (Kubes et al., 1991, Sato et al., 
1996). The neutrophil anti-adhesive effects mediated by NO occurs via NO’s 
ability to inhibit the vascular endothelial expression of adhesion molecules, in 
  
32 
 
particular P-selectin, E-selectin and ICAM-1 (De Caterina et al., 1995, Ohashi 
et al., 1997).  
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1.5 Ischaemic Reperfusion Injury & Heat 
Shock Proteins 
Studies in the early 1990’s demonstrated that increased 
expression of Heat Shock Protein (Hsp) may protect the myocardium from a 
stressful stimulus such as ischaemia and reperfusion (Donnelly et al., 1992, 
Heads et al., 1996, Radford et al., 1996, Yellon et al., 1992). Amongst the 
many Hsp, the major inducible form of the Hsp70 stress protein, Hsp72, has 
been shown to directly protect against myocardial ischaemic damage, improve 
metabolic and functional recovery and, reduce myocardial infarct size (Hutter 
et al., 1996, Marber et al., 1995, Radford et al., 1996). 
Experimental studies have demonstrated that short durations of 
global or regional myocardial ischaemia lead to the induction of myocardial 
Hsp70 (Currie, 1987, Dillmann et al., 1986, Marber et al., 1993) and that the 
increase in Hsp70 was associated with the protection of the myocardium 
against a subsequent ischaemic episode (Currie et al., 1988). This increase in 
Hsp70 was also observed following repeated, brief episodes of coronary artery 
occlusion prior to prolonged ischaemia and was associated with reductions in 
myocardial infarct size (Marber et al., 1993). The latter findings also suggests 
that the degree of cardioprotection correlated directly with the quantity of 
Hsp70 produced by the preceding stress event (Marber et al., 1994). 
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1.5.1 Heat Shock Protein 70 & Its Mechanism For 
Myocardial Protection 
  During myocardial IRI, there is an oxidative stress that is 
associated with the generation of ROS (Misra et al., 2009). When the 
production of ROS exceeds the capacity of endogenous detoxification 
mechanisms, myocardial cells are damaged, either by ROS directly or by the 
ROS-dependent triggering of a cascade of pro-inflammatory events. Hsp may 
favourably interfere with the ROS-induced injuries because of its role as 
biological molecular chaperones in ensuring quality control of protein folding 
in major subcellular compartments (Feder and Hofmann, 1999, Li et al., 2002, 
Santoro, 2000). Hsp70 in particular has a number of cytoprotective functions 
such as ensuring the appropriate folding of proteins (Bukau and Horwich, 
1998), the maintenance of structural proteins (Palleros et al., 1991), the 
refolding of misfolded proteins (Palleros et al., 1991), the translocation of 
proteins across membranes and into various cellular  compartments (Bukau 
and Horwich, 1998, Chirico et al., 1988, Deshaies et al., 1988), the prevention 
of protein aggregation (Bukau and Horwich, 1998) and, the degradation of 
unstable proteins (Bukau and Horwich, 1998). Additionally, there are also 
studies that have shown that levels of Hsp closely parallel the activity of 
antioxidant enzymes such as catalase. This indirectly supports the suggestion 
that Hsp may also be involved in pathways which are activated to counteract 
ROS-dependent cellular and tissue damage (Currie et al., 1988, Karmazyn et 
al., 1990, Mocanu et al., 1993). 
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Hsp may also function as immunodominant signalling 
molecules that is capable of downregulating the production of pro-
inflammatory cytokines, such as TNF-α, interferon-γ, IL-1α, IL-1β, and IL-
6 (Pockley, 2002) and also improving cellular tolerance to inflammatory 
cytokines such as TNF-α and IL-1 (Jaattela and Wissing, 1993, Muller et al., 
1993). In a myocardial model of ischaemia and reperfusion, it has been 
demonstrated that the upregulation of Hsp70 is associated with  the 
suppression of inflammatory cytokines in  (Grunenfelder et al., 2001).  It has 
also been proposed that Hsp could interfere with the signaling pathway of the 
transcription factor NFκB. This pathway is involved in the transcription of 
several pro-inflammatory genes. It has been shown that the heat shock 
response inhibits the activation of the NFκB pathway, resulting in suppression 
of the cellular inflammatory response (Malhotra and Wong, 2002).  The down 
regulation of cytokine production by Hsp may account for the Hsp-dependent 
protection of the myocardium during experimental ischaemia and reperfusion.  
The myocardial protection provided by Hsp may also be linked 
to mechanisms involving NO and NOS. Although the exact mechanism 
involved in the interaction between NO and Hsp is unknown, evidence 
suggests that NO could trigger Hsp70 synthesis and expression, and this seems 
to ultimately protect the myocardial cells against the cytotoxic effects of   
TNF-α (Latchman, 2001). Additionally, it has also been demonstrated in an 
experimental model of myocardial ischaemia that increased activity of iNOS 
was associated with reduced myocardial injury and that this protective effect 
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was paralleled by an elevated expression of Hsp70, with reduced activity of 
NFκB (Zingarelli et al., 2002).  
Hsp may also play a role in cellular protection during periods of  
energy depletion as cellular ATP depletion has been shown to induce Hsp 
expression (Benjamin et al., 1992). It has been demonstrated that treatments 
leading to the accumulation of cellular Hsp70 can reduce protein aggregation 
resulting from ATP loss (Kabakov et al., 2002). Furthermore, it has also been 
shown that heat shock not only results in Hsp70 induction but also protection 
from energy deprivation (Gabai and Kabakov, 1993). This suggest that Hsp 
accumulation may confer an ‘ATP-sparing’ effect (Gabai and Kabakov, 1993, 
Kabakov, 1997).  
In addition to an anti-apoptotic function (Garrido et al., 2001, Li 
et al., 1996), Hsp70 has also been reported to improve the process of fibrotic 
repair after myocardial injury by enhancing the synthesis of collagen and repair 
of ion channels (Latchman, 2001). It has been shown that the opening of    
ATP-sensitive potassium channels, especially in the mitochondria, is a crucial 
step for ATP synthesis in myocardial cells (Eells et al., 2000). By repairing 
these ion channels under stressful conditions, Hsp70 upregulation may protect 
the mitochondrial energy metabolism as well as cellular function in the injured 
myocardium (Sammut et al., 2001).  
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1.6  Myocardial Preconditioning 
  The concept of myocardial preconditioning began with the 
understanding from experimental studies in late 1970’s which demonstrated 
that while 40 minutes of sustained ischaemia was associated with severe ATP 
depletion and cell death (Jennings et al., 1978, Reimer and Jennings, 1979), 
four 10 minute periods of coronary artery occlusion produced no more ATP 
depletion than a single 40 minute occlusion and did not cause necrosis (Reimer 
et al., 1986). Its was observed that intermittent brief periods of ischaemia 
prevented the cumulative effects of a prolonged period of ischaemia by 
reducing harmful catabolites  such as lactate and hydrogen ions which were 
washed out with each reperfusion (Reimer et al., 1986). These findings led to 
the hypothesise that multiple brief ischaemic episodes may actually protect the 
myocardium during a subsequent sustained ischemic insult. This hypothesis 
was later proven (Murry et al., 1986) and marked the beginning for the era of 
myocardial preconditioning. In that 1986 study by Murry, anaesthetised open-
chest dogs were exposed to four cycles of 5 minutes of coronary artery 
occlusion followed by 5 minutes reperfusion before being exposed to 40 
minutes of coronary occlusion and 4 days of reperfusion. The protocol of four 
short cycles of ischaemia followed by reperfusion was termed ischaemic 
preconditioning (IPC). That study demonstrated that dogs exposed to IPC 
developed significantly smaller infarct sizes than the control animals. 
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1.6.1  Ischaemic Preconditioning 
Since the discovery of IPC, its myocardial protective capacity 
has been widely studied (Bolli et al., 2007, Das and Das, 2008, Downey et al., 
2007, Hausenloy et al., 2005) and now, it is clear that IPC is cardioprotective 
against myocardial IRI (Bolli, 2001, Bolli et al., 2007). A recent meta-analysis 
concluded that IPC reduces post operative ventricular arrhythmias, inotrope 
use and shortens post operative intensive care unit (ICU) stay (Walsh et al., 
2008). 
IPC induces two distinct windows for myocardial 
protection (Kuzuya et al., 1993, Marber et al., 1993). The first window of 
myocardial protection, known as the ‘early phase’ or ‘Classical 
Preconditioning’ (Pagliaro et al., 2001) develops within minutes and lasts 1-2 
hours after IPC while the second window, known as the ‘late phase’ or 
Delayed Preconditioning’ (Bolli et al., 2007), develops within 24 hours 
following the initial IPC and lasts for  48-72 hours. The early phase of IPC has 
been shown to result from the rapid post-translational modifications of existing 
myocardial proteins whereas the late phase of IPC is mediated by 
cardioprotective gene expression and the synthesis of new proteins in the 
myocardium (Bolli et al., 2007). Furthermore, the early phase of IPC has been 
shown to protect against MI but fails to limit the degree of myocardial 
contractile dysfunction or stunning while, the late phase of IPC protects against 
both myocardial cell death and preserves post ischaemic left ventricular 
function (Bolli et al., 2007). 
  
39 
 
The initial triggers for IPC, which are released within minutes 
of ischaemia, include adenosine, opioids, bradykinins and prostaglandin. In the 
early phase of IPC, these molecules lead to the activation of G-protein-coupled 
receptors and mitochondrial KATP channels, ROS generation and, the 
stimulation of a series of protein kinases which include protein kinase C 
(PKC), tyrosine kinase and members of the Mitogen Activated Protein Kinase 
(MAPK) family (Das and Das, 2008, Penna et al., 2009). Following the initial 
trigger, the effects of the late phase of IPC are mediated mainly via newly 
synthesised proteins such as NOS and maybe even Hsp (Das and Das, 2008, 
Heusch et al., 2008).  
In the first clinical application of IPC in 1993, which involved 
aortic clamping, it was reported that a protocol of IPC during surgery led to 
preservations of ATP levels in the myocardium of patients undergoing on CPB 
CABG (Yellon et al., 1993). It was subsequently reported that in patients 
undergoing on CPB CABG, a protocol of IPC was also capable of reducing 
myocardial injury (Jenkins et al., 1997). In addition to ATP preservation (Lu et 
al., 1997) and attenuating myocardial injury (Ji et al., 2007, Szmagala et al., 
1998, Teoh et al., 2002a, Teoh et al., 2002b), IPC during cardiac surgery has 
also demonstrated the ability to improve ventricular function (Lu et al., 1997, 
Wu et al., 2002, Wu et al., 2001), limit arrthymias (Wu et al., 2002), heart rate 
variability (Wu et al., 2005) and inotrope use (Wu et al., 2002). However, the 
risks associated with repeated clamping and unclamping of the aorta, as 
required for an IPC protocol, in addition to the routine clamping and 
unclamping that has to occur to perform on CPB CABG surgery, has meant 
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that the routine clinical use of IPC has been limited. Due to this, the concept of 
myocardial preconditioning has been further investigated using remote IPC 
(RIPC), which does not require an invasive intra-operative myocardial IPC 
protocol, and, pharmacological preconditioning using adenosine, bradykinin, 
opioids and inhalation anaesthetics (Granfeldt et al., 2009, Hausenloy and 
Yellon, 2009, Venugopal et al., 2009). 
1.6.2 Remote Ischaemic Preconditioning 
Myocardial RIPC involves applying the IPC protocol to an 
organ or tissue which is distant from the heart (Hausenloy and Yellon, 2008). 
This method of myocardial preconditioning was first discovered in 1993, when 
it was observed that a period of  brief ischaemia and reperfusion in the left 
circumflex coronary artery territory of dog hearts, prior to a prolonged period 
of acute coronary occlusion in the left anterior descending (LAD) artery 
territory, later led to a substantial reduction in myocardial infarct 
size (Przyklenk et al., 1993). Subsequently, the cardioprotective effects of 
RIPC has also been demonstrated using RIPC protocols to the kidney (Pell et 
al., 1998), intestine (Gho et al., 1996) and limb (Birnbaum et al., 1997). 
The mechanism for RIPC is unclear but it appears to closely 
resemble that for IPC (Granfeldt et al., 2009). At present, there are three 
general theories regarding the mechanism for RIPC (Hausenloy and Yellon, 
2008, Walsh et al., 2009). The first theory is the neural hypothesis which 
suggests that ischaemic remote organs release endogenous substances, such as 
adenosine and bradykinin, which activate local afferent neural pathways to 
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trigger end-organ protection. The second theory is the humoral theory which 
suggests that the remote organs release humoral mediators, which again maybe 
adenosine and bradykinin, into the bloodstream and these substances are 
transported to distant organs where they directly trigger intracellular survival 
pathways. The third theory is the inflammatory suppression theory which 
suggests that the transient remote organ ischaemia produces a systemic 
inflammatory response which is capable of protecting distant organs from a 
subsequent IRI. While it is unclear which of these theories are accurate, it is 
also possible that all are true and that they maybe an interaction between all 
mechanisms of all three theories. 
In the clinical setting, in 2005, a study was conducted where the 
non-dominant arm was rendered ischaemic by inflation of a blood pressure 
cuff for 5 minutes followed by 5 minutes of reperfusion for 3 
cycles (Loukogeorgakis et al., 2005). Following this, the contralateral arm was 
subjected to 20 minutes of sustained ischaemia via cuff inflation followed by 
critical assessment of conduit vessel vasoreactivity. In that study, it was clearly 
demonstrated that both the early and late phases of IPC were present in RIPC 
and that the effects were mediated via neuronal activity as treatment with an 
autonomic blocker, trimetaphan, abolished the preservation of flow-mediated 
vasodilatation in the subjects that were treated with RIPC protocol.  
The clinical effects of RIPC in cardiac surgery were first 
published in 2006. In that study, 37 children undergoing repair of congenital 
heart defects were randomised to either a RIPC group or a control 
group (Cheung et al., 2006). RIPC was induced by four cycles of 5 minutes of 
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lower limb ischaemia followed by 5 minutes of reperfusion using a blood 
pressure cuff. It was found that post operative serum Troponin-I and inotrope 
use were significantly lower in the RIPC group. Additionally, the RIPC group 
had a significantly lower post operative airway resistance. In the setting of on 
CPB CABG, a randomised control study had been conducted where 57 patients 
undergoing elective surgery were randomly allocated to receive RIPC or 
not (Hausenloy et al., 2007). The RIPC group was subjected to 3 cycles of 5 
minutes of upper arm ischaemia that was induced by an automated blood 
pressure cuff-inflation followed by 5 minutes of reperfusion just prior to the 
start of CABG. The total Troponin-T released from the heart during the 72 
hour study period was significantly reduced by 43% in the RIPC group 
compared to the control group. However, as that was a small study, and a 
previous small under-powered clinical study involving RIPC and CABG found 
no cardioprotective effects (Gunaydin et al., 2000), larger randomised control 
studies are required to conclusively assess the effects of RIPC in patients 
having CABG. 
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1.6.3 Pharmacological Preconditioning 
Despite the cardioprotective effects of IPC and RIPC, both 
these techniques are still not part of the routine myocardial protective strategies 
used during cardiac surgery. This is perhaps because the protocols for each of 
these procedures adds further time to an already long operation and, 
particularly with regards to IPC, there is the added concern of unnecessarily 
cross-clamping an aorta which may already be atherosclerotic. Following the 
understanding of some of the basic mechanisms involved in inducing the 
beneficial effects of IPC and RIPC, it became clear that the cardioprotective 
effects of IPC and RIPC prior to sustained myocardial ischaemia can be 
mimicked with the use of pharmacological agents (Andreadou et al., 2008, 
Huffmyer and Raphael, 2009).  
As pharmacological agents are more readily available and easily 
applicable to clinical practice than IPC or RIPC, it may be of more use in 
attempts to induce myocardial protection. At present there are a large number 
of pharmacological agents which have been shown to induce myocardial 
preconditioning and cardioprotection. This includes NO related agents such as 
NO donors (Takano et al., 1998) and sodium nitrite (Shiva et al., 2007), 
phosphodiaesterase inhibitors (Das et al., 2005), adenosine (Toombs et al., 
1992), bradykinin (Wall et al., 1994), opiod agonist (Das and Das, 2008, 
Downey et al., 2007, Schultz and Gross, 2001), muscarinic agents (Przyklenk 
and Kloner, 1995), angiotensin AT1  agonist (Fryer et al., 2002) and 
endothelin (Erikson and Velasco, 1996). In addition to this, a number of 
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noxious stimuli such as heat stress (Joyeux-Faure et al., 2003), ROS (Penna et 
al., 2009), cytokines (Wang and Yin, 2006) and endotoxins (Harder et al., 
2005, Wang et al., 2002), when applied sparingly, have also been shown to 
trigger myocardial preconditioning. 
In clinical studies involving CABG and pharmacological 
preconditioning, adenosine preconditioning has been shown to reduce peri-
operative myocardial enzyme release and improve post operative myocardial 
function (Lee et al., 1995, Mentzer et al., 1997, Zarro et al., 1998). While the 
Acadesine 1024 Trial (Mangano et al., 2006) which investigated the use of 
acadesine, a purine analoge of adenosine which acts on adenosine receopts to 
increase adenosine levels, failed to show a statistically significant difference in 
post procedure MI, a meta-analysis of acadesine showed that it use led to a 
27% decrease in MI and a 26% decrease in the combined outcome of stroke, 
MI, or cardiac death (Mangano, 1997). Pharmacological preconditioning with 
bradykinin on the other hand, has only demonstrated a weak anti-inflammatory 
cardioprotective effect but at the expense of significant haemodynamic 
compromise (Wang et al., 2009b, Wei et al., 2004). Studies have also shown 
that the use of the mitochondrial KATP channel opener, diazoxide, as a 
pharmacological preconditioner prior to CABG, had an anti-inflammatory 
effect and was associated with improved post operative myocardial functional 
recovery but did not reduce myocardial injury (Wang et al., 2003, Wang et al., 
2004). Where the use of  the pharmacological inhibitor of the Na+-H+ 
exchanger (NHE), which prevents intra-cellular calcium overload, is 
concerned, the GURDIAN clinical trial (Boyce et al., 2003) reported that 
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preconditioning with the NHE inhibitor cariporide, reduced all-cause mortality 
and myocardial infarction at 36 days and 6 months post CBAG. Subsequently, 
the EXPIDITION clinical trial (Mentzer et al., 2008) confirmed the early 
cardioprotective benefits of cariporide, but not the 6 month outcomes. 
However, that study also demonstrated that cariporide was associated with 
increased mortality from cerebrovascular events. In a recent pilot study, 
preconditioning with the calcium sensitizer, levosimendan, was also found to 
reduce myocardial injury in the setting of CABG (Tritapepe et al., 2006). The 
anti-C5a antibody, pexelizumab, which inhibits complement immune 
activation, was in vestigated in the PRIMO-CABG study (Verrier et al., 2004) 
and showed a strong trend twards reduced mortality or MI but again, these 
results were not confirmed in the larger follow-up study PRIMO-CABG 
II (Testa et al., 2008). The pyridoxine metabolite and purinergic receptor 
antagonist, pyridoxal-5’-phosphate, which is capable of reducing intra-cellular 
calcium over load and limiting IRI (Kandzari et al., 2005) was initially shown 
in the MEND-CABG-I clinical study to be capable of possibly lowering post 
CABG MI size (Tardif et al., 2007). However, this finding was not reproduced 
in the larger MEND-CABG II clinical study which instead demonstrated a 
small increase in mortality (Alexander et al., 2008).  
Clinical studies investigating the pharmacological 
preconditioning effects of volatile anaesthetic agents have led to inconsistent 
results with respect to the reduction in myocardial enzyme release (Piriou et 
al., 2004, Tomai et al., 1999, Wang et al., 2004), although a few studies (De 
Hert et al., 2003, Landoni et al., 2008) have demonstrated an anti-stunning 
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effect with higher post operative cardiac index, reduced post operative low-
output states necessitating inotrope use and shorter post operative ICU length 
of stay. A recent meta-analysis however, determined that volatile anaesthetics 
are capable of reducing myocardial injury but had no beneficial effect on 
observed clinical outcomes (Yu and Beattie, 2006). As with RIPC, a large 
multi-centre randomised control study is required to definitively determine if 
preconditioning with volatile anaesthetics can positively impact on clinical 
outcomes post cardiac surgery. 
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1.6.4  Hyperoxic Preconditioning 
 
 The concept of inducing myocardial protection by 
preconditioning with oxygen was first investigated in 2001. It was 
hypothesised that pre-treatment with high doses of oxygen, hyperoxia, to 
induce a low-grade oxidative stress prior to ischaemia and reperfusion, may 
evoke myocardial protection by mimicking both an early and late IPC like 
effects (Tahep ld et al., 2001). In that experimental study, rats were exposed to 
>95% oxygen for 60 or 180 minutes. Isolated rat hearts were then 
Langendorff-perfused immediately (early) or 24 hours (delayed) after 
hyperoxia before being subjected to 25 minutes of global ischaemia followed 
by 60 minutes of reperfusion. It was determined that both 60 and 180 minutes 
of hyperoxia induced a low grade systemic oxidative stress. In the early model, 
only exposure to >95% oxygen for 180 minutes, but not 60 minutes, was 
associated with significantly reduced reperfusion arrhythmias. However, in the 
delayed model, 24 hours after exposure, both 60 and 180 minutes of exposure 
to >95% oxygen were associated with significantly reduced reperfusion 
arrhythmias. In both the early and delayed model, exposure to >95% oxygen 
for both 60 and 180 minutes led to significant reductions in left ventricular end 
diastolic pressure (LVEDP). However, where left ventricular developed 
pressure (LVDP) [LVDP = left ventricular systolic pressure (LVSP) –LVEDP] 
was concerned, only the early model showed significant improvement post IRI 
following both 60 and 180 minutes of exposure to >95% oxygen. The delayed 
model only showed improvement following 60 minutes of >95% oxygen and 
not after 180 minutes. This was also the case for coronary flow. With respect 
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to myocardial infarct size, only the early model that was exposed to >95% 
oxygen for 60 minutes showed a reduction in infarct size post IRI.  
Subsequently, the same group conducted another study to 
determine the dose of oxygen and verify the length of time of hyperoxic 
preconditioning which would induce myocardial protection. In that later study, 
it was shown that preconditioning rats for 60 minutes with ≥95%, 80% or 60%, 
but not 40% oxygen, improved post IRI myocardial function and coronary 
flow (Tahepold et al., 2002). Exposure for 60 minutes to either ≥95% or 80%, 
but not 60% or 40% oxygen, reduced LVEDP and the myocardial infarct size 
after IRI. LVDP and coronary flow were also significantly better in those 
groups. Furthermore, it was also demonstrated that exposure to ≥95% oxygen 
for 60 and 180 minutes in rats, led to significant reductions in LVEDP 
compared to the control group post IRI. Moreover, exposure to ≥95% oxygen 
for 60 and 180 minutes also led to smaller reductions in LVDP and improved 
coronary flow post IRI. Where myocardial infarct size was concern, exposure 
to ≥95% oxygen for 60 minutes in rats, led to reductions in post IRI infarct 
sizes. When the delayed effects of hyperoxic preconditioning were examined, 
it was also found that 24 hours after treatment with ≥95% oxygen for 60 and 
180 minutes, prior to IRI, led to significant inhibition the increase in LVEDP 
and an attenuation in post ischaemic depression of LVDP. The delayed effects 
of 60 minutes of hyperoxia prior to IRI was also associated with a significantly 
reduced attenuation of coronary flow.  
These early studies (Tahepold et al., 2002, Tahepold et al., 
2001) suggest that preconditioning with  ≥95% oxygen is capable of inducing 
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both early and delayed cardiprotective effects following IRI, in a way that 
mimics the cardioprotective effects of IPC and RIPC. Shorter durations (60 
minutes) of hyperoxic preconditioning , in the early model, is capable reducing 
in post IRI myocardial infarct size This is not seen with longer durations (180 
minutes) of hypeoxia in both the early and delayed model of hyperoxia and 
neither is it seen in the delayed models hyperoxia prior to IRI which use a 
shorter duration (60 minutes) of hyperoxia.  In the both the early and delayed 
models of hyperoxia prior to IRI, both the shorter (60 minutes) and the longer 
(180 minutes) durations of hyperoxia are capabale of improving myocardial 
function. Where coronary flow is concerned, while in the early model of 
hyperoxia prior to IRI, both the shorter (60 minutes) and the longer (180 
minutes) durations of hyperoxia are capable of improving flow, this only 
occurs with the shorter (60 minutes) duration hyperoxia in the delayed models 
of hyperoxia prior to IRI. With respect to reperfusion arrhythmias, in the early 
model of hyperoxia prior to IRI, a longer duration (180 minutes) of hyperoxia 
is required to limit the appearence of these while in the delayed model both the 
shorter (60 minutes) and the longer duration (180 minutes) of hyperoxia  have 
the capacity to attenuate arrhythmias. 
More recent studies however, on the duration of hyperoxia in 
relation to the early (Colantuono et al., 2008, Kaljusto et al., 2008) and 
late (Baharvand et al., 2009, Esmaili Dehaj et al., 2009) cardioprotective 
effects of hyperoxic preconditioning prior to IRI have clearly demonstrated 
that higher doses of oxygen (>95% oxygen), for durations of as little as 60 
minutes and, for as long as 180 minutes, are able to reduce myocardial infarct 
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size and arrhythmias following both a short and a long duration between 
hyperoxia and a subsequent event of IRI. Furthermore, it has also been recently 
demonstrated that the myocardial protective effects of the delayed phase of 
hyperoxic preconditioning prior to IRI may last for longer than 48 hours and 
that this phase may be prolonged to up to 72 hours by repeated, intermittent 
exposure prior to the insult of IRI (Baharvand et al., 2009).  
While hyperoxia of ≥95% for 60 minutes immediately prior to 
IRI is capable of reducing myocardial infarct size and reduce the increase in 
LVEDP in mouse hearts, durations of hyperoxia for as short a period of as 30 
minutes, 24 hours prior to IRI, has also been shown to reduce myocardial 
infarct size and limit the increase in LVEDP in an experimental model 
 (Tahepold et al., 2002). In another recent experimental study, it was also 
demonstrated that 100% oxygen for 30 minutes, prior to IRI, is also capable of 
improving coronary flow, LVDP and LVEDP and, reducing myocardial infarct 
size as early as 30 minutes after ischaemia (Colantuono et al., 2008).  
As the administration of 80% oxygen for less than 24 hours is 
considered clinically safe (Kabon and Kurz, 2006), it would indeed be 
interesting to determine the effects of a short duration of preconditioning with 
100% oxygen, prior to IRI, in a clinical setting. While the clinical effects of 
preconditioning with this dose has yet to be investigated, in a recent clinical 
study (Karu et al., 2007), 40 CABG patients were randomly exposed to either 
40% oxygen or >96% oxygen for 120 minutes prior to IRI. In this study, it was 
observed that post operatively, Troponin-I, CK-MB and lactate levels did not 
differ between the groups. Neither were there any differences seen in the post 
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operative haemodynamic parameters. There was however a transient 
significant reduction in the pro-inflammatory cytokine, IL-6 in the first 20 
minutes after reperfusion in the group that was exposed to >96% oxygen. 
Under normal physiological conditions, 1% to 4% of available 
body oxygen is converted to ROS. This process is greatly accelerated in 
conditions which enable the breathing of hyperoxic air, thus leading to oxygen 
tensions higher than normal (Brueckl et al., 2006). While it is unclear how high 
ROS production has to be before it triggers preconditioning effects, what is 
clear is that hyperoxia increases ROS production, reaching the threshold level 
when oxygen  is adminstered for approximately 120 minutes at a saturation of   
between 80% to 95% (Esmaili Dehaj et al., 2009). It has been demonstrated 
that hyperoxia increases ROS generation in a time and dose dependent 
manner (Brueckl et al., 2006). Several studies using infusions of low 
concentrations of ROS (Tritto et al., 1997, Vanden Hoek et al., 1998, Zhai et 
al., 1996) and administration of anti-oxidants (Das et al., 1999b, Tanaka et al., 
2002, Toufektsian et al., 2003) have demonstrated that ROS acts as the trigger 
for the preconditioning process. It is currently the thinking that the 
cardiprotective effect of hyperoxic preconditioning, and the ROS it generates, 
prior to IRI, may have to do with the activation of NFκB and the dual role in 
may play in the adapted myocardium (Choi et al., 2006, Tahepold et al., 2003). 
While the activation of NFκB is know to lead to pro-inflammatory 
effects (Blackwell and Christman, 1997), its activation by hyperoxia prior to 
myocardial IRI, has been shown to lead to the upregulation of the rapidly 
inducible IFκB, which is capable of reducing the inflammation during a 
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subsequent sustained ischaemia by inhibiting NFκB activation (Tahepold et al., 
2003).  
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1.7  Hyperbaric Oxygen 
 
  In hyperbaric oxygen (HBO2) therapy, the patient intermittently 
breathes pure oxygen (100%) at a pressure greater than atmospheric pressure, 
usually between 1.5 absolute atmosphere (ATA) to 3 ATA, at room 
temperature, for a duration not longer than 2 hours,  (Kim et al., 2001) while in 
a steel or polymer chamber. This mode of oxygen therapy is capable of 
increasing arterial and tissue oxygen tension up to 2000mmHg and 400mmHg, 
respectively (Choi et al., 2006).  
HBO2 is known mainly for its use as the treatment of choice in 
carbon monoxide poisoning, gas embolism and decompression 
sickness (Kindwall EP, 2002). In these conditions, generally only one or two 
HBO2 therapy sessions are required. The experience of HBO2 medicine 
specialists and, to a certain extent, the scientific literature, also support the use 
of HBO2 as an adjuvant treatment for a number of other clinical conditions 
such as complex, refractory wounds (Morykwas and Argenta, 1997), 
intracranial abscess, radiation tissue injury, crush injuries, compartment 
syndrome, acute traumatic peripheral ischaemia, burns and IRI (Kindwall EP, 
2002). However, such use requires numerous visits, with up to as many as 
sixty sessions lasting between 30 to 90 minutes a session, depending on the 
clinical condition. At present, there are no standard protocols for these clinical 
conditions. The therapeutic protocols vary according to the severity of the 
clinical condition and the treatment centre.  
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1.7.1 Hyperbaric Oxygen In Ischaemic 
Reperfusion Injury 
Two phenomena may be involved to give HBO2 therapy an anti-
ischaemic effect: 
a) The first phenomena is related to Henry’s Law which states that 
“the amount of any given gas that will dissolve in a liquid at a given 
temperature is a function of the partial pressure of the gas in contact with the 
liquid and the solubility coefficient of the gas in the liquid”. As HBO2 involves 
the administration of oxygen at pressures above atmospheric pressure at room 
temperature, this enables higher partial pressures of oxygen to be achieved in 
the blood and this has been clearly demonstrated in a recent clinical 
study (Weaver et al., 2009).  
b) The second phenomena involves the ability for HBO2 to 
improve the elasticity and therefore the deformability of red blood cells, which 
enables them to reach ischaemic tissues (Mathieu D, 1984). 
These two phenomenon are capable of improving tissue oxygenation and thus 
increasing local metabolism. These potential benefits, have led to research into 
the use of HBO2  for attenuating myocardial ischaemia and 
infarction (Shandling et al., 1997, Thomas et al., 1990) and, improving 
myocardial function (Dekleva et al., 2004). 
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A number of experimental studies have investigated the effects 
of HBO2 during ischaemia and reperfusion. It appears that HBO2 treatment 
prior to  (Chen et al., 1998), during  (Yamada et al., 1995) or after 
ischaemia (Nylander et al., 1987) or, immediately upon reperfusion (Yamada 
et al., 1995) is capable of preserving cellular ATP. Furthermore, it has also 
been observed that HBO2 treatment prior to the insult of ischaemia and 
reperfusion (Chen et al., 1998), is capable of leading to an increase in ATP 
concentration that is associated with an attenuation of adherent neutrophils and 
lipid peroxidation. 
In an experimental model of IRI, HBO2 has also been shown to 
enhance endothelial cell-derived fibrinolysis and blood flow (Tjarnstrom et al., 
2001). In that study, cultured endothelial cells were subjected to simulated 
ischaemic reperfusion by anoxia, followed by reperfusion with either HBO2 or 
normobaric air for 1.5 hours. The HBO2 treated cells exhibited significant 
increases in all the measured fibrinolytic factors [tissue plasminogen activator 
(t-PA), urokinase plasminogen activator (uPA) and plasminogen activator 
inhibitor type 1 (PAI-1)], suggesting that HBO2 treatment following ischaemia 
(during reperfusion) has the potential to also limit vascular thrombosis. 
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1.7.2 Hyperbaric  Oxygen & Myocardial 
Ischaemic Reperfusion Injury 
In 1976, an experimental study was conducted to investigate the 
effects of HBO2 on the myocardium (Kawamura et al., 1976). In that study,  
HBO2 treatment consisting of 100% oxygen at 2 ATA was administered to one 
group of dogs before temporary occlusion of the left coronary artery and to 
another group immediately after the temporary occlusion of the left coronary 
artery. The duration of coronary occlusion ranged from 30 minutes to 2 hours.  
A control group of dogs also had durations of temporary left coronary artery 
occlusion in a similar range but did not receive HBO2 treatment.  Following 
sacrifice, which occured 4 hours after HBO2 treatment in the group treated 
with HBO2 prior to coronary artery oclusion and 5 days after coronary 
occlusion in the group that was treated with HBO2 following coronary artery 
oclusion, it was discovered that, compared to the control animals, the 
myocardial ischaemic area in dogs that were treated with HBO2, either before 
or after coronary oclusion, was markedly reduced and the myocardial muscles 
around the arterioles and sinusoids were viable. That study also found that 
serious arrhythmia, especially ventricular fibrillation, was suppressed in the 
treated dogs and they were haemodynamically more stable during the operative 
period. That study was the first to demonstrate, both macroscopically and 
histologically, that treatment with HBO2 either before or after an ischaemic 
reperfusion event, was capable of limiting myocardial infarct size.  
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The myocardial infarct sparing property of HBO2 was later 
further demonstrated in another experimental study. In that study involving an 
open-chest rabbit model, the left coronary artery was occluded for 30 minutes, 
to induce ischaemia, followed by 3 hours of reperfusion (Sterling et al., 1993). 
During this ischaemia and/or reperfusion, the controls group was ventilated 
with 100% oxygen at 1 ATA while the ‘treated’ group was exposed to HBO2 at 
2.5 ATA. The animals exposed to HBO2 during ischaemia only, reperfusion 
only, or ischaemia and reperfusion, had significantly smaller infarcts compared 
to the control animals. When HBO2 was administered 30 minutes after the 
onset of reperfusion, no myocardial protection was seen. This study suggests 
that treatment with HBO2 is only capable of inducing myocardial protection 
during periods of ischaemia and reperfusion but not if administered shortly 
after reperfusion has begun.  
The concept of using HBO2 to limit myocardial IRI has also 
been investigated by using HBO2 enriched solution. In an attempt to determine 
if perfusion with a solution of HBO2 through the anterior interventricular vein 
(AIV) would reduce myocardial infarct size and neutrophil activation, using 
three  groups, animals were exposed to IRI by 60 minutes of balloon occlusion 
of the LAD to induce ischaemia followed by 120 minutes of 
reperfusion (Johnson et al., 2004). Following IRI, the first control group was 
not treated with any further intervention during reperfusion while the second 
control group received arterial blood, drawn from the femoral artery, perfused 
into the AIV for the first 90 minutes of reperfusion. In the third experimental 
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group, a solution of HBO2 enriched arterial blood was perfused through the 
AIV either immediately after reperfusion or 30 minutes after reperfusion, for a 
duration of 90 minutes. The oxygen level of blood delivered into the AIV in 
experimental group was between 1000 and 1400mmHg. In that study, 
compared to the control groups and the experimental group treated with HBO2 
30 minutes after reperfusion, in the experimental group that was treated with 
with HBO2 immediately upon reperfusion, the endocardial blood flow was 
significantly higher in at the risk regions of the myocardium. Furthermore, the 
myocardial infarct size was also significantly smaller in this group compared to 
the other groups. It was also determined that in the HBO2 group the smaller 
infarct size was associated with reduced reperfusion association neutrophil 
activation. This study supports the premise that increasing myocardial tissue 
oxygenation early during reperfusion is cardioprotective but delayed 
oxygenation, during reperfusion, is of limited cardioprotective value. 
1.7.2.1 Hyperbaric Oxygen Preconditioning 
While the the concept of treatment with HBO2, prior to 
ischaemia and reperfusion to mitigate myocardial IRI, was first investigated in 
1976 by  Kawamura et al. (Kawamura et al., 1976), it was not until  2001 when 
the biology behind this mode of treatment was further investigated to 
understand how it may prophylactically induce myocardial protection prior to 
IRI. In a study by Kim et al  (Kim et al., 2001), rats were intermittently 
exposed to 100% oxygen at 3 ATA for 1 hour daily for 5 days and then 
sacrificed after 24 hours of recovery in room air. The isolated rat hearts were 
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subjected to 40 minutes of ischaemia and 90 minutes of reperfusion. It was 
found that HBO2 pre-treatment enhanced enzymatic activity and gene 
expression of the anti-oxidant enzyme catalase and, this was associated with a 
significant reduction in  myocardial infarct size. A catalase inhibitor, 3-amino-
1,2,4-triazole, completely abolished the infarct-limiting effect of HBO2 pre-
treatment. This concept of inducing cellular protection, via HBO2, prior to 
cellular injury is now known as HBO2 preconditioning (Kim et al., 2001) and 
its appears that its myocardial infarct limiting capacity is similar to that 
observed during IPC (Murry et al., 1986).  
Further evidence of the MI sparing capacity of HBO2 
preconditioning comes from another recent experimental study (Han et al., 
2008a). In that study 108 rats were randomly divided into four groups: 
normoxia + sham surgery (CS), normoxia + permanent occlusion of the LAD 
coronary artery (CMI), HBO2 preconditioning + sham surgery (HS) and HBO2 
preconditioning + permanent LAD occlusion (HMI). Rats receiving HBO2 
preconditioning were exposed to 100% oxygen at 2.5 ATA for 60 minutes, 
twice daily for 2 days prior to myocardial ischaemia induced by LAD ligation. 
There was a 12 hour interval between HBO2 preconditioning sessions and, a 12 
hour interval between the last HBO2 preconditioning session and the LAD 
ligation. Rats in the normoxia group were time-matched with the HBO2 group 
and maintained under normoxic conditions prior to LAD occlusion. At day 3 
after LAD ligation, the infarct size of the HMI group was found to be 
significantly smaller than that of the CMI group. The LVSP was significantly 
  
60 
 
improved in the HMI group compared to the CMI group at 3 and 7 days after 
LAD occlusion. That study also found that the capillary density was 
significantly increased in the ischaemic myocardium that was preconditioned 
with HBO2. The findings from this randomised control experimental study 
clearly demonstrates that HBO2 preconditioning is capable of leading to 
cardioprotection by improving myocardial myocardial function and blood flow 
as a result of increased myocardial capillary density and, as such, leading to a 
reduction in myocardial infarct size following ischaemia. 
The concept of utilising HBO2 preconditioning to induce 
myocardial protection has also been investigated in terms of determining the 
effects of HBO2 on a common cause of myocardial ischaemia, coronary 
atherosclerosis.  In a study involving rabbits fed an atherogenic diet, the 
animals were exposed to HBO2 consisting of 100% at 2.5 ATA for 90 minutes, 
5 days a week for 10 weeks (Kudchodkar et al., 2000). The control rabbits had 
the same diet but were not treated with HBO2. In that study it was determined 
that repeated short periods of HBO2 exposure dramatically reduced the 
development of atherosclerosis by reducing the accumulation of cholesterol in 
the aortic wall. Treatment with HBO2 also substantially reduced the 
accumulation oxidised LDL and HDL cholesterol in the plasma, liver and 
aortic tissue which according to the investigators, may explain the slower 
progression of atherosclerosis in the HBO2 treated animals. Furthermore, 
HBO2 treatment also prevented the decrease in the plasma anti-oxidant activity 
of paraoxonase and caused a significant acceleration in the regression of aortic 
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atherosclerotic lesions. The investigators of that study suggests that HBO2 
possibly inhibits the initial development of atherosclerosis by suppressing the 
recruitment and proliferation of macrophages and the thus the formation of 
foam cells via paraoxonase anti-oxidation mediated reduction in the formation 
of lipid-derived oxidative products. This is a reasonable suggestion as others 
have also shown that HBO2 has the capacity to enhance the activity of the 
serum anti-oxidant paraoxonase and this is known to cause a reduction in the 
oxidation of tissue and plasma lipids (Aviram et al., 1998). In a later study, the 
same group also found that HBO2 treatment resulted in significant reduction in 
aortic cholesterol content and decreased fatty streak formation (Kudchodkar et 
al., 2007). In examining the possible biochemical mechanisms for these 
findings, this group found that a 10 week treatment with HBO2 led to 
significant reduction in auto-antibodies against oxidatively modified LDL 
[levels of auto-antibodies to oxidised LDL have been shown to reflect levels of 
oxidised LDL in the circulation and correlate positively with the progression 
and regression of experimental atherosclerosis in mouse models (Tsimikas et 
al., 2001, Zhou et al., 1998)]. There were also profound changes in the redox 
state of aortic tissues with significant increases in aortic glutathione, oxidized 
gluththione reductase activity, glutathione S-transferase activity and catalase 
thus, suggesting that HBO2 treatment had induced an environment that inhibits 
oxidation. They concluded that this anti-oxidant response may be the key to the 
anti-atherogenic effect of HBO2 treatment.  
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1.7.3  Hyperbaric Oxygen Induced Neutrophil 
Attenuation & Adhesion Molecule 
Expression 
One of the possible means for HBO2 induced attenuation of IRI 
may be via the interference of neutrophil infiltration (Atochin et al., 2000, 
Hong et al., 2003). Findings in various experimental models have shown that 
neutrophil recruitment as a result of ischaemia and reperfusion was 
significantly reduced by peri-IRI HBO2 treatment in IRI models of the 
liver (Chen et al., 1998, Kihara et al., 2005), intestine (Tjarnstrom et al., 1999, 
Yamada et al., 1995), gracilis muscle (Zamboni et al., 1996), brain (Atochin et 
al., 2000, Miljkovic-Lolic et al., 2003) and testis (Kolski et al., 1998). Real 
time videomicroscopy of HBO2-treated muscle flaps following ischaemia and 
reperfusion have demonstrated a decrease in the adhesion of neutrophils to the 
vascular endothelium and a greater microvascular diameter (Zamboni et al., 
1993, Zamboni et al., 1996). Studies by others suggest HBO2 limits neutrophil-
endothelial adhesion by inhibiting the polarization of the adhesion molecule 
CD18 on the surface of neutrophils (Khiabani et al., 2008), but not its 
expression (Hong et al., 2003, Larson et al., 2000), and inhibits the expression 
of the cellular adhesion molecule, ICAM-1 (Buras et al., 2000, Hong et al., 
2003).  
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In a recent clinical study (Alex et al., 2005), 64 CAD patients 
were randomised to either a group preconditioned with hyperbaric air (n=31), 
or HBO2 consisting of two 30 minute periods of 100% oxygen at 2.4 ATA 
separated 5 minutes apart (n=33). Preconditioning with air or HBO2 took place 
for 90 minutes, 24 hours, 12 hours and 4 hours, respectively, prior to on CPB 
CABG. In that study it was observed that patients who were preconditioned 
with three sessions of HBO2 (HBO2 preconditioning) prior to the insult of IRI 
during on CPB CABG, in contrast to the control patients, did not experience 
any significant increase in post operative (2 hours and 24 hours post CPB) 
plasma CD18 and this was not accompanied by any significant neurocognitive 
decline 4 months post CABG. This suggests that perhaps cerebral vascular 
flow may have been better preserved in patients preconditioned with HBO2 as 
a result of the attenuation of ischaemia reperfusion induced neutrophil-
endothelial interaction and perhaps a reduction in the ensuing endothelial 
injury. 
In the clinical study by Alex et.al, it was also observed that in 
addition to attenuating the rise in plasma CD18, three sessions of HBO2 prior 
to the insult of IRI  also reduced the post operative expression of serum soluble 
E-selectin (sE-Selectin) following CABG (Alex et al., 2005). However, in that 
study, HBO2 preconditioning was also found to increase the post operative 
expression of serum soluble ICAM-1 (sICAM-1) and soluble P-selectin (sP-
Selectin). In experimental models of IRI, it has been demonstrated that HBO2 
treatment during ischaemia (Hong et al., 2003) or following IRI (Buras et al., 
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2000, Hong et al., 2003), decreased the expression of ICAM-1 in a muscular 
flap (Hong et al., 2003) and in the endothelium (Buras et al., 2000). These 
studies suggest that HBO2 prior to IRI i.e. HBO2 preconditioning (Alex et al., 
2005), is capable of limiting the rise in plasma CD18 and, while HBO2 during 
ischaemia and HBO2 post IRI (Hong et al., 2003) does not alter neutrophilic 
CD18 expression, it does inhibit neutrophilic CD-18 polarization and thus 
neutrophil-endothelium adhesion (Khiabani et al., 2008). It remains unclear as 
to whether the attenuation in the rise of plasma CD-18 is linked to the 
inhibition in the distribution of CD-18 on the surface of neutrophils. Is it 
possible that the oxidative stress of HBO2 redistributes the neutrophilic CD18 
thus limiting the cleavage of CD18 from the surface of neutrophils into the 
plasma? Additionally, while HBO2 during ischaemia (Hong et al., 2003) and 
HBO2 following IRI (Buras et al., 2000, Hong et al., 2003) is capable of 
downregulating endothelial ICAM-1 expression, it also appears that HBO2 
prior to IRI was capable of increasing the presence of serum sICAM-1 (Alex et 
al., 2005). Is there a possible link between HBO2 induced increase in sICAM-1 
and the downregulation in the expression of endothelial ICAM-1?. Could it be 
that the lack of endothelial ICAM-1 following HBO2 treatment is due to these 
adhesion molecules being shed into the circulation, as a result of the oxidative 
stress of HBO2, thus leading to increased circulating sICAM-1?. 
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1.7.4 Mechanisms of Action of Hyperbaric Oxygen 
in Ischaemic Reperfusion Injury 
HBO2 has been demonstrated to increase ROS 
generation (Benedetti et al., 2004, Conconi et al., 2003, Gregorevic et al., 
2001) and has also been shown to be protective to the myocardium (Kim et al., 
2001, Kudchodkar et al., 2000, Shandling et al., 1997, Sharifi et al., 2004, 
Sterling et al., 1993, Swift et al., 1992). It is therefore plausible to suggest that 
there is a therapeutic association between HBO2 generated ROS and 
myocardial protection. There maybe six possible complex and intertwining 
mechanisms by which HBO2 generated ROS may lead to reduced endothelial 
and myocardial injury (Figure 1.1). 
Mechanism 1: eNOS & NO 
ROS, such as superoxide or hydrogen peroxide, are capable of 
modulating the expression of eNOS (Drummond et al., 2000, North et al., 
1996) and NO production (Lebuffe et al., 2003). This may occur by ROS 
functioning as signaling molecules (Hool, 2006, Lebuffe et al., 2003) to 
activate NOS (Drummond et al., 2000, Lopez-Ongil et al., 1998) and produce 
NO (Mathy-Hartert et al., 2002, Whorton et al., 1997). Via direct (Elayan et 
al., 2000) and indirect (Thom et al., 2003) measurements of ROS, HBO2 
induced ROS has been shown to activate NOS (Elayan et al., 2000, Thom et 
al., 2003) and produce NO (Elayan et al., 2000, Thom et al., 2003).  
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Mechanism 1a: Peroxynitrite 
HBO2 generated ROS, in particular, superoxide, may play a 
therapeutic role in the attenuation of neutrophil adhesion via peroxynitrite 
production (Figure 1.1: Mechanism 1a). It is possible that by combining with 
NO to form peroxynitrite (Beckman and Crow, 1993, Beckman and Koppenol, 
1996, Liu et al., 1994), NO may act as a sink to reduce the contribution of IRI 
generated superoxide towards excessive free radical chain reaction 
propagation (Pryor and Squadrito, 1995, Rubanyi et al., 1991). Given the 
suggestions in favor of the use of HBO2 as a therapeutic modality against 
IRI (Alex et al., 2005, Bertoletto et al., 2008, Chen et al., 1998, Henninger et 
al., 2006, Nie et al., 2006, Nylander et al., 1985, Nylander et al., 1987, Sterling 
et al., 1993, Tomur et al., 2005, Yamada et al., 1995, Yin and Zhang, 2005, Yu 
et al., 2005), it is unlikely that HBO2 generated ROS leads to irreversible 
cellular injury. Paradoxically, it is more likely that, in balanced quantities, the 
HBO2 generated ROS, such as superoxide, play a pharmacological role in the 
attenuation of neutrophil adhesion possibly via peroxynitrite production from 
the NO. Peroxynitrite in intermediate concentrations (2-5μM) has been shown 
to reduce neutrophil adhesion by inhibiting P-selectin expression on 
endothelial cell (Nossuli et al., 1998) thus limiting endothelial injury via 
neutrophil-endothelial adhesion. 
In addition to P-Selectin attenuation, in an experimental model 
of IRI, it was demonstrated that peroxynitrite administration was also capable 
of inhibiting the expression of  ICAM-1 mRNA (Liu et al., 2000). This 
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suggests that peroxynitrite is also capable of impairing neutrophil adhesion to 
the vascular endothelium by inhibiting the synthesis of ICAM-1 (Figure 1.1: 
Mechanism 1b). This in turn will limit the neutrophil-endothelial adhesion that 
is known to occur as part of the ‘no-reflow’ phenomenon of IRI (Engler et al., 
1986). As HBO2 generated ROS could react with HBO2 induced NO to 
produce peroxynitrite, and HBO2 has been shown to lead to a down regulation 
of ICAM-1 expression (Buras et al., 2000), this mechanism could account for 
the observed HBO2 associated preservation of capillary flow (Chen et al., 
1998, Sirsjo et al., 1993, Zamboni et al., 1993) and hence the myocardial 
protection in models of IRI (Cabigas et al., 2006a, Sterling et al., 1993).  
Mechanism 1b: CD-18 
Studies have shown that HBO2 exposure inhibits the 
extracellular binding domain of neutrophil guanylate cyclase (Thom et al., 
1997) and impairs the synthesis of cGMP (Chen et al., 1996). This leads to an 
alteration in the function of the neutrophil specific adhesion molecule 
CD18 (Thom et al., 1997) and its distribution on the neutrophilic 
surface (Khiabani et al., 2008). CD18, as part of the heterodimeric protein 
CD11/18, binds to the ligand ICAM-1 that is located on the endothelial 
cell (Malik and Lo, 1996). This alteration in neutrophilc CD18 function and 
distribution, may limit the ability of neutrophils to adhere to endothelial cells 
via the interaction of CD18 with ICAM-1. In keeping with this, HBO2 has also 
been shown to be capable of reducing neutrophil adhesion to the vascular 
wall (Khiabani et al., 2008, Zamboni et al., 1993). It is possible that the 
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mechanism underlying this effect is related to the ability of HBO2 to stimulate 
eNOS  (Cabigas et al., 2006b) and produce NO (Thom et al., 2003) which in 
turn inhibits neutrophil membrane-bound guanylate cyclase (Banick et al., 
1997) thus limiting cGMP synthesis and altering the function of CD18 (Figure 
1.1: Mechanism 1b). Studies have shown that inhibition of eNOS promotes the 
adherence of neutrophils to the microvasculature while increased 
concentrations of eNOS has an anti-adherent effect (Kubes et al., 1991, Lefer 
and Lefer, 1996).  
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Figure 1.1: HBO2 Possible Mechanisms of Action 
 
  
Mechanism 1: HBO2 generated ROS attenuating of endothelial injury via eNOS & NO. Mechanism 2: HBO2 generated ROS activation of PKC inducing anti-oxidation 
and attenuation of ICAM-1. Mechanism 3: HBO2 induced impairment of guanylate cyclase reaction products. Mechanism 4: HBO2 generated ROS attenuating 
endothelial injury via Hsp. Mechanism 5: HBO2 induced ROS attenuating lipid peroxidation. Mechanism 6: HBO2 generated ROS enhancing endothelial cell 
proliferation. 
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Mechanism 2: PKC 
Exposure to HBO2 (Buras et al., 2000, Shinomiya et al., 1998) 
has been demonstrated to downregulate ICAM-1 expression. In studies 
involving myocardial IPC, it appears that the ROS, superoxide, is involved in 
the induction of increased ischemic tolerance (Baines et al., 1997, Mori et al., 
2000, Osada et al., 1994, Tanaka et al., 1994, Tritto et al., 1997). IPC has also 
been shown to induce an endothelial protective effect by suppressing the 
expression of ICAM-1, a process which is mediated by production of NO, 
ROS, and PKC (Beauchamp et al., 1999). Furthermore, there is also evidence 
to suggest that both superoxide and hydrogen peroxide can stimulate PKC 
activity (Ogata et al., 2000). Hence, it may be possible that superoxide and/or 
hydrogen peroxide are able to participate in the regulation of ICAM-1 
expression, through PKC (Beauchamp et al., 1999, Niwa et al., 1996, Suzuki et 
al., 1997a). This activation of PKC in turn, may lead to decreased amounts of 
free radical production during the actual insult of ischaemia and reperfusion 
possibly via PKC mediated anti-oxidant defences (Niwa et al., 1996). This 
mechanism may also partially explain the ability for HBO2 generated ROS to 
limit neutrophil adhesion (Figure 1.1: Mechanism 2). 
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Mechanism 3: Neutrophil Guanylate Cyclase Reaction Products 
Research (Russwurm and Koesling, 2004) suggest that when 
NO encounters guanylate cyclase, it binds to the heame moiety of guanylate 
cyclase to become active and produce cGMP. As such, how is it that in the 
presence of HBO2 induced NO, there is an inhibition of guanylate cyclase, as 
has been previously demonstrated (Banick et al., 1997, Chen et al., 1996), 
which in turn leads to the impairment of cGMP synthesis and alteration in the 
function of CD18. Here in with may lie an another possible mechanism of 
action for HBO2 induced NO (Figure 1.1: Mechanism 3). It is now known that 
for guanylate cyclase to be activated by NO, it requires the presence of its 
reaction products (magnesium/cGMP/pyrophosphate) and sufficient NO 
(substrate) (Russwurm and Koesling, 2004) in order for it to transit, in a 
reversible manner, via a dinitrosyl state, to form an active five-coordinated 
NO-guanylate cyclase species. Based on the available evidence from the 
observed actions of HBO2 on guanylate cyclase, perhaps it would be possible 
to suggest that the lack of activation of guanylate cyclase following HBO2 
could be due to the following two possible scenarios. First, and perhaps more 
easily appreciated, is that some how, HBO2 limits the reaction products of 
guanylate cyclase. HBO2 has certainly been shown to limit cGMP 
production (Chen et al., 1996, Thom et al., 1997) together with an attenuation 
of guanylate cyclase function (Thom et al., 1997). Second, and assuming that 
HBO2 has no effect on guanylate cyclase’s reaction products, while HBO2 may 
generate NO, it also generates ROS such as superoxide. The inactivating 
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reaction between NO and superoxide to form peroxynitrite, may limit the 
available NO that binds to guanylate cyclase. While some NO may bind to 
guanylate cyclase, the lack of sufficient free NO to reversibly bind to it and 
form an active five coordinated species via a dinitosyl state may lock the NO-
bound guanylate cyclase in an inactive five coordinated species or in the 
inactive six coordinated dinitrosyl state. Either of these two scenarios may 
limit guanylate cyclase’s cGMP production. cGMP is not only one of the 
reaction products of guanylate cyclase but also a second messenger needed for 
the appropriate functioning of neutrophil CD18. 
Mechanism 4: Hsp 
It has been shown that the synthesis of Hsp70 is significantly 
induced in the lymphocytes of human subjects after just a single treatment with 
HBO2 (Dennog et al., 1999).  Furthermore, it has also been demonstrated that 
HBO2 administration results in a time and dose dependent increase in Hsp70 
expression at both mRNA and protein levels  (Shyu et al., 2004). This suggests 
that Hsp70 may play a part in the mechanism for HBO2 induced cellular 
protection (Figure 1.1: Mechanism 4). 
It is also possible that this HBO2 induction of Hsp synthesis 
occurs via the expression of NO. Using a rat heart model of IRI at various 
concentrations of oxygen and pressure, it was demonstrated that there was a 4 
fold increase in association of Hsp90 with eNOS following preconditioning 
with HBO2 (Cabigas et al., 2006b). This was in addition to an increase in 
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eNOS and nitrite plus nitrate (breakdown products of NO) content in the 
myocardium of rats preconditioning with HBO2. Furthermore, it was also 
demonstrated that the myocardial protective effects of HBO2 preconditioning 
were reversed by L-Nitro-Arginine Methyl Ester (L-NAME) (an NO inhibitor). 
These findings were also associated with the observation that preconditioning 
with HBO2 resulted in a decrease in myocardial infarct size and increased 
recovery of left ventricular diastolic pressure. While that study did not show a 
significant increase in total Hsp90 content following HBO2 preconditioning, 
the investigators felt that the increased association of Hsp90 with eNOS 
supported the notion that Hsp90 helps eNOS to produce NO and that this was 
responsible for the observed myocardial protection against IRI following 
HBO2 preconditioning.  
Mechanism 5: Lipid Peroxidation 
Superoxide has been hypothesised to be involved in reactions 
antagonizing lipid peroxidation (Thom and Elbuken, 1991) and, in certain 
doses, may function as a terminator of lipid peroxidation (Nelson et al., 1994). 
HBO2 given before ischaemia-reperfusion (Chen et al., 1998, Gurer et al., 
2006) and during ischaemia (Bosco et al., 2007), has also been demonstrated to 
reduce lipid peroxidation. The reduction in ischaemia reperfusion mediated 
lipid peroxidation has also been observed following post IRI treatment with 
HBO2 (Rubinstein et al., 2009). In a model of myocardial IPC, which also 
involves the generation of ROS, it was demonstrated that the beneficial effects 
of IPC was associated with both a reduction in neutrophil adhesion and lipid 
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peroxidation (Zhao et al., 2003). It is therefore also plausible to suggest that, 
HBO2, via its ROS generation, is also capable of mediating the attenuation of 
lipid peroxidation and this leads to the associated reduction in neutrophil 
adhesion (Figure 1.1: Mechanism 5).  
Mechanism 6: Endothelial Cell Proliferation 
HBO2 has been shown to stimulate neovascularization in flaps, 
wounds, irradiated tissue and grafts (Bayati et al., 1998, Manson PN, 1980, 
Marx et al., 1990, Meltzer and Myers, 1986, Nemiroff, 1987, Zhang et al., 
1998) and, angiogenesis (Godman et al., 2009, Han et al., 2008a, Khan et al., 
2009, Ren et al., 2008, Sheikh et al., 2005). ROS have been shown to be able 
to function as signaling molecules (Suzuki et al., 1997b) that are a able to 
stimulate endothelial cell proliferation (Heinloth et al., 2000) and 
neovascularization (Monte et al., 1994). As HBO2 is a modality of treatment 
which is capable of generating ROS, it is also reasonable to suggest that via its 
ROS signaling properties, HBO2 may be capable of improving blood flow 
through endothelial cell proliferation and neovascularisation thus, alleviating 
tissue ischaemia (Figure 1.1: Mechanism 6). 
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1.8  Hypothesis 
The hypothesis of this study is that systemically  
preconditioning CAD patients with 100% oxygen, at a pressure above that of 
atmospheric pressure i.e.  HBO2, prior to first time elective on CPB CABG, 
leads to a remote preconditioning like effect that is capable of leading to post 
operative improvements in cardiovascular function. 
1.9  Objective 
1.9.1 Primary Objective 
The primary cardiovascular efficacy objective of this study was 
to determine if systemically preconditioning CAD patients with HBO2 prior to 
first time elective on CPB CABG, remotely precontioned the myocardium by 
leading to a better post operative improvement in myocardial left ventricular 
stroke work (LVSW) compared to CAD patients who were not preconditioned 
with HBO2.  
1.9.2 Secondary Objectives 
  Main Secondary Objectives: 
The main secondary objectives of this study were to assess, in 
comparison to the Control Group, the effects of HBO2 preconditioning on: 
a) other peri-operative cardiovascular efficacy parameters. 
b) patient outcomes with respect to the safety. 
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Exploratory Secondary Objectives: 
The exploratory secondary objectives for this study were to 
assess, in comparison to the Control Group, the effects of HBO2 
preconditioning on: 
a) surrogate biomarkers of endothelial and neutrophilic 
adhesiveness.  
b) myocardial biomarkers of cardioprotection.  
Additionally, a post-hoc analysis was also done to determine the cost 
effectiveness of HBO2 preconditioning . 
 
 
 
 
 
 
 
 
 
  
77 
 
1.10 End Points 
1.10.1 Primary Endpoint Measure 
The primary cardiovascular efficacy endpoint measure of this 
study was the mean (or median) measurement of myocardial LVSW 24 hours 
post CPB in both groups. 
1.10.2 Secondary Endpoint Measures 
Main Secondary Endpoint Measures: 
The secondary endpoint measures of this study were the mean 
(or median or incidence or proportion) measurements, in both groups, with 
respect to the following: 
a) at all the pre-specified time points, the peri-operative cardiovascular 
haemodynamic parameters, as described in Table 2.4. 
b) post operative adverse events (AEs) described in Table 2.3. 
In this study, an AE was defined as any new untoward medical occurrence or 
worsening of a pre-existing medical condition in a patient treated with HBO2 
and that does not necessarily have a causal relationship with this treatment. An 
AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding or prolonged admission), symptom, or disease 
temporally associated with the use of HBO2, whether or not considered related 
to the HBO2. 
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Exploratory Secondary Endpoints:  
The exploratory secondary endpoint measures of this study were 
the mean (or median) measurements, in both groups, at all of the pre-specified 
time points, with respect to the following: 
a) concentration of serum soluble adhesion molecules which 
included: 
i. soluble E-Selectin 
ii. soluble P-Selectin 
iii. soluble ICAM-1 
iv. soluble PSGL-1 
b) quantity of intra-operative myocardial cardioprotective proteins 
which included: 
c) eNOS  
d) Hsp72 
The post-hoc cost effectiveness analysis of HBO2 preconditioning was done by 
estimating the cost for HBO2 treatment and the daily post operative cost for the 
use of an intensive care bed in both groups. 
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2.  Methods 
2.1  Ethical & Hospital Approvals 
Prior to commencing this study, ethical and hospital approval 
was obtained from the Hull & East Riding Local Research Ethics Committee 
(approval number: 04/Q1104/26) and the Hull & East Yorkshire NHS Trust 
(approval number: R0047), respectively. This clinical study conforms with the 
Declaration of Helsinki, the principals of Good Clinical Practice (GCP) and the 
principals of the International Conference of Harmonisation. 
2.2  Study Population 
The study population was defined as all patients with coronary 
artery atherosclerosis who were admitted to the Hull & East Yorkshire NHS 
Trust for elective first time CABG surgery using CPB and hypothermic 
intermittent ischaemic fibrillatory arrest.  From January 2005 to July 2006, this 
study population consisted of 474 patients who had been admitted under the 
care of the two cardiac surgeons who had agreed to be part of this study.   
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2.2.1  Inclusion Criteria 
 
The inclusion criteria was:  
1. patients undergoing elective first time CABG using CPB 
and hypothermic intermittent ischaemic fibrillatory arrest.  
2.2.2  Exclusion Criteria 
 
The exclusion criteria were: 
1.  Patients with a high surgical risk which included:  
a) Age < 20 and > 85 years.  
b) Ejection fraction < 30%. 
c) Unstable angina.  
d) < 1 month post MI.  
e) Cardiac disease other than CAD.  
f) Organ failure.  
g) History of chronic obstructive pulmonary disease 
(COPD), pneumothorax, pulmonary bullae, 
convulsions, myopia or intraocular lens. Patients with 
a history of any these clinical conditions were excluded 
as exposure to the pressure changes during HBO2 
preconditioning may lead to complications.   
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2. Current use of K+(ATP) channel openers, oral 
hypoglycaemic, opioid analgesics or catecholamines. 
Patients on any form of these agents were excluded as these 
agents have demonstrated some capacity to provide 
myocardial protection.   
2.3  Statistical Plan 
The statistical plan and analysis for this study was done in 
collaboration with the appointed study statistician, Dr.E.Gardiner.  
2.3.1  Sample Size 
Based on the haemodynamic observations from another study 
involving pharmacological preconditioning and myocardial protection (Wang 
et al., 2003), the sample size calculations for this study was based on the 
assumption that compared to the Control Group, treatment with HBO2 
preconditioning in the HBO2 Group, would lead to a 7.5% improvement in 
LVSW, 24 hours post CPB. Furthermore, based on a previous clinical 
study (Alex et al., 2005) involving  HBO2  preconditioning and CBAG, a 
within-group standard deviation of 6.25% was assumed. A two-sided 5% 
significance level and a 90% power were pre-specified for this study.  
Allowing for the detection of a 7.5% difference in the primary 
endpoint measure between the two treatment groups and, allowing for 
increased variance of interaction and estimates relative to the main effect 
 (Piantadosi, 1997), it was estimated that a minimum of 60 patients would be 
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required to show statistically significant difference between the groups, with 
respect to LVSW at the time point ‘24 hours post CPB’. Based on the previous 
clinical study by Alex et.al (2005) involving HBO2 and CABG, a drop-out rate 
of 35% was estimated for this study. Taking this into account, it was estimated 
that a minimum of 80 patients would need to be randomised to detect the a 
difference of 7.5% between the groups with respect to the primary endpoint 
measure. 
However, as the detection of a 7.5% difference between the 
groups is small, it was expected that there would also be the possibility that 
this sample size may not be large enough to detect any difference between the 
groups and a Type 2 error (false negatives) made be made. Additionally, as this 
study has multiple secondary endpoints, which would involve multiple 
statistical testing, this may also increase the risk of a Type 1 error (false 
positives). To avoid making conclusions that were based on Type 1 and Type 2 
errors, it was planned that definitive conclusions, based on statistical analysis, 
can only be drawn for the comparison of the primary endpoint between the 
groups, and not the secondary endpoints. 
In this study, it was also planned that the main analysis for 
comparing the secondary endpoints measures between the groups would be a 
descriptive analysis of the means (or medians or proportions), with the 
statistical analysis only providing a sensitivity measure to support estimates of 
the descriptive differences that are reported.  
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2.3.2  Sample Population 
 Screening for suitable patients from the study population took 
place during the pre-assessment clinical visits. During these visits, which 
occurred up to 30 days prior to surgery, patients had routine investigations 
conducted as part of their work-up prior to surgery. From the study population 
of 474 patients, 81 matched the study criteria and were recruited following 
informed consent. 40 patients were randomised to the Control Group and 41 
patients were randomised to the HBO2 Group. The patients were aware of their 
randomisation group. None of the surgeons, junior doctors, anaesthetists, 
perfusionists or nursing team were aware of the study group allocations of the 
patients.  
Following randomisation, there were 5 drop-outs from the 
Control Group and 7 from the HBO2 Group. The total drop-out rate for this 
study was 13.6%, which was less than was expected. The drop-out rate for the 
Control Group was 13% while for the HBO2 group it was 17%. The reason for 
the 5 drop-outs from the Control Group was a withdrawal of consent following 
randomisation. Of the 7 drop-outs from the HBO2 Group, 4 were due to 
withdrawal of consent following randomisation and 3 were due to ear pain 
during the initial pressurisation protocol of the HBO2 preconditioning 
treatment. Figure 2.1 shows the CONSORT Flow Diagram of patients 
recruited to this study.  
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Figure 2. 1: Consort Flow Diagram 
 
 
 
 
393 Excluded 
-in keeping with 
exclusion 
criteria 81 Suitable Patients 
Consented &  
Randomised (n=81) 
Randomised 
to Control 
Group 
(n=40) 
Randomised 
to HBO2 
Group 
(n=41) 
Drop-outs: n=5 
(withdrew 
consent 
following 
randomisation) 
 
Remained in 
study: n=35 
Drop-outs: n=7 
(n=3 had ear pain 
during HBO2 
treatment; n=4 
withdrew consent 
following 
randomisation) 
 
Remained 
in study: 
n=34 
 
 
 
 
Myocardial 
& Serum 
Biomarkers 
(n=34)   
 
 
Haemo-
dynamic 
Monitoring 
(n=22 
monitored; 
n=12 not 
monitored due            
unavailibity of 
monitoring 
equipment) 
 
 
Haemo- 
dynamic 
Monitoring 
(n=25 
monitored;  
n=10 not 
monitored due 
to unavaibility 
of monitoring 
equipment) 
 
 
 
 
Myocardial 
& Serum 
Biomarker 
Analysis 
(n=35)  
 
 
 
 
Post 
Operative 
Safety 
Monitoring 
(n=35)  
 
 
 
 
Post 
Operative 
Safety 
Monitoring 
(n=34)  
 
474 CAD patients who were having first time 
elective on CPB CABG using hypothermic 
intermittent ischaemic fibrillatory arrest were 
screened within 30 days prior to surgery  
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2.3.3  Study Design 
  This study was designed as a pilot proof of concept, phase 2, 
prospective, single centre randomised control study that was based on a 
previous clinical study involving HBO2 and CABG (Alex et al., 2005). In this 
study, following screening during the pre-admission clinic visit, suitable 
consenting patients were randomised to either the Control Group or to the 
HBO2 Group. Randomisation was done in a 1:1 manner (Figure 2.2). 
Randomisation was carried out by pulling out sealed envelopes in sequence 
from a box. The random treatment allocations were contained within the 
envelope. The random treatment allocation list was prepared by the study 
statistician.  
 
Figure 2. 2: Study Design 
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2.3.4  Statistical Methods 
Repeated measures of ANOVA was used to analyse the data 
involving haemodynamic and safety measurements and, the concentrations of 
serum Troponin-T, soluble adhesion molecules and, myocardial eNOS and 
Hsp72. Wilcoxon Signed Rank Test was used to analyse pre and post HBO2 
data involving serum soluble adhesion molecules concentrations. Independent 
sample t-test was used to analyse post operative length of stay in ICU, intra 
and post operative blood loss and, post operative blood transfusion. The Chi-
Square test was used to analyse categorical differences between the groups.  
  Data were analysed in accordance with the principals of 
intention to treat basis (ITT) (Molenberghs, 2007). Where data were missing, 
no imputation was undertaken. As there was no imputation of data, where large 
amounts of data were missing, only an on-treatment analysis was performed. 
To determine if the data were normally distributed or skewed, both the means 
and the medians were calculated. A large disparity between these would 
suggest that the data were skewed. Where the data were skewed, natural 
logarithmic (ln) transformation of the data were performed to normalise the 
data and enable parametric statistical analysis. Once parametric statistical 
analysis was performed, the data from logged results were transformed back 
into original estimates to provide the geometric mean which represents the 
ratio of the HBO2 Group to Control Group values (Altman, 1991).   
  Where appropriate, the location of the data are displayed in 
tables, as ranges, medians, means and ln means. The p-values provided are for 
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the geometric means. The variability of the the means of the data are displayed 
in bar charts as the standard error of the mean. 
2.4 Hyperbaric Oxygen Preconditioning 
Protocol 
 
The pressure and duration for HBO2 preconditioning was based 
on the optimum effect noted in a previous clinical study (Alex et al., 2005) 
involving HBO2 and CABG. On the morning of surgery, patients randomised 
to the HBO2 Group were transported to the Classic Hospital (Hull, UK) where 
they were preconditioned with HBO2. The protocol for the HBO2 treatment is 
depicted in Figure 2.3.  
 
Figure 2. 3: HBO2 Protocol 
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The HBO2 preconditioning treatment consisted of 
pressurisations over 10 minutes from 1 ATA to 2.4 ATA. During this 
pressurisation period, the patients were breathing air. Once at 2.4 ATA, 
patients placed a clear plastic hood over their heads and 100% oxygen was 
supplied for 30 minutes. This period was followed by a 5 minute interval out of 
the hood at 2.4 ATA, when the patients were breathing only air. After this 
interval, the hood was replaced and the patients again breathed 100% oxygen 
at 2.4 ATA for a further 30 minutes. The two 30 minute periods of 100% 
oxygen at 2.4 ATA effectively constitutes the treatment of HBO2 
preconditioning. Finally, the hood was removed and the chamber was 
depressurised over 25 minutes back to 1 ATA. During this depressurisation 
period, patients were again only breathing air. Treatment with HBO2 
preconditioning was completed approximately 2 hours prior to CPB. This 
duration between the end of HBO2 preconditioning and the start of CPB was 
the minimum duration that this research unit could achieve, as the chamber for 
the administration of HBO2 was not at the site where patients were having their 
CABG surgery.  
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2.5  Anaesthetic & Surgical Procedure 
There were 8 anaesthetists and 2 surgeons who were part of this 
randomised control study. All of them adhered to the same anaesthetic and 
surgical technique.  
2.5.1  Anaesthetic Procedure 
Approximately 1 hour prior to CABG, while the patients were 
on the ward, all the patients were given an anoxylitic, which consisted of either 
Temazepam or Lorazepam. In the Control Group this was given following 
baseline venous blood sampling. In the HBO2 Group, this was given after the 
post HBO2 venous blood sample was taken. 
 In the anaesthetic room, once all the routine monitoring devices 
were attached to the patient, anaesthesia was induced using Fentanyl and 
Propofol. Following anaesthetic induction, a pulmonary artery (PA) catheter 
(Edward Life Sciences, Germany) was inserted to enable peri-operative 
haemodynamic monitoring. During the intra-operative period, Isoflurane and 
Ramifentanyl were used to maintain anaesthesia. 
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2.5.2  Surgical Procedure 
Non-pulsatile (continuous flow) CPB was achieved using a 
Stockert SIII roller pump (Stockert Instrumente GmbH, Germany) together 
with a hollow fibre membrane oxygenator, an integral hard shell venous 
cardiotomy reservoir (Avant Phisio/M-Dideco, Italy) and a 38μm arterial line 
filter (Affinity352 Medtronic Inc, USA). During CPB, systemic hypothermia 
of 32°C was maintained. Intermittent ischaemic fibrillatory arrest was used as 
the intra-operative method for myocardial protection. Re-warming commenced 
during the distal anastamosis of the final coronary artery bypass graft. In this 
study, none of the patients were given Trasylol (serine protease inhibitor) as an 
anti-thrombolytic prior to CABG.  
2.6  Study Data Collection & Measurements 
  The data collected and the measurements made during this 
study consisted of the following: 
a. pre-operative and intra-operative patient data.  
b. post operative patient AEs.  
c. measurements of peri-operative haemodynamic parameters. 
d. measurements of peri-operative venous blood serum biomarker 
concentrations. 
e. measurements of the amount of intra-operative myocardial biomarkers. 
The details of the data collected and the measurements made, will be discussed 
in the following sections. 
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2.6.1  Pre-Operative Patient Data Collection 
  Following screening, to determine suitability for this study, and 
obtaining informed consent, pre-operative patient data were collected as 
described in Table 2.1. Apart from serum Troponin-T, all these data are 
routinely collected as part of pre-operative assessment. 
 
Table 2. 1: Pre-Operative Patient Data Catergories 
 
 
 
 
 
 
 
 
Pre-Operative Patient Data 
Age 
Sex 
Body Mass Index (BMI) 
History of unstable angina 
History of previous MI 
Severity of CAD 
Left ventricular function 
History of hypertension 
History of diabetes mellitus 
History of peripheral vascular disease 
EUROSCORE (Simple Additive Score) 
 (Roques et al., 1999)  
Pre-HBO2 Serum Troponin-T 
(all patients) 
Post HBO2 Serum Troponin-T 
(only patients in HBO2 Group) 
 
These data were collected as these factors may affect the intra and post 
operative clinical outcomes of patients in this study.  
The pre- and post operative measurement of serum Troponin-T 
was not routinely performed in the Cardiothoracic Surgical unit at Castle Hill 
Hospital, Hull. The pre- and post HBO2 serum Tropinin-T measurements were 
used as a surrogate biomarker which enabled further assessment of the 
myocardial safety, with respect to myocardial injury, of HBO2 preconditioning. 
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Serum Troponin-T from all time points were analysed by the Department of 
Biochemistry at the Hull & East Yorkshire NHS Trust within 4 hours of 
collection. This analysis was done using an                               
electrochemiluminescence immunoassay (ELICA) (Troponin T STAT, Roche 
Diagnostics Ltd, Burgess Hill, UK) performed on the Roche Elecsys 2010 
analyser in accordance with the manufacturer’s protocol. The measuring range 
of the kit is 0.01-25.00ng/ml. The analytical sensitivity (lower detection limit) 
and specificity of the kit is 0.01ng/ml and, between 0.001%-0.1%, 
respectively. According to the European Society of Cardiology (ESC) and the 
American College of Cardiology (ACC), MI is diagnosed when the levels of 
cardiac Troponin are above the 99th. percentile of the reference limit in the 
healthy population (Alpert J. S., 2000). According to the manufacturor, the 
99th. percentile for Troponin-T in the healthy population, measured using the 
Troponin-T STAT kit, is <0.01ng/ml. Furthermore, it has also been 
recommended that the Troponin-T concentration that is used to diagnose an MI 
must take in to account an imprecision (coefficient of variation) at the 99th. 
percentile that is equal to or less than 10% (Alpert JS, 2000) and this 
coefficiant of variation must also be taken into account when determining the 
serum Troponin-T concentration that will be used as a medical diagnostic 
guide (Apple FS, 2001). According to the manufacturor of the Troponin-T 
STAT kit, this would make a serum Troponin-T concentration of 0.03ng/ml as 
the medical diagnostic guide for diagnosing an MI. It is the lowest limit of 
quantification that can be reproducibly measuresed with a coefficient of 
variation of 10%. 
  
93 
 
2.6.2  Intra-Operative Patient Data Collection 
  Table 2.2 shows the routine categories of patient data that were 
collected during surgery: 
Table 2. 2: Intra Operative Patient Data Categories 
 
 
Intra Operative Patient Data 
Myocardial ischaemic time 
CPB time 
Intra-operative blood loss 
 
The intra-operative myocardial ischaemic time was measured to determine the 
length of time, during CABG, when the myocardium was exposed to ischaemia 
and thus susceptible to myocardial injury. The time spent on CPB was 
measured to determine the length of time patients were exposed to the 
hypothermia of 32°C and the non-pulsatile flow CPB. Intra-operative blood 
loss was measured by determining the volume of blood collected by the 
Yanker Suckers and the cell savers, as a measure of the amount of intra-
operative bleeding experienced by patients during this study. 
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2.6.3  Post-Operative Patient Adverse Event Data 
  Table 2.3 shows the patient AE data that were collected 
following the CABG surgery, during the in-hospital stay: 
Table 2. 3: Post Operative Patient Adverse Event Data 
 
Type of AE Measurement 
 
 
 
 
Cardiovascular 
Troponin-T ≥ 0.03ng/ml 
Proportion with low cardiac output syndrome 
Proportion with atrial fibrillation 
Proportion with MI 
Proportion with inotrope use 
Proportion needing cardiovascular supportive 
therapy (IABP*, pacing) 
Volume of post operative blood loss 
Volume of  post operative blood transfusion 
 
 
 
Pulmonary 
Duration mechanical ventilation 
Duration of endotracheal inbubation 
Proportion with pneumothorax 
Proportion with pleural effusion 
Proportion with chest infection 
Proportion needing pulmonary supportive 
therapy (BIPAP¥, CPAP§) 
 
Renal 
Proportion with serum creatinine > 200mmols/l 
Proportion with needing renal supportive 
therapy  (CVVH†) 
 
Neurological 
Proportion with confusion 
Proportion with transient ischemic attack (TIA) 
Proportion with stroke 
Gastrointestinal Proportion with diarrhoea 
Proportion with ischaemic bowel 
 
Microbiological Infections 
Proportion with superficial sternal wound 
infections 
Proportion with deep sternal wound infections 
Proportion with leg wound infections 
ICU Stay Number of hours 
Sternal Re-wiring Proportion needing sternal re-wiring 
Mortality Proportion of dead patients 
*IABP-Intra-Aortic Balloon Pump;  
¥BIPAP- Biphasic Positive Airway Pressure;  
§CPAP-Continuous Positive Airway Pressure;                          
†CVVH- Continuous Venovenous Haemofiltration 
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Apart from the measurement of serum Troponin-T ≥ 0.03ng/ml, the above AE 
data were routinely collected post operative data at the Cardiothoracic Surgical 
unit in Castle Hill Hospital, Hull. This AE data enabled descriptive estimates 
of the post operative safety profile of each group and, enabled simple statistical 
comparisons between the groups. Post operative serum creatinine was 
measured by the Department of Biochemistry at the Hull & East Yorkshire 
NHS Trust using Beckman Coulter (UK) Ltd (High Wycombe, UK) Unicel 
DxC800 (Synchron Clinical Systems) modular creatinint (Jaffe) method. 
In the hospital where this study was conducted, and as such for 
this study, patients requiring the used of inotropes, intra or post operatively, 
were identified as experiencing low cardiac output syndrome. Atrial fibrillation 
(AF) in this study was defined as an electrocardiogram (ECG) tracing without 
‘p’ waves at a rate of ≥ 120 per minute. 
2.6.4  Peri-Operative Haemodynamic Measurements 
  During the peri-operative period, haemodynamic measurements 
were taken using the PA catheter which was inserted following anaesthetic 
induction. The haemodynamic parameters and the time points at which they 
were  measured are displayed in Table 2.4. 
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Table 2. 4: Peri-Operative Haemodynamic Parameters 
 
Time Points 
 
 Intra-operative Post-Operative 
 Post 
Anaesthetic 
Induction 
5 minutes 
post CPB 
2 hours 
post CPB 
4 hours 
post 
CPB 
8 hours 
post 
CPB 
12 
hours 
post 
CPB 
24 
hours 
post 
CPB 
 
 
 
 
 
Haemodynamic 
Parameters 
Heart Rate (HR) X X X X X X X 
Mean Arterial Pressure (MAP) X X X X X X X 
Stroke Volume (SV) X X X X X X X 
Cardiac Output (CO) X X X X X X X 
Cardiac Index (CI) X X X X X X X 
Mean Pulmonary Artery 
Pressure (MPAP) 
X X X X X X X 
Pulmonary Capillary Wedge 
Pressure (PCWP) 
X X X X X X X 
Pulmonary Vascular Resistance 
(PVR) 
X X X X X X X 
Pulmonary Vascular Resistance 
Index (PVRI) 
X X X X X X X 
Systemic Vascular Resistance 
(SVR) 
X X X X X X X 
Systemic Vascular Resistance 
Index (SVRI) 
X X X X X X X 
Left Ventricular Stroke Work 
(LVSW) 
X X X X X X X 
Left Ventricular Stroke Work  
Index (LVSWI) 
X X X X X X X 
Right Ventricular Stroke Work 
(RVSW) 
X X X X X X X 
Right Ventricular Stroke Work 
Index (RVSWI) 
X X X X X X X 
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Measurement of these haemodynamic parameters enabled the assessment of 
the effects of HBO2 preconditioning on peri-operative myocardial function 
(HR, MAP, SV, CO, CI, MPAP, LVSW, LVSWI, RVSW and RVSWI), 
systemic vascular function (MAP, SVR and SVRI) and pulmonary vascular 
function (MPAP, PCWP, PVR and PVRI).  
2.6.5  Peri-Operative Serum Biomarker Sampling 
  During the peri-operative period, two 5ml samples of venous 
blood was drawn from each patient at the time points shown in Table 2.5 for 
serum biomarker analysis. 
Table 2. 5: Peri-Operative Venous Blood Sampling 
 
 Time Points 
 Pre- 
HBO2 
Post 
HBO2 
5 
minutes 
on CPB 
5 
minutes 
post IRI 
2 hours 
post 
CPB 
24 hours 
post 
CPB 
Control 
Group 
X † X X X X 
HBO2 
Group 
X X X X X X 
†The Control Group did not have any blood taken at the post HBO2 time point  
 
In this study, the baseline blood samples from each group were 
not taken at the same time. In the Control Group, a baseline (this will be 
classified as the ‘pre-HBO2’ time point in the Control group) blood sample was 
taken approximately 1 hour prior to anaesthetic pre-medication. In the HBO2 
Group, a baseline ‘pre-HBO2’ blood sample was taken approximately 1 hour 
prior to HBO2 preconditioning.  As the Control Group of patients did not have 
any intervention or HBO2 preconditioning prior to anaesthesia and CABG, no 
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blood sample was taken at the ‘post HBO2’ time point in this study. In the 
HBO2 Group, the ‘post HBO2’ blood sample was taken approximately 1 hour 
after HBO2. Only the HBO2 Group had blood taken pre and post HBO2 
preconditioning to allow for assessment of changes in serum biomarkers 
following HBO2 preconditioning. The blood sample at the time point ‘5 
minutes on CPB’ was taken 5 minutes following the onset of CPB. This ‘5 
minutes on CPB’ blood sample allowed for the assessments of the early 
changes in serum biomarkers following the initiation CPB, prior to operative 
IRI, in both groups, when compared to the blood sample taken at the ‘pre- 
HBO2’ time point. The blood sample taken at the time point ‘5 minutes post 
IRI’ was taken 5 minutes following the final release of the aortic cross clamp 
from the aorta i.e. after the final anastamosis of the final bypass graft to the 
coronary artery (distal anastamosis) was complete. This ‘5 minutes post IRI’ 
blood sample allowed for the assessment of changes in serum biomarkers as a 
result of the effects of operative IRI in both groups when compared to blood 
samples taken at earlier time points in this study. The blood samples taken at 
the time point ‘2 hours post CPB’ and ‘24 hours post CPB’, allowed for the 
assessment of the delayed changes in serum biomarkers following the 
termination CPB in both groups when compared with blood samples taken at 
earlier time points in this study. 
Each of the two 5ml blood sample taken was placed in an amber 
top BD Vacutainer Tube (SST11 Advance). One tube was analysed for serum 
Troponin-T and the other was used for the analysis of serum soluble adhesion 
molecule biomarkers. The tube for serum soluble adhesion molecule analysis 
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was centrifuged, within 4 hours of collection, at 1200g for 15 minutes at 2ºC in 
a Rotanta 96R centrifuger (Hettich Zentrifugen, Tuttingen, Germany). The 
supernatant (i.e. the serum) was subsequently pipetted into labelled 1.5ml 
propylene tubes and stored at -80ºC for later serum biomarker analysis. 
2.6.6  Peri-Operative Serum Biomarkers 
Assessment 
  The methods used for the assessment of the biomarkers 
investigated in this study are described below. 
2.6.6.1 Peri-Operative Serum Troponin-T Assessment 
The pre- and post operative measurement of serum Troponin-T 
was not routinely performed in the Cardiothoracic Surgical unit at Castle Hill 
Hospital, Hull. The pre- and post HBO2 serum Tropinin-T measurements were 
used as a surrogate biomarker which enabled further assessment of the 
myocardial safety, with respect to myocardial injury, of HBO2 preconditioning. 
Serum Troponin-T from all time points were analysed by the Department of 
Biochemistry at the Hull & East Yorkshire NHS Trust within 4 hours of 
collection. This analysis was done using an                               
electrochemiluminescence immunoassay (ELICA) (Troponin T STAT, Roche 
Diagnostics Ltd, Burgess Hill, UK) performed on the Roche Elecsys 2010 
analyser in accordance with the manufacturer’s protocol. The measuring range 
of the kit is 0.01-25.00ng/ml. The analytical sensitivity (lower detection limit) 
and specificity of the kit is 0.01ng/ml and, between 0.001%-0.1%, 
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respectively. According to the European Society of Cardiology (ESC) and the 
American College of Cardiology (ACC), MI is diagnosed when the levels of 
cardiac Troponin are above the 99th. percentile of the reference limit in the 
healthy population (Alpert J. S., 2000). According to the manufacturor, the 
99th. percentile for Troponin-T in the healthy population, measured using the 
Troponin-T STAT kit, is <0.01ng/ml. Furthermore, it has also been 
recommended that the Troponin-T concentration that is used to diagnose an MI 
must take in to account an imprecision (coefficient of variation) at the 99th. 
percentile that is equal to or less than 10% (Alpert JS, 2000) and this 
coefficiant of variation must also be taken into account when determining the 
serum Troponin-T concentration that will be used as a medical diagnostic 
guide (Apple FS, 2001). According to the manufacturor of the Troponin-T 
STAT kit, this would make a serum Troponin-T concentration of 0.03ng/ml as 
the medical diagnostic guide for diagnosing an MI. It is the lowest limit of 
quantification that can be reproducibly measuresed with a coefficient of 
variation of 10%. 
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2.6.6.2 Peri-Operative Serum Soluble Adhesion Molecule 
Assessment 
  In this study, the serum soluble adhesion molecule biomarkers 
that were assessed were soluble E-Selectin (sE-Selectin), soluble P-Selectin 
(sP-Selectin), soluble ICAM-1 (sICAM-1) and soluble PSGL-1 (sPSGL-1). 
These serum biomarkers were measured as they are adhesion molecules that 
are known to be shed (Gearing and Newman, 1993, Hayward et al., 1999, 
Hillis et al., 2002, Pigott et al., 1992, Ushiyama et al., 1993) from the surfaces 
of the vascular endothelium (sE-Selectin, sP-Selectin and sICAM-1) or cleaved 
off the surfaces of  neutrophils (sPSGL-1) (Gardiner et al., 2001, Lefer et al., 
1998)  following a period of oxidative stress such as IRI. Following the 
discussion in section 1.2.1, as intact adhesion molecules on the surfaces of the 
vascular endothelium and neutrophils are required for endothelial-neutrophil 
adhesion, it is reasonable to suggest that the presence of the soluble form of 
these adhesion molecules, which are no longer attached to the endothelial or 
neutrophilic surfaces, provides an indirect measure of the reduced 
adhesiveness of those surfaces. Furthermore, following on from the discussion 
in section 1.2.1.3, it is reasonable to suggest that the more of these intact 
adhesion molecules that are shed or cleaved off the surfaces of the vascular 
endothelium and the neutrophils into the circulation, the less likely is it for 
neutrophils to be able to adhere to the vascular endothelium and vice-versa. 
This has the potential to limit neutrophil mediated vascular injury. 
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To measure these serum soluble adhesion molecules, the 
required serum samples were removed from the -80ºC freezer and thawed prior 
to use. Each sample was analysed for the four different serum soluble adhesion 
molecules in the sequence of sE-Selectin, sP-Selectin, sPSGL-1 and sICAM-1. 
As such, samples from each time point for sE-Selectin analysis experienced 
one freeze-thaw cycle, the samples for  sP-Selectin analysis experienced two 
freeze-thaw cycles, the samples for sPSGL-1 analysis experienced three 
freeze-thaw cycles and the samples for sICAM-1 analysis experienced four 
freeze-thaw cycles.  
  All samples for serum soluble adhesion molecule measurement 
were analysed using a quantitative sandwich ELISA procedure. The ELISA 
kits for sE-selectin, sP-selectin and sICAM-1 were purchased from R&D 
Systems (R&D Systems Inc, Minneapolis, USA) while those for sPSGL-1 
analysis were purchased from Bender MedSystems (Bender MedSystems, 
Vienna, Austria).  
The ELISA assay procedure was performed according to the 
methods recommended by the manufacturer. This method was similar for all 
the four  types of assays. As such, for the purpose of describing the ELISA 
method that was used, the general steps involved in the serum sE-Selectin 
ELISA assay procedure will be described in the following section. A summary 
of the differences in between sE-Selectin ELISA assay procedure and the 
ELISA assay procedure for sP-Selectin, sICAM-1 and sPSGL-1, will be 
described in the subsequent sections.  
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2.6.6.2.1  ELISA Assay Procedure For sE-Selectin 
  All the reagents used in this procedure were provided by the 
manufacturer (R&D Systems Inc, Minneapolis, USA) and were brought to 
room temperature prior to use. 
  Sample Preparation 
 All samples were diluted 20 fold by adding 15μl of sample to 
285μl of Sample Diluent. 
Reagent Preparation 
The wash buffer was made by diluting 20ml of the wash buffer 
concentrate with 480ml distilled water. The sE-Selectin conjugate concentrate 
(sheep polyclonal antibody to recombinant human sE-Selectin conjugated to 
horseradish peroxidase in buffer with preservative) was then diluted by 
pipetting 250μl of the concentrate into a bottle containing 11ml of Conjugate 
Diluent (horseradish peroxidase conjugate concentrate). All the provided 
standards were reconstituted by pippeting 1ml of distilled water into each of 
the bottles containing the standards. The reconstituted standards were then 
allowed to sit at room temperature for 10 minutes before use. The 
concentration of each of the reconstituted standards was stated on each of the 
bottles containing the standards (Table 2.6). 
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Table 2. 6: Concentration of sE-Selectin Standards 
 
 
 
 
 
 
Assay Procedure 
Using the 96 well microplate (12 strips, 8 wells per strip, coated 
with a mouse monoclonal antibody to human sE-Selectin), 100μl of sE-
Selectin Standard 5 was pipetted in duplicate in wells A1 & B1. This was 
followed by 100μl sE-Selectin Standard 4 in wells A2 & B2, 100μl sE-Selectin 
Standard 3 in wells A3 & B3, 100μl sE-Selectin Standard 2 in wells A4 & B4, 
100μl sE-Selectin Standard 1 in wells A5 & B5 and 100μl sE-Selectin 
Standard 0 in wells A6 & B6. Wells A7, A8, B7 and B8 were left blank 
(Figure 2.4). In this study, all the blank wells were left empty and not used 
during the assay procedure. 
100μl of a particular patient’s diluted sample, from an appropriate 
study time point, was then added in duplicates to the respective wells in strips 
C to L of the ELISA microplate (Figure 2.4). 100μl of the diluted sE-Selectin 
Conjugate was then added to all the wells in strips A to L (except for the blank 
wells). The microplate was then covered with a plate sealer and allowed to 
incubate for 1.5 hours at room temperature on a rotator set at 100 revolutions 
Standards sE-Selectin Concentration (ng/ml) 
5 10.56 
4 7.91 
3 4.88 
2 2.54 
1 0.57 
0 0 
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per minute (rpm). The plate was then washed six times with 300μl of the 
previously made up wash buffer using a Thermolab Systems Wellwash 4MK2 
autowasher. Once washed and ensuring that all the liquid in each well was 
removed, 100μl of the Substrate Solution (tetramethylbenzidine-TMB) was 
added to each well (except for the blank wells). The micoplate was then once 
again covered with a new plate sealer and allowed to incubate, in the dark, at 
room temperature for approximately 15 minutes on a rotator set at 100rpm. 
Once the most concentrated standard had reached a deep blue colour, 100μl of 
the provided Stop Solution (Sulfuric Acid) was added to each well (except for 
the blank wells). Within 30 minutes of adding the Stop Solution, the 
spectophotometric reading from each well was then determined using the 
Anthos 2010 microtitre plate reader (Anthos Labtec Instrument GmdH, 
Austria) together with the Stingray software (Stingray Software Inc, USA). A 
primary wavelength of 450nm was used during the spectophotometric analysis 
with a correction for optical imperfections in the plate set at 620nm.  
According to the manufacturer (R&D System), the intra-assay coefficient of 
variation for sE-Selectin ELISA microplate was between 4.7% and 5% while 
the inter-assay coefficient of variation was between 5.7% and 8.8%. The 
minimum detectable dose of sE-Selectin was 0.1ng/ml.  
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Figure 2. 4: Schematic Representations of ELISA Microplate Wells Containing ELISA Standards & Samples At Each                             
Time Point In Duplicates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend 2. 1: Legend Colour for Figure 2.4 
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2.6.6.2.2 ELISA Assay Procedure For sP-Selectin 
The reagents, methods used and the steps involved in the  
ELISA assay procedure for sP-Selectin was similar to that used for sE-Selectin 
apart from  
a) the first incubation period was only 1 hour in duration. 
b) the microplate was washed only 3 times on the autowasher.  
The intra-assay coefficient of variation for sP-Selectin ELISA 
microplate was between 4.9% and 5.1% while the inter-assay coefficient of 
variation was between 7.9% and 9.9%. The minimum detectable dose of sP-
Selectin was 0.5ng/ml.  
2.6.6.2.3 ELISA Assay Procedure For sICAM-1 
The reagents, methods used and the steps involved in the  
ELISA assay procedure for sICAM-1 was exactly the same as for sE-Selectin. 
The intra-assay coefficient of variation for sICAM-1 ELISA microplate was 
between 3.3% and 4.8% while the inter-assay coefficient of variation was 6% 
between 10.1%. The minimum detectable dose of sICAM-1 was 0.35ng/ml. 
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2.6.6.2.4 ELISA Assay Procedure For sPSGL-1 
This assay procedure also involved a 20 fold dilution of the 
samples. While the general methods and steps  for the ELISA assay procedure  
for sPSGL-1 was similar to that of sE-Selectin, there were some differences. 
These differences involved the following: 
   Reagent Preparation 
   50ml of the manufacturer provided wash buffer concentrate was 
mixed with 950ml of distilled water to make up a 1liter of 20 fold dilution of 
the wash buffer. 5ml of the manufacturer provided Assay Buffer concentrate 
was then mixed with 95ml of distilled water to make up a 100ml 20 fold 
dilution of the Assay Buffer.  
   A 100 fold dilution of Biotin Conjugate solution was then made 
by mixing 0.06ml of Biotin Conjugate (anti-human sPSGL-1 monoclonal 
antibody) to 5.94ml of the prepared Assay Buffer. After this, a 200 fold 
dilution of the Streptavidin-Horseradish Peroxidase (HRP) concentrate was 
made by adding 60μl of Streptavidin-HRP concentrate to 12 ml of Assay 
Buffer. Then the sPSGL-1 standard was reconstituted by the addition of a 
volume of distilled water that was stated on the bottle of the sPSGL-1 standard. 
The concentration of the reconstituted standard was 100u/ml.  
   Once the standard was reconstituted, a series dilution of the 
standard was then made. This was done by firstly labelling 6 propylene tubes 
as S1, S2, S3, S4, S5, S6, respectively, one for each diluted standard. Then a 2 
fold serial dilution of the provided sPSGL-1 standards was made by firstly 
pipetting 225μl of Sample Diluent into each tube. Then, 225μl of the 
  
109 
 
reconstituted standard was pipetted into the first tube, labelled S1. The contents 
of S1 was mixed (concentration of standard 1 = 50u/ml). Following this, 225μl 
of the diluted standard from S1 was pipette into the second tube, labelled S2. 
This was mix thoroughly before the next transfer (Figure 2.5). This step was 
repeated 4 more times to create a standard dilution series with concentrations 
ranging from 50 to 1.6U/ml. The sample diluent serves as blank. 
 
Figure 2. 5: Series Dilution of sPSGL-1 Standard 
 
 
        (Figure was adapated from Bender MedSystems PSGL-1 ELISA instruction book) 
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Assay Procedure 
The prepared sPSGL-1 standards were pipetted in duplicates 
into columns A and B (rows 1 to 6), as in Figure 2.4, of the 96 well ELISA 
microplate (coated with monoclonal antibodies to human sPSGL-1).  Wells 
A7 A8, B7 and B8 were left blank. 100μl of the diluted patient sample, from 
an appropriate time point, was then respectively added in duplicates to all 
wells, except the standard and blank wells. 50μl of the diluted Biotin-
Conjugate was then added to all wells, except the blank wells. The microplate 
was then covered with a plate cover and left to incubate for 2 hours at room 
temperature on a rotator set at 100rpm.  
After this incubation, the microplate was washed 3 times with 
300μl of the manufacturer provided wash buffer. 100μl of the diluted 
Streptavidin-HRP was added to all wells (except for the blank wells). The 
microplate was covered with a plate cover and allowed to incubate at room 
temperature on a rotator set at 100rpm for a further 1 hour.  
Then the plate was washed again as before. 100μl of the 
Substrate Solution (TMB) was then added to all wells (except for the blank 
wells). The micoplate was once again covered with a new plate sealer and 
allowed to incubate, in the dark, at room temperature for 10 minutes on a 
rotator set at 100rpm.  
Once the most concentrated standard had reached a deep blue 
colour, 100μl of the manufacturer provided Stop Solution (Sulfuric Acid) was 
added to each well (except for the blank wells). The spectophotometric reading 
from each well was then determined using Anthos 2010 microtitre plate reader 
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(Anthos Labtec Instrument GmdH, Austria) together with the Stingray 
software (Stingray Software Inc, USA). A primary wavelength of 450nm was 
used during the spectophotometric analysis with a correction for optical 
imperfections in the plate set at 620nm. The intra-assay coefficient of variation 
for sPSGL-1 ELISA microplate was 3.2% while the inter-assay coefficient of 
variation was 6.6%. The limit of detection of this assay was 0.99u/ml. 
2.6.6.3  Correction For Haemodilution Of Serum 
Biomarkers 
Haemodilution is a standard practice during CPB (Liam et al., 
1998). This is known to result in moderate to severe reduction of the serum 
soluble adhesion molecule (Williams et al., 1998) and Troponin-T (Licker et 
al., 2005) concentrations. As such, a correction for the effects of haemodilution 
on the measured serum biomarker concentration in the venous blood samples 
taken during the intra and post operative periods was required to determine 
their absolute concentration serum. Such a correction was also done in a 
similar previous study (Alex et al., 2005). In this study, this correction was 
done using a formula described by Taylor et al (Taylor et al., 1976). The 
haematocrit measurement in the venous blood samples taken during the intra 
and post operative time points, that was required for use in this formula, was 
measured using a GEM 3000 analyser (Instrumentation Laboratory).  
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Formula for correction of hemodilution: 
Corrected Serum Soluble Adhesion Molecule/Troponin-T 
concentration (ng/ml )= 
Adhesion Molecule Concentration at Sampling Time (ng/ml) x 
(Pre-Op Hct)/(Hct at time of sampling) 
 (Hct=Haematocrit) 
2.6.7 Intra-Operative Myocardial Biopsy 
In this study, a myocardial biopsy of the right atrium was  
taken from each  patient, at the time points shown in Table 2.7. 
 
Table 2. 7: Intra-Operative Time Points For Right Atrial Biopsy 
 
 Time Points 
 Post 
Induction 
5 minutes on 
CPB 
5 minutes 
post IRI 
5 minutes 
post CPB 
Control 
Group 
X X X X 
HBO2 
Group 
X X X X 
 
 Myocardial biopsies were taken by excising a piece of right 
atrium from the part of the atrium above the atrial purse string suture that was 
securing the atrial venous cannula in the right atrium and inferior vena cava. 
Each biopsy measured approximately 0.5cm x 0.5cm.   
The myocardial biopsy taken at time point ‘post induction’ was 
taken after anaesthetic induction, median sternotomy and, cannulation of the 
aorta and the right atrium, prior to the onset of CPB. This biopsy provided a 
baseline for the assessment of myocardial biomarkers. The myocardial biopsy 
taken at time point ‘5 minutes on CPB’ was taken 5 minutes following the 
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onset of CPB to enable the assessments of the early changes in the myocardial 
biomarkers as a result of CPB, prior to operative IRI, in both groups when 
compared to the biopsy taken at the time point ‘post induction’. The 
myocardial biopsy taken at the time point ‘5 minutes post IRI’ was taken 5 
minutes following the final release of the aortic cross clamp from the aorta i.e. 
after the final anastamosis of the final bypass graft to the coronary artery 
(distal anastamosis) was complete. This biopsy allowed for the assessment of 
the changes in myocardial biomarkers as a result of the operative IRI in both 
groups when compared to biopsies taken earlier in the intra-operative period. 
The final myocardial biopsy taken at the time point ‘5 minutes post CPB’ was 
taken 5 minutes following the termination of CPB to enable the assessment of 
the changes in myocardial biomarkers in comparison with the changes prior to 
the onset of CPB. 
Each of the myocardial biopsy was placed in a 2ml cryo-vial 
(Nunc) containing RNA-Later (Qiagen) for immediate stabilisation of RNA 
and was processed according to manufacturer’s recommendations for RNA 
stabilisation. The cryo-vials were then stored in a 4ºC fridge for 24 hours. 
After this period, in a sterile Class 2 Biological Safety Cabinet (Faster, SLS, 
Nottingham), the RNA-Later was removed from the cryo-vial and discarded. 
The biopsy was left in the cryo-vial and stored in a -80ºC for later myocardial 
biomarker analysis. 
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2.6.7.1 Intra-Operative Myocardial Biomarker Assessment 
  In this study, the myocardial biomarkers that were assessed 
were eNOS (Cabigas et al., 2006a) and Hsp72 (Hutter et al., 1996, Iwaki et al., 
1993, Marber et al., 1995, Plumier et al., 1995) as they have been shown to be 
cardioprotective in models of IRI.  
The required myocardial biopsies for eNOS or Hsp72 
measurements, were removed from the -80ºC freezer. Before the samples could 
thaw, in a sterile Class 2 Biological Safety Cabinet (Faster, SLS, Nottingham), 
a small specimen from the biopsy was quickly excised. The remaining biopsy 
was returned to the -80ºC freezer. The myocardial specimen was allowed to 
completely thaw. Once thawed, the myocardial specimen was weighed and the 
weight was recorded. Each myocardial biopsy was analysed in the sequence of 
eNOS first then, followed by Hsp72. As such, the biopsies, from each time 
point, for myocardial eNOS analysis experienced one freeze-thaw cycle while 
those for myocardial Hsp72 analysis experienced two freeze-thaw cycles. 
A quantitative Enzyme Linked ImmunoSorbent Assay (ELISA) 
test was used for measuring myocardial eNOS and myocardial Hsp72. The 
ELISA kits for the measurement of myocardial eNOS were purchased from 
R&D Systems (R&D Systems Inc, Minneapolis, USA) and those for 
myocardial Hsp72 ELISA were purchased from Stressgen Bioreagents 
(Victoria, BC, Canada).  
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2.6.7.2 Myocardial Specimen Lysis 
The lysis of the myocardial specimens was done according to 
the recommendations of the manufacturer for the respective ELISA kits.  
In a sterile Class 2 Biological Safety Cabinet (Faster, SLS, 
Nottingham), using separate petri dishes, each myocardial specimen was teased 
apart and disrupted in 1ml of the manufacturer provided lysis buffer using two 
size 11 blades. The specimens were then homogenised by passing the lysis 
buffer containing the disrupted specimen, 5 times through a 20G needle and 
syringe. The homogenate was then transferred into two separate 1.5ml 
propylene tube and centrifuged at 300g for 5 minutes. The supernatant (lysate) 
from the propylene tube was then removed and transferred into another 
labelled 1.5ml propylene tube. The lysates were then frozen at -80ºC for later 
analysis.   
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2.6.7.3 Myocardial Lysate eNOS  ELISA Assay Procedure 
All the reagents used in this procedure were provided by the 
manufacturer (R&D Systems Inc, Minneapolis, USA). The preparation of the 
reagents and the ELISA assay procedure were carried out according to the 
methods recommended by the manufacturer. 
Sample Preparation 
The required propylene tubes containing myocardial lysate 
samples for analysis, were removed from the -80ºC freezer and allowed to 
thaw. 100μl of the lysate from each propylene tube was then transferred to a 
fresh propylene tube for use in the myocardial eNOS ELISA procedure. The 
remaining myocardial lysate sample was immediately returned to the -80ºC 
freezer. 
For this myocardial eNOS ELISA procedure, the sample lysate did 
not require dilution. The above procedure was repeated for all the sample 
lysates that were required for eNOS ELISA analysis. 
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Reagent Preparation 
All reagents were first brought to room temperature. 500ml 
wash buffer was made by diluting 20ml of the provided Wash Buffer 
Concentrate with 480ml of distilled  water.  
The substrate solution for this ELISA assay procedure was 
made by mixing equal volumes of the provided Colour Reagents A (stabilised 
hydrogen peroxide) & B (stabilised chromogen- tetramethylbenzidine). This 
was done 15 minutes prior to addition of the substrate solution to the wells. 
This substrate solution was light sensitive and needed to be covered from the 
light.   
The eNOS standard (40ng of recombinant human eNOS) was 
then reconstituted with 1ml of distilled water. This reconstitution produced a 
stock solution of 40,000pg/ml. The standard was allowed to sit for 15 minutes 
before a series dilution was made. This was done by pipetting 900μl of 
Calibrator Diluent RD5K (a buffered protein base) into the first propylene 
tubes (Figure 2.6). 500μl of Calibrator Diluent RD5K was then pipetted into 
propylene tube 2, 3, 4, 5, 6 and 7. Then, 100μl of stock was added to propylene 
tube 1. After mixing the 1000μl content of propylene tube 1, 500μl form 
propylene tube 1 was transferred to propylene tube 2 and mixed. Following 
this, 500μl of the content from propylene tube 2 was transferred to propylene 
tube 3. This procedure was continued until propylene tube 7 was reached. 
Propylene tube 7 ended up with a volume of 1000μl. The 4000pg/ml standard, 
in propylene tube 1, served as the high standard. Calibrator Diluent RD5K 
serves as the zero standard (0pg/ml). 
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Figure 2. 6: Series Dilution of eNOS Standard Stock 
 
 
Propylene  tube:         1             2             3              4            5             6          7 
(Figure was adapated from R&D Systems eNOS ELISA  instruction book) 
 
Assay Procedure 
In this myocardial eNOS ELISA assay procedure, the  
manufacturer provided 96 well microplate (12 strips, 8 wells per strip) was 
used. The wells of this plate were coated with a monoclonal antibody against 
eNOS. 100μl of Assay Diluent RD1W (a buffered protein base) was added to 
each well. 100μl of eNOS Standard from propylene tube 1 was pipetted, in 
duplicates, into wells A1 & B1. This was followed by pipetting 100μl eNOS 
Standard from propylene tube 2 into wells A2 & B2, 100μl  eNOS Standard 
from propylene tube 3 into wells A3 & B3, 100μl eNOS Standard from 
propylene tube 4 into wells A4 & B4, 100μl eNOS Standard from propylene 
tube 5 into wells A5 & B5, 100μl eNOS Standard from propylene tube 6 into 
wells A6 & B6 and 100μl eNOS Standard from propylene tube 7 into wells A7 
& B7. Wells A8 and B8 were left blank. 100μl of sample lysate was then 
added to all wells except the standard and blank wells (Figure 2.4). 
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The microplate was covered with an adhesive strip and 
incubated for 2 hours at room temperature on a horizontal microplate shaker 
set at 500rpm. The plate was then washed 3 times with 400μl, of the previously 
made up, manufacturer wash buffer using a Thermolab Systems Wellwash 
4MK2 autowasher. Once washed, and ensuring that all the liquid in each well 
was removed, 200μl of eNOS Conjugate (polyclonal antibody against eNOS 
conjugated to horseradish peroxidase) was added to each well. The microplate 
was then covered with a new adhesive seal prior to incubation for a further 2 
hours at room temperature on a horizontal microplate shaker set at 500rpm. 
Then the plate was washed 3 times with 400μl of the wash buffer using a 
Thermolab Systems Wellwash 4MK2 autowasher. After this second wash step, 
200μl of Substrate Solution was added to each well. The microplate was then 
incubated for 30 minutes on a bench top while protecting it from light. Once 
the most concentrated standard had reached a deep blue colour, 50μl of the 
manufacturer provided Stop Solution (Sulfuric Acid) was added to all the 
wells. Within 30 minutes of adding the Stop Solution, the spectophotometric 
reading from each well was then determined using Anthos 2010 microtitre 
plate reader (Anthos Labtec Instrument GmdH, Austria) together with the 
Stingray software (Stingray Software Inc, USA). A primary wavelength of 
450nm was used during the spectophotometric analysis with a correction for 
optical imperfections in the plate set at 540nm. 
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The intra-assay coefficient of variation for the eNOS ELISA 
microplate was between 3.7% and 4.9% while the inter-assay coefficient of 
variation was between 3.6% and 7.4%. The maximum detectable concentration 
of eNOS is typically less than 25ρg/ml.  
The quantity of eNOS in each milligram of the right atrial 
biopsy, at each time point, was then determined using the following formula: 
Quantity of eNOS in Right Atrial Specimen (pg/mg) = 
[eNOS Concentration at time of sampling (ng/ml) X Lysate Buffer 
Volume(ml)] / Right Atrial Specimen Weight (mg) 
  
121 
 
2.6.7.4 Myocardial Lysate Inducible Hsp70 (Hsp72) 
ELISA Assay Procedure 
All the reagents used in this procedure were provided by the 
manufacturer (Stressgen Bioreagents; Victoria, BC, Canada). The preparation 
of the reagents and the ELISA assay procedure were carried out according to 
the methods recommended by the manufacturer. 
Sample Preparation 
The required propylene tubes containing myocardial lysate 
samples for analysis, were removed from the -80ºC freezer and allowed to 
thaw. 15μl of the lysate from each propylene tube was then transferred to fresh 
propylene tube for use in the Hsp72 ELISA procedure. The remaining 
myocardial lysate sample was immediately returned the -80ºC freezer. 
285μl of the provided Sample Diluent, was then added to the 
propylene tube containing the 15μl of lysate sample. This created a 20 fold 
dilution of the sample lysate that was to be used. The above procedure was 
repeated for all the sample lysates that were required Hsp72 ELISA analysis. 
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Reagent Preparation 
All reagents were brought to room temperature. 
a. Series Dilution of Anti-Human Hsp70 Standard. 
The provided Recombinant Hsp70 Standard (10μg/ml stock  
solution of inducible Hsp70 protein) was used to generate a series dilution of 
Hsp70 Standard concentration, ranging from 0.78 to 50ng/ml. This was done in 
the following manner.  Seven 1.5ml propylene tubes were respectively labelled 
with the following standard values: 
i. Propylene tube 1: 50ng/ml 
ii. Propylene tube 2: 25ng/ml 
iii. Propylene tube 3: 12.5ng/ml 
iv. Propylene tube 4: 6.25ng/ml 
v. Propylene tube 5: 3.125ng/ml 
vi. Propylene tube 6: 1.56ng/ml 
vii. Propylene tube 7: 0.78ng/ml 
995μl of Sample Diluent was added to propylene tube 1. 500μl 
of Sample Diluent was added to propylene tube 2, 3, 4, 5, 6 and 7. 5μl of 
Hsp70 Standard stock solution was added to propylene tube 1 and was mixed 
thoroughly. 500μl of mixture from propylene tube 1 was then transferred to 
propylene tube 2 and mixed thoroughly. The dilution series was then 
completed by transferring 500μl from propylene tube 2 to propylene tube 3 and 
so forth until propylene tube 7 was reached to generate the standard dilutions 
(Figure 2.7). Propylene tube 7 ended up with a volume of 1ml. Finally, 500μl 
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of Sample Diluent was added to another propylene tube (propylene tube 8). 
This served as the blank assay (0ng/ml).  
 
Figure 2. 7: Series Dilution of Hsp70 Standard Stock 
 
 
Propylene tube:          1            2            3            4          5            6          7 
          (Figure was adapated from Stressgen Hsp72 ELISA  instruction book) 
 
b.  Preparation of Anti-Hsp70 Biotin Conjugate 
22μl of the provided Anti-Hsp70 Biotin Conjugate (Rabbit  
polyclonal antibody specific for inducible Hsp70) was diluted in 11ml of    
Anti-Hsp70 Biotin Conjugate Diluent (a buffer) in a propylene tube and mixed.  
            c.  Preparation of Avidin HRP Conjugate 
22μl of Avidin-HRP Conjugate(Horseradish Peroxidise 
conjugated anti-rabbit IgG) was mixed with 11ml of Avidin-HRP 
Conjugate Diluent in a propylene tube. 
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d. Wash Buffer Preparation 
100ml of the provided wash buffer concentrate was diluted with 
900ml of distilled water to make a 10 fold dilution of the wash buffer. 
Assay Procedure 
The manufacturer provided 96 well microplate (12 strips, 8  
wells per strip) was used. The wells were pre-coated with mouse monoclonal 
antibody specific for inducible Hsp70. 100μl of Hsp70 Standard from 
propylene tube 1 was placed in duplicate in wells A1 & B1. This was followed 
by 100μl Hsp70 Standard from propylene tube 2 into wells A2 & B2, 100μl  
Hsp70 Standard from propylene tube 3 into wells A3 & B3, 100μl Hsp70 
Standard from propylene tube 4 into wells A4 & B4, 100μl Hsp70 Standard 
from propylene tube 5 into wells A5 & B5, 100μl Hsp70 Standard from 
propylene tube 6 into wells A6 & B6 and 100μl Hsp70 Standard from 
propylene tube  7 into wells A7 & B7. Wells A8 and B8 were left blank. 100μl 
of sample lysate was then added all well except the standard and blank wells 
(Figure 2.4). 
The microplate was covered with an adhesive seal and 
incubated for 2 hours at room temperature on a horizontal microplate shaker 
set at 500rpm. Then the plate was washed six times with 300μl of the 
previously made up manufacturer wash buffer using a Thermolab Systems 
Wellwash 4MK2 autowasher. Once washed and ensuring that all the liquid in 
each well was removed, 100μl of Anti-Hsp70 Biotin Conjugate was added to 
each well. The microplate was covered with an adhesive seal and incubated for 
1 hour at room temperature on a horizontal microplate shaker set at 500rpm. 
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The plate was then washed six times with 300μl of the wash buffer using a 
Thermolab Systems Wellwash 4MK2 autowasher. Once washed and again 
ensuring that all the liquid in each well was removed, 100μl of Avidin-HRP 
Conjugate was added to each well. The microplate was covered with an 
adhesive seal and incubated for 1 hour at room temperature on a horizontal 
microplate shaker set at 500rpm. The plate was washed again six times with 
300μl of the wash buffer using a Thermolab Systems Wellwash 4MK2 
autowasher. Again after ensuring all the liquid in each well was removed, 
100μl of the provided TMB Substrate Solution was added to each well and the 
plate was left to incubate at room temperature for 10 minutes. 
Once the most concentrated standard had reached a deep blue 
colour, 50μl of Acid Stop solution (Sulfuric Acid) was added to all the wells in 
the same order the TMB Substrate was added. Within 30 minutes of adding the 
Stop Solution, the spectophotometric reading from each well was then 
determined using Anthos 2010 microtitre plate reader (Anthos Labtec 
Instrument GmdH, Austria) together with the Stingray software (Stingray 
Software Inc, USA). A primary wavelength of 450nm with a correction for 
optical imperfections in the plate set for 540nm, was used. 
According to manufacturer (Stressgen Bioreagent), the intra-
assay and the inter-assay coefficient of variation for the Hsp70 ELISA 
microplate was <10%, respectively.  
 
 
  
126 
 
The quantity of inducible Hsp70 (Hsp72) in each milligram of 
the right atrial tissue specimen at each time point was then determined using 
the following formula 
Quantity of Hsp72 in Right Atrial Specimen (ng/mg) = 
[Hsp72 Concentration at time of sampling (ng/ml) X Lysate Buffer Volume 
(ml)] / Right Atrial Specimen Weight (mg) 
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3. The Effects Of HBO2 
Preconditioning On Peri-Operative 
Cardiovascular Efficacy & Clinical 
Safety 
3.1  Introduction 
In 1965, a case report was published describing a case of low 
cardiac output syndrome, following complex cardiac surgery (and therefore 
post IRI), which improved after treatment with HBO2 (Yacoub and Zeitlin, 
1965). This interesting case report was followed up in 1971, by the publication 
of a randomised control study involving HBO2 and patients who had suffered 
an AMI (Thurston, 1971). In that study, in addition to the unit’s protocol for  
treatment of AMI, 127 patients who had suffered an AMI were randomly 
allocated either to a group where patients were treated intermittently for the 
first 48 hours with HBO2 (n=58) or to a group where patients were treated with 
oxygen via a face mask (n=69). It was observed that patients with a history of 
cardiovascular disease and patients who presented with cardiogenic shock or 
heart failure, performed clinically better following treatment with HBO2. In 
particular, it was observed that some arrhythmias appeared to resolve during 
treatment with HBO2, occasionally only to return in air at atmospheric pressure 
but, correctable again when the pressure was raised. There was also less in-
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hospital mortality in the HBO2 group compared to the control group (19% vs. 
24.6%) despite the HBO2 group having patients with slightly more severe MIs. 
In 1973, this same group published the results of an another similar, but larger, 
randomised control study (Thurston et al., 1973). The primary objective of that 
study was to determine the effects of HBO2 on mortality following recent 
AMI. In that study, 103 and 105 patients were randomised to the HBO2 and 
control groups, respectively. Both groups of patients were treated using the 
unit’s protocol for AMI. However, the HBO2 group of patients also received 
100% oxygen at 2 ATA for 2 hours followed by air for 1 hour in a repeating 
cycle, day and night, for 48 hours. It was observed that in the HBO2 group, 
compared to the control group, there was a reduction in mortality 3 weeks after 
an AMI and a reduction in significant dysrrhythmias (complete heart block, 
ventricular fibrillation and asystole). That study concluded that the reduction in 
major adverse coronary events after an AMI in the HBO2 group justified the 
routine use of HBO2 in selected cases of AMI. While the findings of that study 
indicated the favorable use of HBO2 post AMI to reduce mortality, the results 
were however not statistically significant.  
Since those randomised controlled studies of the early 1970s, 
there had been a paucity in the number of reported clinical studies 
investigating the effects of HBO2 on myocardial ischaemia and reperfusion. 
This was probably driven by the lack of statistically significant clinical 
findings and a lack of understanding of the biochemical mechanisms of action 
of HBO2 in models of ischaemia and reperfusion. However, from the 1980s 
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onwards, following a series of studies demonstrating the beneficial effects of 
HBO2 in experimental models of IRI (Nylander et al., 1985, Sterling et al., 
1993, Nylander et al., 1987, Yamada et al., 1995, Chen et al., 1998, Kim et al., 
2001, Choi et al., 2006, Tjarnstrom et al., 2001), there appeared to be a steady 
resurgence in the interest of administering HBO2 to limit                     
ischaemia-reperfusion associated myocardial injury.   
In the earliest clinical study investigating the effects of HBO2 on 
myocardial function following IRI, a study was designed to determine the 
potential for HBO2 to produce an improvement in myocardial function in the 
hibernating myocardium (Swift et al., 1992). That study found that, compared 
to those patients who were not treated with HBO2 post AMI, patients who were 
also treated with HBO2 consisting of 100% oxygen at 2.0 ATA for 30 minutes 
following an AMI, had improved myocardial contraction as observed by 
echocardiography and, demonstrated reversible ischaemia as determined by 
Single Photon Emission Computer Tomography (SPECT). The interesting 
findings from that study were later followed by the first study from ‘HOT-MI’ 
group (Shandling et al., 1997) which was conducted to assess the safety of 
treating patients, who recently suffered from an AMI, with HBO2. In the that 
study by the ‘HOT-MI’ group, 66 patients with an AMI were randomised to 
treatment with HBO2, which consisted of 100% oxygen at 2 ATA for 60 
minutes, in addition to recombinant tissue plasminogen activator (rTPA) 
(n=32) or treatment with rTPA alone (n=34). The results showed that in 
patients who were also treated with HBO2, there was a 35% reduction in mean 
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creatine phosphokinase (CK) (p=0.03) at 12 and 24 hours post MI and, a 
reduction in time to pain relief and ST segment resolution post MI. The 
ejection fraction (EF) on discharge of the HBO2 group of patients was 52.4% 
while that of the control group’s was 47.3%. The study concluded that 
adjunctive HBO2 was a feasible and safe treatment for patients who had 
suffered from an AMI. This group later validated their findings by conducting 
a second similar, but larger randomised controlled study. In that later 
study (Stavitsky et al., 1998), 112 patients who were admitted with an AMI 
were randomised to treatment with either HBO2 and either rTPA or 
streptokinase (STK) or, to a group that was treated with only rTPA or STK. In 
that second study by the ‘HOT MI’ group, it was observed that patients in the 
HBO2 group had a CK that was 7.5% lower than the control group at 12 and 24 
hours post AMI. Additionally, the HBO2 group of patients also experienced a 
shorter time to pain relief. The left ventricular ejection fraction (LVEF) on 
discharge in the HBO2 group was also better than the control group, 48.4% 
compared to 43.4%, respectively. 
The ‘HOT-PI’ study (Sharifi et al., 2004) was conducted to 
assess whether using HBO2 as an adjunct to percutaneous coronary 
intervention (PCI) in patients who presented with unstable angina or AMI, 
could reduce clinical re-stenosis. In that randomised control study, 33 and 36 
patients were randomised to the HBO2 and control group, respectively. All the 
patients presented with unstable angina or AMI and were treated according to 
the unit’s protocol for AMI. The patients randomised to the HBO2 group also 
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received HBO2 treatment 2 hours before or immediately after PCI followed by 
another treatment less than 18 hours after the first HBO2 treatment. The HBO2 
treatment consisted of 100% oxygen at 2 ATA for 90 minutes. In that study, 8 
months post treatment for AMI, the HBO2 group not only had a significant 
reduction of composite adverse cardiac events (p=0.001), which included 
mortality, MI, CABG or revascularization of target lesion, but there was also a 
significant reduction in both the revascularization of the previous target lesion 
(p<0.003) and the recurrence of angina  (p<0.003). However, it was also found 
that while collectively there was a significant reduction in composite adverse 
cardiac event, the reduction in mortality rate in the HBO2 group was not 
statistically significant. That finding was in keeping with findings from earlier 
clinical studies (Sharifi et al., 2002, Thurston, 1971, Thurston et al., 1973).  
In 2005, the Cochrane Collaborative (Bennett et al., 2005) 
conducted a meta-analysis to review the effects of clinical treatment with 
HBO2 following an acute coronary syndrome (ACS). The meta-analysis 
comprised of 6 randomised control trials (Sharifi et al., 2004, Dekleva et al., 
2004, Stavitsky et al., 1998, Shandling et al., 1997, Swift et al., 1992, Thurston 
et al., 1973) consisting of a total of 536 patients (n=273 were treated with 
HBO2, n=263 were not treated with HBO2). This meta-analysis showed that 
while there was a trend towards significance, there was no statistically 
significant decrease in the risk of death in patients who were also treated with 
HBO2 (p=0.08). There was however a significant reduction in the time to pain 
relief following the onset of angina (p<0.0001) in this group of patients. The 
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Cochrane Collaborative Group concluded that despite HBO2 treatment 
following ACS, in individual trials, having the potential to significantly reduce 
the risk of major adverse coronary events (p=0.03) and some dysrrhythmias 
(p=0.01), particularly complete heart block (p=0.02), it did not demonstrate the 
potential to significantly reduce mortality following an ischaemic reperfusion 
event such as ACS. This they determined was due to study flaws in those trials 
such as modest patient numbers, methodological shortcomings and poor 
reporting. As such, until an appropriately powered study of high 
methodological rigor is conducted to identify those cardiac patients who can be 
expected to benefit from HBO2 treatment, the routine application of HBO2 
treatment in clinical practices where IRI is a common occurrence, remains to 
be justified. 
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3.2  Objectives 
 The primary cardiovascular efficacy objective for this part of 
this clinical study was to determine if systemically treating CAD patients with 
HBO2 preconditioning, involving two episodes of 30 minutes of 100% oxygen 
at 2.4 ATA separated 5 minutes apart, which was completed approximately 2 
hours prior to on CPB CABG, is capable of remotely preconditioning the 
myocardium by leading to better post operative improvement in myocardial 
function, as measured by left ventricular stroke work (LVSW) at the time point 
24 hours post CPB. Additionally, the secondary objectives for this part of the 
study was to estimate the effect of HBO2 preconditioning on: 
a. other peri-operative cardiovascular efficacy parameters,  
as measured by the haemodynamic parameters at the  
pre-specified time points listed in Table 2.4. 
b. patient outcomes with respect to post operative safety, as    
measured by the AEs listed in Table 2.3. 
A post hoc analysis of the cost effectiveness HBO2 preconditioning was also 
conducted. 
3.3 Methods 
Peri-operative (pre, intra and post operative) patient data were 
collected as described in section 2.6.1-2.6.3 and peri-operative haemodynamic 
data were collected using a PA catheters as described in section 2.6.4.  
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3.4 Results 
Table 3.1 shows the baseline patient characteristics and Table 
3.2 shows the intra operative disposition of the patients recruited to this 
randomised controlled study. The patient ages and gender were similar between 
the groups. The Control Group had a higher mean pre-operative risk score with a 
Euroscore of 3.78 while the HBO2 Group had a EUROSCORE of 2.83. The 
Control Group also had a slightly higher number of patients with unstable angina, 
previous MI, hypertension and diabetes compared to the HBO2 Group. There 
were however slightly more patients with peripheral vascular disease in the HBO2 
Group compared to the Control Group. The majority of patients in the Control 
Group (n=20; 50%) and HBO2 Group (n=22; 55%) had CABG x 3. More patients 
in the HBO2 Group, compared to the Control Group, had CABG x 1 (n=2; 5% vs. 
n=1; 2.5%) and CABG x 3 (n=22; 55% vs. n=20; 50%). However, more patients 
in the Control Group (n=5; 12.5%), compared to the HBO2 Group, had CABG x 4 
(n=3; 7.5%). The Control Group, compared to the HBO2 Group, had a slightly 
longer mean myocardial ischaemic time (29.2 minutes vs. 27.6 minutes) and a 
slightly longer mean CPB time (65.8 minutes vs. 62.5 minutes).  
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Table 3. 1: Baseline Patient Characteristics 
 
Variable Control Group 
(n=40) 
HBO2 Group 
(n=41) 
Age (years; mean) 69 65 
Men 29 (72.5%) 33 (80.5%) 
BMI 28.8 28.2 
Pre-op Euroscore (mean) 3.78 2.83 
Unstable Angina 3 (7.5%) 1 (2.5%) 
Previous MI 20 (51.3%) 16 (41.0%) 
Left Main Stem Disease 13 (32.5%) 13 (31.7%) 
1 Diseased Coronary Artery 0 1 (2.4%) 
2 Diseased Coronary 
Arteries 
7 (17.5%) 8(19.5%) 
33 Diseased Coronary 
Arteries 
33(82.5%) 32(78.0%) 
Left Ventricular Function   
≥ 50% 
31 (79.5%) 33 (82.5%) 
Left Ventricular Function 
30% -  50% 
7 (17.9%) 7 (17.5%) 
Hypertension 30 (75.0%) 25 (62.5%) 
Diabetes Mellitus 5 (12.5%) 3 (7.5%) 
Peripheral Vascular Disease 1 (2.5%) 3 (7.5%) 
 
 
Table 3. 2: Intra Operative Patient Disposition 
 
Variable Control Group 
(n=40) 
HBO2 Group 
(n=41) 
CABG X 1 1 (2.5%) 2 (5.0%) 
CABG X 2 13 (32.5%) 13 (32.5%) 
CABG X 3 20 (50.0%) 22 (55.0%) 
CABG X 4 5 (12.5%) 3 (7.5%) 
CABG X 5 1 (2.5%) 1 (2.5%) 
Myocardial Ischaemia Time 
(minutes; mean) 
29.2 27.6 
Cardiopulmonary Bypass 
Time (minutes; mean) 
65.8 62.5 
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3.4.1 Effects Of HBO2 Preconditioning On Peri-
Operative Haemodynamic Parameters 
In this study, only 22 patients (54%) in the HBO2 Group and 25 
patients in the Control Group (63%) had their haemodynamic parameters 
measured. This was due to an insufficient number of monitoring equipment 
required for measuring haemodynamic parameters.  This insufficiency 
occurred because the haemodynamic monitoring equipment was required for 
the management of other more critical ICU patients. As 46% (n=19) patients in 
the HBO2 Group and 37% (n=15) patients in the Control Group did not have 
any peri-operative haemodynamic measurements, and no imputation of data 
were carried out in this study, only an on-treatment analysis of the 
haemodynamic measurement was done. This was because, due to the large 
numbers of patients without peri-operative hemdynamic measurements, an 
intention to treat analysis would reveal results that were not clinically 
meaningful. 
Due to the large number of peri-operative haemodynamic 
measurements that were recorded during this study, only the results of the 
primary endpoint (LVSW) and, results which showed statistical significance, 
are reported. In this study, only LVSW, LVSWI, SV, PVR and PVRI show 
statistically significant results.  
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a. Peri-Operative Mean LVSW & LVSWI 
In this study, in both groups, between the baseline ‘post 
induction’ time point and the time point ‘24 hours post CPB’, there were  
general increases in the mean LVSW and mean LVSWI in both the groups. At 
all time points following the baseline ‘post induction’ time point, the mean 
LVSW and mean LVSWI were higher in the HBO2 Group. In this study, it was 
determined that at all the time points following the ‘post induction’ time point, 
there were statistically significant improvements in both the mean LVSW 
(p=0.005; Geometric Mean Estimate & 95% Confidence Interval: 1.28 & 1.05, 
1.31) (Figure 3.1) and the mean LVSWI (p=0.02; Geometric Mean Estimate & 
95% Confidence Interval: 1.12 & 1.02, 1.24) (Figure 3.2)  in the HBO2 Group, 
compared to the Control Group. A summary of the results are provided in 
Table 3.3. In this table, the data are displayed as both mean and median values. 
As the means and medians are not the same at each time point, this indicates 
that the data were skewed. To normalise the data and enable parametric 
statistical analysis, the mean values were transformed into natural logarithmic 
(ln) values.  
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Figure 3. 1: Bar Chart of Peri-Operative Mean LVSW 
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Figure 3. 2: Bar Chart of Peri-Operative Mean LVSWI 
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Table 3. 3: Peri-Operative LVSW & LVSWI 
 
† This is an on treatment analysis; 
Statistical analysis using repeated measures of ANOVA; 
¥95% Confidence Intervals and p values are only given where the result is statistically 
significant;  
*p values are for geometric means 
 
 
 
  LVSW 
(g.m/beat) 
LVSWI 
(g.m/m2/beat) 
 
 
 
 Control 
Group 
[n=25]† 
HBO2 
Group 
[n=22]† 
Control 
Group 
[n=25]† 
HBO2 
Group 
[n=22]† 
 
 
Post Induction 
Range 32-111 29-89 18-55 15-43 
Median 59 62 30 32 
Mean 58 60 31 30 
Mean Ln 4.1 4.1 3.4 3.4 
Geometric  Mean Estimate & 95% Confidence 
Interval¥      (p-value*) 
p=0.08 p=0.08 
 
 
5 minutes post 
CPB 
Range 33-73 35-82 18-37 20-42 
Median 50 55 24 29 
Mean 50 60 26 30 
Mean Ln 3.9 4.1 3.3 3.4 
Geometric  Mean Estimate & 95% Confidence 
Interval¥      (p-value*) 
1.28 & 1.05-1.31 
(p=0.005) 
1.12 & 1.02- 1.24 
(p=0.02) 
 
 
2 hours post 
CPB 
Range 30-115 51-129 16-54 26-76 
Median 61 72 30 36 
Mean 59 76 31 36 
Mean Ln 4.1 4.3 3.4 3.6 
Geometric  Mean Estimate & 95% Confidence 
Interval¥      (p-value*) 
1.28 & 1.05-1.31 
(p=0.005) 
1.12 & 1.02- 1.24 
(p=0.02) 
 
 
4 hours post 
CPB 
Range 35-87 33-111 19-45 18-56 
Median 54 59 39 30 
Mean 54 62 25 31 
Mean Ln 4.0 4.1 3.2 3.4 
Geometric  Mean Estimate & 95% Confidence 
Interval¥      (p-value*) 
1.28 & 1.05-1.31 
(p=0.005) 
1.12 & 1.02- 1.24 
(p=0.02) 
 
 
8 hours post 
CPB 
Range 29-90 34-129 16-40 18-65 
Median 55 65 30 33 
Mean 58 70 30 35 
Mean Ln 4.1 4.2 3.4 3.6 
Geometric  Mean Estimate & 95% Confidence 
Interval¥     (p-value*) 
1.28 & 1.05-1.31 
(p=0.005) 
1.12 & 1.02- 1.24 
(p=0.02) 
 
 
12 hours post 
CPB 
Range 35-93 35-98 19-49 19-51 
Median 63 65 32 35 
Mean 58 68 26 34 
Mean Ln 4.1 4.2 3.2 3.5 
Geometric  Mean Estimate & 95% Confidence 
Interval¥      (p-value*) 
1.28 & 1.05-1.31 
(p=0.005) 
1.122 & 1.02- 1.24 
(p=0.02) 
 
 
24 hours post 
CPB 
Range 35-91 48-144 19-48 21-79 
Median 63 73 33 39 
Mean 67 80 35 48 
Mean Ln 4.2 4.4 3.6 3.9 
Geometric  Mean Estimate & 95% Confidence 
Interval¥     (p-value*) 
1.28 & 1.05-1.31 
(p=0.005) 
1.122 & 1.02- 1.24 
(p=0.02) 
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b. Peri-Operative Mean SV 
In this study, in both groups, between the baseline ‘post 
induction’ time point and the time point ‘24 hours post CPB’, there was a 
general increase in mean SV in both groups. At all time points following the 
baseline ‘post induction’ time point, the mean stroke volume (SV) was higher 
in the HBO2 Group. At all the time points following the ‘post induction’ time 
point, there was a statistically significant improvement in SV                
(p=0.01; Geometric Mean Estimate & 95% Confidence Interval: 1.13 & 1.03, 
1.25) (Figure 3.3) in the HBO2 Group compared to the Control Group. A 
summary of the results are provided in Table 3.4. In this table, the data are 
displayed as both mean and median values. As the means and medians are not 
the same at each time point, this indicates that the data were skewed. To 
normalise the data and enable parametric statistical analysis, the mean values 
were transformed into natural logarithmic (ln) values.  
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Figure 3. 3: Bar Chart of Peri-Operative Mean SV 
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   Bars chart showing mean values and error bars for the standard error of the mean; 
   * p<0.05 following repeated measures of ANOVA analysis 
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Table 3. 4: Peri-Operative SV 
 
 
† This is an on treatment analysis; 
Statistical analysis using repeated measures of ANOVA; 
 ¥95% Confidence Intervals and p values are only given where the result is statistically 
significant;  
*p values are for geometric means 
 
 
 
  SV 
(ml/beat) 
 
 
 
 Control 
Group 
[n=25]† 
HBO2 
Group 
[n=22]† 
 
 
Post Induction 
Range 32-91 37-94 
Median 59 62 
Mean 62 65 
Mean Ln 4.1 4.2 
Geometric  Mean Estimate & 95% Confidence Interval¥                
(p-value*) 
p=0.07 
 
 
5 minutes post 
CPB 
Range 39-86 43-94 
Median 60 63 
Mean 60 66 
Mean Ln 4.1 4.2 
Geometric  Mean Estimate & 95% Confidence Interval¥ 
(p-value*) 
1.13 & 1.03-1.25 
(p=0.01) 
 
 
2 hours post CPB 
Range 26-99 47-81 
Median 57 63 
Mean 57 65 
Mean Ln 4.0 4.2 
Geometric  Mean Estimate & 95% Confidence Interval¥ 
(p-value*) 
1.13 & 1.03-1.25 
(p=0.01) 
 
 
4 hours post CPB 
Range 33-92 35-94 
Median 53 60 
Mean 58 60 
Mean Ln 4.1 4.1 
Geometric  Mean Estimate & 95% Confidence Interval¥ 
(p-value*) 
1.13 & 1.03-1.25 
(p=0.01) 
 
 
8 hours post CPB 
Range 38-97 52-137 
Median 58 64 
Mean 58 72 
Mean Ln 4.1 4.3 
Geometric  Mean Estimate & 95% Confidence Interval¥ 
(p-value*) 
1.13 & 1.03-1.25 
(p=0.01) 
 
 
12 hours post 
CPB 
Range 48-110 41-92 
Median 64 68 
Mean 68 68 
Mean Ln 4.2 4.2 
Geometric  Mean Estimate & 95% Confidence Interval¥ 
(p-value*) 
1.13 & 1.03-1.25 
(p=0.01) 
 
 
24 hours post 
CPB 
Range 43-99 44-115 
Median 63 76 
Mean 63 75 
Mean Ln 4.1 4.3 
Geometric  Mean Estimate & 95% Confidence Interval¥ 
(p-value*) 
1.13 &1.03-1.25 
(p=0.01) 
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c.  Peri-Operative Mean PVR & PVRI 
In this study, in both groups, between the baseline ‘post 
induction’ time point and the time point ‘24 hours post CPB’, there was a 
general decrease in the mean PVR and PVRI in both groups. At all time points 
following the baseline ‘post induction’ time point, both the mean PVR and 
PVRI were lower in the HBO2 Group. In this study it was determined that at 
the baseline ‘post induction’ time point, there was a statistically significant 
decrease in PVR (p=0.03; Geometric Mean Estimate & 95% Confidence 
Interval: 1.55 & 1.05, 2.29) (Figure 3.4) and the PVRI (p=0.05; Geometric 
Mean Estimate & 95% Confidence Interval: 1.49 & 1.02, 2.12) (Figure 3.5) in 
the HBO2 Group compared to the Control Group. A summary of the results are 
provided in Table 3.5. In this table, the data are displayed as both mean and 
median values. As the means and medians are not the same at each time point, 
this indicates that the data were skewed. To normalise the data and enable 
parametric statistical analysis, the mean values were transformed into natural 
logarithmic (ln) values.  
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Figure 3. 4: Bar Chart of Peri-Operative Mean PVR 
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Figure 3. 5: Bar Chart of Peri-Operative Mean PVRI 
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Table 3. 5: Peri-Operative PVR & PVRI 
 
 
 
† This is an on treatment analysis; 
Statistical analysis using repeated measures of ANOVA; 
 ¥95% Confidence Intervals and p values are only given where the result is statistically 
significant;  
*p values are for geometric means 
 
 
 
  PVR 
(dyns.cm5) 
PVRI 
(dyns.cm5/m2) 
 
 
 
 Control 
Group 
[n=25]† 
HBO2 
Group 
[n=22]† 
Control 
Group 
[n=25]† 
HBO2 
Group 
[n=22]† 
 
 
Post Induction 
Range 72-303 21-309 68-530 42-571 
Median 150 100 281 208 
Mean 158 110 292 228 
Mean Ln 5.1 4.7 5.7 5.4 
Geometric  Mean Estimate & 95% 
Confidence Interval¥      (p-value*) 
1.55 & 1.05-2.29 
(p=0.03) 
1.49 & 1.01, 2.19 
(p=0.05) 
 
 
5 minutes post 
CPB 
Range 46-855 12-218 45-349 65-432 
Median 125 101 212 129 
Mean 141 130 230 219 
Mean Ln 4.9 4.9 5.4 5.4 
Geometric  Mean Estimate & 95% 
Confidence Interval¥      (p-value*) 
0.08 0.08 
 
 
2 hours post 
CPB 
Range 51-220 11-341 70-623 22-681 
Median 133 121 248 237 
Mean 140 150 280 263 
Mean Ln 4.9 5.0 5.6 5.6 
Geometric  Mean Estimate & 95% 
Confidence Interval¥      (p-value*) 
0.08 0.08 
 
 
4 hours post 
CPB 
Range 24-1246 53-661 24-1246 53-661 
Median 166 168 227 258 
Mean 149 135 273 253 
Mean Ln 5.0 4.9 5.6 5.5 
Geometric  Mean Estimate & 95% 
Confidence Interval¥      (p-value*) 
0.08 0.08 
 
 
8 hours post 
CPB 
Range 23-589 32-432 23-589 32-432 
Median 141 130 245 229 
Mean 129 121 236 226 
Mean Ln 4.9 4.8 5.5 5.1 
Geometric  Mean Estimate & 95% 
Confidence Interval¥     (p-value*) 
0.08 0.08 
 
 
12 hours post 
CPB 
Range 80-408 27-543 80-408 27-543 
Median 121 123 239 229 
Mean 115 112 236 220 
Mean Ln 4.7 4.7 5.4 5.4 
Geometric  Mean Estimate & 95% 
Confidence Interval¥      (p-value*) 
0.08 0.08 
 
 
24 hours post 
CPB 
Range 28-538 29-406 28-538 29-406 
Median 129 119 243 231 
Mean 113 106 225 219 
Mean Ln 4.7 4.6 5.4 5.4 
Geometric  Mean Estimate & 95% 
Confidence Interval¥     (p-value*) 
0.08 0.08 
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3.4.2 Effects Of HBO2 Preconditioning On Post 
Operative Clinical Safety 
3.4.2.1 Cardiovascular Adverse Events 
  In this study, compared to the Control Group, in the HBO2 
Group, there was a 10.4% reduction in the proportion of patients with low 
cardiac output syndrome (p=0.4), an 8% reduction in the proportion of patients 
requiring the use of inotropes (p=0.1) and an 11% reduction in the proportion 
of patients with AF (p=0.6) (Table 3.6). There were no incidences of the use of 
cardiovascular supportive therapy (IABP or pacing), MI or mortality in either 
group.  
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Table 3. 6: Post Operative Cardiovascular Adverse Events 
 
Values are patient numbers with percentages in brackets; 
 †This is an intention to treat analysis; 
 Statistical analysis using Chi-Squared Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiovascular Adverse Event 
 
Control 
Group 
(n=40)† 
 
HBO2 
Group 
(n=41)† 
 
p- value 
 
Low cardiac output 10 (25%) 6 (14.6%) 0.4 
Inotrope Usage 10 (25%) 7 (17%) 0.4 
1. Adrenaline 
2. Dopamine 
3. Noradrenaline 
4.Adrenaline + Dopamine 
5. Adrenaline +  Noradrenaline 
6. Adrenaline +  Milrinone 
7.Adrenaline +  Noradrenaline + 
Milrinone 
2 
3 
0 
1 
2 
1 
1 
1 
3 
2 
0 
1 
0 
0 
 
Atrial Fibrillation 10 (25%) 6 (14%) 0.4 
Cardiovascular Supportive Therapy 
(IABP, pacing) 
0 0 1.0 
Myocardial Infarction 0 0 1.0 
Mortality 0 0 1.0 
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Patients in the HBO2 Group had a 57% reduction in intra-
operative blood loss compared to patients in the Control Group (p=0.02). 
There were no significant difference between the groups with respect to post 
operative blood loss and blood transfusion. However, in the HBO2 Group, 
compared to the Control Group, there was an 11.6% reduction in post 
operative (p=0.1) blood loss and a 34% reduction in post operative blood 
transfusion (p=0.4) (Table 3.7).  
 
Table 3. 7: Intra-Operative & Post Operative Blood Loss & Blood Transfusion 
 
  
Control 
Group 
(n=40)† 
 
HBO2 
Group  
(n=41) † 
 
% Mean 
Reduction 
in 
HBO2 Group 
 
p- 
value 
 
95% 
Confidence 
Intervals 
(for % 
change) 
 
Intra 
Operative 
Blood Loss 
(ml) 
 
Range 
 
0-1528 
 
0-961 
 
[(309-133)/ 
309] X 100 
= 57 
 
 
 
0.02 
 
 
-318, -32 
 
Mean 
 
309 
 
133 
 
Post 
Operative 
Blood Loss 
(ml) 
 
Range 
 
255-
1295 
 
325-
1330 
 
[(727-643)/ 
727] X 100 
= 11.6 
 
 
 
0.1 
 
 
-31, 200 
 
Mean 
 
727 
 
643 
 
 
Total blood 
transfusion 
(ml) 
 
 
Range 
 
0-612 
 
0-610 
 
[(138-91)/ 
138] X 100 
=34 
 
 
 
0.4 
 
 
-63, 159 
 
Mean 
 
138 
 
91 
†This is an intention to treat analysis 
Statistical analysis using Independent Sample t-test 
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3.4.2.2 Pulmonary Adverse Events 
Patients in the HBO2 Group had a mechanical ventilation time 
and an endotracheal intubation time that was 30 minutes longer compared to 
patients in the Control Group. Neither of these results were significant      
(Table 3.8). 
 
Table 3. 8: Post Operative Duration of Ventilation & Intubation 
 
 Control Group 
(n=40) † 
HBO2 Group 
(n=41) † 
p-value 
Mechanical 
Ventilation Time 
(hours) 
Range Mean Range Mean  
1-13.5 2.5 0-18 3.0 0.2 
Duration of 
Intubation 
(hours) 
1.5-14 3.0 0.5-18.5 3.5 0.2 
   †This is an intention to treat analysis; 
   Statistical analysis using Chi-Squared Test 
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In this study, compared to the Control Group, in the HBO2 
Group, there was a 12.7% reduction in the proportion of patients with  
pulmonary AEs (p=0.3) (Table 3.9). There were no incidences of 
pneumothoraces, pleural effusions or the use of pulmonary supportive therapy 
in the HBO2 Group, all of which were increased in the Control Group. While 
there was a 5.1% reduction in chest infections in the HBO2 Group (p=0.9), 
there was one patient (2.4%) in this group with a chest infection associated 
with pleural effusion.   
 
Table 3. 9: Post Pulmonary Adverse Events 
 
Values are patient numbers with percentages in brackets;  
†This is an intention to treat analysis; 
Statistical analysis using Chi-Squared Test; 
 BiPAP=Biphasic Positive Airway Pressure; CPAP=Continous Positive Airway Pressure   
 
 
 
 
 
 
 
 
Control 
Group 
(n=40)† 
HBO2 
Group 
(n=41)† 
 
p-value 
 
Pulmonary Adverse Events 9 
(22.5%) 
4 
(9.8%) 
0.3 
1. Pneumothorax 1 (2.5%) 0 1 
2. Pleural Effusion 2 (5%) 0 0.9 
3. Chest Infection 4 (10%) 2 (4.9%) 0.9 
4. Pulmonary atelectasis  requiring 
pulmonary supportive therapy  
(BiPAP/CPAP) 
1 (2.5%) 0 
 
1 
5. Chest infection +  Pleural Effusion 0 1 (2.4%) 1 
6. Other 1 (2.5%) 1 (2.4%) 1 
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3.4.2.3 Renal Adverse Events 
  In this study, there were no incidences of serum           
creatinine > 200mmol/l in the HBO2 while in the Control Group, there were 
two patients (5%) (Table 3.10). There were no incidences requiring the use of 
renal supportive therapy in either group. 
Table 3.10: Post Operative Renal Adverse Events 
 
Values are patient numbers with percentages in brackets;  
†This is an intention to treat analysis;  
Statistical analysis using Chi-Squared Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Renal Adverse Event 
Control 
Group 
(n=40)† 
HBO2 
Group 
(n=41)† 
 
p-value 
 
Creatine>200mmols/l 2 (5%) 0 0.9 
Renal Supportive Therapy (CVVH) 0 0 1.0 
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3.4.2.4 Neurological Adverse Events 
In this study, there was one patient (2.5%) who developed 
transient confusion associated with blurred vision in the Control Group. There 
were no incidences of TIAs or strokes in both groups (Table 3.11).  
Table 3.11: Post Operative Neurological Adverse Events 
 
Values are patient numbers with percentages in brackets;  
†This is an intention to treat analysis; 
Statistical analysis  using Chi-Squared Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neurological Adverse Event 
Control 
Group 
(n=40)† 
HBO2 
Group 
(n=41)† 
 
p-value 
 
Confusion  +  blurred vision 1 (2.5%) 0 1.0 
TIA 0 0 1.0 
Stroke 0 0 1.0 
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3.4.2.5 Gastrointestinal Adverse Events 
  In this study, both the HBO2 and the Control Group had similar 
proportions of patients who experienced gastrointestinal AEs (Table 3.12). 
There was one patient (2.5%) in the Control Group who developed Clostridia 
Difficiele diarrhoea while there were none in the HBO2. There were no 
incidences of ischaemic bowel in either group. 
Table 3.12: Post Operative Gastrointestinal Adverse Events 
 
Values are patient numbers with percentages in brackets;  
†This is an intention to treat analysis;  
Statistical analysis using Chi-Squared Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Control 
Group 
(n=40)† 
HBO2 
Group 
(n=41)† 
 
p-value 
 
Gastrointestinal Adverse Event 1 (2.5%) 1 (2.4%) 1.0 
1. Clostridia Difficiele Diarrhoea 1 0 1.0 
2. Ischaemic Bowel 0 0 1.0 
3. Other 0 1 1.0 
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3.4.2.6 Microbiological Adverse Events 
  Compared to the Control Group, in the HBO2 Group there was a 
7.6% reduction in the proportion of patients who experienced microbiological 
AEs (p=0.8) (Table 3.13). There were no incidences of superficial sternal or 
deep sternal wound infections in the HBO2 Group, of which there were three 
patients (7.3%) and one patient (2.5%), respectively in the Control Group. 
There was however, one patient (2.4%) who developed leg wound infection in 
the HBO2 Group while there were none in the Control Group. There were no 
incidences of patients requiring sternal wound re-wiring secondary to deep 
sternal wound infection in the HBO2 while there was one (2.5%) patient in the 
Control Group. 
Table 3.13: Post Operative Microbiological Adverse Events 
 
Values are patient numbers with percentages in brackets; 
 †This is an intention to treat analysis;  
Statistical analysis using Chi-Squared Test 
 
 
 
 
 
 
 Control 
Group 
(n=40)† 
HBO2 
Group 
(n=41)† 
 
p-value 
 
Microbiological Adverse Event 
(based on bacterial culture results) 
4 (10%) 1 (2.4%) 0.8 
1. Superficial  sternal wound infections 3 (7.3%) 0 0.8 
2. Deep sternal  wound infections 1 (2.5%) 0 1.0 
3. Leg  wound infections 0 1 (2.4%) 1.0 
Sternal infection requiring re-wiring 1 (2.5%) 0 1.0 
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3.4.2.7 Post Operative ICU Length of Stay 
In this study, after adjusting for longest aortic cross clamp and 
CPB time, there was a statistically significant reduction in the post operative 
ICU length of stay of patients in the HBO2 Group compared to those in the 
Control Group (p=0.05; Geometric Mean Estimate & 95% Confidence Interval 
for the difference: 1.18 and 0.02, 7.96). On the average, patients in the HBO2 
Group spent 4 hours less in ICU. A summary of the results are provided in 
Table 3.14. In this table, the data are displayed as both mean and median 
values. As the means and medians are not the same at each time point, this 
indicates that the data were skewed. To normalise the data and enable 
parametric statistical analysis, the mean values were transformed into natural 
logarithmic (ln) values.  
 
Table 3.14: Post Operative ICU Length of Stay 
 
 
 
 
 
Control 
Group 
(n=40) † 
HBO2 
Group 
(n=41) † 
Geometric Mean 
Estimate & 95% 
Confidence Interval 
(p-value *) 
 
 
 
Length of 
ICU Stay 
(hours) 
Total 1051 
 
850 
 
 
 
 
 
1.18 & 0.99, 1.39 
(p=0.05) 
Range 21-76 
 
6-28 
Median 24 18 
Mean 18 14 
Mean Ln 2.89 2.64 
*p values are for geometric means; 
 †This is an intention to treat analysis; 
Statistical analysis using Independent Sample t-test 
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3.4.3  Cost Effectiveness of HBO2 Preconditioning  
The post hoc cost effectiveness analysis of HBO2 
preconditioning is shown in Table 3.15. For this study, the HBO2 treatment as 
a whole was estimated to be approximately £200 per patient. The cost for the 
use of the ICU bed per day at Castle Hill Hospital (Hull & East Yorkshire NHS 
Trust) was estimated to be approximately £2,000. Using these cost estimates, it 
was calculated that patients treated with HBO2 prior to CABG saved 
approximately £292.63 per patient, in terms of ICU bed cost. This equated to 
an estimated savings of approximately £73.16 per saved ICU hour.   
 
Table 3.15: Summary of Cost 
 
Item Cost (£) 
HBO2 Treatment 200 
HBO2 treatment for 34 patients 6,800 
ICU bed per day (24 hours) 2000 
ICU bed per hour 2000/24 = 83.33 
ICU stay for 35 Control patients (A) 
(see Table 3.14) 
83.33 x 1051 = 87,579.83 
ICU stay for 34 HBO2 patients 
(see Table 3.14) 
83.33 x 850 = 70,830.50 
HBO2 treatment  + ICU stay for 34 
patients (B) 
6,800 + 70,830.50 = 77,630. 50 
Total Savings for HBO2 patients  
(A-B=C) 
(savings made by 34 HBO2 patients 
who spent a total of 1051-850=201 
hours less in ICU; see Table 3.14) 
 
 
87,579.83 - 77,630. 50 = 9,949.33 
Savings per HBO2 patient in ICU 
(C/34=D) 
9,949.33/34 = 292.63 
Savings per mean ICU hour saved 
(see Table 3.14) in each HBO2 
patient (D/4) 
 
292.63/4 = 73.16 
*This is an on treatment analysis 
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3.5  Discussion 
3.5.1  Peri-Operative Cardiovascular Efficacy of 
HBO2 Preconditioning 
In this study it was observed that following the termination of CPB, 
in the HBO2 Group, there were statistically significant increases in the mean LVSW 
(Figure 3.1), LVSWI (Figure 3.2) and SV (Figure 3.3). At present, there are no 
other published clinical studies that have determined the effects of HBO2 
preconditioning on myocardial function following IRI. These findings, however, do 
not corroborate with the findings of an experimental study of HBO2 
preconditioning prior to IRI (Radice et al., 1997). In that study, it was found that 
preconditioning rats with 100% O2 at 2.5 ATA for 1 hour, 3 hours or 6 hours, prior 
to ischaemia of 40 minutes and reperfusion of 20 minutes, resulted in a time 
proportional increase in the heart resting tension (left ventricular end-diastolic 
pressure). This reflects an increased degree of ventricular stiffness and depression 
of myocardial mechanics. In that study, it was suggested that the findings were in 
keeping with the observation by others that high oxygen tension (100%) increased 
isometric systolic tension and alters coronary flow as a result of oxygen 
toxicity (Daniell and Bagwell, 1968). This may well be the explanation for the 
findings in that experimental study but is one that cannot be used in the current 
HBO2 clinical study which demonstrated haemodynamic benefits from HBO2 
preconditioning. In this clinical HBO2 preconditioning protocol, the possibility of 
oxygen toxicity was mitigated by having a 5 minute air break between the two 30 
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minute periods of 100% O2 at 2.4 ATA. This HBO2 preconditioning protocol has 
also been safely used before (Alex et al., 2005) with no report of any 
cardiopulmonary decompensation or oxygen toxicity. By reducing the duration of 
exposure to HBO2 that is intermittent in nature and limiting the compression 
pressure to a level that is known to be clinically safe, the results from this clinical 
study indicate that preconditioning CAD patients with HBO2 prior to CABG may 
have the potential to enhance myocardial mechanical function post CABG and IRI.
  An indirect measure of support for the haemodynamic findings of the 
current clinical study comes from clinical studies where HBO2 was administered 
following the ischaemic-reperfusion event. Dekleva et.al  conducted a randomised 
control study to assess the benefits of HBO2, after thrombolysis, on the ventricular 
function and remodelling in patients who had suffered from an AMI  (Dekleva et 
al., 2004). 74 patients with first time AMI were randomly assigned to HBO2 
treatment consisting of 100% oxygen at 2 ATA for 60 minutes in addition to STK 
or treatment with just STK alone. In that study, it was observed that there was a 
significant decrease in end-systolic volume index from the first day to the third 
week after HBO2 treatment, in HBO2 group of patients compared with control 
group of patients. This was accompanied by a lack of changes in end diastolic 
volume index in the HBO2 group compared to increased values in the control 
group. The EF was also significantly improved in the HBO2 group while it 
decreased in the control group of patients 3 weeks after AMI. That study concluded 
that adjunctive HBO2 after thrombolysis in patients with an AMI, had a favourable 
effect on left ventricular function and the remodelling process. Further support 
comes from the ‘HOT MI’ study group (Shandling et al., 1997, Stavitsky et al., 
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1998). In the studies conducted by that group, it was observed that in the patients 
who were also treated with HBO2 following an AMI, there was an improvement in 
post MI EF. The ‘HOT-MI’ clinical studies demonstrated that HBO2, as a drug to 
adjunct thrombolysis, was capable improving systolic function while at the same 
time arresting any further deterioration in diastolic function following AMI. 
Furthermore, it showed that in the absence of HBO2 to adjunct thrombolysis, the 
control group went on to develop systolic and diastolic dysfunction post AMI. 
More recently, it was also observed that in diabetic patients who were being treated 
for non-healing lower extremity ulcers, after 10 HBO2 treatment sessions, these 
patients had an improved diastolic function (Aparci et al., 2008). Those clinical 
studies, together with the results from this current study, further support the premise 
that HBO2 treatment, pre and post myocardial ischaemia and reperfusion may be 
capable of improving myocardial function.   
In this study, it was also observed that prior to the onset of CPB 
(i.e. at the time point ‘post induction’), the PVR (Figure 3.4) and PVRI (Figure 
3.5) were significantly lower in the HBO2 Group compared to in the Control 
Group. This reduction in PVR and PVRI suggest that preconditioning CAD 
patients with HBO2 prior to CABG and IRI has the potential to reduce 
pulmonary vascular resistance and as such, improve pulmonary vascular blood 
flow. Physiologically, this finding is in keeping with what is known about 
pulmonary vascular reactivity following exposure to hyperoxia i.e. in response 
to hyperoxia, the pulmonary vessels dilate thus allowing improved blood flow. 
Furthermore, it also possible that these observations may be related to changes 
in the kinetics of sPSGL-1 and, this shall be discussed later in section 5. 
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3.5.2  Safety of HBO2 Preconditioning 
3.5.2.1 Cardiovascular Safety 
  While there were no statistically significant differences between 
the groups with respect to cardiovascular AEs, the proportion of patients with 
low cardiac output syndrome, AF or requiring inotrope use was lower in the 
HBO2 (Table 3. 6). This suggests that preconditioning CAD patients with 
HBO2 prior to on CPB CABG is a relatively safe procedure that does not lead 
significant post operative cardiovascular AEs. 
3.5.2.2 Pulmonary Safety 
  In this study, it was observed that patients in the HBO2 
Group had a post operative duration of mechanical ventilation and 
endotracheal intubation that was 30 minutes longer compared to patients in the 
Control Group (Table 3.8). These findings were not statistically significant and 
indicates that preconditioning CAD patients with HBO2 prior to on CPB 
CABG does not lead to prolonged post operative pulmonary support. This, in 
addition to the observation that this group of patients had a lower PVR and 
PVRI (Table 3.4) prior to CPB and, post operatively there was a lower 
proportion of patients who experienced combined pulmonary AEs (Table 3.9), 
suggests that this modality of treatment is a relatively safe procedure that does 
not lead significant post operative pulmonary AEs.  
     
 
  
163 
 
3.5.2.3 Renal, Neurological & Gastrointestinal Safety 
  In this study, the proportion of patients with renal and 
neurological AEs were lower in the HBO2 Group while the proportion of 
patients with gastrointestinal AEs were similar between the groups (Tables 
3.10-3.12). While none of these findings were statistically significant, it does 
suggest that  preconditioning CAD patients with HBO2 prior to on CPB CABG 
is a relatively safe procedure that does not lead significant post operative renal, 
neurological and GI AEs.  
3.5.2.4 Microbiological Safety 
In this study, the proportions of patients with wound infections 
was lower in the HBO2 Group. In particular, while the Control Group had 4 
cases of sternal wound infection, HBO2 Group had none. While there are a 
number of studies (Barili et al., 2007, De Feo et al., 2001, Lappa et al., 2003, 
Petzold et al., 1999) that have shown that treatment with HBO2 was a useful 
adjunct to promote sternal wound healing following post operative sternal 
wound infection, the results from this study suggests that HBO2 treatment prior 
to median sternotomy may also be capable of limiting post operative sternal 
wound infections (Table 3.13). Perhaps this may have been due to the 
induction of prophylactic anti-microbial effects of treatment with HBO2. This 
is plausible because oxygen and HBO2 have been described to have anti-
microbial properties (Park et al., 1992).   
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3.5.2.5 Post Operative Length of ICU Stay 
In this study it was observed that patients who were 
preconditioned with HBO2 prior to CABG and IRI had a significantly shorter 
post operative length of stay in ICU compared to patients in the Control Group.  
Age, CPB time, pre-CABG chronic COPD and pre-CABG pulmonary function 
are known to affect ICU length of stay (Nakasuji et al., 2005, Rosenfeld et al., 
2006). In this study, the ages of patients in both groups were similar (Table 
3.1). While the Control Group had slightly longer mean ischaemic and CPB 
times (Table 3.2), the potential confounding effect of these were mitigated by 
performing a multivariable linear regression analysis which adjusted for 
longest cross aortic clamp and CPB times. Patients with COPD were excluded 
from this study as they are more susceptible to pneumothoraces and this risk is 
increased in a HBO2 chamber where there are changes in pressure during the 
compression and decompression stages of the HBO2 treatment. As patients in 
both groups were of similar ages and appropriate statistical analysis had been 
performed to adjust for the potential confounding effect of time on CPB, it 
would be reasonable to suggest that HBO2 preconditioning was, in part, the 
cause for the shorter ICU stay that was observed in the HBO2 Group. This may 
have been the result of the HBO2 Group of patients having lower incidences of 
post operative AEs.  
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3.5.3  Cost Effectiveness 
  In this clinical study, the post hoc cost effectiveness analysis 
revealed that preconditioning CAD patients with HBO2 prior to CABG and IRI 
was a cost effective means of reducing post operative length of stay in ICU. 
This was found to be the case despite the slightly longer mechanical ventilation 
and intubation time in this group of patients. The saving made by the HBO2 
Group of patients were based on the cost per hour for the use of an ICU bed. 
This analysis did not take into account the added cost of any post operative 
AEs and the treatments required to resolve these AEs or, the staff and infra-
structure cost. As the proportion of patients with post operative AEs was lower 
in the HBO2 Group than in the Control Group, it is quite likely that the overall 
savings made by the HBO2 Group, in addition to the savings made from the 
shorter post operative ICU length of stay, may have been greater. The health 
technology assessment involving the cost effectiveness of HBO2 as a modality 
of treatment, has been reviewed by others (Guo et al., 2003b), particularly in 
the area of wound management (Chuck et al., 2008, Guo et al., 2003a, 
McEwen and Smith, 1997, Treweek and James, 2006). It is clear from these 
assessments that HBO2 is a cost effective treatment. This clinical study is the 
first to attempt to assess the cost effectiveness of HBO2 in a clinical model of 
CABG and IRI. While it was shown to be cost effective, no assessment was 
made of the possible ‘Quality Added Life Years’ (QUALY) that may have 
been made as a result of HBO2 preconditioning. However, based on the clinical 
study by Alex et.al, involving HBO2 preconditioning and CABG patients, 
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which found that patients who were preconditioned with HBO2 prior to CABG 
had significantly less post operative neurocognitive dysfunction (Alex et al., 
2005), it is quite possible that this modality of treatment may have the capacity 
to increase QUALY in patients following CABG. To accurately determine the 
cost effectiveness and QALY associated with the use of HBO2 in this group of 
patients, health technology assessment models will need to be developed in 
collaboration with health economists. 
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3.6  Conclusion 
This study met its primary cardiovascular efficacy endpoint and 
demonstrated that preconditioning CAD patients with HBO2 prior to CABG 
led to a significant improvement in LVSW 24 hours post CPB. As such, it can 
be concluded that HBO2 preconditioning in this group of patients leads to an 
improvement in myocardial function following CABG.   
As this study was not designed to determine the effects of HBO2 
preconditioning with respect to all the other clinical endpoints, which were all 
secondary endpoints, despite some statistically significant results, no definitive 
conclusions can be made with regards to the effects of HBO2 preconditioning 
on these endpoints. Where there were findings of statistical significance, this 
only provided a sensitivity analysis to support the estimates for any numerical 
differences between the groups. However, based on some of the estimates of 
the differences between the groups with respect to the clinical secondary 
endpoints, it is possible to make a few comments with regards to these 
differences.  
In addition to the observed improvement in LVSW 24 hours 
post CPB, in this study it was also observed that treating CAD patients with 
HBO2 prior to CABG, also leads to significant improvements in the LVSWI 
and SV 24 hours post CPB. These data supports the hypothesis that this 
modality of pre-treatment is capable of improving myocardial function in this 
group of patients. Furthermore, HBO2 preconditioning also led to significant 
reductions in PVR and PVRI prior to CPB. This indicates that preconditioning 
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CAD patients with HBO2 prior to CABG has the potential to improve 
pulmonary vascular blood flow prior to surgery. 
This study also demonstrated that despite the longer post 
operative mechanical ventilation and intubation times, the patients who were 
preconditioned with HBO2 had a significantly shorter post-operative length of 
stay in ICU. As such, it is reasonable to suggest that HBO2 preconditioning 
was in part, the cause for the shorter ICU stay. It was also observed that HBO2 
preconditioning, in this group of patients, was a safe modality of treatment as it 
was associated with a smaller proportion of patients experiencing post 
operative cardiovascular, pulmonary, renal, neurological and microbiological 
AEs. Where cost effectiveness was concerned, it was determined that the 
shorter length of post operative ICU stay amongst patients preconditioned with 
HBO2, was also associated with savings in hospital ICU bed cost. 
The main limitation of this study, that may have an impact on 
the observed clinical outcomes, is that patients in both groups had variable 
durations of intra-operative ischaemia, reperfusion and CPB and, a variety of 
ischaemic-reperfusion cycles as patients had a variable number of coronary 
artery bypasses (Table 3.1). While it would have been difficult to standardise 
the duration of ischaemia, reperfusion and CPB in a clinical study, perhaps one 
way to limit the variability in these durations was to limit the study population 
to patient who were only going to have a particular number of coronary artery 
bypass grafts. 
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4. Effects of HBO2 Preconditioning on 
A Surrogate Biomarker of 
Myocardial Injury: Serum 
Troponin-T 
4.1  Introduction 
To date, there are no other experimental or clinical studies 
where the effects of HBO2 on serum Troponin-T had been investigated. 
However, the ‘HOT-MI’ study group (Shandling et al., 1997) found that in 
AMI patients who were treated with HBO2 in addition to routine therapy, there 
was a 35% reduction in mean CK at 12 and 24 hours post MI. In a later similar 
study by the ‘HOT-MI’ group of investigators (Stavitsky et al., 1998), it was 
again observed that, compared to a control group, in AMI patients who were 
also treated with HBO2 in addition to routine therapy, the mean CK was 7.5% 
lower at 12 and 24 hours post AMI.  
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4.2  Objective 
The objective for this part of this clinical study was to assess the 
myocardial safety of systemically preconditioning CAD patients with one 
session of HBO2 preconditioning, involving two episodes of 30 minutes of 
100% oxygen at 2.4 ATA. Treatment with  HBO2 preconditioning  was 
completed approximately 2 hours prior to on CPB CABG. The assessment of 
the myocardial safety of this modality of treatment was done by determining 
the degree of myocardial injury as measured by the concentration of the 
surrogate biomarker of myocardial injury, serum Troponin-T at the pre-
specified time points (Table 2.5).  
4.3  Methods 
The time points for the collection of venous blood samples in 
this study and the method used for the measurement of serum Troponin-T have 
already been described in section 2.6.5. The measurement for serum Troponin-
T was done by the Department of Biochemistry at the Hull & East Yorkshire 
NHS Trust within 4 hours of collection using an ELICA method as described 
in section 2.6.6.1. Correction for the effects of hemodilution of serum 
Troponin-T during CPB, was done as described in section 2.6.6.3. 
 
  
171 
 
4.4  Results 
a. Pre- & Post HBO2 Mean Concentration of Serum    
Troponin-T in the HBO2 Group 
In this study, any value for Troponin-T that was between           
0 and 0.03ng/ml was reported as <0.03ng/ml by the Department of 
Biochemistry at the Hull & East Yorkshire NHS Trust. This is because, as 
described in section 2.6.1, the medical diagnostic guide for diagnosing an MI 
using the Troponin-T STAT kit is a Troponin-T concentration of 0.03ng/ml 
and greater. Furthermore, for clinical purposes, 0.03ng/ml is the lowest limit of 
quantification that can be reproducibly measuresed using this kit.  In this study, 
in the HBO2 Group of patients, the pre- and post HBO2 serum Troponin-T 
concentrations, in all patients, were reported as <0.03ng/ml. As in this study 
there were no plans for data imputation, it was not possible to determine the 
range, median, mean, ln mean or statistical significance of serum Troponin-T 
measurements from both these time points in this group of patients (Table 4.1). 
 
Table 4. 1: Pre & Post HBO2 Mean Concentration of Serum Troponin-T in the 
HBO2 Group 
 
HBO2 Group (n=41) † 
Concentration of Serum Serum Troponin-T(ng/ml) 
 Range Median 
 
Mean Ln 
Mean 
p-value 
Pre-HBO2 Unable to 
determine 
Unable to 
determine 
Unable to 
determine 
Unable to 
determine 
 
- 
 1 hour post HBO2 Unable to 
determine 
Unable to 
determine 
Unable to 
determine 
Unable to 
determine 
   †This is an intention to treat analysis 
 
  
172 
 
b. Peri Operative Mean Concentration of  Serum Troponin-T 
Between The Groups 
Just as in the HBO2 Group of this study, in the Control Group of 
patients, the serum Tropinin-T taken at the time point labelled ‘pre-HBO2’, 
were also reported as <0.03ng/ml. Again, as no imputation of data were done 
during this study, serum Troponin-T values that were reported as <0.03ng/ml 
were not used for statistical analysis. As such, for the purposes of this part of 
this study, when comparing serum Troponin-T between the groups, the time 
point which was taken as the baseline for serum Troponin-T analysis was the 
time point ‘5 minutes on CPB’.   
In this study, after adjusting for longest aortic cross-clamp time and CPB time, 
no statistically significant changes in serum Troponin-T were found between 
the groups at any of the time points. It was observed, however, that at all time 
points, apart from at the time point ‘5 minutes on CPB’, the mean 
concentration of serum Troponin-T was lower in the HBO2 Group (Figure 
4.1). In both groups, the mean concentration of serum Troponin-T appeared to 
rise from the time point ‘5 minutes on CPB’ up to the time point ‘2 hours post 
CPB’. After this time point, the mean concentration of serum Troponin-T 
continued to rise in the Control Group but remained unchanged in the HBO2 
Group. A summary of the results are provided in Table 4.2. In this table, the 
data are displayed as both mean and median values. As the means and medians 
are not the same at each time point, this indicates that the data were skewed. 
To normalise the data and enable parametric statistical analysis, the mean 
values were transformed into natural logarithmic (ln) values. 
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Figure 4. 1: Bar Chart of Peri-Operative Mean Concentration of Serum Troponin-T 
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Table 4. 2: Peri-Operative Concentration of Serum Troponin-T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†This is an Intention to treat analysis;  
Statistical analysis using repeated measures of ANOVA; 
*p-values are for geometric means; 
Serum Troponin-T (ng/ml) 
Control Group 
(n=40)† 
HBO2 Group 
(n=41)† 
 
 Range Median Mean Ln 
Mean 
Range Median Mean Ln 
Mean 
p-
value* 
Pre- 
HBO2 
Unable to 
determine 
Unable to 
determine 
Unable to 
determine 
 
- 
Unable to 
determine 
Unable to 
determine 
Unable to 
determine 
 
- 
 
- 
5 minutes 
on CPB 
 
0.03-0.11 
 
0.03 
 
0.03 
 
-3.4 
 
0.02-0.15 
 
0.03 
 
0.03 
 
-3.4 
 
0.90 
5 minutes 
post IRI 
 
0.03-0.59 
 
0.10 
 
0.16 
 
-1.9 
 
0.03-0.34 
 
0.1 
 
0.12 
 
-2.1 
 
0.61 
2 hours 
post CPB 
 
0.22-1.50 
 
0.22 
 
0.59 
 
-0.5 
 
0.17-1.43 
 
0.5 
 
 
0.50 
 
-0.7 
 
0.99 
24 hours 
post CPB 
 
0.14-7.62 
 
0.14 
 
0.79 
 
-0.2 
 
0.10-2.90 
 
0.49 
 
0.50 
 
-0.7 
 
0.99 
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4.5  Discussion 
 In this study, it was observed that 1 hour following HBO2 
treatment, serum from patients in HBO2 Group did not show any clinically 
meaningful change in serum Troponin-T.  This suggests that 1 hour following 
HBO2 preconditioning, the oxidative stress of this modality of treatment did 
not cause any clinically significant myocardial injury. Furthermore, during the 
peri-operative period, it appeared that HBO2 preconditioning induced a degree 
of cardioprotection by limiting the amount of myocardial injury and hence the 
release of Troponin-T into the circulation. In fact following the time point ‘2 
hours post CPB’, the serum concentration of Troponin-T in the HBO2 Group 
appeared to plateau off while in the Control Group it continued to rise 
suggesting that there was no progressive myocardial injury in the HBO2 Group 
after that time point but a continued to escalation of injury in the Control 
Group. As such, these observations provide some further support that in a 
group of patients with ischaemic heart disease, HBO2 preconditioning is a safe 
modality of treatment. This in keeping with the findings of other randomised 
controlled studies  (Shandling et al., 1997, Stavitsky et al., 1998).  
As a modality of treatment that induces an oxidative stress, it is 
still not entirely clear how HBO2 preconditioning and its generated ROS, 
paradoxically, limits myocardial injury and reduces the release of biomarkers 
of myocardial injury such as CK and Troponin-T during ischaemia and 
reperfusion. Clinical studies also have yet to find any correlation between ROS 
generation and, myocardial injury and Troponin-T release (Berg et al., 2006, 
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Berg et al., 2005, Berg et al., 2004). In a recent study, it was demonstrated that 
while oxidative stress does occur following IRI and CABG, this does not 
necessarily equate to cellular injury and clinical deterioration (Milei et al., 
2007). While high doses (100-200μM) of ROS (such as H2O2) have been 
shown to have deleterious effects on the structure and function of the 
myocardium (Evans et al., 1995, Janero et al., 1991, Miki et al., 1988, Onodera 
et al., 1992), it has also been demonstrated in an experimental model, that low 
doses of  H2O2 (between 1μM and 2 μM), added during reperfusion, can 
reduce myocardial infarct size  (Ytrehus et al., 1995). In another experimental 
study, it was demonstrated 25μM of H2O2 administered during reperfusion, 
resulted in a beneficial effect on functional and metabolic recovery in isolated 
rat hearts (Hegstad et al., 1997). Coronary flow and, left ventricular developed 
pressure and relaxation, were improved in the group that was exposed to 25μM 
of H2O2 compared to the untreated control group. Furthermore, the addition of 
25μM of H2O2 increased the levels of high energy phosphates (ATP) at the end 
of the reperfusion period compared to the control group. Additionally, it has 
also been demonstrated that low concentrations of H2O2 causes 
vasodilatation (Burke and Wolin, 1987). These beneficial ROS induced effects 
may account for the reduction in myocardial injury observed in the HBO2 
Group of this study, who were indirectly exposed to ROS during treatment 
with HBO2 preconditioning prior to CABG and IRI. As myocardial protection 
via ROS preconditioning, has been successfully demonstrated by others (Das et 
al., 1999a), it is possible that the HBO2 induced ROS preconditioned the 
myocardium to better tolerate the subsequent stress of IRI induced ROS.  
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4.6  Conclusion 
 
In this clinical study, no statistically or clinically significant 
results were observed when determining the effects of HBO2 preconditioning 
on serum Troponin-T. As such, and as per the statistical plan for analysing the 
secondary endpoints of this study, no definitive conclusions can be made with 
respect to the changes that were observed. However, based on the observed 
mean differences between the groups with respect to this secondary endpoint, 
it would not be unreasonable to further reinforce the suggestion that 
preconditioning CAD patients with HBO2 prior to CABG is a safe as it did not 
exacebate the peri-operative myocardial injury and may have even contributed 
to limiting this injury post operatively.  
 The main limitations to this part of the study was the inability to 
accurately quantify the concentrations of serum Troponin-T for values 
<0.03ng/ml. As no imputation of data was done for this study, there were no 
available serum Troponin-T measurements  at the time points ‘pre-HBO2’ 
(both groups) and ‘post HBO2’ (HBO2 Group only), that could be used in the 
statistical analysis. As a result of this, the all the serum Troponin-T values at 
the time point ‘5 minutes on CPB’ had to be used as the baseline measurement. 
This meant that there was no assessment of changes in serum Troponin-T 
between the pre-HBO2 period and the post HBO2 period or between the        
pre-CPB period and on-CPB period. In this study, there was also no 
assessment of ROS generation or, for the presence of its metabolites, as a result 
of HBO2, ischaemia and reperfusion. As such, the correlation between ROS 
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generation and serum Troponin-T could not be determined. Furthermore, the 
duration of ischaemia, reperfusion and CPB and, the number of ischaemic-
reperfusion cycles in both groups were not standardised in this clinical study 
and this may limit the value of the results from this study. 
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5. Effects of HBO2 Preconditioning on 
Surrogate Biomarkers of 
Neutrophilic & Endothelial 
Adhesiveness: Serum Soluble 
Adhesion Molecules 
5.1 Introduction 
HBO2 prior to the insult of IRI (HBO2 preconditioning), has 
been shown to limit myocardial infarct size (Kim et al., 2001) and improve 
myocardial function (Dekleva et al., 2004). It appears that part of the 
mechanism by which HBO2 limits IRI is by decreasing neutrophil 
sequestration (Tjarnstrom et al., 1999), decreasing the polarization expression 
of the neutrophil adhesion molecule, CD18 (Khiabani et al., 2008), and 
decreasing the expression of the endothelial cell adhesion molecule, ICAM-
1 (Buras et al., 2000) which is a ligand for CD18. A clinical study involving 
two episodes of 30 minutes of 100%  oxygen at 2.4 ATA at 24, 12, and 4 hours 
prior to on CPB CABG, showed that preconditioning with three sessions of 
HBO2 prior to the insult of IRI during on CPB CABG, was capable of 
significantly attenuating the rise in plasma CD18 and sE-Selectin (Alex et al., 
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2005). However, this study also found that HBO2 preconditioning increased 
the expression of sICAM-1 and sP-selectin.  
5.2 Objective 
 The objective of this part of this clinical study was to evaluate 
the effects of systemically preconditioning CAD patients with one session of 
HBO2 preconditioning, involving two episodes of 30 minutes of 100% oxygen 
at 2.4 ATA, which was completed approximately 2 hours prior to on CPB 
CABG, on the on the expression of surrogate biomarkers (soluble adhesion 
molecules) of endothelial  (sP-Selectin, sE-Selectin and sICAM-1), platelet 
(sP-Selectin) and neutrophilic (sPSGL-1) adhesiveness as measured by the 
concentration of these biomarkers at the pre-specified time points (Table 2.5).  
5.3 Methods 
The time points for the collection of venous blood samples in 
this study and the method used for the measurement of serum soluble adhesion 
molecules have been described in sections 2.6.5 and 2.6.6.2, respectively. 
Correction for the effects of hemodilution on the concentration of serum 
soluble adhesion molecules during CPB, was done as described in section 
2.6.6.3. 
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5.4  Results 
  From the 81 patients recruited to this study who had venous 
blood samples taken at 6 different time points for ELISA serum soluble 
adhesion molecule analysis, a total of 486 samples were analysed. Each sample 
was analysed in duplicates in a 96 well ELISA microplate. In this microplate, 
80 wells were used to analyse a total of 40 samples. The 12 remaining wells 
were used to analyse, in duplicates, the standards for each serum soluble 
adhesion molecule. The remaining 4 wells on each plate were left as blanks.  
  As each ELISA microplate was only used to analyse 40 of the 
total 486 samples, 13 ELISA microplates were used for the analysis of each 
type of serum soluble adhesion molecules. As there were 4 different types of 
serum soluble adhesion molecules that were measured, a total of 52 ELISA 
microplates were used in total. 
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5.4.1  Serum Adhesion Molecule Results 
Figure 5.1 shows an example of a set of spectrophotometric 
results that were obtained from an ELISA microplate following an ELISA 
assay procedure for a particular batch of samples for sE-Selectin analysis. As 
each sample analysed during the sE-Selectin ELISA assay procedure was 
analysed in duplicates on the ELISA microplate, the spectrophotometric results 
are also in duplicates. As part of this study, it had been pre-defined that if 
either of the spectrophotometric duplicates were more or less than 50% of the 
other’s value, that pair of reading would be labelled as unreliable and omitted 
from the analysis. From Figure 5.1 for example, the readings in E6 is greater 
than 50% of F6 and F6 is less than 50% of E6. As such, these readings were 
labelled as unreliable and were omitted from the analysis. This error may have 
occurred due to an operator error in pipetting. From all the 52 plates analysed, 
there were only 10 pairs of results that were unreliable and omitted from 
subsequent analysis.  
The duplicates from each pair of spectrophotometric results 
were then averaged to determine the average spectrophotometric result for 
each sample that was analysed in a particular ELISA microplate. Figure 5.2 
shows the averaged spectrophotometric results for the sE-Selectin 
spectrophotometric results from Figure 5.1. 
Using the manufacturer provided concentrations for each of the 
serum soluble adhesion molecule standards and by using the average of the 
duplicates of these standard’s spectrophotometric results, a standard curve and 
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its equation was determined using Microsoft Excel 2003. Figure 5.3 shows the 
standard curve obtained from the sE-Selectin ELISA microplate example that 
was used earlier to determine the spectrophotometric results.  
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Figure 5. 1: Spectrophotometric Readings From Serum sE-Selectin ELISA Plate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend 5. 1: Legend Colour for Figure 5.1 
 
 
 
 
 
 
 
 
 
 A B C D E F G H I J K L 
1 2.57 2.22 0.56 0.42 0.39 0.35 0.2 0.2 0.45 0.48 0.27 0.26 
2 1.77 1.82 0.49 0.43 0.37 0.35 0.54 0.56 0.44 0.42 0.28 0.25 
3 1.28 1.19 0.39 0.32 0.44 0.38 0.40 0.42 0.39 0.39 0.30 0.24 
4 0.60 0.64 0.33 0.32 0.30 0.28 0.36 0.37 0.36 0.42 0.29 0.28 
5 0.18 0.18 0.40 0.46 0.22 0.15 0.29 0.30 0.4 0.43 0.41 0.24 
6 0.06 0.06 0.29 0.29 0.65 0.15 0.28 0.27 0.42 0.45 0.31 0.26 
7   0.46 0.34 0.29 0.16 0.83 0.45 0.31 0.32 0.25 0.23 
8   0.53 0.43 0.27 0.38 0.45 0.49 0.31 0.33 0.24 0.24 
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Figure 5. 2: Averages Of Spectrophotometric Reading For Each Patient From Each Time Point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend 5. 2: Legend Colour for Figure 5.2 
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Figure 5. 3: Example of a Standard Curve For Serum sE-Selectin 
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The equation obtained for this standard curve was: 
 y = -0.002x2 + 0.242x + 0.0467.  
The r2 value for this standard curve was 0.99. Using this standard curve, the 
concentration of sE-Selectin at each time point was determined using 
Microsoft Excel 2003. 
This method of determining the serum soluble adhesion 
molecule concentration was also used during the analysis of all the other 
ELISA microplates in this study. The r2 values for all the standard curves 
obtained ranged from 1.0 to 0.97.  
In this study, following the ELISA assay procedure and 
spectrophotometry analysis, where necessary, a correction for sample dilution 
during the assay procedure was calculated. In addition to this, to correct for the 
effect of hemodilution during CPB, a further correction for the concentration 
of serum soluble adhesion molecule during the intra-operative period was 
calculated as described in section 2.6.6.3.  
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The results will be discussed in the sequence of sPSGL-1, sP-
Selectin, sE-Selectin and sICAM-1, as this sequence of serum soluble adhesion 
molecule discussion enables a more logical discussion of the findings. 
5.4.2  Serum sPSGL-1 Results 
a. Pre- & Post HBO2 Mean Concentration of Serum sPSGL-1 
in the HBO2 Group 
In this study, approximately 1 hour following HBO2 
preconditioning, there was a statistically significant increase in the mean 
concentration of serum sPSGL-1 (p=0.03) (Table 5.1). 
 
Table 5. 1: Pre & Post HBO2 Mean Concentration of Serum sPSGL-1 in the 
HBO2 Group 
   †This is an intention to treat analysis 
   Statistical results obtained using Wilcoxon Signed Rank Test 
 
 
 
 
 
 
 
 
HBO2 Group (n=41)† 
Concentration of Serum sPSGL-1 (ng/ml) 
 Range Mean p-value 
Pre-HBO2 12-1187 265  
0.03 1 hour post  HBO2 149-875 278 
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b. Peri Operative Mean Concentration of Serum sPSGL-1 
Between The Groups 
In this study, after adjusting for longest aortic cross-clamp time and CPB time, 
none of the changes at any of the time points between the groups were 
statistically significant. In both groups (Figure 5.4), there was a decrease in the 
mean concentration of serum sPSGL-1 from the time point ‘pre-HBO2’ to the 
time point ‘5 minutes on CPB’. At the time point ‘5 minutes on CPB’, the 
concentration of of sPSGL-1 was higher in the HBO2 Group. During the period 
of IRI, (i.e. from the time point ‘5 minutes on CPB’ to the time point ‘5 
minutes post IRI’), there was a small decrease in the concentration of sPSGL-1 
in the HBO2 Group while in the Control Group there was a small increase. 
Despite this decrease, at the time point ‘5 minutes post IRI’, the concentration 
of serum sPSGL-1 was higher in the HBO2 Group than in the Control Group. 
From the time point ‘5 minutes post IRI’ to the time point ‘2 hours post CPB’, 
the concentration of sPSGL-1 increased in both groups. At the time point ‘2 
hours post CPB’, the concentration of serum sPSGL-1 continued to remain 
higher in the HBO2 Group. From the time point ‘2 hours post CPB’ up to the 
time point ‘24 hours post CPB’, in both groups, the concentration of sPSGL-1 
decreased but remained higher in the HBO2 Group. A summary of the results 
are provided in Table 5.2. In this table, the data are displayed as both mean and 
median values. As the means and medians are not the same at each time point, 
this indicates that the data were skewed. To normalise the data and enable 
parametric statistical analysis, the mean values were transformed into natural 
logarithmic (ln) values. 
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Figure 5. 4: Bar Chart of Peri-Operative Mean Concentration of Serum sPSGL-1 
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Table 5. 2: Peri-Operative Concentration of Serum sPSGL-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         †This is an intention to treat analysis; 
                               Statistical analysis using repeated measures of ANOVA; 
 *p-values are for Geometric Means 
Peri-Operative Concentration of Serum sPSGL-1 (ng/ml) 
 Control Group 
(n=40)† 
HBO2 Group 
(n=41)† 
 
  
Range 
 
Median 
 
Mean 
 
Ln 
Mean 
 
 
Range 
 
 
Median 
 
Mean 
 
Ln 
Mean 
 
 
p-value* 
 
 
Pre-HBO2 
(baseline) 
24-611 211 265 5.6 12-1187 245 265 5.8 - 
5 minutes on CPB 62-930 199 221 5.4 93-703 225 244 5.5 0.09 
5 minutes 
post IRI 
70-847 220 226 5.4 108-804 229 237 5.5 0.16 
2 hours 
post CPB 
78-485 214 238 5.5 94-1212 242 263 5.6 0.13 
24 hours 
post CPB 
78-485 180 180 5.2 80-605 190 204 5.3 0.13 
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5.4.3  Serum sP-Selectin Results 
a. Pre- & Post HBO2 Mean Concentration of Serum sP-
Selectin in the HBO2 Group 
In this study, approximately 1 hour following HBO2 
preconditioning, there was a very small, statistically non-significant, increase 
in the mean concentration of serum sP-Selectin (Table 5.3). 
 
Table 5. 3: Pre & Post HBO2 Mean Concentration of Serum sP-Selectin in the 
HBO2 Group 
 
HBO2 Group (n=41) † 
Concentration of Serum sP-Selectin (ng/ml) 
 Range Mean p-value 
Pre-HBO2 30-238 86  
0.9 1 hour post HBO2 33-233 90 
  †This is an intention to treat analysis; 
  Statistical analysis using Wilcoxon Signed Rank Test 
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b. Peri Operative Mean Concentration of  Serum sP-Selectin 
Between The Groups 
After adjusting for longest aortic cross-clamp time and CPB time, none of the 
changes at any of the time points between the groups were statistically 
significant. In both groups (Figure 5.5), between the time point ‘pre-HBO2’ 
and ‘5 minutes on CPB’ the mean concentration of serum sP-Selectin 
decreased. At the time point ‘5 minutes on CPB’, the mean concentration of 
serum sP-Selectin was higher in the HBO2 Group. During the period of IRI 
(between time points ‘5 minutes on CPB’ and ‘5 minutes post IRI’), there was 
a further small decrease in the mean concentration of serum sP-Selectin in the 
HBO2 Group while in the Control Group, there was an increase. At the time 
point ‘5 minutes post IRI’, the mean concentration of serum sP-Selectin was 
lower in the HBO2 Group. In both groups, from the time point ‘5 minutes post 
IRI’ to the time point ‘2 hours post CPB’, the mean concentration of serum sP-
Selectin increased. At time point ‘2 hours post CPB’ the mean concentration of 
sP-Selectin was slightly higher in the HBO2 Group. Following this, from the 
time point ‘2 hours post CPB’ to ‘24 hours post CPB’ the mean concentration 
of serum sP-Selectin decreased in both groups but remained higher in the 
HBO2 Group. A summary of the results are provided in Table 5.4. In this table, 
the data are displayed as both mean and median values. As the means and 
medians are not the same at each time point, this indicates that the data were 
skewed. To normalise the data and enable parametric statistical analysis, the 
mean values were transformed into natural logarithmic (ln) values. 
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Figure 5. 5: Bar Chart of Peri-Operative Mean Concentration of Serum sP-Selectin 
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Table 5. 4: Peri-Operative Concentration of Serum sP-Selectin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      †This is an intention to treat analysis; 
    Statistical analysis using repeated measures of ANOVA; 
   *p-values are for Geometric Means 
Peri-Operative Concentration of Serum sP-Selectin (μg/ml) 
 Control Group 
(n=40)† 
HBO2 Group 
(n=41)† 
 
  
Range 
 
Median 
 
Mean 
 
Ln 
Mean 
 
 
Range 
 
 
Median 
 
Mean 
 
 
Ln 
Mean 
 
 
p-value* 
 
 
Pre-HBO2 
(baseline) 
30-238 91 86 4.0 50-232 89 86 4.4 - 
5 minutes on CPB 1-114 39 40 3.5 11-178 39 46 3.8 0.36 
5 minutes 
post IRI 
7-139 43 45 3.6 14-175 38 42 3.7 0.61 
2 hours 
post CPB 
39-258 94 101 4.8 19-352 102 103 4.6 0.22 
24 hours 
post CPB 
22-296 72 82 4.1 52-502 74 88 4.5 0.82 
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5.4.4  Serum sE-Selectin Results 
a. Pre- & Post HBO2 Mean Concentration of Serum sE-
Selectin in the HBO2 Group 
 In this study, approximately 1 hour following HBO2 
preconditioning, there was a no change in the mean concentration of serum  
sE-Selectin (Table 5.5). 
 
Table 5. 5: Pre & Post HBO2 Mean Concentration of Serum sE-Selectin in the 
HBO2 Group 
 
HBO2 Group (n=41)† 
Concentration of Serum sE-Selectin (ng/ml) 
 Range Mean p-value 
Pre-HBO2 3-54 16  
0.3 1 hour post HBO2 3-53 16 
†This is an intention to treat analysis; 
Statistical analysis using Wilcoxon Signed Rank Test 
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b. Peri Operative Mean Concentration of Serum sE-Selectin 
Between The Groups 
At all time points, Figure 5.6, the mean concentration of serum        
sE-Selectin was higher in the HBO2 Group compared to in the Control Group. 
From the time points ‘pre-HBO2’ to ‘5 minutes on CPB’, the mean 
concentration of serum sE-Selectin increased in both groups. At the time point 
‘5 minutes on CPB’, the mean concentration of serum sE-Selectin was higher 
in the HBO2 Group. After adjusting for longest aortic cross-clamp time and 
CPB time, the mean concentration of serum sE-Selectin at the time point ‘5 
minutes on CPB’ was found to be significantly higher in the HBO2 Group than 
in the Control Group (Geometric Mean Estimate & 95% Confidence Interval; 
1.21 & 1.03, 1.42; p=0.02). During the period of IRI (between the time points 
‘5 minutes on CPB’ and ‘5 minutes post IRI’), there was a very small increase 
in the mean concentration of serum sE-Selectin in HBO2 Group and no change 
in the Control Group. At the time point ‘5 minutes post IRI’, the mean 
concentration of serum sE-Selectin was higher in the HBO2 Group. After 
adjusting for longest aortic cross-clamp time and CPB time, the mean 
concentration of serum sE-Selectin at the time point ‘5 minutes post IRI’  was 
found to be significantly higher in the HBO2 Group than in the Control Group 
(Geometric Mean Estimate & 95% Confidence Interval; 1.26 & 1.04, 1.52; 
p=0.02). Between the time points ‘5 minutes post IRI’ and ‘24 hours post 
CPB’, the mean concentration of serum sE-Selectin increased in both groups 
and continued to remain higher in the HBO2 Group. None of the changes 
between the the time points ‘5 minutes post IRI’ and ‘24 hours post CPB’ were 
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statistically significant. A summary of the results are provided in Table 5.6. In 
this table, the data are displayed as both mean and median values. As the 
means and medians are not the same at each time point, this indicates that the 
data were skewed. To normalise the data and enable parametric statistical 
analysis, the mean values were transformed into natural logarithmic (ln) 
values.  
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Figure 5. 6: Bar Chart of Peri-Operative Mean Concentration of Serum sE-Selectin 
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Table 5. 6: Peri-Operative Concentration of Serum sE-Selectin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  †This is an intention to treat analysis 
        Statistical analysis using repeated measures of ANOVA 
       *p-values are for the Geometric Means 
Peri-Operative Concentration of Serum sE-Selectin (ng/ml) 
 Control Group 
(n=40)† 
 
HBO2 Group 
(n=41)† 
 
 
  
 
Range 
 
 
Median 
 
 
Mean 
 
 
Ln 
Mean 
 
 
 
Range 
 
 
Median 
 
 
Mean 
 
 
Ln 
Mean 
 
 
p-value* 
(Geometric 
Mean Estimate & 
95% Confidence Interval) 
Pre-HBO2 
(baseline) 
3-39 11 14 2.6 4-53 13 16 2.8 - 
5 minutes 
on CPB 
4-48 13 17 2.8 5-66 19 22 3.1 0.02 
1.21 & 1.03, 1.42 
5 minutes 
post IRI 
2-46 14 17 2.8 4-66 22 23 3.1 0.02 
(1.26 & 1.04, 1.52) 
2 hours 
post CPB 
0.5-54 18 21 3.0 5-79 20 25 3.2 0.42 
24 hours 
post CPB 
6-75 19 23 3.1 4-138 22 27 3.3 0.42 
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5.4.5  Serum sICAM-1 Results 
a. Pre- & Post HBO2 Mean Concentration of Serum sICAM-1 
in the HBO2 Group 
In this study, approximately 1 hour following HBO2 
preconditioning, there was a small, statistically non-significant increase in the 
mean concentration of serum sICAM-1 concentration (Table 5.7). 
 
Table 5. 7: Pre & Post HBO2 Mean Serum sICAM-1 Concentrations in the 
HBO2 Group 
 
HBO2 Group (n=41)† 
Concentration of Serum sICAM-1 (ng/ml) 
 Range Mean p-value 
Pre-HBO2 33-451 258  
0.3 1 hour post HBO2 35-464 261 
†This is an intention to treat analysis 
Statistical analysis using Wilcoxon Signed Rank Test 
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b. Peri Operative Mean Concentration of Serum sICAM-1 
Between The Groups 
In this study, at all time points, the mean concentration of serum 
sICAM-1 was higher in the HBO2 Group than in the Control Group (Figure 
5.7). In both groups, between the time points ‘pre-HBO2’ and ‘5 minutes on 
CPB’, there was a small decrease in the mean concentration of serum of 
sICAM-1. At the time point ‘5 minutes on CPB’, the mean concentration of 
serum sICAM-1 was higher in the HBO2 Group but this was not a statistically 
significant result. During the period of IRI, (i.e. from the time points ‘5 
minutes on CPB’ to 5 minutes post IRI), in the HBO2 Group there was a small 
increase in the mean concentration of serum sICAM-1 while in the Control 
Group there was a small decrease. At the time point ‘5 minutes post IRI’, the 
mean concentration of serum sICAM-1 was higher in the HBO2 Group. At the 
time point ‘5 minutes post IRI’, after correction for longest aortic cross-clamp 
time and CPB time, the HBO2 Group had a significantly higher mean 
concentration of serum sICAM-1 compared to the Control Group (Geometric 
Mean Estimate & 95% Confidence Interval; 1.17 & 1.02, 1.34; p=0.03). From 
the time point ‘5 minutes post IRI’ up to the time point ‘24 hours post CPB’, 
the mean concentration of serum of sICAM-1 increased in both groups and 
remained higher in the HBO2 Group. None of the changes between the time 
point ‘5 minutes post IRI’ and the time point ‘24 hours post CPB’ were 
statistically significant. A summary of the results are provided in Table 5.8. In 
this table, the data are displayed as both mean and median values. As the 
means and medians are not the same at each time point, this indicates that the 
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data were skewed. To normalise the data and enable parametric statistical 
analysis, the mean values were transformed into natural logarithmic (ln) 
values.  
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Figure 5. 7: Bar Chart of Peri-Operative Mean Concentration of Serum sICAM-1 
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Table 5. 8: Peri-Operative Concentration of Serum sICAM-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   †This is an intention to treat analysis 
                          Statistical analysis using repeated measures of ANOVA 
                         *p-values are for Geometric Means 
Peri-Operative Concentration of Serum sICAM-1 (ng/ml) 
 Control Group 
(n=40)† 
HBO2 Group 
(n=41)† 
 
  
 
Range 
 
 
Median 
 
 
Mean 
 
 
Ln 
Mean 
 
 
 
Range 
 
 
Median 
 
 
Mean 
 
 
Ln 
Mean 
 
p-value* 
(Geometric 
Mean 
Estimate & 
95% 
Confidence 
Interval) 
Pre-HBO2 
(baseline) 
33-326 212 175 5.2 34-451 258 211 5.6 - 
5 minutes 
on CPB 
39-316 196 165 5.1 105-509 223 207 5.5 0.07 
5 minutes 
post IRI 
37-321 191 162 5.1 135-478 254 209 5.5 0.03 
(1.17 & 1.02, 
1.34) 
2 hours 
post CPB 
28-399 221 183 5.2 95-727 281 237 5.7 0.06 
24 hours 
post CPB 
40-442 246 214 5.3 151-1798 308 299 5.9 0.06 
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5.5  Discussion 
5.5.1  sPSGL-1 
In the HBO2 Group, 1 hour following HBO2 preconditioning 
(Table 5.1), there was a statistically significant increase in the mean 
concentration of serum of sPSGL-1 (p=0.03). A possible explanation for this 
may have been the oxidative stress that is known to be generated by treatment 
with HBO2 (Benedetti et al., 2004, Conconi et al., 2003, Gregorevic et al., 
2001, Thom, 2009). At present there are no other clinical studies involving 
HBO2, CABG and the oxidative stress of ischaemia and reperfusion, that have 
investigated the kinetics of sPSGL-1 in this group of patients. However, in in-
vivo (Dulkanchainun et al., 1998, Hayward et al., 1999) and ex-
vivo (Dulkanchainun et al., 1998) models of IRI, the presence of sPSGL-1 
appears to be associated with reduced myocardial (Hayward et al., 1999) and 
liver (Dulkanchainun et al., 1998) reperfusion injury and, the preservation of 
endothelial function (Hayward et al., 1999). These cellular protective effects 
were largely the result of reduced neutrophil infiltration (Dulkanchainun et al., 
1998) and reduced neutrophil-endothelial cell interaction (Hayward et al., 
1999). The latter appears to be the result of the ability for sPSGL-1 to inhibit 
the adhesion between neutrophil bound PSGL-1 and its endothelial bound 
ligand, P-Selectin by binding to either of these intact adhesion 
molecules (Hayward et al., 1999). This suggests that in this study, 
preconditioning CAD patients with HBO2 prior to CABG and IRI, may have 
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had the potential to reduce neutrophil mediated ischaemia reperfusion 
endothelial injury as the circulation of this group of patients had an increased 
load of sPSGL-1 that maybe capable of inhibiting endothelial P-Selectin 
adhesion to neutrophil PSGL-1.  
5.5.2  sE-Selectin 
During the period of anaesthetic pre-medication, induction and, 
maintenance, prior to the onset of CPB (i.e. between the time point              
‘pre-HBO2’ and ‘5 minutes on CPB’) (Figure 5.6), there was an increase in the 
mean concentration of serum sE-Selectin in both groups with the concentration 
being higher in the HBO2 Group at the time point ‘5 minutes on CPB’. At this 
time point ‘5 minutes on CPB’, the concentration in the HBO2 Groups was 
significantly greater than in the Control Group (p=0.02). A reason for this may 
be that by the time point ‘5 minutes on CPB’, approximately 4 hours would 
have passed since the end of the HBO2 treatment. This may have provided 
sufficient time for the oxidative stress of HBO2 to not only stimulate the 
transcription of E-Selectin but also for its eventual expression on the vascular 
endothelium. Increased levels of ROS, as generated during HBO2, have not 
only been shown to stimulate E-Selectin expression (Rupin et al., 2004, 
Russell et al., 2000) but also possibly cleave them off the surfaces of 
endothelial cells to produce sE-Selectin (Eguchi et al., 2005). 
During the period of ischaemia and reperfusion (i.e. between the 
time point ‘5 minutes on CPB’ and ‘5 minutes post IRI’) (Figure 5.6), in the 
HBO2 Group there was a small increase in the serum concentration of sE-
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Selectin while in the Control Group, there was no change. At the time point ‘5 
minutes post IRI’, the serum concentration was higher in the HBO2 Group.    
At this time point, the HBO2 Group had a significantly higher mean serum 
concentration of sE-Selectin (p=0.02). As ischaemia and reperfusion are 
generally known to cause an increase in serum sE-Selectin (Kalawski et al., 
1998, Matata and Galinanes, 2000), one possible reason for only a small 
increase in the circulating load of sE-Selectin during the period of IRI in the 
HBO2 Group could perhaps be because prior to the period of IRI, there was 
also a high circulating load of sPSGL-1. It has been reported (Takada et al., 
1997) that sPSGL-1 is capable of limiting the transcription of E-Selectin by 
limiting cytokines, such as TNF-α, that are necessary for the induction of E-
Selectin expression on the vascular endothelium. This may limit the amount of 
available endothelial bound E-Selectin that maybe shed into the circulation as a 
result of ischaemia and reperfusion. While it has been demonstrated that 
sPSGL-1 is capable of inhibiting the adhesion between neutrophil bound 
PSGL-1 and its endothelial bound ligand, P-Selectin (Hayward et al., 1999), it 
has also been suggested that the interaction between PSGL-1 and P-Selectin is 
required for sE-Selectin expression (Bodary et al., 2007). As in this study, in 
the HBO2 Group of patients, there was a high circulating sPSGL-1 prior to IRI, 
it would be reasonable to suggest that this too may have indirectly led to an 
attenuation of sE-Selectin expression in this group of patients during this 
period.  
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5.5.3  sICAM-1 
In this study, during the period of ischaemia and reperfusion 
(i.e. between the time point ‘5 minutes on CPB’ and ‘5 minutes post IRI’), the 
mean concentration of serum sICAM-1 increased a little in the HBO2 Group 
and decreased a little in the Control Group. At the time point ‘5 minutes post 
IRI’, the concentration was significantly higher in the HBO2 Group (p=0.03) 
compared to in the Control Group (Figure 5.7). It is possible that the 
adjunctive oxidative effects of ischaemia and reperfusion in combination with 
the earlier oxidative stress of HBO2, was the cause for this small increase in 
sICAM-1 in the HBO2 Group. In an experimental model, where whole blood 
was exposed to the oxidative  effects of lipopolysaccharise (LPS) followed by 
the oxidative stress of HBO2 i.e. 2 consecutive adjunctive oxidative events, a 
significant increase in sICAM-1 was also observed (Fildissis et al., 2004). The 
decrease in sICAM-1 in the Control Group is in keeping with the observations 
of another clinical study (Hambsch et al., 2002).  
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5.6 Conclusion 
 
  In this clinical study, estimating the effects of HBO2 
preconditioning on the serum biomarkers were only the secondary endpoints of 
the study. As such, despite a mix of statistically significant and non-significant 
findings, and as pre the statistical plan for the analysis of the secondary 
endpoint of this study, no definitive conclusions can be made with respect to 
the changes that were observed for these endpoints. However, based on the 
findings of this study, it is possible to suggest that systemically 
preconditioning CAD patients with HBO2 prior to CABG, has the potential to 
lead to an overall increase in the serum concentration of all the serum soluble 
adhesion molecules. This may be of potential benefit as it indirectly suggest 
vascular, platelet and neutrophilic adhesion molecules are being cleaved off 
their respective surfaces and bering shed into the circulation, thus limiting the 
degree of neutrophil and endothelial interaction and, hence the ensuing 
ischaemia reperfusion mediated injury. 
The main limitations to this part of the study, was that there was 
no assessment of the generation of ROS or its metabolites as a result of HBO2, 
ischaemia and reperfusion and, as such an assessment of the correlation with 
soluble adhesion molecule expression was not possible. Additionally, this 
study did not assess the expression of adhesion molecules on the surfaces of 
the endothelium and neutrophils. As such, it was again not possible to assess 
the correlation between the ROS generation as a result of HBO2, ischaemia and 
reperfusion with the expression of endothelial and neutrophilic adhesion 
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molecules. Furthermore, the actual correlation between endothelial and 
neutrophilc adhesion molecule expression and the expression of the soluble 
form of these adhesion molecules in the serum was not possible. Finally, as the 
durations of ischaemia, reperfusion and CPB and, the number of ischaemic 
reperfusion cycles in this study were not standardised, there is always the 
possibility that a different set of results may have been obtained if it was 
possible to standardise these intervals in a clinical study. 
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6.  Effects of HBO2 Preconditioning on 
Biomarkers of Cardioprotection: 
Myocardial eNOS & Hsp72 
6.1  Introduction 
6.1.1  HBO2 & eNOS     
HBO2 has been shown to increase the expression of 
eNOS (Atochin et al., 2003, Buras et al., 2000, Cabigas et al., 2006b, Xu et al., 
2009) and NO (Boykin and Baylis, 2007, Demchenko et al., 2000, Gurdol et 
al., 2009, Thom et al., 2006, Thom et al., 2003, Wang et al., 2009a). Studies 
have also shown that inhibition of eNOS promotes the adherence of 
neutrophils to the microvasculature while increased concentrations of eNOS 
have an anti-adherent effect (Kubes et al., 1991, Lefer and Lefer, 1996). In an 
experimental model of endothelial ischaemia and reperfusion, the 
downregulation of ICAM-1, as a result of treatment with HBO2, correlated 
with an increase in eNOS concentration (Buras et al., 2000). As this 
downregulation of ICAM-1 prevents neutrophils from adhering to endothelial 
cells, this suggests that the mechanism for HBO2 mediated downregulation of 
ICAM-1, and the attenuation of IRI, may be modulated by eNOS and NO. 
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Recently, in a rat heart model of IRI, it was observed that 
preconditioning with HBO2 not only resulted in a greater decrease in 
myocardial infarct size and increased the recovery of left ventricular diastolic 
pressure but also led to an increase in myocardial eNOS and nitrite plus nitrate 
content (Cabigas et al., 2006b). This study suggested that preconditioning with 
HBO2 prior to ischaemia and reperfusion induced endogenous myocardial 
protective effects which involved the increased expression of eNOS and NO. 
6.1.2  HBO2 & Hsp72 
Only a limited amount of knowledge is known about the effects 
of HBO2 on Hsp72 and, even less is known about its effects on myocardial 
Hsp72. There are however, studies examining the effects of HBO2 in non-
cardiac models.  
In an experimental model of ischaemic tolerance, HBO2 
consisting of 60 minutes of 100% oxygen at 2.0 ATA, was administered to 
gerbils either for a single session or every other day for 5 sessions (Wada et al., 
1996). 2 days after HBO2 pre-treatment, the gerbils were subjected to 5 
minutes of forebrain ischaemia by occlusion of both common carotid arteries 
under anesthesia. Immunohistochemical staining for Hsp72 in the gerbil 
hippocampus, showed that 5 sessions of HBO2 prior to ischaemia and 
reperfusion increased the amount of Hsp72  compared to that in the ischaemic 
control group and in the single HBO2 pre-treatment group. They concluded 
that tolerance against ischaemic neuronal damaged can be induced by repeated 
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treatment with HBO2 prior to ischaemia and this tolerance occurrs through the 
induction of Hsp72 synthesis. Another group later determined, in a rat model 
of cerebral ischaemia, that when HBO2 treatment was administered after 
ischaemia, in comparison to the control group, there was a weaker induction of 
Hsp72 (Konda et al., 1996). These observations suggest that HBO2 treatment 
prior to an ischaemic event induces better cellular protection compared to 
treatment after an ischaemic event. However, the importance of this 
observation is a little difficult to confirm as while pre-treatment with HBO2 
before cerebral ischaemia has been shown to increase Hsp72 (Wada et al., 
1996), this finding was not observed in a rat liver model of IRI that was pre-
treated with HBO2  (Yu et al., 2005). In fact the experimental findings by Yu 
et.al were similar to the findings of a recent clinical study involving HBO2 pre-
treatment and patients undergoing CABG (Alex et al., 2005). In that clinical 
study, in CAD patients who were treated with 3 sessions of HBO2, consisting 
of 100% oxygen at 2.4 ATA for 90 minutes, prior to on CPB CABG, there 
were lower levels of inducible Hsp70 (Hsp72) compared to the control group. 
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6.2  Objective 
The objective of this part of this clinical study was to evaluate 
the effects of systemically preconditioning CAD patients with one session of 
HBO2 preconditioning, involving two episodes of 30 minutes of 100% oxygen 
at  2.4 ATA, which was completed approximately 2 hours prior to on CPB 
CABG, on the expression of two  myocardial biomarkers of cardioprotection, 
eNOS and Hsp72, as measured by the quantity of these biomarkers in 
specimens from right atrial biopsies taken at the pre-specified time points 
(Table 2.7).  
6.3  Methods 
The intra-operative time points at which right atrial biopsies 
were taken in this study and the methods used for the measurement of 
myocardial eNOS and Hsp72 have been described in sections 2.6.7. 
6.4  Results 
  From the 81 patients randomised to this study who had intra-
operative right atrial biopsies taken at 4 different time points for myocardial 
ELISA eNOS and Hsp72 analysis, there were a total of 324 right atrial tissue 
specimens that were analysed. As the myocardial lysate samples from each 
specimen was analysed in duplicates during the ELISA analysis, in each 96 
well ELISA microplate, 80 wells were used to analyse the lysate from 40 
different right atrial specimens. 14 wells from each microplate were used to 
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analyse the standards for either eNOS or Hsp72 in duplicates. The remaining 2 
wells on each plate were left as blanks. 
As each ELISA microplate was only used to analyse the lysate 
from 40 of the total of 324 right atrial specimens, 8 ELISA microplates each 
were used for the analysis of myocardial eNOS and Hsp72, respectively. As 
such, a total of 16 ELISA microplates were used in the ELISA analysis of all 
the myocardial biomarkers.  
6.4.1  Myocardial Biomarker ELISA Results 
 Spectrophotometric analysis for each of the myocardial 
biomarkers was done in a similar way as described for sE-Selectin in section 
5.4.1. From the total of 16 ELISA microplates used for myocardial biomarker 
analysis, there were 3 pairs of unreliable spectrophotometric readings that were 
omitted from subsequent analysis.  
Using the manufacturer provided concentrations for each of the 
myocardial biomarker standards and by using the average of the duplicates of 
these standard’s spectrophotometric results, a standard curve and its equation 
was determined using Microsoft Excel 2003. R2 values for all the standard 
curves for the myocardial biomarkers ranged from 1 to 0.98. Using the 
standard curve equation that was obtained, the concentration of the myocardial 
biomarker at each time point was determined. The quantity of each biomarker, 
in each milligram of the right atrial specimen that was analysed, from each 
time point, was then determined using the formula described in sections 2.6.7.3 
and 2.6.7.4, respectively. 
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6.4.2  Myocardial eNOS ELISA Results 
In this study, there were no statistically significant changes in 
the mean quantity of myocardial eNOS at any of the time points between the 
groups. At all time points, the mean quantity of myocardial eNOS was higher 
in the Control Group (Figure 6.1). Between the time points ‘post induction’ 
and ‘5 minutes on CPB’, the mean quantity of myocardial of eNOS decreased 
in both groups. Between the time points ‘5 minutes on CPB’ and ‘5 minutes 
post IRI’, the mean quantity of myocardial eNOS increased slightly in the 
HBO2 Group but decreased in the Control Group. Finally, between the time 
points ‘5 minutes post IRI’ and ‘5 minutes post CPB’, the mean quantity of 
myocardial eNOS decreased in both groups and remained lower in the HBO2 
Group. A summary of the results are provided in Table 6.1. In this table, the 
data are displayed as both mean and median values. As the means and medians 
are not the same at each time point, this indicates that the data were skewed. 
To normalise the data and enable parametric statistical analysis, the mean 
values were transformed into natural logarithmic (ln) values.  
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Figure 6. 1: Bar Chart of Intra-Operative Mean Quantity of Myocardial eNOS 
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Table 6. 1: Intra-Operative Quantity of Myocardial eNOS Atrial Biopsy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       †This is an intention to treat analysis; 
    Statistical analysis using repeated measures of ANOVA; 
   *p-values are for Geometric Means 
 Quantity of eNOS in the Right Atrial Biopsy (pg/mg) 
 Control Group 
(n=40)† 
HBO2 Group 
(n=41)† 
 
 Range Median Mean Mean 
ln 
Range Median Mean Mean 
ln 
p-value* 
 
Post 
induction 
(baseline) 
 
5-416 
 
17.2 
 
35.3 
 
3.7 
 
3-146 
 
18.9 
 
23.7 
 
3.4 
 
0.9 
5 minutes 
on CPB 
4-257 15.6 29.7 3.5 5-89 12.6 19.3 3.1 0.8 
5 minutes 
post IRI 
4-272 14.5 21.6 3.2 2-73 15.7 20.7 3.2 1.0 
5 minutes 
post CPB 
1-255 11.8 19.4 3.1 3-93 13.6 17.1 3.0 1.0 
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6.4.3 Myocardial Hsp72 ELISA Results 
 In this study, there were no statistically significant changes in 
the mean quantity of myocardial Hsp72 at any of the time points between the 
groups. At all time points, the mean quantity of myocardial Hsp72 was lower 
in the HBO2 Group (Figure 6.2). Between the time points ‘post induction’ and 
‘5 minutes on CPB’, there was a small decrease in the mean quantity of 
myocardial Hsp72 in the HBO2 Group while in the Control Group there was a 
very small increase. Between the time points ‘5 minutes on CPB’ and ‘5 
minutes post IRI’, there was a small increase in the mean quantity of 
myocardial Hsp72 in the HBO2 Group while in the Control Group there was a 
decrease. Finally, between the time points ‘5 minutes post IRI’ and ‘5 minutes 
post CPB’, the mean quantity of myocardial Hsp72 decreased in both groups 
and remained lower in the HBO2 Group. A summary of the results are 
provided in Table 6.2. In this table, the data are displayed as both mean and 
median values. As the means and medians are not the same at each time point, 
this indicates that the data were skewed. To normalise the data and enable 
parametric statistical analysis, the mean values were transformed into natural 
logarithmic (ln) values.  
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Figure 6. 2: Bar Chart of Intra-Operative Mean Quantity of Myocardial Hsp72 
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Table 6. 2: Intra-Operative Quantity of Myocardial Hsp72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 †This is an intention to treat analysis; 
                               Stattistical analysis using repeated measures of ANOVA;  
                              *p-values are for Geometric Means 
 Quantity of Hsp72  in the Right Atrial Biopsy (ng/mg) 
 Control Group 
(n=40)† 
HBO2 Group 
(n=41)† 
 
 Range Median Mean Mean 
ln 
Range Median Mean Mean 
ln 
p-value* 
Post 
induction 
(baseline) 
 
0.2-67.0 
 
1.4 
 
4.0 
 
1.4 
 
0.6-16.5 
 
1.8 
 
2.4 
 
0.9 
 
0.09 
5 minutes 
on CPB 
0.5-58.8 1.9 4.1 1.4 0.6-8.2 1.5 2.0 0.7 0.09 
5 minutes 
post IRI 
0.4-33.4 1.4 2.5 0.9 0.8-18.6 1.8 2.4 0.9 1.0 
5 minutes 
post CPB 
0.7-30.1 1.7 2.4 0.9 0.5-9.8 1.8 2.2 0.8 1.0 
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6.5  Discussion 
6.5.1  Myocardial eNOS 
 In this study it was observed that following HBO2 
preconditioning, in the baseline right atrial biopsy taken at the time point ‘post 
induction’, the myocardium of patients in the HBO2 Group had a lower mean 
quantity of myocardial eNOS compared to the Control Group (Figure 6.1). 
While this was not a statistically significant finding, this finding suggests that 
preconditioning CAD patients with HBO2 prior to CABG leads to a reduction 
in myocardial eNOS. This is the first time such a result has been observed in a 
clinical study. While there are no clinical studies to compare with, the findings 
of this study are contradictory to those of an experimental model of HBO2 
 (Liu et al., 2008). In that mouse brain model, it was observed that exposure to 
HBO2, consisting of twice daily 100% oxygen for 60 minutes at  2.4 ATA for 3 
consecutive days, led to an increase in brain eNOS. However, in this 
experimental model, as the tissue being examined and, the dose and intervals 
for treatment with HBO2 were different, this may provide some explanation for 
the differences seen between that experimental study and this clinical study.  A 
reasonable possibility for the generally lower eNOS expression in the HBO2 
Group at the ‘post induction’ time point may be the negative feedback 
mechanism involving NO and eNOS (Abu-Soud et al., 2000, Assreuy et al., 
1993, Grumbach et al., 2005, Santolini et al., 2001). During this feedback 
inhibition, a portion of the enzyme is trapped in a NO-bound form, thus 
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decreasing the portion of the enzyme that is able to participate in NO 
synthesis (Santolini et al., 2001). As HBO2 in other studies has also been 
demonstrated to increase NO  (Cabigas et al., 2006b) and NOS (Cabigas et al., 
2006a, Buras et al., 2000), it is highly plausible that the negative feedback 
inhibition caused by an increased amount of NO as a result of HBO2 in the 
HBO2 Group of this study, may have led to partial inhibition eNOS thus 
reducing the presence of fully active, free, myocardial eNOS.  
In the period between the ‘post induction’ time point and the 
time point ‘5 minutes on CPB’, there was a decrease in the mean quantity of 
myocardial eNOS in both groups (Figure 6.1). This decrease was greater in the 
HBO2 Group resulting in a lower quantity of myocardial eNOS at the time 
point ‘5 minutes on CPB’. One possible explanation for this decrease in 
myocardial eNOS expression in both groups may lie in use of non-pulsatile 
flow (continuous flow) of blood during CPB in this study. The decrease in 
eNOS expression following the onset of CPB has also been described by 
others (Zhou et al., 2000).  As it has been demonstrated that pulsatile flow (Li 
et al., 2005) and shear stress (Cheng et al., 2005, Nishida et al., 1992, Tao et 
al., 2006, Xiao et al., 1997) leads to an increase myocardial eNOS expression, 
it is quite possible that the loss of pulsatile flow, and as such a reduction in 
shear stress, following the onset of continuous flow during CPB in this study, 
may have led to the decrease in eNOS expression. It may also account for the 
general decreasing trend in myocardial eNOS expression in both groups of this 
study. Another possibility for the general decrease in eNOS expression may 
again be, as previously described, the negative feedback mechanism involving 
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NO and eNOS (Abu-Soud et al., 2000, Assreuy et al., 1993, Grumbach et al., 
2005, Santolini et al., 2001).  
During the period of ischaemia and reperfusion (i.e. between the 
time points ‘5 minutes post CPB’ and ‘5 minutes post IRI’) (Figure 6.1), in the 
HBO2 Group there was a small increase in myocardial eNOS quantity while in 
the Control Group there was a decrease. The increase in myocardial eNOS as a 
result of ischaemia and reperfusion following HBO2 preconditioning  has also 
been demonstrated by Cabigas et al (Cabigas et al., 2006b) in a rat model of 
IRI. It has been shown that eNOS expression may also be regulated by protein-
protein interaction (Venema et al., 1996) and it has been suggested that this 
protein may be Hsp90 (Alderton et al., 2001, Garcia-Cardena et al., 1998). 
Cabigas et al (Cabigas et al., 2006b), in their experimental HBO2 model of IRI, 
showed that following IRI, rats pre-treated with HBO2 had an increase in the 
association of Hsp90 with eNOS and this occurred without any further increase 
in total Hsp90. This suggests that one possibility for the increase in myocardial 
eNOS expression during the period of ischaemia and reperfusion in the HBO2 
Group of this study, may be due to the protein-protein interaction between the 
HBO2 induced myocardial eNOS and existing myocardial Hsp90, leading to a 
burst of further eNOS expression during this period in the HBO2 Group. This 
observation, during the period of ischaemia and reperfusion, in the HBO2 
Group indicates that preconditioning CAD patients with HBO2 prior to CABG 
may be capable of enhancing endogenous myocardial protection during 
ischaemia and reperfusion by increasing myocardial eNOS expression.  
  
225 
 
Following the period of ischaemia and reperfusion, between the 
time points ‘5 minutes post IRI’ and ‘5 minutes post CPB’ (Figure 6.1), both 
groups again, showed a decrease in the mean quantity of myocardial eNOS and 
the final quantity of myocardial eNOS in the HBO2 Group at the time point ‘5 
minutes post CPB’ was lower than in the Control Group. It is possible that the 
decrease seen in the HBO2 Group may be again due to the negative feedback 
effect of high levels of NO on myocardial eNOS following the period of 
ischaemia and reperfusion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
226 
 
6.5.2  Myocardial Hsp72 
In this study it was observed that following HBO2 
preconditioning, in the baseline right atrial biopsy taken at the time point ‘post 
induction’, the myocardium of patients in the HBO2 Group had a lower mean 
quantity of myocardial Hsp72 compared to the Control Group (Figure 6.2). 
Although this was not a statistically significant result, it does suggest that 
preconditioning CAD patients with HBO2 prior to CABG leads to a reduction 
in myocardial Hsp72 expression. To date, this is the first and only clinical 
study that has demonstrated such as result. There are also no available 
experimental studies that have examined the tissue changes of Hsp72 before 
and after HBO2 treatment, prior to IRI. As such, at present it is difficult to offer 
a reasonable explanation for this observation other than to suggest that 
perhaps, the initial oxidative stress of HBO2 may have led to a degree of 
myocardial injury which required the chaperoning effect of Hsp72. This may 
have led to the reduced detection of myocardial Hsp72 in the HBO2 Group of 
patients 1 hour following HBO2 preconditioning. This explanation can only be 
confirmed if the actual concentration of serum Tropoin-T at the time points 
‘pre-HBO2’ and ‘post HBO2’ are known. However, as the concentration of 
serum Tropoin-T at these time points were reported as <0.03ng/ml and, the 
absolute concentrations were not reported by the laboratory, it is not possible 
to determine if there were minor degrees (i.e. not clinically relevant) of the 
myocardial injury, that may have resulted from HBO2 trearment, that could be 
correlated to changes in levels of myocardial Hsp72.  
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In the period between the time point ‘post induction’ and the 
time point ‘5 minutes on CPB’, there was a decrease in the mean quantity of 
myocardial Hsp72 in the HBO2 Group while in the Control Group there was a 
very small increase (Figure 6.1). A possible explanation for the decrease in 
Hsp72 in the HBO2 Group at the time point ‘5 minutes on CPB’ may be the 
following. It has been documented that CPB causes myocardial 
damage (Cosgrave et al., 2006, Dahlin et al., 2003, Lehrke et al., 2004). As 
such, it could be possible that at this time point in the HBO2 Group, the 
available myocardial Hsp72 may be chaperoning myocardial proteins that have 
unfolded as a result of 5 minutes of CPB. It has been suggested that any 
increase in the presence of unfolded proteins, shifts the equilibrium between 
Hsp and its transcription factor, Heat Shock Factor (HSF), to binding with the 
unfolded proteins (Abravaya et al., 1992, Morimoto, 1993). This may account 
for the reduced quantity of myocardial Hsp72 in the HBO2 Group. Cellular 
ATP depletion has also been shown to induce Hsp72 expression in the 
recovering cells (Vogt et al., 2007). HBO2 has been shown to preserve ATP 
levels  (Chen et al., 1998, Nylander et al., 1987, Yamada et al., 1995) while 
CPB causes ATP depletion (Khuri et al., 1993). As such, it is possible to 
further speculate that the Hsp72 chaperoning of unfolding proteins during the 
initiation of CPB and, the loss of the ATP mediated stimulus for the induction 
of Hsp72 expression as a result of HBO2 induced preservation of ATP, may 
have possibly led to the observed reduction in myocardial Hsp72 at the time 
point ‘5 minutes on CPB’ 
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During the period of ischaemia and reperfusion (i.e. between the 
time points ‘5 minutes on CPB’ and ‘5 minutes post IRI’), in the HBO2 Group 
there was a small increase in the mean quantity of myocardial Hsp72 while in 
the Control Group there was a decrease. The finding in the HBO2 Group of this 
study is similar to the previously described experimental findings of a HBO2 
IRI model (Wada et al., 1996) where the effects of repeated HBO2 exposure on 
ischaemic tolerance in gerbil hippocampus was investigated. The findings from 
that experimental study and the of this clinical study, further suggest that 
HBO2 preconditioning prior to ischaemia and reperfusion may be capable of 
increasing Hsp72 expression. 
Following the period of ischaemia and reperfusion, between the 
time points ‘5 minutes post IRI’ and ‘5 minutes post CPB’ (Figure 6.2), in 
both groups there was a decrease in the mean quantity of myocardial Hsp72. It 
could be possible that the decrease in myocardial Hsp72 in both the groups 
during this period may have been due to either, the further chaperoning of 
unfolded proteins as a result of IRI or post chaperoning structural changes to 
free Hsp72 (Kiang and Tsokos, 1998, Snoeckx et al., 2001) resulting in a 
reduction of free myocardial Hsp72.  
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6.6  Conclusion 
 
In this clinical study, no statistically or clinically significant 
results were found when estimating the effects of HBO2 preconditioning on the 
myocardial biomarkers of cardioprotection. As such, no definitive conclusions 
can be made with respect to the changes that were observed for these 
endpoints. Furthermore, as these were secondary endpoints, it was not part of 
the statistical plan of this study to make firm conclusions based on secondary 
endpoints. In keeping with this statistical plan, only an explanation for the 
results of the descriptive statistical were provided.  
In this study, it was observed that following HBO2 
preconditioning, this group of patients, compared to the Control Group of 
patients, had a lower amount of both myocardial eNOS and Hsp72 during the 
peri-operative period. However, it was also observed that during the period of 
ischaemia and reperfusion, both these biomarkers increased in the HBO2 
Group but decreased in the Control Group. Despite these changes during 
ischaemia and reperfusion, the amount of both biomarkers remained lower in 
the HBO2 Group when compared to in the Control Group. These results 
indirectly suggests (see section 6.5) that NO, from the catalytic action of 
eNOS, and Hsp72 may be functioning to protect the myocardium via their 
individual mechanisms of action, hence accounting for the limited pre-CPB 
detection of free eNOS and Hsp72 in the myocardium. Furthermore, as it was 
also observed that patients who were preconditioned with HBO2 experienced 
an increase in eNOS and Hsp72 following ischaemia and reperfusion, this 
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possibly also suggest that HBO2 preconditioning of this group of patients may 
be able to further induce the endogenous expression of these biomarkers to 
provide additional protection to the myocardium during the period of 
ischaemia and reperfusion.  
The main limitation to this part of the study was that there was 
no assessment of myocardial NO production. As a result of this, the correlation 
between eNOS activity and NO production could not be determined. 
Additionally, as eNOS catalyses the production of NO, which in turn leads to a 
variety of haemodynamic changes, the correlation between NO production and 
the haemodynamic changes observed in this study also could not be 
determined. Finally, as was the case with the serum soluble adhesion 
molecules, as the durations of ischaemia, reperfusion, CPB and, the number of 
ischaemic reperfusion cycles in both groups of this study were not 
standardised, there is always the possibility that a different set of results for 
both eNOS and Hsp72 expression may have been obtained if it was possible to 
standardise these intervals in a clinical study. 
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7.  Effects of HBO2 Preconditioning on 
the Myocardial Molecular 
Expression of NOS & Hsp72  
7.1  Introduction 
CABG is associated with periods of ischaemia and reperfusion 
that leads to IRI (Venugopal et al., 2009). The induction however, of 
endogenous myocardial eNOS  (Elrod et al., 2008, Han et al., 2008b, Iwase et 
al., 2007, Kim et al., 2007) and Hsp72 (Radford et al., 1996, Vahlhaus et al., 
2005) have been shown to protect the myocardium against IRI.    
Experimental models of IRI have demonstrated that treatment 
with HBO2 prior to  (Cabigas et al., 2006b, Kim et al., 2001) and, during 
ischaemia and reperfusion (Sterling et al., 1993) is capable of limiting 
myocardial infarct size as a result of IRI. It has also been demonstrated that 
HBO2 preconditioning prior to ischaemia and reperfusion is also capable of 
increasing myocardial eNOS expression (Cabigas et al., 2006a). While 
currently no work has been published on the effects of HBO2 and, ischaemia 
and reperfusion on myocardial Hsp72 expression, experimental work in gerbil 
brain tissue (Wada et al., 1996) has demonstrated that HBO2 preconditioning 
prior to ischaemia and reperfusion is capable of increasing cerebral Hsp72.  
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7.2  Objective 
The objective of this part of the study was to determine a 
method for the quantification of myocardial eNOS, iNOS and Hsp72 mRNA in 
myocardial tissue sample from the time point ‘5 minutes post CPB’ in patients 
who had been preconditioned with two episodes of 30 minutes of 100%  
oxygen at 2.4 ATA, which was completed approximately 2 hours prior to on 
CPB CABG.  
7.3  Methods 
7.3.1  Selection of Primers for RT-PCR 
The selection of primers and the primer sequences (Table 7.1) 
that were used for the reverse transcriptase polymerase chain reaction (RT-
PCR) were based on previously published literature investigating the effects of 
ischaemia and reperfusion on the expression of myocardial eNOS (Valen et al., 
2000), iNOS (Valen et al., 2000) and Hsp72 (Giannessi et al., 2003). The 
housekeeping gene used was β-Actin and its primer sequence too was obtained 
from the published literature (Giannessi et al., 2003). 
7.3.1.1 Primers 
Primers were purchased from Yorkshire Bioscience Ltd 
(Biocentre, York Science Park, Heslington, York, UK). The primers were 
reconstituted in RNase Free Water (Qiagen, UK) and had a concentration of 
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100μM. The primers were diluted 10 fold to a concentration of 10μM and 
stored as 10μl aliquots at -20ºC. 
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Table 7. 1: Primers used for RT-PCR 
 
 Hsp72 
Forward 
Primer 
Hsp72   
Reverse 
Primer 
β-Actin 
Forward 
Primer 
β-Actin 
Reverse 
Primer 
iNOS 
Forward 
Primer 
iNOS   
Reverse 
Primer 
 
eNOS  
Forward 
Primer 
eNOS   
Reverse 
Primer 
 
Sequence      
(5’-3’) 
5’GCT-
GAC-CAA-
GAT-GAA-
GGA-GAT-
3’ 
5’-GAG-
TCG-ATC-
TCC-AGG-
CTG-GC-3’ 
5’-GAG-
ACC-TTC-
AAC-ACC-
CCA-GCC-
3’ 
5’-GCC-
CAT-CTC-
TTG-CTC-
GAA-GTC-
3’ 
5’-AGT-
TTC-TGG-
CAG-CAA-
CGG-3’ 
5’-TTA-
AGT-TCT-
GTC-CCG-
GCA-G-3’ 
5’-ACC-
TGC-AAA-
GCA-GCA-
AGT-CCA-
GC-3’ 
5’-CCG-
AAC-ACC-
AAA-GTC-
ATG-GGA-
GT-3’ 
Product 
Size (bp) 
467 457 532 737 
Melting 
Temperature 
(Tm) 
 
60.3 
 
63.4 
 
63.7 
 
61.8 
 
56 
 
56.7 
 
64.2 
 
62.4 
No. Bases 22 20 21 21 18 19 23 23 
GC% 50 65 61.9 67.1 55.6 52.6 56.5 52.2 
   bp = base pairs 
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7.3.2  RNA Extraction from Myocardial Biopsy 
To determine the expression of iNOS, eNOS and Hsp72 mRNA 
in the right atrial biopsies, the myocardial samples were first removed from the    
-80ºC freezer. For the purpose of establishing a method, all the samples used 
were samples obtained at the time point ‘5 minutes post CPB’ from 20 patients 
who were preconditioned with HBO2.  
All steps for RNA extraction were done in a Class 2 Biological 
Safety Cabinet (Faster, SLS, Nottingham). Prior to use, the working surface of 
this cabinet was cleaned with RNaseZap (Sigma, UK) to ensure the surface 
was free of RNase. Before the samples could thaw, a small piece of tissue from 
the sample was quickly excised and the remaining portion of the right atrial 
biopsy sample was returned to the -80ºC freezer. The excised right atrial tissue 
specimen was allowed to completely thaw and then weighed. Trizol 
(Invitrogen, UK) was used, in accordance with the manufacturer’s protocol,  to 
extract RNA from the right atrial tissue specimens.  
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Myocardial Specimen Disruption & Homogenisation 
In a petri dish, the right atrial tissue specimen was teased apart 
and disrupted in 800μl of Trizol using two size 11 scalpels prior to 
homogenisation by passing it 5 times through a 20G needle and syringe. The 
homogenate was incubated for 5 minutes at room temperature before being 
centrifuged at 12,000g for 10 minutes at 4ºC. The supernatant (lysate) was then 
used for subsequent analysis.  
Phase Separation 
160μl of chloroform was added to the lysate, shaken vigorously 
for 15 seconds and then incubated for 2 minutes at room temperature before 
centrifugation at 10,000g for 15 minutes at 4ºC. The colourless upper aqueous 
phase containing RNA was decanted for subsequent use. 
RNA Precipitation 
  At room temperature, 400μl of isopropyl alcohol was mixed 
with the aqueous phase to precipitate RNA. This was subsequently incubated 
for 10 minutes at room temperature before centrifugation at 10,000g for         
10 minutes at 4ºC. The RNA precipitate formed a gel-like pellet on the bottom 
of the propylene tube. 
  RNA Wash 
The RNA pellet was washed once with 800μl of 75% Ethanol 
[in Diethylpyrocarbonate (DEPC)-treated water] and then centrifuged at 
7,500g for 5 minutes at 4 ºC. 
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Redissolving the RNA 
The RNA gel pellet was allowed to dry at room temperature for 
5 minutes and then dissolved in 50μl RNase Free Water by incubation in a 
water bath for 10 minutes at 55ºC. Typically, the volume of RNA solution 
obtained following this incubation was between 60 to 64μl. 
Quantification of RNA 
  In order to quantify the concentration of the RNA that was 
extracted, the absorbance of the RNA at 260nm (A260) was determined by 
using a spectrophotometer (GeneQuant [Pharmacia, UK]). The quantity of 
protein contaminants in the volume of extracted RNA was then determined by 
measuring the absorbances at 280nm (A280) using the same spectrophotometer 
(GeneQuant [Pharmacia, UK]). By calculating the A260/280 ratio, the purity of 
the extracted RNA was determined. 10mM of 
tris(hydroxymethyl)aminomethane choride (Tris.Cl) (pH=7.5) was used as the 
buffer during the process of measuring the A260 and A280 RNA absorbance. As 
per manufacturer requirements, when using the Trizol RNA extraction reagent, 
the RNA extracted was only used for RT-PCR when the A260/280 ratio (i.e. 
purity of extracted RNA) was >1.65. Below is an example of how the A260 and 
A280 absorbance was measured and how the eventual quantity of extracted 
RNA was determined. 
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1. Control calibration of the spectrophotometer was done by pippeting 
200μl of 10mM Tris.Cl (pH= 7.5) into a cuvette which was then 
placed in the spectrophotometer for spectorphotometric measurement.  
2. The Tris.Cl was then removed from the cuvette and the cuvette was 
cleaned with distilled water. 
3. 2μl of RNA (for example, from a total volume of 64μl) was then 
mixed with 198μl 10mM Tris.Cl (pH=7.5) in a propylene tube to 
make a 100 fold RNA dilution (200μl). 
4. The diluted RNA was pipetted into the cuvette and placed into the 
calibrated spectrophotometer for RNA absorbance measurement. 
5. The following is an example of the reading provided by the 
spectrophotometer:  
a. A260 = 0.043 
b. A280 = 0.024 
c. A260/280 = 1.8 
d. RNA Concentration = 2.1μg/ml 
6. Using the RNA concentration measurement provided by the 
spectrophotometer, a corrected RNA concentration was then 
calculated to take into account the previous 100 fold dilution of the 
RNA. This correction was done as such:   
2.1 x 100 = 210μg/ml 
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7. Using the corrected RNA concentration, the quantity of RNA in the 
64μl of RNA that was obtained following the redissolving of the 
RNA, was calculated as such: 
64/1000 x 210 = 13.44μg of RNA 
8. Therefore, 
a. 1μg of RNA is contained in:  
1/13.44 x 64 = 4.8μl of RNA 
b. 1μl of RNA contains: 
1/64 x 13.44 = 0.21μg of RNA 
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7.3.3  Two Step RT-PCR 
In order to detect β-actin, eNOS, iNOS and Hsp72 DNA in the 
right atrial tissue specimen, initially, a Two Step RT-PCR technique was used. 
The 2 steps of this technique are:  
a) synthesis of cDNA, from the extracted RNA, via reverse 
transcription. 
b) amplification of the respective DNA sequences via 
polymerase chain reaction (PCR) using primers for β-
actin, eNOS, iNOS and Hsp72 DNA. 
7.3.3.1  cDNA Synthesis 
All the reagents required for this, apart from the Moloney 
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT), were thawed 
and kept on ice. The M-MLV RT was only removed from the -20ºC when it 
was required for use. The cDNA synthesis process consisted of the following: 
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1. In a 0.5ml thin wall plastic tube, the following were added: 
a. 1μl oligo-dT Primer (0.5μg/μl) [Invitrogen, UK] 
b. an appropriate volume of RNA containing 1μg of RNA 
c. 1μl 10mM dNTP Mix [10mM each of dATP, dGTP, dCTP, 
dTTP in a solution of 0.6mM Tris-HCl (pH=7.5)] 
(Invitrogen, UK) 
d. 12μl DEPC treated distilled sterile water 
2. The reaction mixture was heated in a thermal cycler (Techne Genius-
Techne, Sone, UK) for 5 minutes at 65ºC to denature the dNTP probe 
and then chilled quickly in ice.  
3. The following was then added to the reaction mixture: 
a. 4μl 5 x First Strand Buffer (Invitrogen, UK) 
b. 2μl Dithiothreitol (DTT) Buffer (Invitrogen, UK) 
4. The contents of the tube was mixed and incubated in a thermal cycler 
(Techne Genius-Techne, Stone, UK) for 2 minutes at 37ºC.  
5. 1μl of M-MLV RT (200U/μl) (Invitrogen, UK) was then added and 
mixed. 
6. This reaction mixture was incubated in a thermal cycler (Techne 
Genius-Techne, Stone, UK) for 50 minutes at 37ºC to allow cDNA 
synthesis. 
7. The reaction was inactivated by heating the sample in a thermal cycler 
(Techne Genius-Techne, Stone, UK) at 70ºC for 15 minutes. 
8. The cDNA synthesised was stored at 4ºC for further analysis. 
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7.3.3.2 Quantification of cDNA 
The cDNA was quantified using a spectrophotometer 
(GeneQuant [Pharmacia, Kent, UK]) in a manner that similar to RNA 
quantification as described in section 7.3.2.  
7.3.3.3 PCR Of cDNA 
All the primers and PCR Master Mix (Promega, UK), were 
removed from the -20ºC freezer, thawed and kept cool on ice. The cDNA that 
was required was removed from the 4ºC refrigerator and also kept cool on ice. 
The primers used had a final concentration of 10μM. 
The PCR Master Mix consisted of  
a) 50units/ml  of Taq DNA Polymerase (in a 
propriety reaction buffer with pH=8.5) 
b) 400μM each of dATP, dGTP, dCTP, dTTP 
c) 3μM of MgCl2 
Preparation of Components for PCR of cDNA 
1. 5 separate thin-walled tubes were set up, in duplicates, 
containing the components as described in Table 7.2. 
2. All tubes were then place in a thermal cycler       
(Techne Genius-Techne, Stone, UK). The PCR cycling 
conditions used are given in Table 7.3.  
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Table 7. 2: Reaction Mixture for PCR of cDNA 
 
 Tube 1 
 
Tube 2 
 
Tube 3 
 
Tube 4 
 
Tube 5 
β-Actin 
(Positive 
Control) 
iNOS eNOS Hsp72 Negative 
Control 
Forward β-
Actin Primer 
(10μM) 
1μl    1μl 
Reverse      
β-Actin 
Primer 
(10μM) 
1μl    1μl 
Forward 
iNOS Primer 
(10μM) 
 1μl    
Reverse 
iNOS Primer 
(10μM) 
 1μl    
Forward 
eNOS 
Primer 
(10μM) 
  1μl   
Reverse 
eNOS 
Primer 
(10μM) 
  1μl   
Forward 
Hsp72 
Primer 
(10μM) 
   1μl  
Reverse 
Hsp72 
Primer 
(10μM) 
   1μl  
Template 
cDNA (1μg) 
1μl 1μl 1μl 1μl  
PCR Master 
Mix 
12.5μl 12.5μl 12.5μl 12.5μl 12.5μl 
Nuclease 
Free H2O 
9.5μl 9.5μl 9.5μl 9.5μl 10.5μl 
Total 
Reaction 
Volume 
25μl 25μl 25μl 25μl 25μl 
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Table 7. 3: PCR Cycling Conditions 
 
Cycles Temperature Time 
1 x Denaturation at 95ºC 5 minutes 
 
28x 
Denaturation at 94ºC 1 minute 
Annealing at 59ºC 1 minute 
Extension at 72ºC 1 minute 
1 x Prolonged extension at 
60ºC 
45 minutes 
 4ºC Holding post PCR 
 
7.3.3.4 Gel Electrophoresis 
In order to identify the size of the RT-PCR products, agarose gel 
electrophoresis was performed using a 2% gel.  
7.3.3.4.1  2% Agarose Gel Preparation 
3gm of Agarose 1000 gel powder (Invitrogen, UK) was 
dissolved in 150ml of 1x Tris/Borate/Ethylene Diamine Tetraacetate (EDTA) 
[TBE] by heating this mixture in a 500W microwave for 8 minutes. The gel 
was then allowed to cool for 5 minutes before 3μl of Ethidium Bromide (10 
mg/ml stock) was mixed into the gel. The gel was then poured into a horizontal 
gel tank with a comb and left to set for approximately 2 hours.  
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7.3.3.4.2 Electrophoresis 
Once the gel wells had been loaded with the appropriate 
contents (details of the content of each of the gel wells during the 
electrophoresis procedure, will be discussed later in the relevant sections), the 
gel was then placed in an electrophoresis tank containing TBE. In a 4ºC room, 
a 100V current was then run through the tank for approximately 1 hour or until 
the blue dye front had moved through 80% of the gel. The gel was then 
removed from the tank and DNA bands were visualised under UV light using a 
gel documentation system (UVItec, Cambridge, UK).  
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7.3.4  One Step RT-PCR 
In a One Step RT-PCR, cDNA synthesis and PCR are 
performed using an optimized buffer system in a single reaction tube without 
the requirement to add further reagents between cDNA synthesis and PCR. 
This simplified procedure reduced the potential for pipetting errors. 
For this procedure, the Titan One Step RT-PCR kit was used 
(Roche Diagnostics GmbH, Germany). The components of the kit are shown in 
Table 7.4. 
Table 7. 4: Titan One Step RT-PCR Kit Components 
 
Component Content 
 
Titan Enzyme Mix 
50μl of Titan enzyme mix [Avian 
Myeloblastosis Virus (AMV) and 
Expand High Fidelity] in storage 
buffer (1 reaction/μl) 
dNTP mix 200μl; 10mM total (2.5mM each 
dNTP) 
RNase Inhibitor 50μl (5U/μl) 
Human Control RNA 50μl (2pg/μl); K562 total RNA with 
MS2 carrier RNA 
Housekeeping (Control) Primer Mix 20μl; 20μM (See Table 7.5) 
PCR H2O 2 x 1ml 
 
RT-PCR reaction buffer 
1ml of 5 fold concentration with 
7.5mM MgCl2 and Dimethyl 
sulfoxide (DMSO) 
DTT solution 1ml (100mM) 
MgCl2 stock solution 1ml (25mM) 
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Table 7. 5: Roche Titan One Step RT-PCR Control Primer 
 
Control 
Primer 
Sequence (5’-3’) Size 
(bp) 
β-Actin (f) 5’-CCA-AGG-CCA-ACC-GCG-AGA-AGA-
TGA-C-3’ 
 
587 
β-Actin (r) 5’-AGG-GTA-CAT-GGT-GGT-GCC-GCC-
AGA-C-3’ 
f = forward primer r = reverse primer  bp = base pairs 
 
The preparation of the required reagents and the PCR cycling conditions for 
this analysis were performed according to the manufacturer’s instructions. 
  Preparation of Master Mix 1 
All the components for Master Mix 1 were thawed and placed 
on ice. All reagents were vortexed before setting up reactions. The initial 
concentration of the Yorkshire Bioscience primers that were used prior to 
making up Master Mix 1 was 10μM. A Nuclease Free thin wall plastic tube 
was used to set up each of the reaction mixture (Master Mix 1) as in Table 7.6. 
In total there were 7 thin wall plastic tubes, in duplicates, containing the 
necessary components for Master Mix 1. Following the addition of each of the 
components for Master Mix 1 into each of the thin wall plastic tubes, the tubes 
were then pulsed for 30 seconds at 10,000g. 
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Table 7. 6: Reaction Mixture for Master Mix 1 
 
  
Tube 1 
 
Tube 2 
 
Tube 3 
 
Tube 4 
 
Tube 5 
 
Tube 6 
 
Tube 7 
 
 
Final 
Concentration Negative 
Control-1 
β-Actin 
(Positive 
Control 1) 
β-Actin 
(Positive 
Control 2) 
β-Actin 
(Positive 
Control 3) 
 
iNOS 
 
eNOS 
 
Hsp72 
 
 
H2O 
 
 
15.5μl 
 
 
10.5μl 
Make up 
volume to 
25μl 
Make up 
volume to 
25μl 
Make up 
volume to 
25μl 
Make up 
volume to 
25μl 
Make up 
volume to 
25μl 
 
dNTP 4μl 4μl 4μl 4μl 4μl 4μl 4μl 0.2mM (each) 
DTT 2.5μl 2.5μl 2.5μl 2.5μl 2.5μl 2.5μl 2.5μl 5mM 
RNase Inhibitor 1μl 1μl 1μl 1μl 1μl 1μl 1μl  
Control RNA  5μl 5μl     10pg 
 
Sample RNA 
   Appropriate 
Volume 
Containing 
1μg RNA 
Appropriate 
Volume 
Containing 
1μg RNA 
Appropriate 
Volume 
Containing 
1μg RNA 
Appropriate 
Volume 
Containing 
1μg RNA 
 
1μg 
β-Actin Primer Mix 
(Roche) (f + r) 
 
2μl 
 
2μl 
      
0.4μM 
β-Actin Primer (YB) 
(f) 
  1μl 1μl    0.4μM 
β-Actin Primer 
(YB)(r) 
  1μl 1μl    0.4μM 
iNOS Primer (YB) (f)     1μl   0.4μM 
iNOS Primer (YB)(r)     1μl   0.4μM 
eNOS Primer (YB) (f)      1μl  0.4μM 
eNOS Primer (YB)(r)      1μl  0.4μM 
Hsp72 Primer (YB) (f)       1μl 0.4μM 
Hsp72 Primer (YB)(r)       1μl 0.4μM 
Total Volume (μl) 
per thin wall plastic 
tube 
 
25 
 
25 
 
25 
 
25 
 
25 
 
25 
 
25 
 
          f=forward;   r=reverse 
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Preparation of Master Mix 2 
All the components for Master Mix 2 were thawed and vortexed 
before setting up the reactions. A Nuclease Free thin wall plastic tube was used 
to set up each of the reaction mixture (Master Mix 2) as in Table 7.7. In total 
there were 7 thin wall plastic tubes, in duplicates, containing the necessary 
components for Master Mix 2. Each of the Master Mix 2 thin wall plastic tubes 
were then pulsed for 30 seconds at 10,000g. In this study, Master Mix 1 & 2 
were prepared separately, as per manufacturer’s instructions. The separate 
preparation of Master Mix 1 & 2, allows, if necessary, for a further step 
involving only Master Mix 2, to reduce DNA contamination with RNA or 
DNA from previous amplification procedures. This step involves heating 
Master Mix 2 for 2 minutes at 94ºC to inactivate reverse transcriptase AVM. 
This step was not done in this set of experiments as all other precautions to 
reduce error from DNA contamination were taken and this included having 
appropriate positive and negative controls, setting up a control reaction without 
RNA template and using RNase during the RNA extraction procedure. 
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Table 7. 7: Reaction Mixture for Master Mix 2 
 
 Tube 1 Tube 2 Tube 3 Tube 4 Tube 5 Tube 6 Tube 7  
 
Final 
Concentration 
Negative 
Control-1 
β-Actin 
(Positive 
Control 1) 
β-Actin 
(Positive 
Control 2) 
β-Actin 
(Positive 
Control 3) 
 
iNOS 
 
eNOS 
 
Hsp72 
H2O 14μl 14μl 14μl 14μl 14μl 14μl 14μl  
 
5 x RT-
PCR 
Buffer 
 
 
10μl 
 
 
10μl 
 
 
10μl 
 
 
10μl 
 
 
10μl 
 
 
10μl 
 
 
10μl 
1 x 
concentration 
with 1.5mM 
MgCl2 and 
DMSO 
Titan 
Enzyme 
Mix 
 
1μl 
 
1μl 
 
1μl 
 
1μl 
 
1μl 
 
1μl 
 
1μl 
 
Total 
Volume 
(μl) per 
thin wall 
plastic 
tube 
 
 
25 
 
 
25 
 
 
25 
 
 
25 
 
 
25 
 
 
25 
 
 
25 
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RT-PCR Protocol 
Master Mix 2 was mixed into Master Mix 1. The 50μl mixture 
of Master Mix 1 and 2 was then pulsed for 30 seconds at 10,000g before being 
placed in a thermal cycler (Techne Genius-Techne, Stone, UK)  for 30 minutes 
at 60ºC to allow for reverse transcription. Following this, PCR was performed 
using the manufacturer recommended cycling conditions as in Table 7.8.  
 
Table 7. 8: One Step RT-PCR Cycling Conditions 
 
Cycles Temperature Time 
1 x Denaturation at 94ºC 2 minutes 
 
35 x 
Denaturation at 94ºC 30 seconds 
Annealing at 55ºC 30 seconds 
Elongation at 68ºC 30 seconds 
1 x Prolonged elongation at 
68ºC 
7 minutes 
 4ºC Holding post PCR 
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7.3.4.1 Gel Electrophoresis 
  A 2% agarose was made as described in section 7.3.3.4.1. 8μl of 
each of the RT-PCR product was mixed with 2μl of 1x PCR Loading Buffer 
before being loaded into the wells of the gel as shown in Table 7.9.  
Table 7. 9: Gel Well Content for Electrophoresis of One Step RT-PCR 
Products 
 
Well Content 
1 10μl Mixture of Negative Control* 1 + 
Loading Buffer 
2 1μl 1000bp DNA Ladder (Promega, 
UK) 
3 10μl Mixture of Positive Control 1* + 
Loading Buffer 
4 10μl Mixture of Positive Control 2* + 
Loading Buffer 
5 10μl Mixture of Positive Control 3* + 
Loading Buffer 
6 10μl Mixture of iNOS RT-PCR 
product + Loading Buffer 
7 10μl Mixture of eNOS RT-PCR 
product + Loading Buffer 
8 10μl Mixture of Hsp72 RT-PCR 
product + Loading Buffer 
9 1μl 100bp DNA Ladder 
*(For the constituents of the positive and negative controls, see Table 7.6) 
Once the gel wells were loaded, electrophoresis was carried out 
as in section 7.3.3.4.2. Following the completion of the gel electrophoresis, 
DNA bands were visualised under UV light as in section 7.3.3.4.2. 
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7.4  Results 
7.4.1  RNA Quantification Results 
In this thesis, as per manufacturer’s recommendations (see 
section 7.3.2), the RNA extracted from each of the 20 post CPB right atrial  
specimens were only used for RT-PCR if the A260/280 was >1.65. The A260/ A280 
in this study ranged from 1.7 to 1.9.  
7.4.2  cDNA Quantification Results 
  All the 20 post CPB right atrial specimens that were used for 
cDNA synthesis, via the 2 Step RT-PCR, had their cDNA quantified. In this 
study, the cDNA that was synthesised had an A260/280 ratio that ranged from 
between 1.56 to 1.62.  
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7.4.3 Demonstrating Effective Function of      
Purchased Primers 
7.4.3.1 Amplification of β-Actin and Hsp72 in human 
buccal mucosa DNA 
  The aim of this experiment was to determine if the primers that 
were purchased from Yorkshire Bioscience functioned effectively when using 
the PCR cycling conditions described in Table 7.3. For this experiment, only 
the purchased β-Actin and Hsp72 primers were used. Human buccal mucosa 
DNA was used as the sample DNA and D16S539 was used as the positive 
control gene. The human buccal mucosal DNA was used as the sample DNA 
as it was readily available in the lab at the time of this experiment. It was 
obtained following a swab of the buccal mucosal surface of a volunteer in the 
lab. The DNA was extracted using a Qiagen QIAamp DNA Micro Kit. The 
D16S539 gene is a polymorphic microsatellite found on chromosome 16 at 
location q24.1 and is composed of the tetrameric repeat sequence GATA. It is 
a commonly used positive control gene during forensic testing. It was used as 
the positive control gene in this experiment as the primers (purchased from 
Eurofins MWG Operon, Germany) for this gene were readily available in the 
lab at the time.  
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  In this experiment, 3 thin wall plastic tubes, in duplicates, were 
made up to a 10μl volume containing the PCR components listed in Table 
7.10. 
Table 7. 10: PCR MixtureTo Demonstrate Effective Function of Purchased 
Primers (β-Actin & Hsp72) 
 
Components Volume 
1 x NH4 Buffer [contains 16mM 
(NH4)2SO4 and 67mM of Tris.HCL) 
(Bioline, UK) 
1.0μl 
MgCl2 (3mM) (Bioline, UK) 0.3μl 
dNTP (10μM) (Bioline, UK) 0.5μl 
Forward primer (either β-Actin, 
Hsp72 or D16S539; 10μM) 
1.0μl 
Reverse primer (either β-Actin, 
Hsp72 or D16S539; 10μM) 
1.0μl 
Bovine Serum A (New England 
Biolabs, UK) 
1.0μl 
 
PCR H2O (Bioline, UK) 4.0μl 
Taq DNA Polymerase (50units/ml) 
(Bioline, UK) 
0.2μl 
 
Human buccal mucosa DNA (0.5μg) 1.0μl 
Total Volume 10μl 
 
Each tube was then place in a thermal cycler (Techne Genius-Techne, Stone, 
UK). The thermal cycling conditions used are listed in Table 7.3.  
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Table 7. 11: Gel Well Content for Electrophoresis to Demonstrate Effective 
Function of Purchased Primers (β-Actin & Hsp72) 
 
Well Content 
1 1μl 100bp DNA Ladder (Promega, 
UK) 
2 1μl 1000bp DNA Ladder (Promega, 
UK) 
3 The 10μl mixture of β-Actin RT-PCR 
product + 1x PCR Loading Buffer 
4 The 10μl mixture of Hsp72 RT-PCR 
product + 1x PCR Loading Buffer 
5 The 10μl mixture of D16S539 RT-
PCR product (Positive Control) + 1x 
PCR Loading Buffer 
6 The 10μl mixture of β-Actin RT-PCR 
product + 1x PCR Loading Buffer 
7 The 10μl mixture of Hsp72 RT-PCR 
product + 1x PCR Loading Buffer 
8 1μl 1000bp DNA Ladder (Promega, 
UK) 
9 1μl 100bp DNA Ladder (Promega, 
UK) 
 
Following PCR, the RT-PCR products were loaded into a 2% 
agarose gel that was made as described in section 7.3.3.4.1. 8μl of each of the 
RT-PCR product was mixed with 2μl of 1x PCR Loading Buffer before being 
loaded into the gel wells.  The contents of the gel well are shown in Table 7.11. 
Once the gel wells were loaded satisfactorily, electrophoresis 
was then conducted as in section 7.3.3.4.2. Following the completion of the gel 
electrophoresis, DNA bands were visualised under UV light as in section 
7.3.3.4.3. Figure 7.1 shows the image of the gel electrophoresis viewed under 
UV light.  
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Figure 7. 1: UV image of gel showing the product bands for β-Actin & Hsp72 
following PCR using the purchased primers & human buccal mucosal DNA 
and, showing the product band for the positive control gene, D16S539. 
 
     Lane:    1          2         3          4        5         6         7          8         9 
   
                                Yellow arrow indicates 100bp band (100-1000bp ladder) 
                                 Blue arrow indicate 1000bp band (1000-10000bp ladder) 
 
Legend 7. 1: Legend for Figure 7.1 
 
Lane Content 
1 100bp ladder 
2 1000bp ladder 
3 β-Actin 
4 Hsp72 
5 D16S539 
6 β-Actin 
7 Hsp72 
8 1000bp ladder 
9 100bp ladder 
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 In Figure 7.1, RT-PCR products were visible under UV light 
for β-Actin (457bp), Hsp72 (467bp) and D16S539 (330bp). A 100bp and 
1000bp DNA ladder were used to enable easier identification of the RT-PCR 
products base pair sizes. This experiment demonstrated that the purchased β-
Actin and Hsp72 primers functioned optimally using the PCR conditions listed 
in Table 7.3.  
This experiment was repeated twice and gave the similar results. 
Optimisation experiments for the purchased eNOS and iNOS primers, using 
the PCR conditions listed in Table 7.3, were not performed as the success of 
this experiment, using the purchased primers for β-Actin and Hsp72, provided 
sufficient evidence that primers purchased from Yorkshire Bioscience were 
reliable and would functioned appropriately. 
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7.4.4 Assessment of Myocardial Specimen DNA 
Expression using Purchased Primers. 
7.4.4.1 Detection of β-Actin, Hsp72, eNOS and iNOS in 
sample myocardial DNA using a Two Step RT-PCR 
  These experiments were conducted to assess the expression of 
mRNA for β-Actin, Hsp72, eNOS and iNOS in the 20 post CPB right atrial 
myocardial specimens, following the RNA extraction procedure, as in section 
7.3.2 and, the Two Step RT-PCR procedure, as in section 7.3.3. In this series 
of experiments, in the second step of the Two Step RT-PCR procedure, the 
Promega PCR Master Mix was used rather than individual PCR components as 
in section 7.4.3. This was done due to the simplicity and ease of use of a PCR 
Master Mix.  
In this series of experiments, following the Two Step RT-PCR 
procedure (see section 7.3.3) and 2% agarose gel preparation (see section 
7.3.3.4.1), 8μl of each of the RT-PCR product was mixed with 2μl of 1x PCR 
Loading Buffer. The 10μl mixture was then loaded into the gel wells. The 
content of each gel well is described in Table 7.12. 
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Table 7. 12: Gel Well Content for Electrophoresis to Demonstrate Presence of 
β-Actin, eNOS, iNOS and Hsp72 in Sample Myocardial cDNA following Two 
Step RT-PCR. 
 
Well Content 
1 1μl 100bp DNA Ladder (Promega, 
UK) 
2 1μl 1000bp DNA Ladder (Promega, 
UK) 
3 The 10μl mixture of Hsp72 RT-PCR 
product + 1x PCR Loading Buffer 
4 The 10μl mixture of eNOS RT-PCR 
product + 1x PCR Loading Buffer 
5 The 10μl mixture of iNOS RT-PCR 
product + 1x PCR Loading Buffer 
6 The 10μl mixture of β-Actin RT-PCR 
product (Positive Control) + 1x PCR 
Loading Buffer 
7 The 10μl mixture of Negative Control 
(β-Actin RT-PCR without sample 
myocardial DNA) product + 1x PCR 
Loading Buffer 
8 1μl 1000bp DNA Ladder (Promega, 
UK) 
9 1μl 100bp DNA Ladder (Promega, 
UK) 
 
Once the gel wells were loaded satisfactorily, electrophoresis 
was then conducted as in section 7.3.3.4.2. Following the completion of the gel 
electrophoresis, DNA bands were visualised under UV light as in section 
7.3.3.4.3. 
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For each of the 20 post CPB right atrial myocardial specimen 
used, a similar experiment was performed using 4 increasing amounts of RNA, 
0.03μg, 0.05μg, 0.3μg and 1μg, respectively. To optimise conditions, a range 
of denaturation (94ºC-98ºC) and annealing (58ºC-62ºC) temperatures were also 
used during the PCR procedure. However, in all the optimisation experiments, 
none of the β-Actin, Hsp72, eNOS or iNOS  RT-PCR product bands were 
visible, in the gel, under UV light. Figure 7.2 is an example of one of those 
gels. A 100bp and 1000bp DNA ladder was used to enable easier identification 
of the base pair product band of interest. 
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Figure 7. 2: UV image of gel showing no product bands bands following 
electrophoresis of the Two Step RT-PCR products (β-Actin, Hsp72, eNOS and 
iNOS) that was obtained from 0.03μg of sample myocardial RNA. 
 
            Lane:        1      2     3      4      5        6       7      8        9 
 
                                 Yellow arrow indicates 100bp band (100-1000bp ladder) 
                                  Blue arrow indicates 1000bp band (1000-10000bp ladder)            
  
 
Legend 7. 2: Legend for Figure 7.2 
 
Lane Content 
1 100bp ladder 
2 1000bp ladder 
3 Hsp72 
4 eNOS 
5 iNOS 
6 Positive Control 
7 Negative Control 
8 1000bp ladder 
9 100bp ladder 
 
  
263 
 
7.4.4.2 Two Step RT-PCR involving human buccal mucosa 
DNA and sample myocardial DNA  
  As the RT-PCR experiments in section 7.4.4.1, where sample 
myocardial DNA and a PCR Master Mix were used during the second step of 
the Two Step RT-PCR procedure, did not yielded any bands, one possible 
reason for this may have been the Two Step RT-PCR process itself. The 
problem could arise either in the process of synthesising cDNA from the 
extracted myocardial RNA (first step of the Two Step RT-PCR process) or 
during the PCR step (second step of the Two Step RT-PCR) of the process.  
In order to establish if there was a problem in synthesising 
cDNA from the myocardial RNA (section 7.3.3.1) during the first step of the 
Two Step RT-PCR process, an experiment was set up using post CPB right 
atrial myocardial sample DNA (obtained following RNA extraction as in 
section 7.3.2 and cDNA production as in section 7.3.3.1) and human buccal 
mucosa DNA (as used in the experiment in section 7.4.3.1). 
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  In this experiment, 10 thin wall plastic tubes, in duplicates, were 
made up to a 25μl volume containing the PCR components listed in Table 
7.13. 
 
Table 7. 13: PCR Mixture to produce the required PCR products from Human 
Buccal Mucosa DNA & Myocardial Sample cDNA (obtained follwing Two 
Step RT-PCR) 
 
Components Volume 
Promega PCR Master Mix 12.5μl 
Forward Primer (β-Actin, 
D16S539, Hsp72, eNOS or iNOS; 
10μM) 
          1μl 
 
Reverse Primer (β-Actin, D16S539, 
Hsp72, eNOS or iNOS; 10μM) 
          1μl 
 
Sample myocardial (0.7μg/μl) or 
human buccal mucosa DNA 
(0.5μg/μl) 
 
1μl 
Nuclease Free H2O 9.5μl 
Total Volume 25μl 
 
Each tube was then place in a thermal cycler (Techne Genius-Techne, Stone, 
UK). The thermal cycling conditions listed in Table 7.3 were used.  
 RT-PCR products were then loaded into a 2% agarose that was 
made as described in section 7.3.3.4.1. 8μl of each of the RT-PCR product was 
mixed with 2μl of 1x PCR Loading Buffer before being loaded into the gel 
wells. The contents of each gel well is described in Table 7.14.  
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Table 7. 14: Gel Well Content for Electrophoresis using Human Buccal 
Mucosa DNA & Sample Myocardial cDNA (obtained following Two Step RT-
PCR). 
 
Well Content 
1 1μl 100bp DNA Ladder (Promega, 
UK) 
2 1μl 1000bp DNA Ladder (Promega, 
UK) 
3 10μl mixture of sample myocardial 
Hsp72 RT-PCR product + 1x PCR 
Loading Buffer 
4 10μl mixture of sample myocardial 
eNOS RT-PCR product + 1x PCR 
Loading Buffer 
5 10μl mixture of sample myocardial 
iNOS RT-PCR product + 1x PCR 
Loading Buffer 
6 10μl mixture of sample myocardial β-
Actin RT-PCR product + 1x PCR 
Loading Buffer 
7 10μl mixture of sample myocardial 
D16S539 RT-PCR product + 1x PCR 
Loading Buffer 
8 10μl mixture of buccal mucosa Hsp72 
RT-PCR product + 1x PCR Loading 
Buffer 
9 10μl mixture of buccal mucosa eNOS 
RT-PCR product + 1x PCR Loading 
Buffer 
10 10μl mixture of buccal mucosa iNOS 
RT-PCR product + 1x PCR Loading 
Buffer 
11 10μl mixture of buccal mucosa β-
Actin RT-PCR product + 1x PCR 
Loading Buffer 
12 10μl mixture of buccal mucosa 
D16S539 RT-PCR product + 1x PCR 
Loading Buffer 
13 1μl 1000bp DNA Ladder (Promega, 
UK) 
14 1μl 100bp DNA Ladder (Promega, 
UK) 
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Once the gel wells were loaded satisfactorily, electrophoresis 
was then carried out as in section 7.3.3.4.2. Following the completion of the 
gel electrophoresis, DNA bands were visualised under UV light as in section 
7.3.3.4.3. The image of the gel as viewed under UV light are shown in Figures 
7.3.  
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Figure 7. 3: UV image gel showing no products bands from the of sample 
myocardial cDNA (obtained following the Two Step RT-PCR) but showing 
product bands for Human Buccal Mucosal Hsp72 & D16S539. 
 
      Lane:            1   2      3      4     5     6    7     8      9     10   11  12  13  14    
 
                     Arrow indicating 100bp band (100-1000bp ladder) 
                     Arrow indicating 1000bp band (1000-10000bp ladder).  
Legend 7. 3: Legend for Figure 7.3 
 
Lane Content 
1 100bp ladder 
2 1000bp ladder 
3 Myocardial Hsp72 
4 Myocardial eNOS 
5 Myocardial iNOS 
6 Myocardial  β-Actin 
7 Myocardial D16S539 
8 Buccal Mucosa Hsp72 
9 Buccal Mucosa eNOS 
10 Buccal Mucosa iNOS 
11 Buccal Mucosa  β-Actin 
12 Buccal Mucosa D16S539 
13 100bp ladder 
14 1000bp ladder 
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The above experiment was repeated twice with similar results. 
None of the sample myocardial RT-PCR products i.e. β-Actin (expected at 
457bp), D16S539 (expected at 330bp), Hsp72 (expected at 467bp), eNOS 
(expected at 737bp) or iNOS (expected at 532bp) were visible under UV light. 
However, from the buccal mucosa RT-PCR products, apart from eNOS and 
iNOS, the RT-PCR products for β-Actin, D16S539 and Hsp72 (Lanes 10, 11 
and 12) were visible under UV light at the appropriate band scale. It is possible 
that eNOS and iNOS RT-PCR products from the buccal mucosa DNA were 
not visualised because the purchased primers for eNOS and iNOS required 
further optimisation before being used this study. This may be the case as, 
while in section 7.4.3, it was demonstrated that the purchased primers for       
β-Actin and the Hsp72 functioned appropriately, this was not demonstrated for 
the purchased primers of eNOS and iNOS. An assumption was made then that 
as the purchased primers for β-Actin and the Hsp72 functioned appropriately, 
the same would be the case for the purchased eNOS and iNOS primers. 
However, the detection of β-Actin and Hsp72 RT-PCR product using the 
buccal mucosa DNA, also suggest that the failure to produce any RT-PCR 
product from the sample myocardial DNA may also lie in the process of 
synthesising cDNA from the sample myocardial RNA. One  possible reason 
that may have led to this, when using the right atrial myocardial spample RNA 
and the Two Step RT-PCR process, may have been contamination of the 
cDNA that was synthesised. In this study, the cDNA that was synthesised had 
a A260/280 ratio which was between 1.56-1.62. Conventionally, a cDNA A260/280 
ratio which is less than 1.8 is suggestive of some cDNA contamination (Clark 
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W, 2001) and this may have affected the outcome of the eNOS and iNOS PCR 
results. Another factor which may have affected the PCR results of the Two 
Step RT-PCR process, may be the possibility that there was an excess of 
reverse transcriptase enzyme (M-MLV RT) that was being used during the 
cDNA synthesis (see section 7.3.3.1) and this was inhibiting the PCR step of 
this two step process. This problem has been published in the literature (Suslov 
and Steindler, 2005). As a means of reducing cDNA contamination and 
limiting possible inhibition of the PCR process during the Two Step RT-PCR, 
due to excessive reverse transcriptase enzymes, a One Step RT-PCR was 
subsequently used to directly synthesise target myocardial DNA from the 
extracted RNA.  
7.4.4.3 Results of the One Step RT-PCR using sample 
myocardial DNA  
  Following the One Step RT-PCR process (section 7.3.4), a 2% 
agarose gel was prepared as in section 7.3.3.4.1. Gel loading and 
electrophoresis was done as in section 7.3.4.2. Following electrophoresis, the 
gel was viewed under UV light as in section 7.3.3.4.3. The image of the gel as 
viewed under UV light is shown in Figures 7.4.  
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Figure 7. 4: UV image of gel showing product bands for myocardial β-Actin 
and iNOS &, product band for Control β-Actin following One Step RT-PCR. 
 
      Lane 1        2          3        4         5         6        7        8          9    
 
                      Blue arrow indicates 1000bp band (1000-10000bp ladder) 
                      Yellow arrow indicates 100bp band (100-1000bp ladder) 
*(For the constituents of the positive and negative controls, see Table 7.5) 
 
Legend 7. 4: Legend for Figure 7.4 
        *(For the constituents of the positive and negative controls, see Table 7.6) 
 
 
 
Lane Content 
1 Negative Control* 1 
2 1000bp ladder 
3 Positive Control 1* 
4 Positive Control 2* 
5 Positive Control 3* 
6 iNOS  
7 eNOS 
8 Hsp72 
9 1000bp ladder 
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 From the Figure 7.4  it can be seen that the Negative Control, 
in Lane 1, has no product band but Positive Control 1 (β-Actin RT-PCR 
product using control RNA) and Positive Control 3 (β-Actin RT-PCR product 
using sample RNA), in Lanes 3 and 5, respectively, have a product band each 
that have been illuminated by UV light at about the 500bp mark. The iNOS 
RT-PCR product in Lane 6 produced a faint band at about the 500bp mark. The 
RT-PCR products for eNOS (Lane 7) and Hsp72 (Lane 8) did not produce any 
bands. The above experiment was repeated for each of the 20 post CPB 
myocardial samples with similar results. 
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7.5  Discussion 
The objective of this part of this study was to develop a RT-
PCR method for analysing the expression of eNOS, iNOS and Hsp72 mRNA 
in the collected right atrial biopsies. Based on the results from this study, it is 
not possible to deduce any conclusion with regards to the effects of HBO2 
preconditioning on myocardial eNOS, iNOS and Hsp72 mRNA in the patients 
recruited to this study.  
 The results from the One Step RT-PCR experiment in section 
7.4.4.3 showed that in the 20 analysed post CPB right atrial biopsies from 
patients who were preconditioned with HBO2 prior to CABG and IRI, in 
addition to β-Actin [from Positive Control 1 (using the Control RNA and β-
Actin primers provided by the One Step RT-PCR kit) and Positive Control 3 
(using sample myocardial RNA and purchased β-Actin primers)], only a faint  
iNOS DNA band was detectable. It suggests that, of the 3 genes (eNOS, iNOS 
and Hsp72) examined for mRNA expression at the time point ‘5 minutes post 
CPB’ in these 20 patients, there was only low level expression of myocardial 
iNOS mRNA with no mRNA for eNOS or Hsp72. From the series of 
experiments involving the methods used in section 7.4.4.3, it is unclear why no 
DNA band was observed for the Positive Control 2 (using Control RNA from 
the One Step RT-PCR kit and the purchased β-Actin primers).  
In this study, the iNOS protein was not measured in the 
myocardial samples that were obtained. This was because it had been 
demonstrated, in an experimental model of HBO2 and IRI, that HBO2 had no 
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effect on iNOS protein expression (Buras et al., 2000). iNOS is not a 
constitutive protein and its expressions needs to be induced by a stress event, 
such as an oxidative stress or ischaemia and reperfusion, which initiates its 
transcription. As such, instead of attempting  to determine the expression of 
iNOS protein, this study attempted to determine if the oxidative stress of HBO2 
preconditioning in patients with CAD disease, administered prior to CABG 
and IRI, had any effect on the mRNA expression of iNOS. The results of this 
study appear to indicate that in patients who were exposed to the oxidative 
stress of HBO2 preconditioning prior to on CPB CABG and IRI,  by the end of 
the period of ischaemia and reperfusion and, CPB (i.e. at the time point ‘5 
minutes post CPB’), there was some expression of iNOS mRNA.  
With respect to eNOS and Hsp72 expression, in this study it was 
observed that, in the HBO2 Group, following the termination of CPB, while 
there was no eNOS and Hsp72 mRNA detected, there was an abundance of 
eNOS (see section 6.4.2) and Hsp72 (see section 6.4.3)  protein present. Could 
this suggest that by the time point ‘5 minutes post CPB’ in this study, the RNA 
turnover process leading to eNOS and Hsp72 protein synthesis was complete, 
leaving only the final products of this process i.e. eNOS and Hsp72 protein, 
with no detectable mRNA for these proteins? To answer this questions, the 
expression of eNOS and Hsp72 mRNA in myocardial samples from earlier 
time points in this study need to be determined and, comparisons made with 
other patients in the HBO2 and Control Groups. 
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7.6  Future Molecular Work 
  To further develop a functional method for the molecular 
analysis of myocardial eNOS, iNOS and Hsp72 mRNA, using the samples 
obtained from study, the following future work is proposed: 
a. As optimisation of the conditions for use of the purchased eNOS and 
iNOS primers were not done, a set of experiments will be required to 
confirm the optimal conditions required for the function of these 
purchased primers, using an appropriate polymerase enzyme and PCR 
cycling conditions. 
b. Reducing cDNA contamination during the reverse transcriptase process 
by preparing cDNA in a room that is separate from the room where 
PCR products are analysed. In addition to this, it would be important to 
verify that the purity of the cDNA is >1.65 before using in the PCR 
process.  
c. Further optimisation of the RT-PCR process is required. As the best 
PCR result in this study were obtained when individual PCR 
components were used, as was done in section 7.4.3.1, as part of the 
second step of the Two Step RT-PCR, perhaps a return to this method 
of RT-PCR, using purer cDNA, may lead to more positive outcomes 
following gel electrophoresis. The use of individual PCR components, 
rather than a commercially available master mixes, will allow for 
further individualisation and optimisation of each of the PCR 
  
275 
 
components in particular, the magnesium and primer concentration 
used. 
d. mRNA analysis in myocardial samples from time points earlier than the 
time point ‘5 minutes post CPB’ in the HBO2 Group. This will allow 
comparisons to be made with other time points in this group and hence 
enable deductions to be drawn on the effects of HBO2 preconditioning 
on mRNA expression and mRNA turnover in this group of patients. 
e. mRNA analysis in myocardial samples from patients in the Control 
Group. This will enable a comparison to be made with the HBO2 Group 
and conclusions to be made on the possible molecular cardioprotective 
effects of HBO2 preconditioning in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
276 
 
8.  Discussion 
8.1  Cardioprotection Via Systemic HBO2 
Remote Preconditioning?  
 This small, pilot, proof of concept, phase 2, randomised 
controlled clinical study provides some level 2a evidence (Phillips B, March 
2009) that remotely preconditioning CAD patients with systemic HBO2, prior 
to first time elective on CPB CABG, with the use of intermittent ischaemic 
fibrillatory arrest, may be capable of leading to beneficial clinical, health 
economic and biological outcomes in a low risk group of patients.  It met its 
primary objective and demonstrated that this modality of treatment was 
capable of improving myocardial LVSW following CABG. In addition to this, 
it was also observed that it may potentially improve  peri-operative SV, 
pulmonary vascular flow prior to CABG and may also be a safe modality of 
treatment as it had the capacity to limit myocardial injury and post operative 
AEs. Furthermore, it was also shown that it may even be a cost effective 
treatment as it reduced the post operative length of stay in ICU.  
Biologically, where the serum biomarkers were concerned, this 
study indirectly provided some evidence to suggest that HBO2 preconditioning 
of this group of patients may be capable of facilitating endothelial protection 
by possibly causing the shedding of endothelial and/or platelet and, 
neutrophilic adhesion molecules into the circulation, hence leading to an 
increased post operative circulating load of soluble adhesion molecule. This 
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may lead to less neutrophil-endothelial adhesion and thus limit the ensuing 
deleterious consequences of this interaction. It was also observed that 
preconditioning with HBO2 prior to ischaemia and reperfusion leads to a 
reduction in the amount of eNOS and Hsp72. This indirectly suggests (see 
section 6.5) that NO from the catalytic action of eNOS and Hsp72 are 
functioning to protect the myocardium via their individual mechanisms of 
action, hence accounting for the limited detection of free eNOS and Hsp72 in 
the myocardium. Furthermore, it was also observed that HBO2 preconditioning   
may be able to further induce the endogenous expression of these biomarkers 
thus providing additional protection to the myocardium during the period of 
ischaemia and reperfusion.  
All these observations, appear to suggest that preconditioning 
CAD patients with HBO2, prior to on CPB CABG and IRI, may have the 
ability  to enhance the cardiovascular protection available to this group of 
patients to allow for the better tolerance of the stress of IRI during CABG. 
8.2  Study Limitations 
 Despite encouraging results from this study, the strength of the 
evidence is weak, particularly with respect to the secondary objectives. This is 
a consequence of the major limitation of this study, which was that the sample 
size was not large enough to assess multiple secondary endpoints. The 90% 
probability (power of the study) of detecting a difference of only 7.5% between 
the groups, and hence the sample size determination, was only estimated to be 
sufficient to assess the primary endpoint between the groups. As the pre-
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defined statistical plan did not include a statistical analysis for the correction 
for multiple statistical testing when comparing the differences in the secondary 
endpoints between the groups, it was not possible to draw any statistical 
conclusions from the secondary endpoints. Hence, firm statistical conclusions 
could only be drawn from the primary endpoint. In keeping with this, from the 
analysis of the secondary endpoints, only comparative descriptive estimates 
between the groups were possible. The statistical results which accompanied 
any of the comparisons between those descriptive estimates, only provided a 
sensitivity analysis for the observed difference in estimates of the secondary 
endpoints between the groups. While no firm conclusions could be made from 
the results of the secondary endpoints, where possible and reasonable, an 
appropriate explanation was offered for the observed differences.  
The patients recruited to this study had a relatively low 
operative risk. As such, the actual impact of HBO2 preconditioning may not 
have been easy to appreciate. This low risk group of patients was selected for 
this study as the safety of HBO2 in this group of patients is not well 
documented. It is quite to assume that more encouraging results may have been 
observed if the patients recruited to this study had a higher operative risk. In 
the case report by Yacoub et.al (Yacoub and Zeitlin, 1965), a clinically 
significant improvement was observed in a post operative, cardiac patient with 
low cardiac output following treatment with HBO2. If a high risk post 
operative patient, following IRI, responded well to post operative adjunctive 
treatment involving HBO2 (i.e. HBO2 post conditioning), it is also possible that 
high risk pre-operative patients may be preconditioned with HBO2, prior to 
  
279 
 
IRI, to enable better tolerance to the stress of IRI. Furthermore, in the clinical 
study by Thurston et.al (Thurston, 1971), it was observed that AMI patients 
with more severe MIs, cardiogenic shock or heart failure, performed better 
following treatment with HBO2 compared to those patients who were less 
unwell. This further re-inforces the suggestion that this modality of treatment 
may be more beneficial for high risk patients. 
In this study, the Control Group of patients were, pre-
operatively, slightly more unwell compared to those in the HBO2 Group. The 
former had a higher mean EUROSCORE and, consisted of more patients with 
a history of unstable angina, previous MIs, hypertension and diabetes mellitus. 
While all these are chance occurance despite randomisation, it may have led to 
a selection bias in the Control Group, which resulted in the slightly poorer 
outcomes of this group. Furthermore, in this group, the mean ischaemic and 
CPB times were also slightly longer. An attempt to minimise the confounding 
effects of ischaemic and CPB time were done by performing linear 
multivariate analysis that adjusted for longest cross-clamp time and CPB time. 
Moreover, as the number of coronary bupass to be performed has an impact on 
the duration of ischaemia and reperfusion and, hence the degree of IRI during 
CABG, the number of coronary bypasses can also be regarded as another 
potential confounder. In retrospect, the confounding effect of this could have 
been limited by startifying patients according to the number of coronary artety 
bypasses that were plan for them pre-operatively.   
Finally, there was also no attempt to measure ROS, NO, the 
expression of adhesion molecules on the neutrophilic and endothelial surfaces, 
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neutrophil-endothelial interaction or an assessment of the long term effects of 
HBO2 preconditioning on quality of life. As such, it was not possible to 
correlate the changes in ROS and NO generation with the changes in the 
expression of surface adhesion molecules or the expression of serum soluble 
adhesion molecules and, the long term effects this may have had on quality of 
life. 
8.3  HBO2 Preconditioning: A Method For 
ROS Preconditioning 
Essentially, HBO2 preconditioning prior to ischaemia and 
reperfusion is a mode of pharmacological preconditioning involving ROS. 
Various studies have demonstrated that low doses of ROS (Hegstad et al., 
1997, Valen et al., 1996, Ytrehus et al., 1995) and ROS preconditioning (Sun 
et al., 1996, Takeshima et al., 1997, Valen et al., 1998) leads to myocardial 
protection. In fact, it has also been demonstrated that ROS preconditioning 
leads to better myocardial protection than just IPC alone (Yaguchi et al., 2003). 
Both HBO2 therapy (Conconi et al., 2003) and, ischaemia and 
reperfusion (Robin et al., 2007) generate ROS. By preconditioning patients 
with HBO2, which indirectly means exposing them to a non-lethal, controlled 
dose of ROS, a complex set of  yet to be fully understood, biological pathways 
are initiated. As suggested by this study, the two possible pathways that maybe 
induced by HBO2 are the peri-operative increase in circulating soluble 
adhesion molecules and the increased expression of cardioprotective proteins 
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(e.g. eNOS and Hsp72) during ischaemia and reperfusion. As such, when 
patients are later exposed to a further, possibly lethal, burst of ROS during 
ischaemia and reperfusion, which normally leads to cellular injury and clinical 
dysfunction (Moens et al., 2005), not only is there a protective mechanism (as 
a result of myocardial eNOS and Hsp72 expression) already in place to enable 
better tolerance to this insult but, there is possibly also a diminished ability to 
propagate the insult of IRI as there may be a reduced capacity for neutrophilic 
attachment to the endothelium (due to the increase in circulating soluble 
adhesion molecules).  
8.4  The Future For HBO2 Preconditioning 
The area of HBO2 preconditioning is intriguing as it opens up 
the concept that prophylactic treatment with HBO2 may be capable of inducing 
cellular protection to enable better tolerance to a subsequent stressful event. 
Despite interesting, the future of HBO2 preconditioning remains unclear. This 
is primarily because the field of HBO2 medicine is still not widely appreciated 
as a possible treatment option in any particular area of unmet medical need. As 
such, it is not an area of high priority academic or pharmaceutical research. 
Moreover, as a modality of treatment without a specific disease area to treat, 
interest in using HBO2 to treat patients is further impeded by the lack of it’s  
availability in major tertiatry hospitals. Where it is available, its feasibility for 
providing treatment to patients, particularly the critically ill, is challenged by 
chamber design and size issues which may make it unsuitable for routine 
clinical use. This particular obstacle has recently been addressed by a number 
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of centres around the world (USA, Sweden, Norway and Australia), by 
customising the design of HBO2 chambers so that they resemble and function 
more like hospital wards and ICUs. This has enabled these centres to address 
the other challenge to HBO2 medicine, which is the shortage of well-conducted 
randomised control clinical trials to demonstrate its efficacy and safety across 
therapeutic areas. While there are ample experimental studies and case reports 
demonstrating the biological and potential clinical benefits of HBO2 treatment, 
there has been a shortage of clinical trials which support its beneficial use in a 
patient populations.  
HBO2 treatment is after all a therapy which involves the use of a 
drug, oxygen, at a dose of 100%, that is delivered at a pressure above 
atmospheric pressure, in a pressurised chamber. Just like any other drug, for 
HBO2 to become a drug that is confidently used, its characteristics as a drug in 
clinical practice needs to be better understood. This can only be done by 
appropriately designed randomised control clinical trials to assess its clinical 
efficacy, safety and longer term side effects in a wide variety of clinical 
indications, other than CAD. Of particular interest would be the area of 
oncology and stem cell therapy. Early clinical trials appear to indicate that 
there may be a role for HBO2, as a chemotherapeutic drug to adjunct other 
oncological agents, in the treatment of cancer (Ohguri et al., 2009). Where 
stem cells are concerned, HBO2 treatment has been shown to enhance stem cell 
growth (Milovanova et al., 2009), mobilisation (Thom et al., 2006) and 
survival (Khan et al., 2009) and, thus may be utilised to adjunct to therapies 
which rely on stem cells. 
  
283 
 
With respect to HBO2 preconditioning, CABG, IRI and 
myocardial protection, larger randomised control clinical studies are required 
to determine the not only the early effects of HBO2 on myocardial function but 
also its delayed effects and, its durability over a longer period of time. Studies 
should be designed to compare HBO2 to the current standard of care (SOC) 
treatment for inducing myocardial protection during CABG and IRI (e.g. 
anaesthetic agents). Instead of attempting to prove that HBO2 is better than or 
superior to the current SOC treatment, studies should be designed to 
demonstrate the equivalence or non-inferiority of HBO2 treatment compared to 
the SOC treatment. This is because demonstrating equivalence or non-
inferiority, provides physicians with an alternative means, which is just as 
good or no worse than the current SOC treatment but, possibly safer and more 
tolerable, for optimising their patient’s clinical condition prior to a planned 
clinical oxidative stress such as IRI as a result of vascular interventions. This 
message is not conveyed in a superiority trial which only demonstrates one 
drug as being better than the other instead of demonstrating one drug as being 
just as good as the other. As echoed by the Cochrane Collaborative (Bennett et 
al., 2005), methodological rigour is crucial in the assessment of the 
effectiveness of HBO2 as a treatment option. As the awareness of the potential 
therapeutic benefits of HBO2 preconditioning and, the commericial interest in 
this modality of treatment grows, so will more robust clinical studies. While 
the momentum in this area of research builds up, HBO2 therapy will be highly 
reliant on on small focus groups that continue to pasionately investigate the its 
benefits.  
  
284 
 
References 
 
ABBO, K. M., DOORIS, M., GLAZIER, S., O'NEILL, W. W., BYRD, D., 
GRINES, C. L. & SAFIAN, R. D. (1995) Features and outcome of no-
reflow after percutaneous coronary intervention. Am J Cardiol, 75, 
778-82. 
ABD-ELFATTAH, A. S., DING, M. & WECHSLER, A. S. (1995) 
Intermittent aortic crossclamping prevents cumulative adenosine 
triphosphate depletion, ventricular fibrillation, and dysfunction 
(stunning): is it preconditioning? J Thorac Cardiovasc Surg, 110, 328-
39. 
ABRAVAYA, K., MYERS, M. P., MURPHY, S. P. & MORIMOTO, R. I. 
(1992) The human heat shock protein hsp70 interacts with HSF, the 
transcription factor that regulates heat shock gene expression. Genes 
Dev, 6, 1153-64. 
ABU-SOUD, H. M., ICHIMORI, K., PRESTA, A. & STUEHR, D. J. (2000) 
Electron transfer, oxygen binding, and nitric oxide feedback inhibition 
in endothelial nitric-oxide synthase. J Biol Chem, 275, 17349-57. 
ALBELDA, S. M., SMITH, C. W. & WARD, P. A. (1994) Adhesion 
molecules and inflammatory injury. Faseb J, 8, 504-12. 
ALDERTON, W. K., COOPER, C. E. & KNOWLES, R. G. (2001) Nitric 
oxide synthases: structure, function and inhibition. Biochem J, 357, 
593-615. 
ALEX, J., LADEN, G., CALE, A. R., BENNETT, S., FLOWERS, K., 
MADDEN, L., GARDINER, E., MCCOLLUM, P. T. & GRIFFIN, S. 
C. (2005) Pretreatment with hyperbaric oxygen and its effect on 
neuropsychometric dysfunction and systemic inflammatory response 
after cardiopulmonary bypass: A prospective randomized double-blind 
trial. J Thorac Cardiovasc Surg, 130, 1623-1630. 
ALEXANDER, J. H., EMERY, R. W., JR., CARRIER, M., ELLIS, S. J., 
MEHTA, R. H., HASSELBLAD, V., MENASCHE, P., KHALIL, A., 
COTE, R., BENNETT-GUERRERO, E., MACK, M. J., SCHULER, 
G., HARRINGTON, R. A. & TARDIF, J. C. (2008) Efficacy and safety 
of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing 
coronary artery bypass graft surgery: the MEND-CABG II randomized 
clinical trial. Jama, 299, 1777-87. 
ALEXANDER, J. H., HAFLEY, G., HARRINGTON, R. A., PETERSON, E. 
D., FERGUSON, T. B., JR., LORENZ, T. J., GOYAL, A., GIBSON, 
M., MACK, M. J., GENNEVOIS, D., CALIFF, R. M. & 
KOUCHOUKOS, N. T. (2005) Efficacy and safety of edifoligide, an 
E2F transcription factor decoy, for prevention of vein graft failure 
following coronary artery bypass graft surgery: PREVENT IV: a 
randomized controlled trial. JAMA, 294, 2446-54. 
ALHAN, H. C., KARABULUT, H., TOSUN, R., KARAKOC, F., OKAR, I., 
DEMIRAY, E., TARCAN, S. & YIGITER, B. (1996) Intermittent 
  
285 
 
aortic cross-clamping and cold crystalloid cardioplegia for low-risk 
coronary patients. Ann Thorac Surg, 61, 834-9. 
ALPERT J. S., T. K. (2000) Myocardial Infarction Redefined-A consensus 
document of the joint European Society of Cardiology/American 
College of Cardiology committee for the redefinition of myocardial 
infarction. JACC, 36, 959-969. 
ALPERT JS, T. K. (2000) Myocardial Infarction Redefined-A consensus 
document of the joint European Society of Cardiology/American 
College of Cardiology committee for the redefinition of myocardial 
infarction. JACC, 36, 959-969. 
ALTMAN, D. (1991) Analysis Of Skewed Data. Practical Statistics for 
Medical Research. Chapman & Hall. 
AMBROSIO, G., BECKER, L. C., HUTCHINS, G. M., WEISMAN, H. F. & 
WEISFELDT, M. L. (1986) Reduction in experimental infarct size by 
recombinant human superoxide dismutase: insights into the 
pathophysiology of reperfusion injury. Circulation, 74, 1424-33. 
ANDERSON, J. R., HOSSEIN-NIA, M., KALLIS, P., PYE, M., HOLT, D. 
W., MURDAY, A. J. & TREASURE, T. (1994) Comparison of two 
strategies for myocardial management during coronary artery 
operations. Ann Thorac Surg, 58, 768-72; discussion 772-3. 
ANDREADOU, I., ILIODROMITIS, E. K., KOUFAKI, M., FARMAKIS, D., 
TSOTINIS, A. & KREMASTINOS, D. T. (2008) Alternative 
pharmacological interventions that limit myocardial infarction. Curr 
Med Chem, 15, 3204-13. 
APARCI, M., KARDESOGLU, E., SULEYMANOGLU, S., UZUN, G., 
ONEM, Y., UZ, O., KUCUKARDALI, Y. & OZKAN, S. (2008) 
Hyperbaric oxygen therapy improves myocardial diastolic function in 
diabetic patients. Tohoku J Exp Med, 214, 281-9. 
APPLE FS, W. A. (2001) Myocardial infarction redefined: Role cardiac 
troponin testing. Clin Chem, 47, 377-379. 
ASANUMA, H., KITAKAZE, M., FUNAYA, H., TAKASHIMA, S., 
MINAMINO, T., NODE, K., SAKATA, Y., ASAKURA, M., 
SANADA, S., SHINOZAKI, Y., MORI, H., KUZUYA, T., TADA, M. 
& HORI, M. (2001) Nifedipine limits infarct size via NO-dependent 
mechanisms in dogs. Basic Res Cardiol, 96, 497-505. 
ASSREUY, J., CUNHA, F. Q., LIEW, F. Y. & MONCADA, S. (1993) 
Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br 
J Pharmacol, 108, 833-7. 
ATOCHIN, D. N., DEMCHENKO, I. T., ASTERN, J., BOSO, A. E., 
PIANTADOSI, C. A. & HUANG, P. L. (2003) Contributions of 
endothelial and neuronal nitric oxide synthases to cerebrovascular 
responses to hyperoxia. J Cereb Blood Flow Metab, 23, 1219-26. 
ATOCHIN, D. N., FISHER, D., DEMCHENKO, I. T. & THOM, S. R. (2000) 
Neutrophil sequestration and the effect of hyperbaric oxygen in a rat 
model of temporary middle cerebral artery occlusion. Undersea Hyperb 
Med, 27, 185-90. 
  
286 
 
AVIRAM, M., ROSENBLAT, M., BISGAIER, C. L., NEWTON, R. S., 
PRIMO-PARMO, S. L. & LA DU, B. N. (1998) Paraoxonase inhibits 
high-density lipoprotein oxidation and preserves its functions. A 
possible peroxidative role for paraoxonase. J Clin Invest, 101, 1581-90. 
BAHARVAND, B., DEHAJ, M. E., FOADADDINI, M., RASOULIAN, B., 
POORKHALILI, K., AGHAI, H. W. & KHOSHBATEN, A. (2009) 
Delayed Cardioprotective Effects of Hyperoxia Preconditioning 
Prolonged by Intermittent Exposure. J Surg Res. 
BAINES, C. P., GOTO, M. & DOWNEY, J. M. (1997) Oxygen radicals 
released during ischemic preconditioning contribute to cardioprotection 
in the rabbit myocardium. J Mol Cell Cardiol, 29, 207-16. 
BALLIGAND, J. L., UNGUREANU-LONGROIS, D., SIMMONS, W. W., 
PIMENTAL, D., MALINSKI, T. A., KAPTURCZAK, M., TAHA, Z., 
LOWENSTEIN, C. J., DAVIDOFF, A. J., KELLY, R. A. & ET AL. 
(1994) Cytokine-inducible nitric oxide synthase (iNOS) expression in 
cardiac myocytes. Characterization and regulation of iNOS expression 
and detection of iNOS activity in single cardiac myocytes in vitro. J 
Biol Chem, 269, 27580-8. 
BANICK, P. D., CHEN, Q., XU, Y. A. & THOM, S. R. (1997) Nitric oxide 
inhibits neutrophil beta 2 integrin function by inhibiting membrane-
associated cyclic GMP synthesis. J Cell Physiol, 172, 12-24. 
BARILI, F., POLVANI, G., TOPKARA, V. K., DAINESE, L., CHEEMA, F. 
H., ROBERTO, M., NALIATO, M., PAROLARI, A., ALAMANNI, F. 
& BIGLIOLI, P. (2007) Role of Hyperbaric Oxygen Therapy in the 
Treatment of Postoperative Organ/Space Sternal Surgical Site 
Infections. World J Surg. 
BAYATI, S., RUSSELL, R. C. & ROTH, A. C. (1998) Stimulation of 
angiogenesis to improve the viability of prefabricated flaps. Plast 
Reconstr Surg, 101, 1290-5. 
BEAUCHAMP, P., RICHARD, V., TAMION, F., LALLEMAND, F., 
LEBRETON, J. P., VAUDRY, H., DAVEAU, M. & THUILLEZ, C. 
(1999) Protective effects of preconditioning in cultured rat endothelial 
cells: effects on neutrophil adhesion and expression of ICAM-1 after 
anoxia and reoxygenation. Circulation, 100, 541-6. 
BECKMAN, J. S. & CROW, J. P. (1993) Pathological implications of nitric 
oxide, superoxide and peroxynitrite formation. Biochem Soc Trans, 21, 
330-4. 
BECKMAN, J. S. & KOPPENOL, W. H. (1996) Nitric oxide, superoxide, and 
peroxynitrite: the good, the bad, and ugly. Am J Physiol, 271, C1424-
37. 
BENEDETTI, S., LAMORGESE, A., PIERSANTELLI, M., PAGLIARANI, 
S., BENVENUTI, F. & CANESTRARI, F. (2004) Oxidative stress and 
antioxidant status in patients undergoing prolonged exposure to 
hyperbaric oxygen. Clin Biochem, 37, 312-7. 
BENJAMIN, I. J., HORIE, S., GREENBERG, M. L., ALPERN, R. J. & 
WILLIAMS, R. S. (1992) Induction of stress proteins in cultured 
  
287 
 
myogenic cells. Molecular signals for the activation of heat shock 
transcription factor during ischemia. J Clin Invest, 89, 1685-9. 
BENNETT, M., JEPSON, N. & LEHM, J. (2005) Hyperbaric oxygen therapy 
for acute coronary syndrome. Cochrane Database Syst Rev, CD004818. 
BERG, K., HAAVERSTAD, R., ASTUDILLO, R., BJORNGAARD, M., 
SKARRA, S., WISETH, R., BASU, S. & JYNGE, P. (2006) Oxidative 
stress during coronary artery bypass operations: importance of surgical 
trauma and drug treatment. Scand Cardiovasc J, 40, 291-7. 
BERG, K., JYNGE, P., BJERVE, K., SKARRA, S., BASU, S. & WISETH, R. 
(2005) Oxidative stress and inflammatory response during and 
following coronary interventions for acute myocardial infarction. Free 
Radic Res, 39, 629-36. 
BERG, K., WISETH, R., BJERVE, K., BRUROK, H., GUNNES, S., 
SKARRA, S., JYNGE, P. & BASU, S. (2004) Oxidative stress and 
myocardial damage during elective percutaneous coronary 
interventions and coronary angiography. A comparison of blood-borne 
isoprostane and troponin release. Free Radic Res, 38, 517-25. 
BERTOLETTO, P. R., CHAVES, J. C., FAGUNDES, A. T., SIMOES, R. S., 
OSHIMA, C. T., SIMOES MDE, J. & FAGUNDES, D. J. (2008) 
Effect of different periods of hyperbaric oxygen on ischemia-
reperfusion injury of rat small bowel. Acta Cir Bras, 23, 11-5. 
BEVILACQUA, M. P. & NELSON, R. M. (1993) Selectins. J Clin Invest, 91, 
379-87. 
BEVILACQUA, M. P., STENGELIN, S., GIMBRONE, M. A., JR. & SEED, 
B. (1989) Endothelial leukocyte adhesion molecule 1: an inducible 
receptor for neutrophils related to complement regulatory proteins and 
lectins. Science, 243, 1160-5. 
BIRNBAUM, Y., HALE, S. L. & KLONER, R. A. (1997) Ischemic 
preconditioning at a distance: reduction of myocardial infarct size by 
partial reduction of blood supply combined with rapid stimulation of 
the gastrocnemius muscle in the rabbit. Circulation, 96, 1641-6. 
BLACKWELL, T. S. & CHRISTMAN, J. W. (1997) The role of nuclear 
factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol, 
17, 3-9. 
BODARY, P. F., HOMEISTER, J. W., VARGAS, F. B., WICKENHEISER, 
K. J., CUDNEY, S. S., BAHROU, K. L., OHMAN, M., RABBANI, A. 
B. & EITZMAN, D. T. (2007) Generation of soluble P- and E-selectins 
in vivo is dependent on expression of P-selectin glycoprotein ligand-1. 
J Thromb Haemost, 5, 599-603. 
BOLLI, R. (2000) The late phase of preconditioning. Circ Res, 87, 972-83. 
BOLLI, R. (2001) Cardioprotective function of inducible nitric oxide synthase 
and role of nitric oxide in myocardial ischemia and preconditioning: an 
overview of a decade of research. J Mol Cell Cardiol, 33, 1897-918. 
BOLLI, R., LI, Q. H., TANG, X. L., GUO, Y., XUAN, Y. T., ROKOSH, G. & 
DAWN, B. (2007) The late phase of preconditioning and its natural 
clinical application--gene therapy. Heart Fail Rev, 12, 189-99. 
  
288 
 
BOLLI, R., MANCHIKALAPUDI, S., TANG, X. L., TAKANO, H., QIU, Y., 
GUO, Y., ZHANG, Q. & JADOON, A. K. (1997) The protective effect 
of late preconditioning against myocardial stunning in conscious 
rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide 
acts both as a trigger and as a mediator of the late phase of ischemic 
preconditioning. Circ Res, 81, 1094-107. 
BOSCO, G., YANG, Z. J., NANDI, J., WANG, J., CHEN, C. & 
CAMPORESI, E. M. (2007) Effects of hyperbaric oxygen on glucose, 
lactate, glycerol and anti-oxidant enzymes in the skeletal muscle of rats 
during ischaemia and reperfusion. Clin Exp Pharmacol Physiol, 34, 70-
6. 
BOYCE, S. W., BARTELS, C., BOLLI, R., CHAITMAN, B., CHEN, J. C., 
CHI, E., JESSEL, A., KEREIAKES, D., KNIGHT, J., THULIN, L. & 
THEROUX, P. (2003) Impact of sodium-hydrogen exchange inhibition 
by cariporide on death or myocardial infarction in high-risk CABG 
surgery patients: results of the CABG surgery cohort of the 
GUARDIAN study. J Thorac Cardiovasc Surg, 126, 420-7. 
BOYKIN, J. V., JR. & BAYLIS, C. (2007) Hyperbaric oxygen therapy 
mediates increased nitric oxide production associated with wound 
healing: a preliminary study. Adv Skin Wound Care, 20, 382-8. 
BRADY, A. J., WARREN, J. B., POOLE-WILSON, P. A., WILLIAMS, T. J. 
& HARDING, S. E. (1993) Nitric oxide attenuates cardiac myocyte 
contraction. Am J Physiol, 265, H176-82. 
BRAUNWALD, E. & KLONER, R. A. (1985) Myocardial reperfusion: a 
double-edged sword? J Clin Invest, 76, 1713-9. 
BROWN, P. P., KUGELMASS, A. D., COHEN, D. J., REYNOLDS, M. R., 
CULLER, S. D., DEE, A. D. & SIMON, A. W. (2008) The frequency 
and cost of complications associated with coronary artery bypass 
grafting surgery: results from the United States Medicare program. Ann 
Thorac Surg, 85, 1980-6. 
BRUECKL, C., KAESTLE, S., KEREM, A., HABAZETTL, H., 
KROMBACH, F., KUPPE, H. & KUEBLER, W. M. (2006) 
Hyperoxia-induced reactive oxygen species formation in pulmonary 
capillary endothelial cells in situ. Am J Respir Cell Mol Biol, 34, 453-
63. 
BUKAU, B. & HORWICH, A. L. (1998) The Hsp70 and Hsp60 chaperone 
machines. Cell, 92, 351-66. 
BULKELY, B. H. & HUTCHINS, G. M. (1977) Myocardial consequences of 
coronary artery bypass graft surgery. The paradox of necrosis in areas 
of revascularization. Circulation, 56, 906-13. 
BURAS, J. A. & REENSTRA, W. R. (2007) Endothelial-neutrophil 
interactions during ischemia and reperfusion injury: basic mechanisms 
of hyperbaric oxygen. Neurol Res, 29, 127-31. 
BURAS, J. A., STAHL, G. L., SVOBODA, K. K. & REENSTRA, W. R. 
(2000) Hyperbaric oxygen downregulates ICAM-1 expression induced 
by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell 
Physiol, 278, C292-302. 
  
289 
 
BURKE, T. M. & WOLIN, M. S. (1987) Hydrogen peroxide elicits pulmonary 
arterial relaxation and guanylate cyclase activation. Am J Physiol, 252, 
H721-32. 
BUTTKE, T. M. & SANDSTROM, P. A. (1994) Oxidative stress as a 
mediator of apoptosis. Immunol Today, 15, 7-10. 
CABIGAS, B. P., SU, J., HUTCHINS, W., SHI, Y., SCHAEFER, R. B., 
RECINOS, R. F., NILAKANTAN, V., KINDWALL, E., NIEZGODA, 
J. A. & BAKER, J. E. (2006a) Hyperoxic and hyperbaric-induced 
cardioprotection: role of nitric oxide synthase 3. Cardiovasc Res, 72, 
143-51. 
CABIGAS, B. P., SU, J., HUTCHINS, W., SHI, Y., SCHAEFER, R. B., 
RECINOS, R. F., NILAKANTAN, V., KINDWALL, E., NIEZGODA, 
J. A. & BAKER, J. E. (2006b) Hyperoxic and hyperbaric-induced 
cardioprotection: Role of nitric oxide synthase 3. Cardiovasc Res. 
CHEN, M. F., CHEN, H. M., UENG, S. W. & SHYR, M. H. (1998) 
Hyperbaric oxygen pretreatment attenuates hepatic reperfusion injury. 
Liver, 18, 110-6. 
CHEN, Q., BANICK, P. D. & THOM, S. R. (1996) Functional inhibition of rat 
polymorphonuclear leukocyte B2 integrins by hyperbaric oxygen is 
associated with impaired cGMP synthesis. J Pharmacol Exp Ther, 276, 
929-33. 
CHENG, C., VAN HAPEREN, R., DE WAARD, M., VAN DAMME, L. C., 
TEMPEL, D., HANEMAAIJER, L., VAN CAPPELLEN, G. W., BOS, 
J., SLAGER, C. J., DUNCKER, D. J., VAN DER STEEN, A. F., DE 
CROM, R. & KRAMS, R. (2005) Shear stress affects the intracellular 
distribution of eNOS: direct demonstration by a novel in vivo 
technique. Blood, 106, 3691-8. 
CHEUNG, M. M., KHARBANDA, R. K., KONSTANTINOV, I. E., 
SHIMIZU, M., FRNDOVA, H., LI, J., HOLTBY, H. M., COX, P. N., 
SMALLHORN, J. F., VAN ARSDELL, G. S. & REDINGTON, A. N. 
(2006) Randomized controlled trial of the effects of remote ischemic 
preconditioning on children undergoing cardiac surgery: first clinical 
application in humans. J Am Coll Cardiol, 47, 2277-82. 
CHI, L. G., TAMURA, Y., HOFF, P. T., MACHA, M., GALLAGHER, K. P., 
SCHORK, M. A. & LUCCHESI, B. R. (1989) Effect of superoxide 
dismutase on myocardial infarct size in the canine heart after 6 hours of 
regional ischemia and reperfusion: a demonstration of myocardial 
salvage. Circ Res, 64, 665-75. 
CHIRICO, W. J., WATERS, M. G. & BLOBEL, G. (1988) 70K heat shock 
related proteins stimulate protein translocation into microsomes. 
Nature, 332, 805-10. 
CHOI, H., KIM, S. H., CHUN, Y. S., CHO, Y. S., PARK, J. W. & KIM, M. S. 
(2006) In vivo hyperoxic preconditioning prevents myocardial 
infarction by expressing bcl-2. Exp Biol Med (Maywood), 231, 463-72. 
CHUCK, A. W., HAILEY, D., JACOBS, P. & PERRY, D. C. (2008) Cost-
effectiveness and budget impact of adjunctive hyperbaric oxygen 
  
290 
 
therapy for diabetic foot ulcers. Int J Technol Assess Health Care, 24, 
178-83. 
CLARK W, C. K. (2001) An Introduction to DNA: Spectrophotometry, 
Degradation and the 'Frankengel' Experiment. IN S. J. KARCHER, E. 
(Ed.) Tested studies for laboratory teaching. Proceedings of the 22nd 
Workshop/Conference of the Association for 
Biology Laboratory Education (ABLE). 2001 ed. Edmonton, Alberta, Canada, 
University of Toronto. 
COLANTUONO, G., TIRAVANTI, E. A., DI VENOSA, N., CAZZATO, A., 
RASTALDO, R., CAGIANO, R., D'AGOSTINO, D., FEDERICI, A. & 
FIORE, T. (2008) Hyperoxia confers myocardial protection in 
mechanically ventilated rats through the generation of free radicals and 
opening of mitochondrial ATP-sensitive potassium channels. Clin Exp 
Pharmacol Physiol, 35, 64-71. 
CONCONI, M. T., BAIGUERA, S., GUIDOLIN, D., FURLAN, C., MENTI, 
A. M., VIGOLO, S., BELLONI, A. S., PARNIGOTTO, P. P. & 
NUSSDORFER, G. G. (2003) Effects of hyperbaric oxygen on 
proliferative and apoptotic activities and reactive oxygen species 
generation in mouse fibroblast 3T3/J2 cell line. J Investig Med, 51, 
227-32. 
CONGER, J. D. & WEIL, J. V. (1995) Abnormal vascular function following 
ischemia-reperfusion injury. J Investig Med, 43, 431-42. 
COSGRAVE, J., FOLEY, B., HO, E., BENNETT, K., MCGOVERN, E., 
TOLAN, M., YOUNG, V. & CREAN, P. (2006) Troponin T elevation 
after coronary bypass surgery: clinical relevance and correlation with 
perioperative variables. J Cardiovasc Med (Hagerstown), 7, 669-74. 
CUMMINGS, R. D. (1999) Structure and function of the selectin ligand 
PSGL-1. Braz J Med Biol Res, 32, 519-28. 
CURRIE, R. W. (1987) Effects of ischemia and perfusion temperature on the 
synthesis of stress-induced (heat shock) proteins in isolated and 
perfused rat hearts. J Mol Cell Cardiol, 19, 795-808. 
CURRIE, R. W., KARMAZYN, M., KLOC, M. & MAILER, K. (1988) Heat-
shock response is associated with enhanced postischemic ventricular 
recovery. Circ Res, 63, 543-9. 
DAHLIN, L. G., KAGEDAL, B., NYLANDER, E., OLIN, C., RUTBERG, H. 
& SVEDJEHOLM, R. (2003) Unspecific elevation of plasma troponin-
T and CK-MB after coronary surgery. Scand Cardiovasc J, 37, 283-7. 
DANIELL, H. B. & BAGWELL, E. E. (1968) Effects of high oxygen on 
coronary flor and heart force. Am J Physiol, 214, 1454-9. 
DAS, A., XI, L. & KUKREJA, R. C. (2005) Phosphodiesterase-5 inhibitor 
sildenafil preconditions adult cardiac myocytes against necrosis and 
apoptosis. Essential role of nitric oxide signaling. J Biol Chem, 280, 
12944-55. 
DAS, D. K. (2001) Redox regulation of cardiomyocyte survival and death. 
Antioxid Redox Signal, 3, 23-37. 
  
291 
 
DAS, D. K., ENGELMAN, R. M. & MAULIK, N. (1999a) Oxygen free 
radical signaling in ischemic preconditioning. Ann N Y Acad Sci, 874, 
49-65. 
DAS, D. K. & MAULIK, N. (2003) Preconditioning potentiates redox 
signaling and converts death signal into survival signal. Arch Biochem 
Biophys, 420, 305-11. 
DAS, D. K. & MAULIK, N. (2004) Conversion of death signal into survival 
signal by redox signaling. Biochemistry (Mosc), 69, 10-7. 
DAS, D. K., MAULIK, N., SATO, M. & RAY, P. S. (1999b) Reactive oxygen 
species function as second messenger during ischemic preconditioning 
of heart. Mol Cell Biochem, 196, 59-67. 
DAS, M. & DAS, D. K. (2008) Molecular mechanism of preconditioning. 
IUBMB Life, 60, 199-203. 
DE CATERINA, R., LIBBY, P., PENG, H. B., THANNICKAL, V. J., 
RAJAVASHISTH, T. B., GIMBRONE, M. A., JR., SHIN, W. S. & 
LIAO, J. K. (1995) Nitric oxide decreases cytokine-induced endothelial 
activation. Nitric oxide selectively reduces endothelial expression of 
adhesion molecules and proinflammatory cytokines. J Clin Invest, 96, 
60-8. 
DE FEO, M., GREGORIO, R., DELLA CORTE, A., MARRA, C., 
AMARELLI, C., RENZULLI, A., UTILI, R. & COTRUFO, M. (2001) 
Deep sternal wound infection: the role of early debridement surgery. 
Eur J Cardiothorac Surg, 19, 811-6. 
DE HERT, S. G., CROMHEECKE, S., TEN BROECKE, P. W., MERTENS, 
E., DE BLIER, I. G., STOCKMAN, B. A., RODRIGUS, I. E. & VAN 
DER LINDEN, P. J. (2003) Effects of propofol, desflurane, and 
sevoflurane on recovery of myocardial function after coronary surgery 
in elderly high-risk patients. Anesthesiology, 99, 314-23. 
DEKLEVA, M., NESKOVIC, A., VLAHOVIC, A., PUTNIKOVIC, B., 
BELESLIN, B. & OSTOJIC, M. (2004) Adjunctive effect of hyperbaric 
oxygen treatment after thrombolysis on left ventricular function in 
patients with acute myocardial infarction. Am Heart J, 148, E14. 
DEMCHENKO, I. T., BOSO, A. E., O'NEILL, T. J., BENNETT, P. B. & 
PIANTADOSI, C. A. (2000) Nitric oxide and cerebral blood flow 
responses to hyperbaric oxygen. J Appl Physiol, 88, 1381-9. 
DENNOG, C., RADERMACHER, P., BARNETT, Y. A. & SPEIT, G. (1999) 
Antioxidant status in humans after exposure to hyperbaric oxygen. 
Mutat Res, 428, 83-9. 
DESAI, N. D., COHEN, E. A., NAYLOR, C. D. & FREMES, S. E. (2004) A 
randomized comparison of radial-artery and saphenous-vein coronary 
bypass grafts. N Engl J Med, 351, 2302-9. 
DESHAIES, R. J., KOCH, B. D., WERNER-WASHBURNE, M., CRAIG, E. 
A. & SCHEKMAN, R. (1988) A subfamily of stress proteins facilitates 
translocation of secretory and mitochondrial precursor polypeptides. 
Nature, 332, 800-5. 
DILLMANN, W. H., MEHTA, H. B., BARRIEUX, A., GUTH, B. D., 
NEELEY, W. E. & ROSS, J., JR. (1986) Ischemia of the dog heart 
  
292 
 
induces the appearance of a cardiac mRNA coding for a protein with 
migration characteristics similar to heat-shock/stress protein 71. Circ 
Res, 59, 110-4. 
DONNELLY, T. J., SIEVERS, R. E., VISSERN, F. L., WELCH, W. J. & 
WOLFE, C. L. (1992) Heat shock protein induction in rat hearts. A role 
for improved myocardial salvage after ischemia and reperfusion? 
Circulation, 85, 769-78. 
DOWNEY, J. M., DAVIS, A. M. & COHEN, M. V. (2007) Signaling 
pathways in ischemic preconditioning. Heart Fail Rev, 12, 181-8. 
DOWNEY, J. M., OMAR, B., OOIWA, H. & MCCORD, J. (1991) Superoxide 
dismutase therapy for myocardial ischemia. Free Radic Res Commun, 
12-13 Pt 2, 703-20. 
DRUMMOND, G. R., CAI, H., DAVIS, M. E., RAMASAMY, S. & 
HARRISON, D. G. (2000) Transcriptional and posttranscriptional 
regulation of endothelial nitric oxide synthase expression by hydrogen 
peroxide. Circ Res, 86, 347-54. 
DULKANCHAINUN, T. S., GOSS, J. A., IMAGAWA, D. K., SHAW, G. D., 
ANSELMO, D. M., KALDAS, F., WANG, T., ZHAO, D., 
BUSUTTIL, A. A., KATO, H., MURRAY, N. G., KUPIEC-
WEGLINSKI, J. W. & BUSUTTIL, R. W. (1998) Reduction of hepatic 
ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-
1. Ann Surg, 227, 832-40. 
EAGLE, K. A., GUYTON, R. A., DAVIDOFF, R., EDWARDS, F. H., EWY, 
G. A., GARDNER, T. J., HART, J. C., HERRMANN, H. C., HILLIS, 
L. D., HUTTER, A. M., JR., LYTLE, B. W., MARLOW, R. A., 
NUGENT, W. C. & ORSZULAK, T. A. (2004) ACC/AHA 2004 
guideline update for coronary artery bypass graft surgery: a report of 
the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (Committee to Update the 1999 
Guidelines for Coronary Artery Bypass Graft Surgery). Circulation, 
110, e340-437. 
EBNET, K. & VESTWEBER, D. (1999) Molecular mechanisms that control 
leukocyte extravasation: the selectins and the chemokines. Histochem 
Cell Biol, 112, 1-23. 
EDWARDS, F. H., CLARK, R. E. & SCHWARTZ, M. (1994) Coronary 
artery bypass grafting: the Society of Thoracic Surgeons National 
Database experience. Ann Thorac Surg, 57, 12-9. 
EELLS, J. T., HENRY, M. M., GROSS, G. J. & BAKER, J. E. (2000) 
Increased mitochondrial K(ATP) channel activity during chronic 
myocardial hypoxia: is cardioprotection mediated by improved 
bioenergetics? Circ Res, 87, 915-21. 
EGUCHI, H., IKEDA, Y., OOKAWARA, T., KOYOTA, S., FUJIWARA, N., 
HONKE, K., WANG, P. G., TANIGUCHI, N. & SUZUKI, K. (2005) 
Modification of oligosaccharides by reactive oxygen species decreases 
sialyl lewis x-mediated cell adhesion. Glycobiology, 15, 1094-101. 
  
293 
 
ELAYAN, I. M., AXLEY, M. J., PRASAD, P. V., AHLERS, S. T. & AUKER, 
C. R. (2000) Effect of hyperbaric oxygen treatment on nitric oxide and 
oxygen free radicals in rat brain. J Neurophysiol, 83, 2022-9. 
ELROD, J. W., CALVERT, J. W., GUNDEWAR, S., BRYAN, N. S. & 
LEFER, D. J. (2008) Nitric oxide promotes distant organ protection: 
evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci U S 
A, 105, 11430-5. 
ENGLER, R. L., DAHLGREN, M. D., MORRIS, D. D., PETERSON, M. A. & 
SCHMID-SCHONBEIN, G. W. (1986) Role of leukocytes in response 
to acute myocardial ischemia and reflow in dogs. Am J Physiol, 251, 
H314-23. 
ENGLER, R. L., SCHMID-SCHONBEIN, G. W. & PAVELEC, R. S. (1983) 
Leukocyte capillary plugging in myocardial ischemia and reperfusion 
in the dog. Am J Pathol, 111, 98-111. 
ENTMAN, M. L., MICHAEL, L., ROSSEN, R. D., DREYER, W. J., 
ANDERSON, D. C., TAYLOR, A. A. & SMITH, C. W. (1991) 
Inflammation in the course of early myocardial ischemia. Faseb J, 5, 
2529-37. 
ERIKSON, J. M. & VELASCO, C. E. (1996) Endothelin-1 and myocardial 
preconditioning. Am Heart J, 132, 84-90. 
ESMAILI DEHAJ, M., BAHARVAND, B., RASOULIAN, B., 
FOADADDINI, M., ASGARI, A., NOROOZZADEH, A., 
POORKHALILI, K., WAHHAB AGHAI, H. & KHOSHBATEN, A. 
(2009) Delayed protective effects of hyperoxia against cardiac 
arrhythmias and infarction in anesthetized rats. J Surg Res, 151, 55-61. 
EVANS, T., JIN, H., ELKINS, N. & SHAPIRO, J. I. (1995) Effect of acidosis 
on hydrogen peroxide injury to the isolated perfused rat heart. Am J 
Physiol, 269, H308-12. 
FEDER, M. E. & HOFMANN, G. E. (1999) Heat-shock proteins, molecular 
chaperones, and the stress response: evolutionary and ecological 
physiology. Annu Rev Physiol, 61, 243-82. 
FERGUSON, T. B., JR., HAMMILL, B. G., PETERSON, E. D., DELONG, E. 
R. & GROVER, F. L. (2002) A decade of change--risk profiles and 
outcomes for isolated coronary artery bypass grafting procedures, 
1990-1999: a report from the STS National Database Committee and 
the Duke Clinical Research Institute. Society of Thoracic Surgeons. 
Ann Thorac Surg, 73, 480-9; discussion 489-90. 
FERRARI, R., CECONI, C., CURELLO, S., ALFIERI, O. & VISIOLI, O. 
(1993) Myocardial damage during ischaemia and reperfusion. Eur 
Heart J, 14 Suppl G, 25-30. 
FILDISSIS, G., VENETSANOU, K., MYRIANTHEFS, P., KARATZAS, S., 
ZIDIANAKIS, V. & BALTOPOULOS, G. (2004) Whole blood pro-
inflammatory cytokines and adhesion molecules post-
lipopolysaccharides exposure in hyperbaric conditions. Eur Cytokine 
Netw, 15, 217-21. 
  
294 
 
FINKEL, M. S., ODDIS, C. V., JACOB, T. D., WATKINS, S. C., HATTLER, 
B. G. & SIMMONS, R. L. (1992) Negative inotropic effects of 
cytokines on the heart mediated by nitric oxide. Science, 257, 387-9. 
FORSTERMANN, U., CLOSS, E. I., POLLOCK, J. S., NAKANE, M., 
SCHWARZ, P., GATH, I. & KLEINERT, H. (1994) Nitric oxide 
synthase isozymes. Characterization, purification, molecular cloning, 
and functions. Hypertension, 23, 1121-31. 
FRANGOGIANNIS, N. G., SMITH, C. W. & ENTMAN, M. L. (2002) The 
inflammatory response in myocardial infarction. Cardiovasc Res, 53, 
31-47. 
FRANGOGIANNIS, N. G., YOUKER, K. A., ROSSEN, R. D., 
GWECHENBERGER, M., LINDSEY, M. H., MENDOZA, L. H., 
MICHAEL, L. H., BALLANTYNE, C. M., SMITH, C. W. & 
ENTMAN, M. L. (1998) Cytokines and the microcirculation in 
ischemia and reperfusion. J Mol Cell Cardiol, 30, 2567-76. 
FRYER, R. M., AUCHAMPACH, J. A. & GROSS, G. J. (2002) Therapeutic 
receptor targets of ischemic preconditioning. Cardiovasc Res, 55, 520-
5. 
GABAI, V. L. & KABAKOV, A. E. (1993) Rise in heat-shock protein level 
confers tolerance to energy deprivation. FEBS Lett, 327, 247-50. 
GARCIA-CARDENA, G., FAN, R., SHAH, V., SORRENTINO, R., CIRINO, 
G., PAPAPETROPOULOS, A. & SESSA, W. C. (1998) Dynamic 
activation of endothelial nitric oxide synthase by Hsp90. Nature, 392, 
821-4. 
GARDINER, E. E., DE LUCA, M., MCNALLY, T., MICHELSON, A. D., 
ANDREWS, R. K. & BERNDT, M. C. (2001) Regulation of P-selectin 
binding to the neutrophil P-selectin counter-receptor P-selectin 
glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood, 
98, 1440-7. 
GARRIDO, C., GURBUXANI, S., RAVAGNAN, L. & KROEMER, G. 
(2001) Heat shock proteins: endogenous modulators of apoptotic cell 
death. Biochem Biophys Res Commun, 286, 433-42. 
GEARING, A. J. & NEWMAN, W. (1993) Circulating adhesion molecules in 
disease. Immunol Today, 14, 506-12. 
GELLER, D. A. & BILLIAR, T. R. (1998) Molecular biology of nitric oxide 
synthases. Cancer Metastasis Rev, 17, 7-23. 
GHO, B. C., SCHOEMAKER, R. G., VAN DEN DOEL, M. A., DUNCKER, 
D. J. & VERDOUW, P. D. (1996) Myocardial protection by brief 
ischemia in noncardiac tissue. Circulation, 94, 2193-200. 
GODMAN, C. A., CHHEDA, K. P., HIGHTOWER, L. E., PERDRIZET, G., 
SHIN, D. G. & GIARDINA, C. (2009) Hyperbaric oxygen induces a 
cytoprotective and angiogenic response in human microvascular 
endothelial cells. Cell Stress Chaperones. 
GONG, L., PITARI, G. M., SCHULZ, S. & WALDMAN, S. A. (2004) Nitric 
oxide signaling: systems integration of oxygen balance in defense of 
cell integrity. Curr Opin Hematol, 11, 7-14. 
  
295 
 
GRANFELDT, A., LEFER, D. J. & VINTEN-JOHANSEN, J. (2009) 
Protective ischaemia in patients: preconditioning and postconditioning. 
Cardiovasc Res, 83, 234-46. 
GREGOREVIC, P., LYNCH, G. S. & WILLIAMS, D. A. (2001) Hyperbaric 
oxygen modulates antioxidant enzyme activity in rat skeletal muscles. 
Eur J Appl Physiol, 86, 24-7. 
GRIFFIN, J. D., SPERTINI, O., ERNST, T. J., BELVIN, M. P., LEVINE, H. 
B., KANAKURA, Y. & TEDDER, T. F. (1990) Granulocyte-
macrophage colony-stimulating factor and other cytokines regulate 
surface expression of the leukocyte adhesion molecule-1 on human 
neutrophils, monocytes, and their precursors. J Immunol, 145, 576-84. 
GRUMBACH, I. M., CHEN, W., MERTENS, S. A. & HARRISON, D. G. 
(2005) A negative feedback mechanism involving nitric oxide and 
nuclear factor kappa-B modulates endothelial nitric oxide synthase 
transcription. J Mol Cell Cardiol, 39, 595-603. 
GRUNENFELDER, J., ZUND, G., STUCKI, V., HOERSTRUP, S. P., 
KADNER, A., SCHOEBERLEIN, A. & TURINA, M. (2001) Heat 
shock protein upregulation lowers cytokine levels after ischemia and 
reperfusion. Eur Surg Res, 33, 383-7. 
GUNAYDIN, B., CAKICI, I., SONCUL, H., KALAYCIOGLU, S., CEVIK, 
C., SANCAK, B., KANZIK, I. & KARADENIZLI, Y. (2000) Does 
remote organ ischaemia trigger cardiac preconditioning during 
coronary artery surgery? Pharmacol Res, 41, 493-6. 
GUO, S., COUNTE, M. A., GILLESPIE, K. N. & SCHMITZ, H. (2003a) 
Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of 
diabetic ulcers. Int J Technol Assess Health Care, 19, 731-7. 
GUO, S., COUNTE, M. A. & ROMEIS, J. C. (2003b) Hyperbaric oxygen 
technology: an overview of its applications, efficacy, and cost-
effectiveness. Int J Technol Assess Health Care, 19, 339-46. 
GURDOL, F., CIMSIT, M., ONER-IYIDOGAN, Y., KOCAK, H., SENGUN, 
S. & YALCINKAYA-DEMIRSOZ, S. (2009) Collagen synthesis, nitric 
oxide and asymmetric dimethylarginine in diabetic subjects undergoing 
hyperbaric oxygen therapy. Physiol Res. 
GURER, A., OZDOGAN, M., GOMCELI, I., DEMIRAG, A., GULBAHAR, 
O., ARIKOK, T., KULACOGLU, H., DUNDAR, K. & OZLEM, N. 
(2006) Hyperbaric oxygenation attenuates renal ischemia-reperfusion 
injury in rats. Transplant Proc, 38, 3337-40. 
GUYTON, R. A. (2006) Coronary artery bypass is superior to drug-eluting 
stents in multivessel coronary artery disease. Ann Thorac Surg, 81, 
1949-57. 
HAFEZI-MOGHADAM, A., SIMONCINI, T., YANG, Z., LIMBOURG, F. P., 
PLUMIER, J. C., REBSAMEN, M. C., HSIEH, C. M., CHUI, D. S., 
THOMAS, K. L., PROROCK, A. J., LAUBACH, V. E., 
MOSKOWITZ, M. A., FRENCH, B. A., LEY, K. & LIAO, J. K. 
(2002) Acute cardiovascular protective effects of corticosteroids are 
mediated by non-transcriptional activation of endothelial nitric oxide 
synthase. Nat Med, 8, 473-9. 
  
296 
 
HAN, C., LIN, L., ZHANG, W., ZHANG, L., LV, S., SUN, Q., TAO, H., 
ZHANG, J. H. & SUN, X. (2008a) Hyperbaric oxygen preconditioning 
alleviates myocardial ischemic injury in rats. Exp Biol Med (Maywood), 
233, 1448-53. 
HAN, H. G., WANG, Z. W., ZHANG, N. B. & ZHU, H. Y. (2008b) Role of 
nitric oxide during early phase myocardial ischemic preconditioning in 
rats. Chin Med J (Engl), 121, 1210-4. 
HAN, X., KOBZIK, L., BALLIGAND, J. L., KELLY, R. A. & SMITH, T. W. 
(1996) Nitric oxide synthase (NOS3)-mediated cholinergic modulation 
of Ca2+ current in adult rabbit atrioventricular nodal cells. Circ Res, 
78, 998-1008. 
HARDER, Y., CONTALDO, C., KLENK, J., BANIC, A., JAKOB, S. M. & 
ERNI, D. (2005) Preconditioning with monophosphoryl lipid A 
improves survival of critically ischemic tissue. Anesth Analg, 100, 
1786-92. 
HARTMAN, J. C., KURC, G. M., HULLINGER, T. G., WALL, T. M., 
SHEEHY, R. M. & SHEBUSKI, R. J. (1994) Inhibition of nitric oxide 
synthase prevents myocardial protection by ramiprilat. J Pharmacol 
Exp Ther, 270, 1071-6. 
HAUSENLOY, D. J., MWAMURE, P. K., VENUGOPAL, V., HARRIS, J., 
BARNARD, M., GRUNDY, E., ASHLEY, E., VICHARE, S., DI 
SALVO, C., KOLVEKAR, S., HAYWARD, M., KEOGH, B., 
MACALLISTER, R. J. & YELLON, D. M. (2007) Effect of remote 
ischaemic preconditioning on myocardial injury in patients undergoing 
coronary artery bypass graft surgery: a randomised controlled trial. 
Lancet, 370, 575-9. 
HAUSENLOY, D. J., TSANG, A. & YELLON, D. M. (2005) The reperfusion 
injury salvage kinase pathway: a common target for both ischemic 
preconditioning and postconditioning. Trends Cardiovasc Med, 15, 69-
75. 
HAUSENLOY, D. J. & YELLON, D. M. (2008) Remote ischaemic 
preconditioning: underlying mechanisms and clinical application. 
Cardiovasc Res, 79, 377-86. 
HAUSENLOY, D. J. & YELLON, D. M. (2009) Preconditioning and 
postconditioning: underlying mechanisms and clinical application. 
Atherosclerosis, 204, 334-41. 
HAYWARD, R., CAMPBELL, B., SHIN, Y. K., SCALIA, R. & LEFER, A. 
M. (1999) Recombinant soluble P-selectin glycoprotein ligand-1 
protects against myocardial ischemic reperfusion injury in cats. 
Cardiovasc Res, 41, 65-76. 
HEADS, R. J., LATCHMAN, D. S. & YELLON, D. M. (1996) The molecular 
basis of adaptation to ischemia in the heart: the role of stress proteins 
and anti-oxidants in the ischemic and reperfused heart. EXS, 76, 383-
407. 
HEARSE, D. J. & BOLLI, R. (1992) Reperfusion induced injury: 
manifestations, mechanisms, and clinical relevance. Cardiovasc Res, 
26, 101-8. 
  
297 
 
HEARSE, D. J., HUMPHREY, S. M. & CHAIN, E. B. (1973) Abrupt 
reoxygenation of the anoxic potassium-arrested perfused rat heart: a 
study of myocardial enzyme release. J Mol Cell Cardiol, 5, 395-407. 
HEARSE, D. J., STEWART, D. A. & BRAIMBRIDGE, M. V. (1976) Cellular 
protection during myocardial ischemia: the development and 
characterization of a procedure for the induction of reversible ischemic 
arrest. Circulation, 54, 193-202. 
HEGSTAD, A. C., ANTONSEN, O. H. & YTREHUS, K. (1997) Low 
concentrations of hydrogen peroxide improve post-ischaemic metabolic 
and functional recovery in isolated perfused rat hearts. J Mol Cell 
Cardiol, 29, 2779-87. 
HEINLOTH, A., HEERMEIER, K., RAFF, U., WANNER, C. & GALLE, J. 
(2000) Stimulation of NADPH oxidase by oxidized low-density 
lipoprotein induces proliferation of human vascular endothelial cells. J 
Am Soc Nephrol, 11, 1819-25. 
HENNINGER, N., KUPPERS-TIEDT, L., SICARD, K. M., GUNTHER, A., 
SCHNEIDER, D. & SCHWAB, S. (2006) Neuroprotective effect of 
hyperbaric oxygen therapy monitored by MR-imaging after embolic 
stroke in rats. Exp Neurol, 201, 316-23. 
HERRLICH, P. & BOHMER, F. D. (2000) Redox regulation of signal 
transduction in mammalian cells. Biochem Pharmacol, 59, 35-41. 
HESS, M. L. & KUKREJA, R. C. (1995) Free radicals, calcium homeostasis, 
heat shock proteins, and myocardial stunning. Ann Thorac Surg, 60, 
760-6. 
HEUSCH, G., BOENGLER, K. & SCHULZ, R. (2008) Cardioprotection: 
nitric oxide, protein kinases, and mitochondria. Circulation, 118, 1915-
9. 
HILLIS, G. S., TERREGINO, C., TAGGART, P., KILLIAN, A., ZHAO, N., 
DALSEY, W. C. & MANGIONE, A. (2002) Elevated soluble P-
selectin levels are associated with an increased risk of early adverse 
events in patients with presumed myocardial ischemia. Am Heart J, 
143, 235-41. 
HONG, J. P., KWON, H., CHUNG, Y. K. & JUNG, S. H. (2003) The effect of 
hyperbaric oxygen on ischemia-reperfusion injury: an experimental 
study in a rat musculocutaneous flap. Ann Plast Surg, 51, 478-87. 
HOOL, L. C. (2006) Reactive oxygen species in cardiac signalling: from 
mitochondria to plasma membrane ion channels. Clin Exp Pharmacol 
Physiol, 33, 146-51. 
HUFFMYER, J. & RAPHAEL, J. (2009) Physiology and pharmacology of 
myocardial preconditioning and postconditioning. Semin Cardiothorac 
Vasc Anesth, 13, 5-18. 
HUTTER, J. J., MESTRIL, R., TAM, E. K., SIEVERS, R. E., DILLMANN, 
W. H. & WOLFE, C. L. (1996) Overexpression of heat shock protein 
72 in transgenic mice decreases infarct size in vivo. Circulation, 94, 
1408-11. 
INAUEN, W., GRANGER, D. N., MEININGER, C. J., SCHELLING, M. E., 
GRANGER, H. J. & KVIETYS, P. R. (1990) Anoxia-reoxygenation-
  
298 
 
induced, neutrophil-mediated endothelial cell injury: role of elastase. 
Am J Physiol, 259, H925-31. 
ITO, H. (2006) No-reflow phenomenon and prognosis in patients with acute 
myocardial infarction. Nat Clin Pract Cardiovasc Med, 3, 499-506. 
IWAKI, K., CHI, S. H., DILLMANN, W. H. & MESTRIL, R. (1993) 
Induction of HSP70 in cultured rat neonatal cardiomyocytes by hypoxia 
and metabolic stress. Circulation, 87, 2023-32. 
IWASE, H., ROBIN, E., GUZY, R. D., MUNGAI, P. T., VANDEN HOEK, T. 
L., CHANDEL, N. S., LEVRAUT, J. & SCHUMACKER, P. T. (2007) 
Nitric oxide during ischemia attenuates oxidant stress and cell death 
during ischemia and reperfusion in cardiomyocytes. Free Radic Biol 
Med, 43, 590-9. 
JAATTELA, M. & WISSING, D. (1993) Heat-shock proteins protect cells 
from monocyte cytotoxicity: possible mechanism of self-protection. J 
Exp Med, 177, 231-6. 
JANERO, D. R., HRENIUK, D. & SHARIF, H. M. (1991) Hydrogen 
peroxide-induced oxidative stress to the mammalian heart-muscle cell 
(cardiomyocyte): lethal peroxidative membrane injury. J Cell Physiol, 
149, 347-64. 
JENKINS, D. P., PUGSLEY, W. B., ALKHULAIFI, A. M., KEMP, M., 
HOOPER, J. & YELLON, D. M. (1997) Ischaemic preconditioning 
reduces troponin T release in patients undergoing coronary artery 
bypass surgery. Heart, 77, 314-8. 
JENNINGS, R. B., HAWKINS, H. K., LOWE, J. E., HILL, M. L., 
KLOTMAN, S. & REIMER, K. A. (1978) Relation between high 
energy phosphate and lethal injury in myocardial ischemia in the dog. 
Am J Pathol, 92, 187-214. 
JENNINGS, R. B. & REIMER, K. A. (1983) Factors involved in salvaging 
ischemic myocardium: effect of reperfusion of arterial blood. 
Circulation, 68, I25-36. 
JENNINGS, R. B. & REIMER, K. A. (1991) The cell biology of acute 
myocardial ischemia. Annu Rev Med, 42, 225-46. 
JI, B., LIU, M., LIU, J., WANG, G., FENG, W., LU, F. & SHENGSHOU, H. 
(2007) Evaluation by cardiac troponin I: the effect of ischemic 
preconditioning as an adjunct to intermittent blood cardioplegia on 
coronary artery bypass grafting. J Card Surg, 22, 394-400. 
JOHNSON, G., 3RD, TSAO, P. S., MULLOY, D. & LEFER, A. M. (1990) 
Cardioprotective effects of acidified sodium nitrite in myocardial 
ischemia with reperfusion. J Pharmacol Exp Ther, 252, 35-41. 
JOHNSON, L. L., SCHOFIELD, L., BOUCHARD, M., CHAVES, L., 
POPPAS, A., REINERT, S., ZALESKY, P., CREECH, J. & 
WILLIAMS, D. O. (2004) Hyperbaric oxygen solution infused into the 
anterior interventricular vein at reperfusion reduces infarct size in 
swine. Am J Physiol Heart Circ Physiol, 287, H2234-40. 
JONES, S. P., TROCHA, S. D., STRANGE, M. B., GRANGER, D. N., 
KEVIL, C. G., BULLARD, D. C. & LEFER, D. J. (2000) Leukocyte 
and endothelial cell adhesion molecules in a chronic murine model of 
  
299 
 
myocardial reperfusion injury. Am J Physiol Heart Circ Physiol, 279, 
H2196-201. 
JORDAN, J. E., ZHAO, Z. Q. & VINTEN-JOHANSEN, J. (1999) The role of 
neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res, 
43, 860-78. 
JOYEUX-FAURE, M., ARNAUD, C., GODIN-RIBUOT, D. & RIBUOT, C. 
(2003) Heat stress preconditioning and delayed myocardial protection: 
what is new? Cardiovasc Res, 60, 469-77. 
JUGDUTT, B. I. (2002) Nitric oxide and cardioprotection during ischemia-
reperfusion. Heart Fail Rev, 7, 391-405. 
JUNG, F., PALMER, L. A., ZHOU, N. & JOHNS, R. A. (2000) Hypoxic 
regulation of inducible nitric oxide synthase via hypoxia inducible 
factor-1 in cardiac myocytes. Circ Res, 86, 319-25. 
KABAKOV, A. (1997) Heat shock proteins and cytoprotection. ATP-deprived 
mammalian cells. Heidelberg, Springer-Verlag. 
KABAKOV, A. E., BUDAGOVA, K. R., LATCHMAN, D. S. & 
KAMPINGA, H. H. (2002) Stressful preconditioning and HSP70 
overexpression attenuate proteotoxicity of cellular ATP depletion. Am J 
Physiol Cell Physiol, 283, C521-34. 
KABON, B. & KURZ, A. (2006) Optimal perioperative oxygen 
administration. Curr Opin Anaesthesiol, 19, 11-8. 
KALAWSKI, R., BUGAJSKI, P., SMIELECKI, J., WYSOCKI, H., 
OLSZEWSKI, R., MORE, R., SHERIDAN, D. J. & SIMINIAK, T. 
(1998) Soluble adhesion molecules in reperfusion during coronary 
bypass grafting. Eur J Cardiothorac Surg, 14, 290-5. 
KALJUSTO, M. L., STENSLOKKEN, K. O., MORI, T., PANCHENKO, A., 
FRANTZEN, M. L., VALEN, G. & VAAGE, J. (2008) Preconditioning 
effects of steroids and hyperoxia on cardiac ischemia-reperfusion injury 
and vascular reactivity. Eur J Cardiothorac Surg, 33, 355-63. 
KANDZARI, D. E., DERY, J. P., ARMSTRONG, P. W., DOUGLAS, D. A., 
ZETTLER, M. E., HIDINGER, G. K., FRIESEN, A. D. & 
HARRINGTON, R. A. (2005) MC-1 (pyridoxal 5'-phosphate): novel 
therapeutic applications to reduce ischaemic injury. Expert Opin 
Investig Drugs, 14, 1435-42. 
KARMAZYN, M., MAILER, K. & CURRIE, R. W. (1990) Acquisition and 
decay of heat-shock-enhanced postischemic ventricular recovery. Am J 
Physiol, 259, H424-31. 
KARU, I., LOIT, R., ZILMER, K., KAIRANE, C., PAAPSTEL, A., ZILMER, 
M. & STARKOPF, J. (2007) Pre-treatment with hyperoxia before 
coronary artery bypass grafting - effects on myocardial injury and 
inflammatory response. Acta Anaesthesiol Scand, 51, 1305-13. 
KAWAMURA, M., SAKAKIBARA, K., SAKAKIBARA, B., KIDOKORO, 
H., TAKAHASHI, H., KOBAYASKI, S., KONISHI, S. & UNO, Y. 
(1976) Protective effect of hyperbaric oxygen for the temporary 
ischaemic myocardium. Macroscopic and histological data. Cardiovasc 
Res, 10, 599-604. 
  
300 
 
KEVIN, L. G., CAMARA, A. K., RIESS, M. L., NOVALIJA, E. & STOWE, 
D. F. (2003) Ischemic preconditioning alters real-time measure of O2 
radicals in intact hearts with ischemia and reperfusion. Am J Physiol 
Heart Circ Physiol, 284, H566-74. 
KEVIN, L. G., NOVALIJA, E. & STOWE, D. F. (2005) Reactive oxygen 
species as mediators of cardiac injury and protection: the relevance to 
anesthesia practice. Anesth Analg, 101, 1275-87. 
KHAN, M., MEDURU, S., MOHAN, I. K., KUPPUSAMY, M. L., WISEL, S., 
KULKARNI, A., RIVERA, B. K., HAMLIN, R. L. & KUPPUSAMY, 
P. (2009) Hyperbaric oxygenation enhances transplanted cell graft and 
functional recovery in the infarct heart. J Mol Cell Cardiol, 47, 275-87. 
KHIABANI, K. T., BELLISTER, S. A., SKAGGS, S. S., STEPHENSON, L. 
L., NATARAJ, C., WANG, W. Z. & ZAMBONI, W. A. (2008) 
Reperfusion-induced neutrophil CD18 polarization: effect of 
hyperbaric oxygen. J Surg Res, 150, 11-6. 
KHURI, S. F., AXFORD, T. C., GARCIA, J. P., KHABBAZ, K. R., 
DEARANI, J. A., KHAIT, I., ZOLKEWITZ, M. & HEALEY, N. A. 
(1993) Metabolic correlates of myocardial stunning and the effect of 
cardiopulmonary bypass. J Card Surg, 8, 262-70. 
KIANG, J. G. & TSOKOS, G. C. (1998) Heat shock protein 70 kDa: molecular 
biology, biochemistry, and physiology. Pharmacol Ther, 80, 183-201. 
KIHARA, K., UENO, S., SAKODA, M. & AIKOU, T. (2005) Effects of 
hyperbaric oxygen exposure on experimental hepatic ischemia 
reperfusion injury: relationship between its timing and neutrophil 
sequestration. Liver Transpl, 11, 1574-80. 
KILGORE, K. S., FRIEDRICHS, G. S., JOHNSON, C. R., SCHASTEEN, C. 
S., RILEY, D. P., WEISS, R. H., RYAN, U. & LUCCHESI, B. R. 
(1994) Protective effects of the SOD-mimetic SC-52608 against 
ischemia/reperfusion damage in the rabbit isolated heart. J Mol Cell 
Cardiol, 26, 995-1006. 
KIM, C. H., CHOI, H., CHUN, Y. S., KIM, G. T., PARK, J. W. & KIM, M. S. 
(2001) Hyperbaric oxygenation pretreatment induces catalase and 
reduces infarct size in ischemic rat myocardium. Pflugers Arch, 442, 
519-25. 
KIM, S. J., ZHANG, X., XU, X., CHEN, A., GONZALEZ, J. B., KOUL, S., 
VIJAYAN, K., CRYSTAL, G. J., VATNER, S. F. & HINTZE, T. H. 
(2007) Evidence for enhanced eNOS function in coronary microvessels 
during the second window of protection. Am J Physiol Heart Circ 
Physiol, 292, H2152-8. 
KINDWALL EP, W. H. (2002) Hyperbaric Medicine Practice, Flagtaff, 
Arozina, USA, Best Publishing Company. 
KISHIMOTO, T. K., JUTILA, M. A., BERG, E. L. & BUTCHER, E. C. 
(1989) Neutrophil Mac-1 and MEL-14 adhesion proteins inversely 
regulated by chemotactic factors. Science, 245, 1238-41. 
KLONER, R. A., GANOTE, C. E. & JENNINGS, R. B. (1974) The "no-
reflow" phenomenon after temporary coronary occlusion in the dog. J 
Clin Invest, 54, 1496-508. 
  
301 
 
KLONER, R. A., PRZYKLENK, K. & WHITTAKER, P. (1989) Deleterious 
effects of oxygen radicals in ischemia/reperfusion. Resolved and 
unresolved issues. Circulation, 80, 1115-27. 
KOLSKI, J. M., MAZOLEWSKI, P. J., STEPHENSON, L. L., TEXTER, J., 
GRIGORIEV, V. E. & ZAMBONI, W. A. (1998) Effect of hyperbaric 
oxygen therapy on testicular ischemia-reperfusion injury. J Urol, 160, 
601-4. 
KONDA, A., BABA, S., IWAKI, T., HARAI, H., KOGA, H., KIMURA, T. & 
TAKAMATSU, J. (1996) Hyperbaric oxygenation prevents delayed 
neuronal death following transient ischaemia in the gerbil 
hippocampus. Neuropathol Appl Neurobiol, 22, 350-60. 
KRUG, A., DU MESNIL DE, R. & KORB, G. (1966) Blood supply of the 
myocardium after temporary coronary occlusion. Circ Res, 19, 57-62. 
KUBES, P. & GRANGER, D. N. (1992) Nitric oxide modulates microvascular 
permeability. Am J Physiol, 262, H611-5. 
KUBES, P., SUZUKI, M. & GRANGER, D. N. (1991) Nitric oxide: an 
endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S 
A, 88, 4651-5. 
KUDCHODKAR, B. J., PIERCE, A. & DORY, L. (2007) Chronic hyperbaric 
oxygen treatment elicits an anti-oxidant response and attenuates 
atherosclerosis in apoE knockout mice. Atherosclerosis, 193, 28-35. 
KUDCHODKAR, B. J., WILSON, J., LACKO, A. & DORY, L. (2000) 
Hyperbaric oxygen reduces the progression and accelerates the 
regression of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol, 
20, 1637-43. 
KUKREJA, R. C. & HESS, M. L. (1992) The oxygen free radical system: from 
equations through membrane-protein interactions to cardiovascular 
injury and protection. Cardiovasc Res, 26, 641-55. 
KUZUYA, T., HOSHIDA, S., YAMASHITA, N., FUJI, H., OE, H., HORI, 
M., KAMADA, T. & TADA, M. (1993) Delayed effects of sublethal 
ischemia on the acquisition of tolerance to ischemia. Circ Res, 72, 
1293-9. 
LANDONI, G., FOCHI, O. & TORRI, G. (2008) Cardiac protection by 
volatile anaesthetics: a review. Curr Vasc Pharmacol, 6, 108-11. 
LAPPA, A., MALPIERI, M. R., CICCO, M., BUCCI, A., MALPIERI, M., 
ARAIMO, F. & ALAMPI, D. (2003) An alternative inexpensive 
treatment for deep sternal wound infections after sternotomy. Interact 
Cardiovasc Thorac Surg, 2, 629-32. 
LARSON, J. L., STEPHENSON, L. L. & ZAMBONI, W. A. (2000) Effect of 
hyperbaric oxygen on neutrophil CD18 expression. Plast Reconstr 
Surg, 105, 1375-81. 
LASKY, L. A. (1995) Selectin-carbohydrate interactions and the initiation of 
the inflammatory response. Annu Rev Biochem, 64, 113-39. 
LATCHMAN, D. S. (2001) Heat shock proteins and cardiac protection. 
Cardiovasc Res, 51, 637-46. 
LEBUFFE, G., SCHUMACKER, P. T., SHAO, Z. H., ANDERSON, T., 
IWASE, H. & VANDEN HOEK, T. L. (2003) ROS and NO trigger 
  
302 
 
early preconditioning: relationship to mitochondrial KATP channel. Am 
J Physiol Heart Circ Physiol, 284, H299-308. 
LEE, H. T., LAFARO, R. J. & REED, G. E. (1995) Pretreatment of human 
myocardium with adenosine during open heart surgery. J Card Surg, 
10, 665-76. 
LEFER, A. M., CAMPBELL, B. & SHIN, Y. K. (1998) Effects of a 
metalloproteinase that truncates P-selectin glycoprotein ligand on 
neutrophil-induced cardiac dysfunction in ischemia/reperfusion. J Mol 
Cell Cardiol, 30, 2561-6. 
LEFER, A. M., CAMPBELL, B., SHIN, Y. K., SCALIA, R., HAYWARD, R. 
& LEFER, D. J. (1999) Simvastatin preserves the ischemic-reperfused 
myocardium in normocholesterolemic rat hearts. Circulation, 100, 178-
84. 
LEFER, A. M. & LEFER, D. J. (1996) The role of nitric oxide and cell 
adhesion molecules on the microcirculation in ischaemia-reperfusion. 
Cardiovasc Res, 32, 743-51. 
LEHRKE, S., STEEN, H., SIEVERS, H. H., PETERS, H., OPITZ, A., 
MULLER-BARDORFF, M., WIEGAND, U. K., KATUS, H. A. & 
GIANNITSIS, E. (2004) Cardiac troponin T for prediction of short- 
and long-term morbidity and mortality after elective open heart 
surgery. Clin Chem, 50, 1560-7. 
LEY, K. (2003) The role of selectins in inflammation and disease. Trends Mol 
Med, 9, 263-8. 
LI, J., WU, F., ZHANG, H., FU, F., JI, L., DONG, L., LI, Q., LIU, W., 
ZHANG, Y., LV, A., WANG, H., REN, J. & GAO, F. (2009) Insulin 
inhibits leukocyte-endothelium adherence via an Akt-NO-dependent 
mechanism in myocardial ischemia/reperfusion. J Mol Cell Cardiol, 47, 
512-9. 
LI, W. X., CHEN, C. H., LING, C. C. & LI, G. C. (1996) Apoptosis in heat-
induced cell killing: the protective role of hsp-70 and the sensitization 
effect of the c-myc gene. Radiat Res, 145, 324-30. 
LI, Y., ZHENG, J., BIRD, I. M. & MAGNESS, R. R. (2005) Effects of 
pulsatile shear stress on signaling mechanisms controlling nitric oxide 
production, endothelial nitric oxide synthase phosphorylation, and 
expression in ovine fetoplacental artery endothelial cells. Endothelium, 
12, 21-39. 
LI, Z., MENORET, A. & SRIVASTAVA, P. (2002) Roles of heat-shock 
proteins in antigen presentation and cross-presentation. Curr Opin 
Immunol, 14, 45-51. 
LIAM, B. L., PLOCHL, W., COOK, D. J., ORSZULAK, T. A. & DALY, R. 
C. (1998) Hemodilution and whole body oxygen balance during 
normothermic cardiopulmonary bypass in dogs. J Thorac Cardiovasc 
Surg, 115, 1203-8. 
LICKER, M., ELLENBERGER, C., SIERRA, J., KALANGOS, A., DIAPER, 
J. & MOREL, D. (2005) Cardioprotective effects of acute 
normovolemic hemodilution in patients undergoing coronary artery 
bypass surgery. Chest, 128, 838-47. 
  
303 
 
LINDSBERG, P. J., CARPEN, O., PAETAU, A., KARJALAINEN-
LINDSBERG, M. L. & KASTE, M. (1996) Endothelial ICAM-1 
expression associated with inflammatory cell response in human 
ischemic stroke. Circulation, 94, 939-45. 
LIU, P., XU, B., QUILLEY, J. & WONG, P. Y. (2000) Peroxynitrite 
attenuates hepatic ischemia-reperfusion injury. Am J Physiol Cell 
Physiol, 279, C1970-7. 
LIU, S., BECKMAN, J. S. & KU, D. D. (1994) Peroxynitrite, a product of 
superoxide and nitric oxide, produces coronary vasorelaxation in dogs. 
J Pharmacol Exp Ther, 268, 1114-21. 
LIU, W., LI, J., SUN, X., LIU, K., ZHANG, J. H., XU, W. & TAO, H. (2008) 
Repetitive hyperbaric oxygen exposures enhance sensitivity to 
convulsion by upregulation of eNOS and nNOS. Brain Res, 1201, 128-
34. 
LIU, Z., VALENCIA, O., TREASURE, T. & MURDAY, A. J. (1998) Cold 
blood cardioplegia or intermittent cross-clamping in coronary artery 
bypass grafting? Ann Thorac Surg, 66, 462-5. 
LOPEZ-ONGIL, S., HERNANDEZ-PERERA, O., NAVARRO-ANTOLIN, J., 
PEREZ DE LEMA, G., RODRIGUEZ-PUYOL, M., LAMAS, S. & 
RODRIGUEZ-PUYOL, D. (1998) Role of reactive oxygen species in 
the signalling cascade of cyclosporine A-mediated up-regulation of 
eNOS in vascular endothelial cells. Br J Pharmacol, 124, 447-54. 
LOPONEN, P., LUTHER, M., WISTBACKA, J. O., KORPILAHTI, K., 
LAURIKKA, J., SINTONEN, H., HUHTALA, H. & TARKKA, M. R. 
(2007) Quality of life during 18 months after coronary artery bypass 
grafting. Eur J Cardiothorac Surg. 
LORANT, D. E., PATEL, K. D., MCINTYRE, T. M., MCEVER, R. P., 
PRESCOTT, S. M. & ZIMMERMAN, G. A. (1991) Coexpression of 
GMP-140 and PAF by endothelium stimulated by histamine or 
thrombin: a juxtacrine system for adhesion and activation of 
neutrophils. J Cell Biol, 115, 223-34. 
LOUKOGEORGAKIS, S. P., PANAGIOTIDOU, A. T., BROADHEAD, M. 
W., DONALD, A., DEANFIELD, J. E. & MACALLISTER, R. J. 
(2005) Remote ischemic preconditioning provides early and late 
protection against endothelial ischemia-reperfusion injury in humans: 
role of the autonomic nervous system. J Am Coll Cardiol, 46, 450-6. 
LU, E. X., CHEN, S. X., YUAN, M. D., HU, T. H., ZHOU, H. C., LUO, W. J., 
LI, G. H. & XU, L. M. (1997) Preconditioning improves myocardial 
preservation in patients undergoing open heart operations. Ann Thorac 
Surg, 64, 1320-4. 
LUCAS, S. K., GARDNER, T. J., ELMER, E. B., FLAHERTY, J. T., 
BULKLEY, B. H. & GOTT, V. L. (1980) Comparison of the effects of 
left ventricular distention during cardioplegic-induced ischemic arrest 
and ventricular fibrillation. Circulation, 62, I42-9. 
MALHOTRA, V. & WONG, H. R. (2002) Interactions between the heat shock 
response and the nuclear factor-kappaB signaling pathway. Crit Care 
Med, 30, S89-S95. 
  
304 
 
MALIK, A. B. & LO, S. K. (1996) Vascular endothelial adhesion molecules 
and tissue inflammation. Pharmacol Rev, 48, 213-29. 
MANCIET, L. H., POOLE, D. C., MCDONAGH, P. F., COPELAND, J. G. & 
MATHIEU-COSTELLO, O. (1994) Microvascular compression during 
myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am 
J Physiol, 266, H1541-50. 
MANGANO, D. T. (1997) Effects of acadesine on myocardial infarction, 
stroke, and death following surgery. A meta-analysis of the 5 
international randomized trials. The Multicenter Study of Perioperative 
Ischemia (McSPI) Research Group. Jama, 277, 325-32. 
MANGANO, D. T., MIAO, Y., TUDOR, I. C. & DIETZEL, C. (2006) Post-
reperfusion myocardial infarction: long-term survival improvement 
using adenosine regulation with acadesine. J Am Coll Cardiol, 48, 206-
14. 
MANNING, A. S. & HEARSE, D. J. (1984) Reperfusion-induced arrhythmias: 
mechanisms and prevention. J Mol Cell Cardiol, 16, 497-518. 
MANSON PN, I. M., MYERS RAM, HOOPES JE (1980) Improved 
capillaries by hyperbaric oxygen in skin flaps. Surgical fORUM, 31, 
564-566. 
MARBER, M. S., LATCHMAN, D. S., WALKER, J. M. & YELLON, D. M. 
(1993) Cardiac stress protein elevation 24 hours after brief ischemia or 
heat stress is associated with resistance to myocardial infarction. 
Circulation, 88, 1264-72. 
MARBER, M. S., MESTRIL, R., CHI, S. H., SAYEN, M. R., YELLON, D. 
M. & DILLMANN, W. H. (1995) Overexpression of the rat inducible 
70-kD heat stress protein in a transgenic mouse increases the resistance 
of the heart to ischemic injury. J Clin Invest, 95, 1446-56. 
MARBER, M. S., WALKER, J. M., LATCHMAN, D. S. & YELLON, D. M. 
(1994) Myocardial protection after whole body heat stress in the rabbit 
is dependent on metabolic substrate and is related to the amount of the 
inducible 70-kD heat stress protein. J Clin Invest, 93, 1087-94. 
MARX, R. E., EHLER, W. J., TAYAPONGSAK, P. & PIERCE, L. W. (1990) 
Relationship of oxygen dose to angiogenesis induction in irradiated 
tissue. Am J Surg, 160, 519-24. 
MASSION, P. B., PELAT, M., BELGE, C. & BALLIGAND, J. L. (2005) 
Regulation of the mammalian heart function by nitric oxide. Comp 
Biochem Physiol A Mol Integr Physiol, 142, 144-50. 
MATATA, B. M. & GALINANES, M. (2000) Cardiopulmonary bypass 
exacerbates oxidative stress but does not increase proinflammatory 
cytokine release in patients with diabetes compared with patients 
without diabetes: regulatory effects of exogenous nitric oxide. J Thorac 
Cardiovasc Surg, 120, 1-11. 
MATHIEU D, C. J., VINCKIER F, SAULNIER A, DUROCHER ET, 
WATTEL F. (1984) Red blood cell deformability and hyperbaric 
oxygen. Med Subaquatique Hyperbar, 3, 100-104. 
MATHY-HARTERT, M., DEBY-DUPONT, G. P., REGINSTER, J. Y., 
AYACHE, N., PUJOL, J. P. & HENROTIN, Y. E. (2002) Regulation 
  
305 
 
by reactive oxygen species of interleukin-1beta, nitric oxide and 
prostaglandin E(2) production by human chondrocytes. Osteoarthritis 
Cartilage, 10, 547-55. 
MAULIK, N., YOSHIDA, T. & DAS, D. K. (1998) Oxidative stress developed 
during the reperfusion of ischemic myocardium induces apoptosis. Free 
Radic Biol Med, 24, 869-75. 
MCEWEN, A. W. & SMITH, M. B. (1997) Chronic venous ulcer. Hyperbaric 
oxygen treatment is a cost effective option. BMJ, 315, 188-9; author 
reply 189. 
MCGOWAN, F. X., JR., DAVIS, P. J., DEL NIDO, P. J., SOBEK, M., 
ALLEN, J. W. & DOWNING, S. E. (1994) Endothelium-dependent 
regulation of coronary tone in the neonatal pig. Anesth Analg, 79, 1094-
101. 
MEHTA, J. L., NICHOLS, W. W. & MEHTA, P. (1988) Neutrophils as 
potential participants in acute myocardial ischemia: relevance to 
reperfusion. J Am Coll Cardiol, 11, 1309-16. 
MELTZER, T. & MYERS, B. (1986) The effect of hyperbaric oxygen on the 
bursting strength and rate of vascularization of skin wounds in the rat. 
Am Surg, 52, 659-62. 
MENTZER, R. M., JR., BARTELS, C., BOLLI, R., BOYCE, S., 
BUCKBERG, G. D., CHAITMAN, B., HAVERICH, A., KNIGHT, J., 
MENASCHE, P., MYERS, M. L., NICOLAU, J., SIMOONS, M., 
THULIN, L. & WEISEL, R. D. (2008) Sodium-hydrogen exchange 
inhibition by cariporide to reduce the risk of ischemic cardiac events in 
patients undergoing coronary artery bypass grafting: results of the 
EXPEDITION study. Ann Thorac Surg, 85, 1261-70. 
MENTZER, R. M., JR., RAHKO, P. S., MOLINA-VIAMONTE, V., 
CANVER, C. C., CHOPRA, P. S., LOVE, R. B., COOK, T. D., 
HEGGE, J. O. & LASLEY, R. D. (1997) Safety, tolerance, and efficacy 
of adenosine as an additive to blood cardioplegia in humans during 
coronary artery bypass surgery. Am J Cardiol, 79, 38-43. 
MERY, P. F., PAVOINE, C., BELHASSEN, L., PECKER, F. & 
FISCHMEISTER, R. (1993) Nitric oxide regulates cardiac Ca2+ 
current. Involvement of cGMP-inhibited and cGMP-stimulated 
phosphodiesterases through guanylyl cyclase activation. J Biol Chem, 
268, 26286-95. 
MICHAELS, A. D., GIBSON, C. M. & BARRON, H. V. (2000) 
Microvascular dysfunction in acute myocardial infarction: focus on the 
roles of platelet and inflammatory mediators in the no-reflow 
phenomenon. Am J Cardiol, 85, 50B-60B. 
MIKI, S., ASHRAF, M., SALKA, S. & SPERELAKIS, N. (1988) Myocardial 
dysfunction and ultrastructural alterations mediated by oxygen 
metabolites. J Mol Cell Cardiol, 20, 1009-24. 
MILEI, J., FORCADA, P., FRAGA, C. G., GRANA, D. R., IANNELLI, G., 
CHIARIELLO, M., TRITTO, I. & AMBROSIO, G. (2007) 
Relationship between oxidative stress, lipid peroxidation, and 
  
306 
 
ultrastructural damage in patients with coronary artery disease 
undergoing cardioplegic arrest/reperfusion. Cardiovasc Res, 73, 710-9. 
MILJKOVIC-LOLIC, M., SILBERGLEIT, R., FISKUM, G. & ROSENTHAL, 
R. E. (2003) Neuroprotective effects of hyperbaric oxygen treatment in 
experimental focal cerebral ischemia are associated with reduced brain 
leukocyte myeloperoxidase activity. Brain Res, 971, 90-4. 
MILOVANOVA, T. N., BHOPALE, V. M., SOROKINA, E. M., MOORE, J. 
S., HUNT, T. K., HAUER-JENSEN, M., VELAZQUEZ, O. C. & 
THOM, S. R. (2009) Hyperbaric oxygen stimulates vasculogenic stem 
cell growth and differentiation in vivo. J Appl Physiol, 106, 711-28. 
MISRA, M. K., SARWAT, M., BHAKUNI, P., TUTEJA, R. & TUTEJA, N. 
(2009) Oxidative stress and ischemic myocardial syndromes. Med Sci 
Monit, 15, RA209-219. 
MITTAL CK, M. F. (1982) Guanylate Cyclase: Regulation of cyclic GMP 
Metabolism. IN NATHANSON JA, K. J. (Ed.) Cyclic Nucleotides 1. 
Berlin, Heidelberg, New York, Springer. 
MOCANU, M. M., STEARE, S. E., EVANS, M. C., NUGENT, J. H. & 
YELLON, D. M. (1993) Heat stress attenuates free radical release in 
the isolated perfused rat heart. Free Radic Biol Med, 15, 459-63. 
MOENS, A. L., CLAEYS, M. J., TIMMERMANS, J. P. & VRINTS, C. J. 
(2005) Myocardial ischemia/reperfusion-injury, a clinical view on a 
complex pathophysiological process. Int J Cardiol, 100, 179-90. 
MOLENBERGHS, G. K., MG (2007) Missing data in Clinical Studies. 
Chicchester, John Wiley & Sons Inc. 
MONCADA, S., PALMER, R. M. & HIGGS, E. A. (1988) The discovery of 
nitric oxide as the endogenous nitrovasodilator. Hypertension, 12, 365-
72. 
MONTE, M., DAVEL, L. E. & DE LUSTIG, E. S. (1994) Inhibition of 
lymphocyte-induced angiogenesis by free radical scavengers. Free 
Radic Biol Med, 17, 259-66. 
MOORE, G. W. & HUTCHINS, G. M. (1981) Coronary artery bypass grafts in 
109 autopsied patients. Statistical analysis of graft and anastomosis 
patency and regional myocardial injury. Jama, 246, 1785-9. 
MOORE, K. L., STULTS, N. L., DIAZ, S., SMITH, D. F., CUMMINGS, R. 
D., VARKI, A. & MCEVER, R. P. (1992) Identification of a specific 
glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol, 
118, 445-56. 
MORI, T., MURAMATSU, H., MATSUI, T., MCKEE, A. & ASANO, T. 
(2000) Possible role of the superoxide anion in the development of 
neuronal tolerance following ischaemic preconditioning in rats. 
Neuropathol Appl Neurobiol, 26, 31-40. 
MORIMOTO, R. I. (1993) Cells in stress: transcriptional activation of heat 
shock genes. Science, 259, 1409-10. 
MORYKWAS, M. J. & ARGENTA, L. C. (1997) Nonsurgical modalities to 
enhance healing and care of soft tissue wounds. J South Orthop Assoc, 
6, 279-88. 
  
307 
 
MULLER, E., MUNKER, R., ISSELS, R. & WILMANNS, W. (1993) 
Interaction between tumor necrosis factor-alpha and HSP 70 in human 
leukemia cells. Leuk Res, 17, 523-6. 
MURRY, C. E., JENNINGS, R. B. & REIMER, K. A. (1986) Preconditioning 
with ischemia: a delay of lethal cell injury in ischemic myocardium. 
Circulation, 74, 1124-36. 
NAKASUJI, M., MATSUSHITA, M. & ASADA, A. (2005) Risk factors for 
prolonged ICU stay in patients following coronary artery bypass 
grafting with a long duration of cardiopulmonary bypass. J Anesth, 19, 
118-23. 
NASLUND, U., HAGGMARK, S., JOHANSSON, G., MARKLUND, S. L., 
REIZ, S. & OBERG, A. (1986) Superoxide dismutase and catalase 
reduce infarct size in a porcine myocardial occlusion-reperfusion 
model. J Mol Cell Cardiol, 18, 1077-84. 
NEJIMA, J., KNIGHT, D. R., FALLON, J. T., UEMURA, N., MANDERS, 
W. T., CANFIELD, D. R., COHEN, M. V. & VATNER, S. F. (1989) 
Superoxide dismutase reduces reperfusion arrhythmias but fails to 
salvage regional function or myocardium at risk in conscious dogs. 
Circulation, 79, 143-53. 
NELSON, S. K., BOSE, S. K. & MCCORD, J. M. (1994) The toxicity of high-
dose superoxide dismutase suggests that superoxide can both initiate 
and terminate lipid peroxidation in the reperfused heart. Free Radic 
Biol Med, 16, 195-200. 
NEMIROFF, P. M., LUNGU AP (1987) Influence of hyperbaric oxygen and 
irradiatio on vascularity in skin flaps: a controlled study. Surgical 
forum, 38, 565-567. 
NIE, H., XIONG, L., LAO, N., CHEN, S., XU, N. & ZHU, Z. (2006) 
Hyperbaric oxygen preconditioning induces tolerance against spinal 
cord ischemia by upregulation of antioxidant enzymes in rabbits. J 
Cereb Blood Flow Metab, 26, 666-74. 
NIGAM, A. & KOPECKY, S. L. (2002) Therapeutic potential of monoclonal 
antibodies in myocardial reperfusion injury. Am J Cardiovasc Drugs, 2, 
367-76. 
NISHIDA, K., HARRISON, D. G., NAVAS, J. P., FISHER, A. A., 
DOCKERY, S. P., UEMATSU, M., NEREM, R. M., ALEXANDER, 
R. W. & MURPHY, T. J. (1992) Molecular cloning and 
characterization of the constitutive bovine aortic endothelial cell nitric 
oxide synthase. J Clin Invest, 90, 2092-6. 
NIWA, Y., OZAKI, Y., KANOH, T., AKAMATSU, H. & KURISAKA, M. 
(1996) Role of cytokines, tyrosine kinase, and protein kinase C on 
production of superoxide and induction of scavenging enzymes in 
human leukocytes. Clin Immunol Immunopathol, 79, 303-13. 
NOEL, A. A., FALLEK, S. R., HOBSON, R. W., 2ND & DURAN, W. N. 
(1995) Inhibition of nitric oxide synthase attenuates primed 
microvascular permeability in the in vivo microcirculation. J Vasc 
Surg, 22, 661-9; discussion 669-70. 
  
308 
 
NORTH, A. J., LAU, K. S., BRANNON, T. S., WU, L. C., WELLS, L. B., 
GERMAN, Z. & SHAUL, P. W. (1996) Oxygen upregulates nitric 
oxide synthase gene expression in ovine fetal pulmonary artery 
endothelial cells. Am J Physiol, 270, L643-9. 
NOSSULI, T. O., HAYWARD, R., JENSEN, D., SCALIA, R. & LEFER, A. 
M. (1998) Mechanisms of cardioprotection by peroxynitrite in 
myocardial ischemia and reperfusion injury. Am J Physiol, 275, H509-
19. 
NYLANDER, G., LEWIS, D., NORDSTROM, H. & LARSSON, J. (1985) 
Reduction of postischemic edema with hyperbaric oxygen. Plast 
Reconstr Surg, 76, 596-603. 
NYLANDER, G., NORDSTROM, H., LEWIS, D. & LARSSON, J. (1987) 
Metabolic effects of hyperbaric oxygen in postischemic muscle. Plast 
Reconstr Surg, 79, 91-7. 
O'CONNOR, G. T., BIRKMEYER, J. D., DACEY, L. J., QUINTON, H. B., 
MARRIN, C. A., BIRKMEYER, N. J., MORTON, J. R., LEAVITT, B. 
J., MALONEY, C. T., HERNANDEZ, F., CLOUGH, R. A., NUGENT, 
W. C., OLMSTEAD, E. M., CHARLESWORTH, D. C. & PLUME, S. 
K. (1998) Results of a regional study of modes of death associated with 
coronary artery bypass grafting. Northern New England Cardiovascular 
Disease Study Group. Ann Thorac Surg, 66, 1323-8. 
OGATA, N., YAMAMOTO, H., KUGIYAMA, K., YASUE, H. & 
MIYAMOTO, E. (2000) Involvement of protein kinase C in superoxide 
anion-induced activation of nuclear factor-kappa B in human 
endothelial cells. Cardiovasc Res, 45, 513-21. 
OHASHI, Y., KAWASHIMA, S., HIRATA, K., AKITA, H. & YOKOYAMA, 
M. (1997) Nitric oxide inhibits neutrophil adhesion to cytokine-
activated cardiac myocytes. Am J Physiol, 272, H2807-14. 
OHGURI, T., IMADA, H., NARISADA, H., YAHARA, K., MORIOKA, T., 
NAKANO, K., MIYAGUNI, Y. & KOROGI, Y. (2009) Systemic 
chemotherapy using paclitaxel and carboplatin plus regional 
hyperthermia and hyperbaric oxygen treatment for non-small cell lung 
cancer with multiple pulmonary metastases: preliminary results. Int J 
Hyperthermia, 25, 160-7. 
ONAI, Y., SUZUKI, J., NISHIWAKI, Y., GOTOH, R., BERENS, K., 
DIXON, R., YOSHIDA, M., ITO, H. & ISOBE, M. (2003) Blockade of 
cell adhesion by a small molecule selectin antagonist attenuates 
myocardial ischemia/reperfusion injury. Eur J Pharmacol, 481, 217-25. 
ONODERA, T., TAKEMURA, G., OGURO, T. & ASHRAF, M. (1992) Effect 
of exogenous hydrogen peroxide on myocardial function and structure 
in isolated rat heart. Can J Cardiol, 8, 989-97. 
OOIWA, H., STANLEY, A., FELANEOUS-BYLUND, A. C., WILBORN, W. 
& DOWNEY, J. M. (1991) Superoxide dismutase conjugated to 
polyethylene glycol fails to limit myocardial infarct size after 30 min 
ischemia followed by 72 h of reperfusion in the rabbit. J Mol Cell 
Cardiol, 23, 119-25. 
  
309 
 
OSADA, M., TAKEDA, S., SATO, T., KOMORI, S. & TAMURA, K. (1994) 
The protective effect of preconditioning on reperfusion-induced 
arrhythmia is lost by treatment with superoxide dismutase. Jpn Circ J, 
58, 259-63. 
PAGLIARO, P., GATTULLO, D., RASTALDO, R. & LOSANO, G. (2001) 
Ischemic preconditioning: from the first to the second window of 
protection. Life Sci, 69, 1-15. 
PALAZZO, A. J., JONES, S. P., ANDERSON, D. C., GRANGER, D. N. & 
LEFER, D. J. (1998a) Coronary endothelial P-selectin in pathogenesis 
of myocardial ischemia-reperfusion injury. Am J Physiol, 275, H1865-
72. 
PALAZZO, A. J., JONES, S. P., GIROD, W. G., ANDERSON, D. C., 
GRANGER, D. N. & LEFER, D. J. (1998b) Myocardial ischemia-
reperfusion injury in CD18- and ICAM-1-deficient mice. Am J Physiol, 
275, H2300-7. 
PALLEROS, D. R., WELCH, W. J. & FINK, A. L. (1991) Interaction of hsp70 
with unfolded proteins: effects of temperature and nucleotides on the 
kinetics of binding. Proc Natl Acad Sci U S A, 88, 5719-23. 
PARK, J. L. & LUCCHESI, B. R. (1999) Mechanisms of myocardial 
reperfusion injury. Ann Thorac Surg, 68, 1905-12. 
PARK, M. K., MYERS, R. A. & MARZELLA, L. (1992) Oxygen tensions and 
infections: modulation of microbial growth, activity of antimicrobial 
agents, and immunologic responses. Clin Infect Dis, 14, 720-40. 
PATEL, K. D., ZIMMERMAN, G. A., PRESCOTT, S. M., MCEVER, R. P. & 
MCINTYRE, T. M. (1991) Oxygen radicals induce human endothelial 
cells to express GMP-140 and bind neutrophils. J Cell Biol, 112, 749-
59. 
PELL, T. J., BAXTER, G. F., YELLON, D. M. & DREW, G. M. (1998) Renal 
ischemia preconditions myocardium: role of adenosine receptors and 
ATP-sensitive potassium channels. Am J Physiol, 275, H1542-7. 
PENNA, C., MANCARDI, D., RASTALDO, R. & PAGLIARO, P. (2009) 
Cardioprotection: a radical view Free radicals in pre and 
postconditioning. Biochim Biophys Acta, 1787, 781-93. 
PETZOLD, T., FEINDT, P. R., CARL, U. M. & GAMS, E. (1999) Hyperbaric 
oxygen therapy in deep sternal wound infection after heart 
transplantation. Chest, 115, 1455-8. 
PHILLIPS B, B. C., SACKETT D, BADENOCH D, STRAUS S, HAYNES B, 
DAWES M (March 2009) Level of Evidence. IN J, H. (Ed.) Oxford, 
Oxford Centre For Evidenc Based Medicine, University of Oxford. 
PIANTADOSI, S. (1997) Clinical Trials. Clinical Trials: A Methodologic 
Perspective. John Wiley & Sons. 
PIGOTT, R., DILLON, L. P., HEMINGWAY, I. H. & GEARING, A. J. 
(1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present 
in the supernatants of cytokine activated cultured endothelial cells. 
Biochem Biophys Res Commun, 187, 584-9. 
PIPER, H. M., GARCIA-DORADO, D. & OVIZE, M. (1998) A fresh look at 
reperfusion injury. Cardiovasc Res, 38, 291-300. 
  
310 
 
PIRIOU, V., CHIARI, P., GATEAU-ROESCH, O., ARGAUD, L., 
MUNTEAN, D., SALLES, D., LOUFOUAT, J., GUEUGNIAUD, P. 
Y., LEHOT, J. J. & OVIZE, M. (2004) Desflurane-induced 
preconditioning alters calcium-induced mitochondrial permeability 
transition. Anesthesiology, 100, 581-8. 
PLUMIER, J. C., ROSS, B. M., CURRIE, R. W., ANGELIDIS, C. E., 
KAZLARIS, H., KOLLIAS, G. & PAGOULATOS, G. N. (1995) 
Transgenic mice expressing the human heat shock protein 70 have 
improved post-ischemic myocardial recovery. J Clin Invest, 95, 1854-
60. 
POCKLEY, A. G. (2002) Heat shock proteins, inflammation, and 
cardiovascular disease. Circulation, 105, 1012-7. 
PRASAD, A., STONE, G. W., HOLMES, D. R. & GERSH, B. (2009) 
Reperfusion injury, microvascular dysfunction, and cardioprotection: 
the "dark side" of reperfusion. Circulation, 120, 2105-12. 
PRYOR, W. A. & SQUADRITO, G. L. (1995) The chemistry of peroxynitrite: 
a product from the reaction of nitric oxide with superoxide. Am J 
Physiol, 268, L699-722. 
PRZYKLENK, K., BAUER, B., OVIZE, M., KLONER, R. A. & 
WHITTAKER, P. (1993) Regional ischemic 'preconditioning' protects 
remote virgin myocardium from subsequent sustained coronary 
occlusion. Circulation, 87, 893-9. 
PRZYKLENK, K. & KLONER, R. A. (1995) Low-dose i.v. acetylcholine acts 
as a "preconditioning-mimetic" in the canine model. J Card Surg, 10, 
389-95. 
RADFORD, N. B., FINA, M., BENJAMIN, I. J., MOREADITH, R. W., 
GRAVES, K. H., ZHAO, P., GAVVA, S., WIETHOFF, A., SHERRY, 
A. D., MALLOY, C. R. & WILLIAMS, R. S. (1996) Cardioprotective 
effects of 70-kDa heat shock protein in transgenic mice. Proc Natl 
Acad Sci U S A, 93, 2339-42. 
RADICE, S., ROSSONI, G., ORIANI, G., MICHAEL, M., CHIESARA, E. & 
BERTI, F. (1997) Hyperbaric oxygen worsens myocardial low flow 
ischemia-reperfusion injury in isolated rat heart. Eur J Pharmacol, 320, 
43-9. 
RADOMSKI, M. W., PALMER, R. M. & MONCADA, S. (1987) 
Comparative pharmacology of endothelium-derived relaxing factor, 
nitric oxide and prostacyclin in platelets. Br J Pharmacol, 92, 181-7. 
REIMER, K. A. & JENNINGS, R. B. (1979) The "wavefront phenomenon" of 
myocardial ischemic cell death. II. Transmural progression of necrosis 
within the framework of ischemic bed size (myocardium at risk) and 
collateral flow. Lab Invest, 40, 633-44. 
REIMER, K. A., MURRY, C. E. & RICHARD, V. J. (1989) The role of 
neutrophils and free radicals in the ischemic-reperfused heart: why the 
confusion and controversy? J Mol Cell Cardiol, 21, 1225-39. 
REIMER, K. A., MURRY, C. E., YAMASAWA, I., HILL, M. L. & 
JENNINGS, R. B. (1986) Four brief periods of myocardial ischemia 
  
311 
 
cause no cumulative ATP loss or necrosis. Am J Physiol, 251, H1306-
15. 
REN, P., KANG, Z., GU, G., LIU, Y., XU, W., TAO, H., ZHANG, J. H., 
SUN, X. & JI, H. (2008) Hyperbaric oxygen preconditioning promotes 
angiogenesis in rat liver after partial hepatectomy. Life Sci, 83, 236-41. 
ROBIN, E., GUZY, R. D., LOOR, G., IWASE, H., WAYPA, G. B., MARKS, 
J. D., HOEK, T. L. & SCHUMACKER, P. T. (2007) Oxidant Stress 
during Simulated Ischemia Primes Cardiomyocytes for Cell Death 
during Reperfusion. J Biol Chem, 282, 19133-43. 
RONSON, R. S., NAKAMURA, M. & VINTEN-JOHANSEN, J. (1999) The 
cardiovascular effects and implications of peroxynitrite. Cardiovasc 
Res, 44, 47-59. 
ROQUES, F., NASHEF, S. A., MICHEL, P., GAUDUCHEAU, E., DE 
VINCENTIIS, C., BAUDET, E., CORTINA, J., DAVID, M., 
FAICHNEY, A., GABRIELLE, F., GAMS, E., HARJULA, A., 
JONES, M. T., PINTOR, P. P., SALAMON, R. & THULIN, L. (1999) 
Risk factors and outcome in European cardiac surgery: analysis of the 
EuroSCORE multinational database of 19030 patients. Eur J 
Cardiothorac Surg, 15, 816-22; discussion 822-3. 
ROSENFELD, R., SMITH, J. M., WOODS, S. E. & ENGEL, A. M. (2006) 
Predictors and outcomes of extended intensive care unit length of stay 
in patients undergoing coronary artery bypass graft surgery. J Card 
Surg, 21, 146-50. 
ROSENKRANZ, E. R. (1995) Substrate enhancement of cardioplegic solution: 
experimental studies and clinical evaluation. Ann Thorac Surg, 60, 797-
800. 
ROSETTE, C. & KARIN, M. (1996) Ultraviolet light and osmotic stress: 
activation of the JNK cascade through multiple growth factor and 
cytokine receptors. Science, 274, 1194-7. 
ROTHLEIN, R., DUSTIN, M. L., MARLIN, S. D. & SPRINGER, T. A. 
(1986) A human intercellular adhesion molecule (ICAM-1) distinct 
from LFA-1. J Immunol, 137, 1270-4. 
RUBANYI, G. M., HO, E. H., CANTOR, E. H., LUMMA, W. C. & 
BOTELHO, L. H. (1991) Cytoprotective function of nitric oxide: 
inactivation of superoxide radicals produced by human leukocytes. 
Biochem Biophys Res Commun, 181, 1392-7. 
RUBINSTEIN, I., ABASSI, Z., MILMAN, F., OVCHARENKO, E., 
COLEMAN, R., WINAVER, J. & BETTER, O. S. (2009) Hyperbaric 
oxygen treatment improves GFR in rats with ischaemia/reperfusion 
renal injury: a possible role for the antioxidant/oxidant balance in the 
ischaemic kidney. Nephrol Dial Transplant, 24, 428-36. 
RUPIN, A., PAYSANT, J., SANSILVESTRI-MOREL, P., LEMBREZ, N., 
LACOSTE, J. M., CORDI, A. & VERBEUREN, T. J. (2004) Role of 
NADPH oxidase-mediated superoxide production in the regulation of 
E-selectin expression by endothelial cells subjected to 
anoxia/reoxygenation. Cardiovasc Res, 63, 323-30. 
  
312 
 
RUSSELL, J., EPSTEIN, C. J., GRISHAM, M. B., ALEXANDER, J. S., YEH, 
K. Y. & GRANGER, D. N. (2000) Regulation of E-selectin expression 
in postischemic intestinal microvasculature. Am J Physiol Gastrointest 
Liver Physiol, 278, G878-85. 
RUSSWURM, M. & KOESLING, D. (2004) NO activation of guanylyl 
cyclase. Embo J, 23, 4443-50. 
SAMMUT, I. A., JAYAKUMAR, J., LATIF, N., ROTHERY, S., SEVERS, N. 
J., SMOLENSKI, R. T., BATES, T. E. & YACOUB, M. H. (2001) 
Heat stress contributes to the enhancement of cardiac mitochondrial 
complex activity. Am J Pathol, 158, 1821-31. 
SANTOLINI, J., MEADE, A. L. & STUEHR, D. J. (2001) Differences in three 
kinetic parameters underpin the unique catalytic profiles of nitric-oxide 
synthases I, II, and III. J Biol Chem, 276, 48887-98. 
SANTORO, M. G. (2000) Heat shock factors and the control of the stress 
response. Biochem Pharmacol, 59, 55-63. 
SATO, H., ZHAO, Z. Q. & VINTEN-JOHANSEN, J. (1996) L-Arginine 
inhibits neutrophil adherence and coronary artery dysfunction. 
Cardiovasc Res, 31, 63-72. 
SCARCI, M., FALLOUH, H. B., YOUNG, C. P. & CHAMBERS, D. J. (2009) 
Does intermittent cross-clamp fibrillation provide equivalent 
myocardial protection compared to cardioplegia in patients undergoing 
bypass graft revascularisation? Interact Cardiovasc Thorac Surg, 9, 
872-8. 
SCHULTZ, J. E. & GROSS, G. J. (2001) Opioids and cardioprotection. 
Pharmacol Ther, 89, 123-37. 
SCHULZ, R., KELM, M. & HEUSCH, G. (2004) Nitric oxide in myocardial 
ischemia/reperfusion injury. Cardiovasc Res, 61, 402-13. 
SHANDLING, A. H., ELLESTAD, M. H., HART, G. B., CRUMP, R., 
MARLOW, D., VAN NATTA, B., MESSENGER, J. C., STRAUSS, 
M. & STAVITSKY, Y. (1997) Hyperbaric oxygen and thrombolysis in 
myocardial infarction: the "HOT MI" pilot study. Am Heart J, 134, 
544-50. 
SHARIFI, M., FARES, W., ABDEL-KARIM, I., KOCH, J. M., SOPKO, J. & 
ADLER, D. (2004) Usefulness of hyperbaric oxygen therapy to inhibit 
restenosis after percutaneous coronary intervention for acute 
myocardial infarction or unstable angina pectoris. Am J Cardiol, 93, 
1533-5. 
SHARIFI, M., FARES, W., ABDEL-KARIM, I., PETREA, D., KOCH, J. M., 
ADLER, D. & SOPKO, J. (2002) Inhibition of restenosis by hyperbaric 
oxygen: a novel indication for an old modality. Cardiovasc Radiat 
Med, 3, 124-6. 
SHEIKH, A. Y., ROLLINS, M. D., HOPF, H. W. & HUNT, T. K. (2005) 
Hyperoxia improves microvascular perfusion in a murine wound 
model. Wound Repair Regen, 13, 303-8. 
SHINOMIYA, N., SUZUKI, S., HASHIMOTO, A., ITO, M., TAKAAI, Y. & 
OIWA, H. (1998) Effect of hyperbaric oxygen on intercellular adhesion 
  
313 
 
molecule-1 (ICAM-1) expression in murine lung. Aviat Space Environ 
Med, 69, 1-7. 
SHIVA, S., SACK, M. N., GREER, J. J., DURANSKI, M., RINGWOOD, L. 
A., BURWELL, L., WANG, X., MACARTHUR, P. H., SHOJA, A., 
RAGHAVACHARI, N., CALVERT, J. W., BROOKES, P. S., LEFER, 
D. J. & GLADWIN, M. T. (2007) Nitrite augments tolerance to 
ischemia/reperfusion injury via the modulation of mitochondrial 
electron transfer. J Exp Med, 204, 2089-102. 
SHYU, W. C., LIN, S. Z., SAEKI, K., KUBOSAKI, A., MATSUMOTO, Y., 
ONODERA, T., CHIANG, M. F., THAJEB, P. & LI, H. (2004) 
Hyperbaric oxygen enhances the expression of prion protein and heat 
shock protein 70 in a mouse neuroblastoma cell line. Cell Mol 
Neurobiol, 24, 257-68. 
SIRSJO, A., LEHR, H. A., NOLTE, D., HAAPANIEMI, T., LEWIS, D. H., 
NYLANDER, G. & MESSMER, K. (1993) Hyperbaric oxygen 
treatment enhances the recovery of blood flow and functional capillary 
density in postischemic striated muscle. Circ Shock, 40, 9-13. 
SLIGH, J. E., JR., BALLANTYNE, C. M., RICH, S. S., HAWKINS, H. K., 
SMITH, C. W., BRADLEY, A. & BEAUDET, A. L. (1993) 
Inflammatory and immune responses are impaired in mice deficient in 
intercellular adhesion molecule 1. Proc Natl Acad Sci U S A, 90, 8529-
33. 
SNOECKX, L. H., CORNELUSSEN, R. N., VAN NIEUWENHOVEN, F. A., 
RENEMAN, R. S. & VAN DER VUSSE, G. J. (2001) Heat shock 
proteins and cardiovascular pathophysiology. Physiol Rev, 81, 1461-97. 
STAVITSKY, Y., SHANDLING, A. H., ELLESTAD, M. H., HART, G. B., 
VAN NATTA, B., MESSENGER, J. C., STRAUSS, M., DEKLEVA, 
M. N., ALEXANDER, J. M., MATTICE, M. & CLARKE, D. (1998) 
Hyperbaric oxygen and thrombolysis in myocardial infarction: the 
'HOT MI' randomized multicenter study. Cardiology, 90, 131-6. 
STEFFENS, S., MONTECUCCO, F. & MACH, F. (2009) The inflammatory 
response as a target to reduce myocardial ischaemia and reperfusion 
injury. Thromb Haemost, 102, 240-7. 
STERLING, D. L., THORNTON, J. D., SWAFFORD, A., GOTTLIEB, S. F., 
BISHOP, S. P., STANLEY, A. W. & DOWNEY, J. M. (1993) 
Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in 
vivo. Circulation, 88, 1931-6. 
SULEIMAN, M. S., ZACHAROWSKI, K. & ANGELINI, G. D. (2008) 
Inflammatory response and cardioprotection during open-heart surgery: 
the importance of anaesthetics. Br J Pharmacol, 153, 21-33. 
SUN, J. Z., TANG, X. L., PARK, S. W., QIU, Y., TURRENS, J. F. & BOLLI, 
R. (1996) Evidence for an essential role of reactive oxygen species in 
the genesis of late preconditioning against myocardial stunning in 
conscious pigs. J Clin Invest, 97, 562-76. 
SUSLOV, O. & STEINDLER, D. A. (2005) PCR inhibition by reverse 
transcriptase leads to an overestimation of amplification efficiency. 
Nucleic Acids Res, 33, e181. 
  
314 
 
SUZUKI, Y., AOKI, T., TAKEUCHI, O., NISHIO, K., SUZUKI, K., 
MIYATA, A., OYAMADA, Y., TAKASUGI, T., MORI, M., FUJITA, 
H. & YAMAGUCHI, K. (1997a) Effect of hyperoxia on adhesion 
molecule expression in human endothelial cells and neutrophils. Am J 
Physiol, 272, L418-25. 
SUZUKI, Y. J., FORMAN, H. J. & SEVANIAN, A. (1997b) Oxidants as 
stimulators of signal transduction. Free Radic Biol Med, 22, 269-85. 
SWIFT, P. C., TURNER, J. H., OXER, H. F., O'SHEA, J. P., LANE, G. K. & 
WOOLLARD, K. V. (1992) Myocardial hibernation identified by 
hyperbaric oxygen treatment and echocardiography in postinfarction 
patients: comparison with exercise thallium scintigraphy. Am Heart J, 
124, 1151-8. 
SZMAGALA, P., MORAWSKI, W., KREJCA, M., GBUREK, T. & 
BOCHENEK, A. (1998) Evaluation of perioperative myocardial tissue 
damage in ischemically preconditioned human heart during aorto 
coronary bypass surgery. J Cardiovasc Surg (Torino), 39, 791-5. 
TAHEP LD, P., VALEN, G., STARKOPF, J., KAIRANE, C., ZILMER, M. & 
VAAGE, J. (2001) Pretreating rats with hyperoxia attenuates ischemia-
reperfusion injury of the heart. Life Sci, 68, 1629-40. 
TAHEPOLD, P., RUUSALEPP, A., LI, G., VAAGE, J., STARKOPF, J. & 
VALEN, G. (2002) Cardioprotection by breathing hyperoxic gas-
relation to oxygen concentration and exposure time in rats and mice. 
Eur J Cardiothorac Surg, 21, 987-94. 
TAHEPOLD, P., VAAGE, J., STARKOPF, J. & VALEN, G. (2003) 
Hyperoxia elicits myocardial protection through a nuclear factor 
kappaB-dependent mechanism in the rat heart. J Thorac Cardiovasc 
Surg, 125, 650-60. 
TAHEPOLD, P., VALEN, G., STARKOPF, J., KAIRANE, C., ZILMER, M. 
& VAAGE, J. (2001) Pretreating rats with hyperoxia attenuates 
ischemia-reperfusion injury of the heart. Life Sci, 68, 1629-40. 
TAKADA, M., NADEAU, K. C., SHAW, G. D., MARQUETTE, K. A. & 
TILNEY, N. L. (1997) The cytokine-adhesion molecule cascade in 
ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-
selectin ligand. J Clin Invest, 99, 2682-90. 
TAKANO, H., TANG, X. L., QIU, Y., GUO, Y., FRENCH, B. A. & BOLLI, 
R. (1998) Nitric oxide donors induce late preconditioning against 
myocardial stunning and infarction in conscious rabbits via an 
antioxidant-sensitive mechanism. Circ Res, 83, 73-84. 
TAKESHIMA, S., VAAGE, J. & VALEN, G. (1997) Can reactive oxygen 
species precondition the isolated rat heart against arrhythmias and 
stunning? Acta Physiol Scand, 161, 263-70. 
TANAKA, K., WEIHRAUCH, D., KEHL, F., LUDWIG, L. M., LADISA, J. 
F., JR., KERSTEN, J. R., PAGEL, P. S. & WARLTIER, D. C. (2002) 
Mechanism of preconditioning by isoflurane in rabbits: a direct role for 
reactive oxygen species. Anesthesiology, 97, 1485-90. 
TANAKA, M., FUJIWARA, H., YAMASAKI, K. & SASAYAMA, S. (1994) 
Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate 
  
315 
 
infarct size limitation effect of ischaemic preconditioning in the rabbit. 
Cardiovasc Res, 28, 980-6. 
TAO, J., YANG, Z., WANG, J. M., TU, C. & PAN, S. R. (2006) Effects of 
fluid shear stress on eNOS mRNA expression and NO production in 
human endothelial progenitor cells. Cardiology, 106, 82-8. 
TARDIF, J. C., CARRIER, M., KANDZARI, D. E., EMERY, R., COTE, R., 
HEINONEN, T., ZETTLER, M., HASSELBLAD, V., GUERTIN, M. 
C. & HARRINGTON, R. A. (2007) Effects of pyridoxal-5'-phosphate 
(MC-1) in patients undergoing high-risk coronary artery bypass 
surgery: results of the MEND-CABG randomized study. J Thorac 
Cardiovasc Surg, 133, 1604-11. 
TAYLOR, K. M., BAIN, W. H., JONES, J. V. & WALKER, M. S. (1976) The 
effect of hemodilution on plasma levels of cortisol and free cortisol. J 
Thorac Cardiovasc Surg, 72, 57-61. 
TEOH, L. K., GRANT, R., HULF, J. A., PUGSLEY, W. B. & YELLON, D. 
M. (2002a) A comparison between ischemic preconditioning, 
intermittent cross-clamp fibrillation and cold crystalloid cardioplegia 
for myocardial protection during coronary artery bypass graft surgery. 
Cardiovasc Surg, 10, 251-5. 
TEOH, L. K., GRANT, R., HULF, J. A., PUGSLEY, W. B. & YELLON, D. 
M. (2002b) The effect of preconditioning (ischemic and 
pharmacological) on myocardial necrosis following coronary artery 
bypass graft surgery. Cardiovasc Res, 53, 175-80. 
TESTA, L., VAN GAAL, W. J., BHINDI, R., BIONDI-ZOCCAI, G. G., 
ABBATE, A., AGOSTONI, P., PORTO, I., ANDREOTTI, F., CREA, 
F. & BANNING, A. P. (2008) Pexelizumab in ischemic heart disease: a 
systematic review and meta-analysis on 15,196 patients. J Thorac 
Cardiovasc Surg, 136, 884-93. 
THOM, S. R. (2009) Oxidative stress is fundamental to hyperbaric oxygen 
therapy. J Appl Physiol, 106, 988-95. 
THOM, S. R., BHOPALE, V. M., VELAZQUEZ, O. C., GOLDSTEIN, L. J., 
THOM, L. H. & BUERK, D. G. (2006) Stem cell mobilization by 
hyperbaric oxygen. Am J Physiol Heart Circ Physiol, 290, H1378-86. 
THOM, S. R. & ELBUKEN, M. E. (1991) Oxygen-dependent antagonism of 
lipid peroxidation. Free Radic Biol Med, 10, 413-26. 
THOM, S. R., FISHER, D., ZHANG, J., BHOPALE, V. M., OHNISHI, S. T., 
KOTAKE, Y., OHNISHI, T. & BUERK, D. G. (2003) Stimulation of 
perivascular nitric oxide synthesis by oxygen. Am J Physiol Heart Circ 
Physiol, 284, H1230-9. 
THOM, S. R., MENDIGUREN, I., HARDY, K., BOLOTIN, T., FISHER, D., 
NEBOLON, M. & KILPATRICK, L. (1997) Inhibition of human 
neutrophil beta2-integrin-dependent adherence by hyperbaric O2. Am J 
Physiol, 272, C770-7. 
THOMAS, M. P., BROWN, L. A., SPONSELLER, D. R., WILLIAMSON, S. 
E., DIAZ, J. A. & GUYTON, D. P. (1990) Myocardial infarct size 
reduction by the synergistic effect of hyperbaric oxygen and 
recombinant tissue plasminogen activator. Am Heart J, 120, 791-800. 
  
316 
 
THURSTON, J. G. (1971) Place of hyperbaric oxygen in intensive care. Proc 
R Soc Med, 64, 1287-8. 
THURSTON, J. G., GREENWOOD, T. W., BENDING, M. R., CONNOR, H. 
& CURWEN, M. P. (1973) A controlled investigation into the effects 
of hyperbaric oxygen on mortality following acute myocardial 
infarction. Q J Med, 42, 751-70. 
TJARNSTROM, J., HOLMDAHL, L., FALK, P., FALKENBERG, M., 
ARNELL, P. & RISBERG, B. (2001) Effects of hyperbaric oxygen on 
expression of fibrinolytic factors of human endothelium in a simulated 
ischaemia/reperfusion situation. Scand J Clin Lab Invest, 61, 539-45. 
TJARNSTROM, J., WIKSTROM, T., BAGGE, U., RISBERG, B. & BRAIDE, 
M. (1999) Effects of hyperbaric oxygen treatment on neutrophil 
activation and pulmonary sequestration in intestinal ischemia-
reperfusion in rats. Eur Surg Res, 31, 147-54. 
TOMAI, F., DANESI, A., GHINI, A. S., CREA, F., PERINO, M., 
GASPARDONE, A., RUGGERI, G., CHIARIELLO, L. & GIOFFRE, 
P. A. (1999) Effects of K(ATP) channel blockade by glibenclamide on 
the warm-up phenomenon. Eur Heart J, 20, 196-202. 
TOMUR, A., ETLIK, O. & GUNDOGAN, N. U. (2005) Hyperbaric 
oxygenation and antioxidant vitamin combination reduces ischemia-
reperfusion injury in a rat epigastric island skin-flap model. J Basic 
Clin Physiol Pharmacol, 16, 275-85. 
TOOMBS, C. F., MCGEE, S., JOHNSTON, W. E. & VINTEN-JOHANSEN, 
J. (1992) Myocardial protective effects of adenosine. Infarct size 
reduction with pretreatment and continued receptor stimulation during 
ischemia. Circulation, 86, 986-94. 
TOUFEKTSIAN, M. C., MOREL, S., TANGUY, S., JEUNET, A., DE 
LEIRIS, J. & BOUCHER, F. (2003) Involvement of reactive oxygen 
species in cardiac preconditioning in rats. Antioxid Redox Signal, 5, 
115-22. 
TREWEEK, S. & JAMES, P. B. (2006) A cost analysis of monoplace 
hyperbaric oxygen therapy with and without recirculation. J Wound 
Care, 15, 235-8. 
TRITAPEPE, L., DE SANTIS, V., VITALE, D., SANTULLI, M., MORELLI, 
A., NOFRONI, I., PUDDU, P. E., SINGER, M. & PIETROPAOLI, P. 
(2006) Preconditioning effects of levosimendan in coronary artery 
bypass grafting--a pilot study. Br J Anaesth, 96, 694-700. 
TRITTO, I., D'ANDREA, D., ERAMO, N., SCOGNAMIGLIO, A., DE 
SIMONE, C., VIOLANTE, A., ESPOSITO, A., CHIARIELLO, M. & 
AMBROSIO, G. (1997) Oxygen radicals can induce preconditioning in 
rabbit hearts. Circ Res, 80, 743-8. 
TSIMIKAS, S., PALINSKI, W. & WITZTUM, J. L. (2001) Circulating 
autoantibodies to oxidized LDL correlate with arterial accumulation 
and depletion of oxidized LDL in LDL receptor-deficient mice. 
Arterioscler Thromb Vasc Biol, 21, 95-100. 
  
317 
 
TUTEJA, N., CHANDRA, M., TUTEJA, R. & MISRA, M. K. (2004) Nitric 
Oxide as a Unique Bioactive Signaling Messenger in Physiology and 
Pathophysiology. J Biomed Biotechnol, 2004, 227-237. 
URAIZEE, A., REIMER, K. A., MURRY, C. E. & JENNINGS, R. B. (1987) 
Failure of superoxide dismutase to limit size of myocardial infarction 
after 40 minutes of ischemia and 4 days of reperfusion in dogs. 
Circulation, 75, 1237-48. 
USHIYAMA, S., LAUE, T. M., MOORE, K. L., ERICKSON, H. P. & 
MCEVER, R. P. (1993) Structural and functional characterization of 
monomeric soluble P-selectin and comparison with membrane P-
selectin. J Biol Chem, 268, 15229-37. 
VAAGE, J. & VALEN, G. (1993) Pathophysiology and mediators of ischemia-
reperfusion injury with special reference to cardiac surgery. A review. 
Scand J Thorac Cardiovasc Surg Suppl, 41, 1-18. 
VAHLHAUS, C., NEUMANN, J., LUSS, H., WENZELBURGER, F., TJAN, 
T. D., HAMMEL, D., SCHELD, H. H., SCHMITZ, W., 
BREITHARDT, G. & WICHTER, T. (2005) Ischemic preconditioning 
by unstable angina reduces the release of CK-MB following CABG and 
stimulates left ventricular HSP-72 protein expression. J Card Surg, 20, 
412-9. 
VALEN, G., PAULSSON, G., BENNET, A. M., HANSSON, G. K. & 
VAAGE, J. (2000) Gene expression of inflammatory mediators in 
different chambers of the human heart. Ann Thorac Surg, 70, 562-7. 
VALEN, G., SKJELBAKKEN, T. & VAAGE, J. (1996) The role of nitric 
oxide in the cardiac effects of hydrogen peroxide. Mol Cell Biochem, 
159, 7-14. 
VALEN, G., STARKOPF, J., TAKESHIMA, S., KULLISAAR, T., 
VIHALEMM, T., KENGSEPP, A. T., LOWBEER, C., VAAGE, J. & 
ZILMER, M. (1998) Preconditioning with hydrogen peroxide (H2O2) 
or ischemia in H2O2-induced cardiac dysfunction. Free Radic Res, 29, 
235-45. 
VANDEN HOEK, T. L., BECKER, L. B., SHAO, Z., LI, C. & 
SCHUMACKER, P. T. (1998) Reactive oxygen species released from 
mitochondria during brief hypoxia induce preconditioning in 
cardiomyocytes. J Biol Chem, 273, 18092-8. 
VANHAECKE, J., VAN DE WERF, F., RONASZEKI, A., FLAMENG, W., 
LESAFFRE, E. & DE GEEST, H. (1991) Effect of superoxide 
dismutase on infarct size and postischemic recovery of myocardial 
contractility and metabolism in dogs. J Am Coll Cardiol, 18, 224-30. 
VENEMA, V. J., MARRERO, M. B. & VENEMA, R. C. (1996) Bradykinin-
stimulated protein tyrosine phosphorylation promotes endothelial nitric 
oxide synthase translocation to the cytoskeleton. Biochem Biophys Res 
Commun, 226, 703-10. 
VENUGOPAL, V., LUDMAN, A., YELLON, D. M. & HAUSENLOY, D. J. 
(2009) 'Conditioning' the heart during surgery. Eur J Cardiothorac 
Surg, 35, 977-87. 
  
318 
 
VERRIER, E. D., SHERNAN, S. K., TAYLOR, K. M., VAN DE WERF, F., 
NEWMAN, M. F., CHEN, J. C., CARRIER, M., HAVERICH, A., 
MALLOY, K. J., ADAMS, P. X., TODARO, T. G., MOJCIK, C. F., 
ROLLINS, S. A. & LEVY, J. H. (2004) Terminal complement 
blockade with pexelizumab during coronary artery bypass graft surgery 
requiring cardiopulmonary bypass: a randomized trial. Jama, 291, 
2319-27. 
VINTEN-JOHANSEN, J. (2004) Involvement of neutrophils in the 
pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res, 
61, 481-97. 
VOGT, S., TROITZSCH, D., ABDUL-KHALIQ, H. & MOOSDORF, R. 
(2007) Heat stress attenuates ATP-depletion and pH-decrease during 
cardioplegic arrest. J Surg Res, 139, 176-81. 
WADA, K., ITO, M., MIYAZAWA, T., KATOH, H., NAWASHIRO, H., 
SHIMA, K. & CHIGASAKI, H. (1996) Repeated hyperbaric oxygen 
induces ischemic tolerance in gerbil hippocampus. Brain Res, 740, 15-
20. 
WALL, T. M., SHEEHY, R. & HARTMAN, J. C. (1994) Role of bradykinin 
in myocardial preconditioning. J Pharmacol Exp Ther, 270, 681-9. 
WALSH, S. R., TANG, T. Y., KULLAR, P., JENKINS, D. P., DUTKA, D. P. 
& GAUNT, M. E. (2008) Ischaemic preconditioning during cardiac 
surgery: systematic review and meta-analysis of perioperative 
outcomes in randomised clinical trials. Eur J Cardiothorac Surg, 34, 
985-94. 
WALSH, S. R., TANG, T. Y., SADAT, U. & GAUNT, M. E. (2009) Remote 
ischemic preconditioning in major vascular surgery. J Vasc Surg, 49, 
240-3. 
WANG, L., LI, W., KANG, Z., LIU, Y., DENG, X., TAO, H., XU, W., LI, R., 
SUN, X. & ZHANG, J. H. (2009a) Hyperbaric oxygen preconditioning 
attenuates early apoptosis after spinal cord ischemia in rats. J 
Neurotrauma, 26, 55-66. 
WANG, X., WEI, M., KUUKASJARVI, P., LAURIKKA, J., JARVINEN, O., 
RINNE, T., HONKONEN, E. L. & TARKKA, M. (2003) Novel 
pharmacological preconditioning with diazoxide attenuates myocardial 
stunning in coronary artery bypass grafting. Eur J Cardiothorac Surg, 
24, 967-73. 
WANG, X., WEI, M., KUUKASJARVI, P., LAURIKKA, J., RINNE, T., 
MOILANEN, E. & TARKKA, M. (2009b) The anti-inflammatory 
effect of bradykinin preconditioning in coronary artery bypass grafting 
(bradykinin and preconditioning). Scand Cardiovasc J, 43, 72-9. 
WANG, X., WEI, M., LAURIKKA, J., KUUKASJARVI, P., RINNE, T., 
HONKONEN, E. L., NIEMINEN, R., MOILANEN, E. & TARKKA, 
M. (2004) The anti-inflammatory effect of diazoxide in coronary artery 
bypass grafting. Shock, 22, 23-8. 
WANG, Y. P., SATO, C., MIZOGUCHI, K., YAMASHITA, Y., OE, M. & 
MAETA, H. (2002) Lipopolysaccharide triggers late preconditioning 
  
319 
 
against myocardial infarction via inducible nitric oxide synthase. 
Cardiovasc Res, 56, 33-42. 
WANG, Y. Y. & YIN, B. L. (2006) Pro-inflammatory cytokines may induce 
late preconditioning in unstable angina patients. Med Hypotheses, 67, 
1121-4. 
WEAVER, L. K., HOWE, S., SNOW, G. L. & DERU, K. (2009) Arterial and 
pulmonary arterial hemodynamics and oxygen delivery/extraction in 
normal humans exposed to hyperbaric air and oxygen. J Appl Physiol, 
107, 336-45. 
WEI, M., WANG, X., KUUKASJARVI, P., LAURIKKA, J., RINNE, T., 
HONKONEN, E. L. & TARKKA, M. (2004) Bradykinin 
preconditioning in coronary artery bypass grafting. Ann Thorac Surg, 
78, 492-7. 
WEMAN, S. M., KARHUNEN, P. J., PENTTILA, A., JARVINEN, A. A. & 
SALMINEN, U. S. (2000) Reperfusion injury associated with one-
fourth of deaths after coronary artery bypass grafting. Ann Thorac 
Surg, 70, 807-12. 
WHORTON, A. R., SIMONDS, D. B. & PIANTADOSI, C. A. (1997) 
Regulation of nitric oxide synthesis by oxygen in vascular endothelial 
cells. Am J Physiol, 272, L1161-6. 
WILLIAMS, H. J., REBUCK, N., ELLIOTT, M. J. & FINN, A. (1998) 
Changes in leucocyte counts and soluble intercellular adhesion 
molecule-1 and E-selectin during cardiopulmonary bypass in children. 
Perfusion, 13, 322-7. 
WU, Z. K., IIVAINEN, T., PEHKONEN, E., LAURIKKA, J. & TARKKA, M. 
R. (2002) Ischemic preconditioning suppresses ventricular 
tachyarrhythmias after myocardial revascularization. Circulation, 106, 
3091-6. 
WU, Z. K., TARKKA, M. R., ELORANTA, J., PEHKONEN, E., 
LAURIKKA, J., KAUKINEN, L., HONKONEN, E. L., VUOLLE, M. 
& KAUKINEN, S. (2001) Effect of ischaemic preconditioning, 
cardiopulmonary bypass and myocardial ischaemic/reperfusion on free 
radical generation in CABG patients. Cardiovasc Surg, 9, 362-8. 
WU, Z. K., VIKMAN, S., LAURIKKA, J., PEHKONEN, E., IIVAINEN, T., 
HUIKURI, H. V. & TARKKA, M. R. (2005) Nonlinear heart rate 
variability in CABG patients and the preconditioning effect. Eur J 
Cardiothorac Surg, 28, 109-13. 
XIAO, Z., ZHANG, Z., RANJAN, V. & DIAMOND, S. L. (1997) Shear stress 
induction of the endothelial nitric oxide synthase gene is calcium-
dependent but not calcium-activated. J Cell Physiol, 171, 205-11. 
XU, X., WANG, Z., LI, Q., XIAO, X., LIAN, Q., XU, W., SUN, X., TAO, H. 
& LI, R. (2009) Endothelial nitric oxide synthase expression is 
progressively increased in primary cerebral microvascular endothelial 
cells during hyperbaric oxygen exposure. Oxid Med Cell Longev, 2, 7-
13. 
XUAN, Y. T., TANG, X. L., QIU, Y., BANERJEE, S., TAKANO, H., HAN, 
H. & BOLLI, R. (2000) Biphasic response of cardiac NO synthase 
  
320 
 
isoforms to ischemic preconditioning in conscious rabbits. Am J 
Physiol Heart Circ Physiol, 279, H2360-71. 
YACOUB, M. H. & ZEITLIN, G. L. (1965) Hyperbaric Oxygen In The 
Treatment Of The Postoperative Low-Cardiac-Output Syndrome. 
Lancet, 191, 581-3. 
YAGUCHI, Y., SATOH, H., WAKAHARA, N., KATOH, H., UEHARA, A., 
TERADA, H., FUJISE, Y. & HAYASHI, H. (2003) Protective effects 
of hydrogen peroxide against ischemia/reperfusion injury in perfused 
rat hearts. Circ J, 67, 253-8. 
YAMADA, T., TAGUCHI, T., HIRATA, Y., SUITA, S. & YAGI, H. (1995) 
The protective effect of hyperbaric oxygenation on the small intestine 
in ischemia-reperfusion injury. J Pediatr Surg, 30, 786-90. 
YELLON, D. M., ALKHULAIFI, A. M. & PUGSLEY, W. B. (1993) 
Preconditioning the human myocardium. Lancet, 342, 276-7. 
YELLON, D. M., PASINI, E., CARGNONI, A., MARBER, M. S., 
LATCHMAN, D. S. & FERRARI, R. (1992) The protective role of 
heat stress in the ischaemic and reperfused rabbit myocardium. J Mol 
Cell Cardiol, 24, 895-907. 
YIN, D. & ZHANG, J. H. (2005) Delayed and multiple hyperbaric oxygen 
treatments expand therapeutic window in rat focal cerebral ischemic 
model. Neurocrit Care, 2, 206-11. 
YIN, G. Q., DU, K. H., GU, F. R., FANG, Z. X., TANG, J. Q., ZHONG, B., 
ZHU, X. Y., WU, Y. W. & LU, C. P. (2007) Early-phase endotoxic 
shock-induced myocardial injury increases iNOS and selectin 
expression in macaque primate. Heart Lung Circ, 16, 85-92. 
YTREHUS, K., WALSH, R. S., RICHARDS, S. C. & DOWNEY, J. M. (1995) 
Hydrogen peroxide as a protective agent during reperfusion. A study in 
the isolated perfused rabbit heart subjected to regional ischemia. 
Cardiovasc Res, 30, 1033-7. 
YU, C. H. & BEATTIE, W. S. (2006) The effects of volatile anesthetics on 
cardiac ischemic complications and mortality in CABG: a meta-
analysis. Can J Anaesth, 53, 906-18. 
YU, S. Y., CHIU, J. H., YANG, S. D., YU, H. Y., HSIEH, C. C., CHEN, P. J., 
LUI, W. Y. & WU, C. W. (2005) Preconditioned hyperbaric 
oxygenation protects the liver against ischemia-reperfusion injury in 
rats. J Surg Res, 128, 28-36. 
ZAMBONI, W. A., ROTH, A. C., RUSSELL, R. C., GRAHAM, B., SUCHY, 
H. & KUCAN, J. O. (1993) Morphologic analysis of the 
microcirculation during reperfusion of ischemic skeletal muscle and the 
effect of hyperbaric oxygen. Plast Reconstr Surg, 91, 1110-23. 
ZAMBONI, W. A., WONG, H. P. & STEPHENSON, L. L. (1996) Effect of 
hyperbaric oxygen on neutrophil concentration and pulmonary 
sequestration in reperfusion injury. Arch Surg, 131, 756-60. 
ZARRO, D. L., PALANZO, D. A. & SADR, F. S. (1998) Myocardial 
preconditioning using adenosine: review and clinical experience. 
Perfusion, 13, 145-50. 
  
321 
 
ZHAI, X., ZHOU, X. & ASHRAF, M. (1996) Late ischemic preconditioning is 
mediated in myocytes by enhanced endogenous antioxidant activity 
stimulated by oxygen-derived free radicals. Ann N Y Acad Sci, 793, 
156-66. 
ZHANG, F., CHENG, C., GERLACH, T., KIM, D. Y., LINEAWEAVER, W. 
C. & BUNCKE, H. J. (1998) Effect of hyperbaric oxygen on survival 
of the composite ear graft in rats. Ann Plast Surg, 41, 530-4. 
ZHAO, Z. Q., CORVERA, J. S., HALKOS, M. E., KERENDI, F., WANG, N. 
P., GUYTON, R. A. & VINTEN-JOHANSEN, J. (2003) Inhibition of 
myocardial injury by ischemic postconditioning during reperfusion: 
comparison with ischemic preconditioning. Am J Physiol Heart Circ 
Physiol, 285, H579-88. 
ZHOU, X., PAULSSON, G., STEMME, S. & HANSSON, G. K. (1998) 
Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch 
of the autoimmune response in atherosclerotic apo E-knockout mice. J 
Clin Invest, 101, 1717-25. 
ZHOU, X., XAO, X., ZHANG, W., YANG, H. & BAO, T. (2000) [The effect 
of cardiopulmonary bypass on expression of myocardial nitric oxide 
synthase in patients for valve replacement]. Hua Xi Yi Ke Da Xue Xue 
Bao, 31, 91-2. 
ZINGARELLI, B., HAKE, P. W., YANG, Z., O'CONNOR, M., 
DENENBERG, A. & WONG, H. R. (2002) Absence of inducible nitric 
oxide synthase modulates early reperfusion-induced NF-kappaB and 
AP-1 activation and enhances myocardial damage. Faseb J, 16, 327-42. 
 
 
